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It is well established that immunological surveillance is an important method by which 
cancer is controlled in healthy people. Cancer immunotherapy aims to exploit the 
power of the host immune system for the targeted destruction of malignancies 
without the undesirable side effects associated with current treatment regimes. This 
requires training the immune system to recognise hostile cancer cells, which emit 
chemical signals to down-regulate the immune system. Vaccine adjuvants are thought 
to be critical in making such immunotherapy vaccines immunogenic enough to break 
through this tolerance to tumour antigens. Herein we report a robust, scalable and 
stereoselective synthesis of one such adjuvant β-mannosylceramide (β-ManCer, 1), 
with late-stage derivatisation affording a series of N-acyl analogues. Furthermore, 
conjugation of β-ManCer to antigenic peptide fragments is designed to create a 
synthetic self-adjuvanting vaccine platform for immunotherapeutic treatments. 
 
β-ManCer (1) was synthesised in 12 steps with an overall yield of 22% from D-mannose 
via key glycoside intermediate 85 (Figure I, A). 85 was formed by β-selective 
glycosylation of sulfoxide donor 73 with phytosphingosine acceptor 78 in 70% yield 
with an α:β ratio of 7:93. Subsequent chemoselective reduction of the azide of 85, 
followed by N-acylation with cerotic acid on global deprotection afforded the 
synthetic adjuvant 1. Alternatively, a comparable intermediate, 116, was synthesised 
in 62% with absolute β selectivity from mannoside donor 105 and phytosphingosine 
triflate 48 using a stannylene acetal mediated glycosylation approach. Global 
deprotection of 116 followed by N-acylation converged the synthesis, affording 1 by 
an expeditious route (Figure I, B). 
 
Alternatively, N-acylation with 11-(para-fluorophenyl)-undecanoic acid (143), 11-
(para-(4-fluorophenoxy)phenyl)-undecanoic acid (144), and elicosadienoic acid 




Figure II). An amino analogue, β-ManPhyt 50, lacking the acyl side chain was also 
synthesised. 
Figure I: Synthesis of β-ManCer (1) via key glucoside intermediates 85, and 116. Reagents and 
conditions: i) (a) DTBMP, 4Å MS, anhydrous DCM, 1 hr; (b) Tf2O, -78°C, 10 min; (c) 78, -78°C to -50°C, 
3hrs, α:β 3:97, 70%; ii) Bu2SnO, tol, reflux, 3 hrs; iii) (a) CsF, DMF, rt, 30 min; (b) 48, rt, o/n, 62%. 
Investigation of a pro-drug strategy for the synthesis of self-adjuvanting vaccine 
constructs of the prototypical glycolipid adjuvant α-GalCer (2), afforded migrated β-
ManCer (MbMC, 161) where an acid catalysed migration of the N-acyl chain to the O-
4’ hydroxyl has occurred (Figure III). The reverse O- to N- migration occurs rapidly 
under phosphate buffered saline (PBS) conditions to regenerate 1. Alternatively, the 
reverse migration can be blocked by capping the free amine of 161, in this case with a 
self-immolative linker scaffold terminating in a bicyclo[6.1.0]nonyne (BCN) scaffold, 
affording 178, with a handle for use in strain promoted azide alkyne cycloaddition 
(SPAAC) reactions. 





Figure III: Acid catalysed intra-molecular migration of the C26 acyl chain gives pro-adjuvant migrated 
β-ManCer (MbMC, 161) which undergoes the reverse migration regenerating 1 under biological 
conditions. Capping the amino functionality of 161 with a self-immolative linker scaffold affords 
construct 178 with a BCN handle for SPAAC conjugation of peptide epitopes. 
Conjugation of antigenic peptide fragments terminated in an alkyl azide residue 
afforded glycopeptide vaccine construct CI207 in 2.0% overall yield, containing an ISA 
peptide HPV16 E7 epitope, and CI243 in 4.1% overall yield, containing an 
ovalbumin (OVA) synthetic long peptide (SLP) CD4+ CD8+ epitope (Structures shown 
Figure IV). It is envisioned that biological evaluation of such compounds will provide 
critical structure activity relationship (SAR) information on this important class of 
invariant natural killer T (iNKT) cell agonists. 
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Chapter I: Introduction 
The work contained in this thesis focuses on β-mannosylceramide (β-ManCer, 1) an 
important CD1d-dependent invariant natural killer T (iNKT) cell agonist. This work 
details the origin of iNKT cell agonists, from the discovery of agelasphins within the 
marine sponge Agelas mauritianus to the synthesis of the prototypical agonist α-
galactosylceramide (α-GalCer, 2). Herein we then describe several efficient 
methodologies for the synthesis of 1, a series of N-acyl analogues, and the 
exemplification of four novel self-adjuvanting glycopeptide vaccines of 1, and their 
potential application within cancer immuno-therapeutic treatment regimes.  
 
Figure 1.1: Chemical structures of β-mannosylceramide (β-ManCer, 1) and α-galactosylceramide (α-
GalCer, 2). 
This chapter introduces the field of cancer research and immunotherapy specifically 
in the context of invariant natural killer T (iNKT) cell agonists/adjuvants. It provides an 
overview of the basic cells of the immune system and their response to foreign 
antigens. Following this is a brief history of vaccines, which provides details on the 
advantages, limitations and progress made in synthetic vaccinations. I then introduce 
the key idea of adjuvants, what they are, and how they are useful, before moving on 
to their role in modern cancer immunotherapy. This leads into cerebrosides, 
specifically the agelasphins, bio-active natural products isolated from the marine 
sponge Agelas mauritianus in 1993. These natural products displayed potent adjuvant 
activity and were the first reported examples of iNKT cell agonist/adjuvants. The 
outcome of this discovery was α-galactosylceramide (α-GalCer, 2) also known as KRN-
7000, a synthetic and potent iNKT cell agonist. Provided below are details on its mode 
of action, bio-activity, synthesis, and outcomes of structural activity relationship 
studies, as well as its limitations. This chapter concludes with details on the recent 
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discovery of β-mannosylceramide (β-ManCer, 1), an iNKT cell agonist that lacks many 
of the limitations that plagued the previous generation and our research objectives 
concerning it. 
1.1. Overview of immunology 
The human immune system is a vastly complex and important collection of cells and 
tissues throughout our body responsible for protecting us from microbes, bacteria, 
viruses and the everyday environment.1 These specialized cells perform a variety of 
roles from identifying foreign pathogens entering the body (recognizing ‘self’ from 
‘non-self’) through to eliminating them via non-specific and/or specific responses. The 
non-specific response is known as innate immunity and is the first line of defence. The 
specific response is termed adaptive immunity, and is further subdivided into humoral 
immunity and cell-mediated immunity.2 The key features and differences of the innate 
and adaptive immune system are summarized below (Table 1.1).3  
 
 Innate Immunity Adaptive Immunity 
Components Physical and chemical barriers 
Phagocytic Leukocytes 
Dendritic cells 
Natural Killer cells 
Plasma proteins 
Humoral immunity 
• Naïve B Cells which mature 
into plasma cells 
Cell-mediated immunity 
• Naïve T Cells which mature 
into CD4+ T cells and CD8+ T 
cells 
Activity Always present Normally silent/inactive 
Response and 
potency 
Immediate low potency response 
(Days) 
Slower more potent response (over 1-
2 weeks) 
Specificity Non-specific (can recognize 
pathogen class e.g. Bacteria, virus, 
fungi, parasites etc. but not 
determine specific pathogen) 
Specific (Capable of recognizing 
unique antigens) 
Course/Duration Attempts to either immediately 
destroy the pathogen or, if it can, 
contains it until the more powerful 
adaptive immune system responds 
Delayed response; effector cells 
normally produced within a week with 
entire response taking 1-2 weeks 
(individuals vary) 
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Memory No memory – reacts with same 
potency upon re-exposure 
Yes - Memory cells remember specific 
pathogens (antigens) leading to 
increased potency and faster 
response upon re-exposure 
Table 1 1: A basic summary of the innate and adaptive immune system. Modified from Coico, R., et al., 
Immunology: A Short Course. John Wiley & Sons: New Jersey, 2003. 
1.1.1. Innate immunity 
An innate immune response is capable of preventing and controlling many infections. 
Its quick response time is credited to the recognition of highly conserved 
molecules/structures known as pathogen associated molecular patterns (PAMPs) that 
are common among microbes. Key cells of the innate immune response are phagocytic 
leukocytes, dendritic cells (DCs) and natural killer cells (NK cells). Phagocytic 
leukocytes such as neutrophils and macrophages contain receptors on their surface 
that recognize foreign pathogens via PAMPs. These receptors are known as pattern 
recognition receptors (PRRs). Once a pathogen is recognized, these cells ingest them 
into vesicles and chemically destroy them, a process known as phagocytosis. 
Recognition of foreign pathogens may also trigger the release of signalling proteins 
known as cytokines. Specifically, macrophages secrete cytokines that stimulate 
inflammation; resulting in capillary dilation, increased blood flow and leakiness, 
triggering a lymphocyte response.  
 
Similar to phagocytic leukocytes, dendritic cells are capable of dealing with microbes 
that overcome epithelial barriers. Dendritic cells are also known to secrete various 
cytokines in response to pathogens. More importantly dendritic cells, as well as 
macrophages, are capable of phagocytizing pathogens, breaking them up and 
displaying part of the pathogen on their surface. Such cells are known as antigen 
presenting cells (APCs) with the portion of the pathogen they display known as an 
antigen or antigenic peptide. APCs form an important link between the innate and 
adaptive immune systems, and along with antigens, will be revisited later in this 
chapter. 
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Natural killer (NK) cells share the same lineage of lymphocyte precursors as the B and 
T lymphocytes of the adaptive immune system (Described in Section 1.1.2). However, 
they express receptors that bind/recognize general classes of pathogens unlike the 
very specific peptide sequences recognized by the related B and T lymphocytes. 
Normally immune cells detect major histocompatibility complexes (MHCs) presented 
on infected cell surfaces (also present on healthy cells) which triggers cytokine release 
and results in lysis or apoptosis. NK cells, however, have the ability to recognize 
stressed or infected cells in the absence of MHCs. This allows for a much faster 
reaction, as they do not require activation to kill cells that are missing ‘self’ markers 
like MHC.4 This effect is shown in Figure 1.25 where the presence of an MHC “self” 
molecule on the surface of the target cell inhibits the cytotoxicity of the NK cell (A) 
whereas lack of the MHC receptor promotes the toxicity of the NK cell leading to cell 
death of the target (B). NK cells are the key effectors of the innate immune system 
and are crucial in passive cancer surveillance. They also produce the macrophage 
activating cytokine interferon-gamma (IFN-γ) which recruits macrophages to infection 
sites resulting in a stronger immune response.  
 
Figure 1.2: NK cell response to MHC I receptor. (a) Shows MHC I complex inhibiting NK cell cytotoxic 
activity whereas (b) lacks the ‘self’ MHC I marker promoting cytotoxic activity leading to target cell 
death. Adapted from Kumar, V.; Abul K. Abbas; Fausto, N.; Mitchell, R. N., Robbins Basic Pathology. 8th 
ed.; Saunders Elsevier : Philadelphia, PA:, 2007. 
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1.1.2. Adaptive immunity 
The adaptive immune system is held in reserve for pathogens that overcome or evade 
the innate immune system and is typified by a diverse range of B and T lymphocytes. 
Adaptive immunity is normally silent, responding or adapting to microbes by 
becoming active and generating potent mechanisms for neutralizing infection. There 
are two major types of adaptive immune responses: humoral immunity and cell-
mediated immunity, with both working in concert to eliminate infection. The humoral 
immune response is mediated by antibodies, which are produced by bone marrow-
derived B lymphocytes. B lymphocytes comprise around 20% of circulating 
lymphocytes and are also present in the bone marrow and other lymphatic tissues. 
They recognize antigens via membrane bound antibody receptors, which unlike the 
related T lymphocytes whose receptors only recognize small peptides, are capable of 
recognizing many different chemical structures including (but not limited to) proteins, 
lipids, carbohydrates, and small molecules. When stimulated by an appropriate 
antigen or a cytokine signal via a CD4+ T lymphocyte, B lymphocytes proliferate and 
differentiate into short lived plasma cells and long lived B memory cells (Figure 1.3).6 
Plasma cells are the effector cells of humoral immunity and the only immune cells 
capable of producing antibodies. These antibodies bind to the microbe from which the 
original antigen was derived, marking it for destruction by a variety of mechanisms, 
including phagocytosis. After an infection B memory cells persist resulting in a faster 
and more potent immune response upon reinfection.  
 
Cell mediated immunity is mediated by thymus-derived or T lymphocytes, which 
comprise around 70% of circulating lymphocytes. Unlike B lymphocytes, which are 
capable of recognizing circulating antigens with a vast array of chemical compositions 
the majority of T lymphocytes (>95%) are only able to recognize peptide antigens 
displayed to them by APCs via MHC molecules. The APC which presents the antigen to 
the T-cell receptor (TCR) of the naïve T lymphocyte via its MHC molecule is normally 
an activated DC. However, other APCs may undertake the role. For full activation, a 
second signal (cytokines produced by a DC) is typically required, promoting 
proliferation and recruitment of three major subsets of T lymphocyte. These are the 
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short-lived CD4+ T lymphocyte also known as a helper T cell (TH cell), CD8+ T 
lymphocyte also known as cytotoxic T lymphocytes (CTL), and the long-lived T memory 
cells. T cells also secrete a vast array of soluble mediators known as cytokines which 
control the immune system and can do everything from activating naïve B 
lymphocytes (secreted by CD4+ T lymphocytes) to triggering apoptosis (programed cell 
death and secreted by CD8+ T lymphocytes) of a cancer cell.  
 
Figure 1.3: Stimulation of Naïve B lymphocyte differentiation by direct binding of antigen to receptor 
or by cytokine signal from activated CD4+ T cell. Adapted from Kwek, S. S.; Cha, E.; Fong, L., Nat. Rev. 
Cancer 2012, 12 (4), 289-297. 
It is important to note there are two different types of MHCs found on the surface of 
antigen presenting cells. Major histocompatibility complex class I (MHC I) are found 
on the surface of all healthy nucleated cells in the body. MHC I molecules display 
peptide antigens found within the cytoplasm of cells, with the antigens they display 
largely being recognized by CD8+ T lymphocytes. Thus CD8+ T lymphocytes are better 
at responding to viruses and microbes that can escape from vesicles into the cytosol. 
Whereas major histocompatibility complex class 2 (MHC II) molecules are restricted 
to specialized types of cells, namely APCs. MHC II molecules display antigens from 
within cell vesicles (e.g. from microbes that have undergone phagocytosis) and are 
largely recognized by CD4+ T lymphocytes. Thus, humoral immunity (CD4+ T 
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lymphocyte dependent) is said to fight against extracellular pathogens whereas cell-
mediated immunity (CD8+ T lymphocytes) is much better at responding to infected 
cells. Figure 1.47 summarizes the MHC I and MHC II pathways for antigen presentation. 
Figure 1.4: Summary of the presentation pathways for MHC I and MHC II molecules by APCs. Adapted 
from Hubbell, J. A.; Thomas, S. N.; Swartz, M. A., Materials engineering for immunomodulation. Nature 
2009, 462 (7272), 449-460. 
Vaccinations provide humanity with the tools to influence the immune system. By 
stimulating or suppressing various immune pathways we can achieve a range of 
outcomes, from training the immune system to fight cancer to better preparing our 
body against future exposures. For example, deliberate inoculation of a patient with 
a non-virulent form of a pathogen can trigger an immune response resulting in the 
production of long lived T and B memory cells. This provides protection from potential 
future exposure to the virulent strain as it can be immediately recognized and either, 
be destroyed before it can infect cells, or those infected cells can be neutralized before 
it can multiply significantly. 
Chapter I: Introduction 
 
9 
1.2. Vaccines and Vaccinations 
1.2.1. Vaccines 
Vaccines are considered one of, if not the most, important medical breakthroughs 
against infectious diseases, cancer, allergy and autoimmune disease of the last few 
centuries.8 Their beginnings can be traced back to 1796 with the first scientific 
investigations on the prevention of smallpox by Edward Jenner.9 Jenner showed the 
pre-inoculation of patients with cowpox virus prevented the onset of smallpox when 
they were subsequently exposed to the virulent strain. Although this was the first 
scientific study into smallpox prevention, a Chinese practice of inoculating people with 
pus from infected smallpox patients to prevent a severe natural infection can be 
traced back to the early 18th century when this practice of inoculation was first 
brought to Europe.9  
 
Advances in vaccinology throughout recent times are demonstrated by the fact some 
diseases such as smallpox are now classed as globally eradicated, and many others are 
now vaccine preventable (Figure 1.5).10 Despite this, infectious disease remains a 
major problem. One such example is tuberculosis (TB), a deadly disease caused by the 
pathogenic bacterium Mycobacterium tuberculosis (MTb). Although some strains of 
TB can be prevented by vaccination, the effectiveness of the current vaccine Bacille 
Calmette-Guérin (BCG) is variable.11 A World Health Organization (WHO) global 
report12 into the TB crisis reported 10 million new cases of the disease for the year 
2017 along with 1.6 million fatalities as a direct result of, or due to, post infectious 
complications. The report focuses on the troubling and growing concern for emerging 
multidrug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). These 
strains of the disease have much higher fatality rates, with MDR-TB fatal in 45% of 
cases. The increasing number of resistant pathogens and lack of effective vaccines that 
promote the immune system to fully combat intracellular pathogens like MTb requires 
addressing. To overcome this, and provide better protection against infectious 
disease, new and more effective vaccines and/or vaccine preparations are required.  




Figure 1.5: Shows a timeline of pathogen identification through to vaccine development. From Vaccine 
Timeline. http://shvarz.livejournal.com/416558.htmL. 
1.2.2. Vaccination 
Historically vaccines made use of live attenuated bacteria or viruses, in which the 
whole organism or virus is used in a weakened state to reduce their pathogenicity. 
However, this resulted in many potential side effects including mutation into the 
virulent strain giving the patient the disease. A well-known example currently in use 
in New Zealand is the MMR II® vaccine,13 used to vaccinate against measles, mumps 
and rubella, containing live attenuated strains of the three viruses. Other main types 
of vaccine protocols use inactivated (killed), toxoid, subunit, and conjugate vaccines 
(Table 1.2).3 
 
Vaccine Type Composition Examples 
Attenuated (Live) Complete bacteria or viruses that have 
been weakened to reduce pathogenicity. 
Yellow fever, Measles, 
Rubella, Mumps, Typhoid 
Inactivated (Killed) Killed bacteria or inactivated viruses. 
Non-pathogenic. 
Influenza, Cholera, Polio, 
Hepatitis A virus (HAV) 
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Toxoid Contain inactivated toxic compounds 
that cause illness rather than complete 
organisms. Usually denatured proteins. 
Tetanus, Diphtheria, 
Pertussis 
Subunit/Component Purified components of bacteria or 
viruses. Non-pathogenic 
Hepatitis B virus (HBV), 
Human papilloma virus 
(HPV) 
Conjugate Poorly immunogenic compounds (e.g. 
bacteria polysaccharide outer coats) are 
linked with toxins to train immune 
system to recognize polysaccharide 
Haemophilus influenza 
type B 
Table 1.2: Vaccine types used in active immunization. Adapted from Immunology: A Short Course, Pg 
296. 
Increased safety concerns and introduction of new regulatory conditions that require 
a decrease in reactogenicity (adverse reactions or side effects) have resulted in a shift 
from the poorly-defined, although well-established, live attenuated vaccines to more 
defined ones wherever possible. Although the successful applications of vaccinations 
in the treatment and prevention of various lethal infections and non-infectious 
diseases have been demonstrated, the lack of vaccines for robust pathogens such as 
hepatitis C virus (HCV), respiratory syncytial virus (RSV), human immune deficiency 
virus (HIV), and XDR-TB, along with the issues that more defined or specific 
composition vaccines show significantly lower immunogenicity, requires further 
exploration.14 Scientifically this has come in the form of research into co-
administration of compounds that increase the potency or immunogenicity of the 
pure antigen within the vaccine. These additives are known as vaccine adjuvants. 
1.3. Adjuvants 
Adjuvants are defined as compounds that can increase and/or modulate the intrinsic 
immunogenicity of an antigen, being completely foreign to the body with minimal 
toxicity or lasting immune effects of their own.15 Although this work largely deals with 
discrete adjuvants, anything that increases the magnitude or quality of an adaptive 
immune response can be said to be an adjuvant. Therefore, formulation techniques 
etc. can also be said to have adjuvant effects. The term adjuvant is derived from the 
Latin word adjuvare: meaning to help or enhance16 and are employed for several 
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reasons:17 (I) to enhance the immunogenicity of highly purified or recombinant 
antigens; (II) to reduce the amount of antigen required and/or the number of 
immunizations; (III) to improve the efficacy in immune-compromised individuals, new-
borns, or the elderly; (IV) and/or as antigen delivery systems to improve uptake by 
APCs. The concept of adjuvants can be traced back to the early 1920s when Ramon 
observed that injection of the diphtheria toxoid along with unrelated substances, in 
horses, lead to an abscess at the injection site and resulted in higher specific antibody 
titers.18-19 In 1926, Genny et al.20 exemplified the use of aluminum salts as adjuvants 
for the diphtheria toxin. They found that on addition of the diphtheria toxin to 
potassium alum (KAl(SO4)2·12H2O) a precipitate formed and, if sufficient potassium 
alum was used, the filtrate no longer contained the toxin.21 The precipitated 
diphtheria toxin was found to have a higher antigenic response compared to the fluid 
toxoid. The results from a 1942 biological study in children are summarized in Table 
1.3 and clearly demonstrate the effectiveness of the adjuvant.22  
 
Immunization Procedure 4 months after first injection 3 Years after first injection 
(20 Lf toxoid per dose) Percentage of children showing detectible antitoxin (0.01 U/mL) 
Fluid, one dose 8 4 
Fluid, two doses 29 19 
Fluid, three doses 67 56 
Alum ppt., one dose 56 26 
Alum ppt., two dose 96 86 
Table 1.3: Comparison of Fluid and Alum-ppt. Diphtheria toxoid. Adapted from Volk VK; Bunney WE, 
Am J Public Health 1942, 32, 690-699. 
It is postulated that alum adjuvants work by causing formation of antigen depots at 
the site of injection by trapping the soluble antigen in the alum gel. This results in a 
slow and sustained release of the antigen providing an extended interaction with the 
immune system, thereby, promoting antigen phagocytosis by APCs such as DCs, 
macrophages and B lymphocytes, which process the antigen and present it to other 
components of the immune system via MHC II molecules.23 
 
A well-known and potent adjuvant is Freund’s complete adjuvant (CFA). Developed by 
Freund in 1936, it is an emulsion of water and mineral oil containing heat killed 
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Mycobacteria.24 The adjuvant elicits a strong immune response, with the activity 
credited to molecules within the cell wall of Mycobacteria. However, it causes severe 
local reactions at the site of administration and is considered too toxic for human use. 
In 1974 Muramyldipeptide (MDP) was found to be one of the Mycobacterial cell wall 
components responsible for the adjuvant activity.25 In some countries, including New 
Zealand, CFA is allowed for use in experimental animal vaccinations under strict 
guidelines.26 Freund’s incomplete adjuvant (IFC) lacks the Mycobacteria component 
making it significantly less toxic, and has been used in many human vaccine 
formulations.27 
 
Nowadays vast arrays of adjuvants possessing remarkable chemo-diversity are known. 
These range from surfactants, mineral salts, liposomes and emulsions to compounds 
intrinsically recognized by the immune system such as peptidoglycans, microbial 
extracts, toxins, lipids, peptides, hormones, cytokines and receptor agonists based on 
small molecules (Table 1.4).28 Some of the more important adjuvants from Table 1.4 
have their structures shown in Figure 1.6. Recently, adjuvants have been divided into 
two classes based on their primary mode of action: Immunopotentiators and delivery 
systems. Immunopotentiators boost the immune response of the innate immune 
system by activating various classes of PRRs, including toll-like receptors (TLRs). 
Whereas adjuvants that increase the uptake of the antigen by APCs are termed 
delivery systems (alum is an example of this class). 
 
Adjuvant class Description Example 
Delivery Systems The Adjuvant promotes antigen 
uptake by APCs 
Alum adjuvants (mineral salts), 
calcium phosphate, liposomes, 
virosomes, emulsions, virus-like 
particles (VLPs), etc. 
Immunopotentiators The adjuvant boosts the immune 
response of the innate immune 
system by activating PRRs 
Muramyl dipeptide (MDP), 
Monophosphoryl lipid A (MPL), 
oligonucleotides, chemokines 
and cytokines 





Biodegradable and biocompatible 
microspheres incorporating antigens 





Complex carbohydrates of natural 
origin activating both humoral and 
cellular immune responses 
Gamma-inulin, glucans, xylans, 
acemannan, etc. 
Cytokines A full-fledged adjuvant class eliciting 
cellular immune response through 
different mechanisms 
IFN-, IL-1, IL-6, IL-12, and GM-
CSF 
Bacterial Products Cell wall products or their synthetic 
derivatives targeting mostly toll like 
receptors (TLRs) a subset of PRRs 
Lipopolysaccharide (LPS), 
peptidoglycan products, 
trehalose dimycolate (TDM), 
etc. 
Table 1.4: Main adjuvant classes with representative examples. Adapted from Banday, A. H.; Jeelani, 
S.; Hruby, V. J., Immunopharmacol. Immunotoxicol. 2015, 37 (1), 1-11. 
 
Figure 1.6:  Structures of trehalose dimycolate (TDM), Muramyl dipeptide (MDP), and Monophosphoryl 
lipid A (MPL). 
The development of new adjuvants for human vaccines has become an expanding 
field of research in the last 40 years with the goal of generating more immunogenic 
vaccines capable of inducing protective and long-lasting immunity in humans. 
However, despite the vast array of known adjuvants toxicity remains an issue and as 
of writing this thesis, very few are licensed for human use, with most containing the 
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long known aluminum hydroxides, phosphates, or sulphates along with oil in water 
emulsions such as IFA. (Table 1.5).28 
 
Adjuvant Name  Class Indications 
Alum Mineral Salts General use for vaccines against 
various diseases 
MF59 Oil-in-water emulsion Influenza (Fluad) and pandemic 
flu29 
AS03 Oil-in-water emulsion and Tocopherol Pandemic flu30 
AS04 Manophosphoryl lipid A and alum Hepatitis B virus (HBV) and 
human papilloma virus (HPV)31 
Virosomes Liposomes Hepatitis A virus (HAV) and flu 
Pam3Cys Lipopeptide and TLR-2 agonist Lyme, cancer and HPV32 
Table 1.5: The limited number of adjuvants licensed for human use, their adjuvant class and 
representative examples of vaccines that contain them. Adapted from Banday, A. H.; Jeelani, S.; Hruby, 
V. J., Immunopharmacol. Immunotoxicol. 2015, 37 (1), 1-11. 
1.4. Cancer Immunotherapy 
It is well established that immunological surveillance is an important method by which 
cancer is controlled in healthy people. As such, cancer immunotherapy has emerged 
as an exciting new field for the treatment and prevention of malignancies, a dream 
that, within the last decade, has advanced to a clinical reality. The advantage is that 
the immune system has the greatest potential for the specific destruction of tumours 
with no toxicity to normal tissue, whilst also providing long-term memory, preventing 
cancer resurgence.33 Despite various clinical failures, the area of cancer 
immunotherapy has been rejuvenated with the recent approval of preventative 
cancer vaccines Gardasil and Cervarix by the US FDA in December 2010, and October 
2009 respectively.28, 34-36 The aim of cancer immunotherapy is to exploit the power of 
the host’s immune system to destroy the malignancy. This requires training of the 
immune system to recognize the hostile cancer cells, which emit chemical signals to 
evade the immune system. An immunotherapeutic strategy that has recently received 
significant media attention and has shown remarkable benefit in the treatment of 
tumours of various histological origins is known as immune checkpoint blockade. 
Immune checkpoint blockade strategies increase antitumuor immunity by blocking 
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tumour-produced down-regulators of immunity, such as cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand, programmed cell 
death ligand 1 (PD-L1).37 Within this area Pembrolizumab (trade name Keytruda), 
Ipilimumab (Yervoy), and Avelumab (Bavencio) have recently received approval by the 
FDA for human use (2014, 2011, and 2017 respectively). 
1.4.1. Anti-cancer immune response 
An effective immune response against tumour cells is a culmination of two key events. 
Firstly, APCs must recognise and process tumour associated antigens (TAAs), 
presenting them via MHC 1 receptors on their cell surface. Subsequent interaction 
with the TCRs on the surface of naïve T-lymphocytes provides targeting information, 
priming the T cell to recognise cancerous cells bearing the presented TAA. Secondly, a 
chemical “danger signal” is released by the APC to the local environment, triggering 
the recruitment, differentiation, and proliferation of trained CD8+ T lymphocytes. The 
result is a potent immune response against cells bearing the TAA protogenic sequence 
(Figure 1.7). 
 
Figure 1.7: Training of naïve T cells by APCs towards specific antigenic peptide sequences (1) uptake of 
TAAs by APCs and presentation to a naïve T cells via MHC I molecules. 
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Unaided targeting of cancer cells by the immune system is complicated, primarily by 
the partial recognition of cancer cells by APCs and to a lesser extent the production of 
extracellular messages by cancerous cells designed to suppress the effect of B- and 
cytotoxic T-cells. These messages suppress the “Danger Signal” required to activate 
the adaptive immune system, allowing the tumour to grow unmolested.  
1.4.2. Current Anti-cancer vaccines 
The development of vaccines for cancer immunotherapy began with attenuated 
whole tumour cells derived from a patient and progressed to sub-unit vaccines, which 
incorporate only a component of the tumour.38-39 More recent classes involve discrete 
TAAs, DC components, DNA, and/or a vector. Most approved vaccines, or those 
undergoing clinical trials are sub-unit vaccines (Table 1.6).28 
 
Type Of cancer Vaccine Nature/composition Clinical-status 
Whole-cell tumour 
vaccine 
Attenuated whole cancer cells derived 
from a patient 
Phase I/II (in progress)40-41 
Antigen based vaccine 
Sub-unit vaccine composed of 
characterized antigens/epitopes 
Phase I/II (in progress)42 
Dendritic-cell vaccines 
Sub-unit vaccine composed of 
autologous immune-cells that have 
been converted to DCs 
Mostly in Phase I/II 
Speuleucel-T FDA approved43 
DNA-vaccines 
Sub-unit vaccine composed of vectors 
transfected with bits of DNA 
Phase I44 
Virus-like particle (VLP) 
based vaccine 
Sub-unit vaccine composed of VLPs 
derived from various HPV types 
Cervarix and Gardasil already 
FDA approved34-36 
Table 1.6: Types of cancer vaccines and their clinical outcomes. Adapted from Banday, A. H.; Jeelani, 
S.; Hruby, V. J., Immunopharmacol. Immunotoxicol. 2015, 37 (1), 1-11. 
In order to properly activate APCs towards the priming of CD4+ and CD8+ T cells, 
vaccines usually incorporate an adjuvant. Many cancer immunotherapy vaccines owe 
their success to this incorporation. Typically these adjuvants serve to enhance or 
otherwise provide an artificial “danger signal” towards the antigenic component of 
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the vaccine. This results in a significantly stronger immune response when compared 
to vaccines containing only the antigenic compound. 
1.4.3. Cancer immunotherapy vaccine adjuvants 
Adjuvants used in cancer vaccines stimulate the immune system to produce a 
heightened response to tumour cells. These adjuvants may include synthetic small 
molecules, natural product derivatives, biological products, and/or non-biological 
substances such as cytokines.45 Many of these adjuvants activate cells of both the 
innate and adaptive immune systems, namely stimulating APCs to effectively process 
and present TAAs to T-cells. 
 
Although a number of adjuvants have been tested for their therapeutic potential 
against cancer only a handful of these are currently approved for human use.28 Two 
of these are 3-O-desacyl-4’-MPL, approved by the US FDA for use in the preventive 
cancer vaccine Cervarix46 and a VLP type adjuvant used in Gardasil47-48 and approved 
by the US FDA for use against HPV types 6, 11, 16, and 18. 
1.5. Cerebrosides 
Kirin Brewery, in Japan isolated a family of glycolipid natural products from a marine 
sponge Agelas mauritianus as part of a research programme in the 1990’s. These 
natural products displayed some interesting bioactivity and sparked current interest 
in glycolipid-based adjuvants. 
1.5.1. Structure and Origin 
Cerebrosides are a family of glycosphingolipids and important components in a wide 
range of tissues and organs in biological systems.49 From a chemical standpoint, 
cerebrosides are composed of a hexose (sugar residue) and a ceramide moiety. The 
ceramide moiety is usually comprised of a long chain aminoalcohol (called a 
‘sphingosine base’) and an amide-linked long-chain fatty acid (Figure 1.8).50-51 Both 
the sphingosine and long-chain fatty amide can vary in their length, saturation, 
hydroxylation and branching. 




Figure 1.8: General structure of cerebrosides. Hexose/sugar residue in pink, aminoalcohol in black and 
amide-linked long-chain fatty acid in red. 
The unrefined structure of the first set of natural cerebrosides was proposed by Carter 
et al. in 1950,52 having previously been isolated from brain tissue by Thudichum in 
early 1874.53 Cerebrosides have been proven to provide structural support and 
texture determinants to cell membranes and/or serve as mediators of important 
biological events such as cell agglutination, intracellular communication and cell 
development, likely through protein binding.54 Cerebrosides display a wide range of 
biological functions that can likely be credited to their amphipathic nature.55 
Importantly it has been shown that cerebrosides in cellular membranes play an 
important role as cell surface antigens and receptors.56-58  
1.5.2. Cerebrosides: Initial synthesis and anti-cancer potential 
The most well studied cerebrosides are the glucopyranosyl- and galatopyranosyl-
ceramides. These contain a single glucose or galactose residue, respectively, bonded 
through the anomeric position to the ceramide moiety. A number of 
glycosphingolipids isolated from the marine sponge Agelas mauritianus in 1993 have 
been found to possess considerable anti-tumour activity.59-60 The isolated 
glycosphingolipids include agelasphin-7a (3),61 agelasphin-9a (4), agelasphin-9b (5), 
agelasphin-11 (6), agelasphin-13 (7), agelasphin-10 (8), and agelasphin-12 (9) (Figure 
1.9).49 In 1993 Akimoto et al.62 reported the total synthesis of agelasphin-9b (5) to 
establish its absolute stereochemistry (Scheme 1.1). 




Figure 1.9: Structure of glycosphingolipids isolated from marine sponge Agelas mauritianus. Adapted 
from Tan, R. X.; Chen, J. H., Nat. Prod. Rep. 2003, 20 (5), 509-534. 
The synthesis of 5 (Scheme 1.1) began with a Wittig reaction between 10 and 11 to 
give 12 upon hydrolysis of the formyl ester. Activation of the hydroxyl group as its 
mesylate followed by hydrogenolysis of the benzyl ethers and reduction of the alkene 
groups, yielded triol 13. Substitution of the mesylate with sodium azide occurred via 
a displacement resulting in inversion of stereochemistry. Orthogonal protection of 
primary hydroxyl with trityl and secondary hydroxyls as benzoates gave fully protected 
sphingosine 14. Removal of the trityl protection and reduction of the azide gave 15 
allowing for coupling of the long-chain fatty acid 16. Acyl substitution of the para-
nitrophenolate (PNP) ester gave the amide linked product 17. Coupling with protected 
galactosyl residue 22 gave a separable mixture of α and β glycosides which with 
complete deprotection of the benzyl ether and ester groups gave the natural product 
agelasphin-9b (5). Structural analysis assigned the complete stereochemistry; 2S 3S, 
4R, 2’R. 
 
A biological study investigating the anti-tumour activity of α- and β-
monoglycosylceramides as well as four diastereomers of 5 conducted by Motoki et al. 
identified that the diastereomer with the 2S,4R absolute configuration possessed the 
strongest anti-tumour activity.63 For a more in-depth look at the structural-activity 
relationships (SARs) of these bioactive cerebrosides, eight more analogues 2, 25-31 
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were synthesized by various groups (Figure 1.10),49 all utilizing the highly potent 
bioactive agelasphin-9b (5) as the lead structure. 
 
Scheme 1.1: Total synthesis of Agelasphin-9b (5) reported by Akimoto et al.62 Reagents and conditions: 
(i) n-BuLi, THF, rt; (ii) MsCl-py, rt; (iii) H2, Pd-black, THF, rt; (iv) NaN3-DMF, 100 °C; (v) TrCl, py, 50 °C; (vi) 
BzCl, 4-DMAP, py, rt; (vii) TsOH, CH2Cl2, MeOH, rt; (viii) H2, Pd-black, THF, rt; (ix) THF, rt; (x) SnCl2, AgCIO4, 
4 Ȧ molecular sieves, THF; (xi) H2, Pd-black, AcOEt, rt; (xii) NaOMe, MeOH, rt. 
 
Figure 1.10: Compounds 25 through 31, importantly is α-GalCer 2, highlighted again in pink. 
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Importantly, a deoxy derivative with slightly different acyl chains form the lead 
agelasphin-9b (5), stood out as a plausible candidate worthy of clinical trials.64-67 This 
candidate, α-galactosylceramide (2), became known under the code KRN-7000 and 
later as α-GalCer. 
1.6. The Clinical Candidate: α-GalCer/KRN-7000 
In 1997, Taniguchi et al. showed KRN-7000 (α-GalCer, 2) was a ligand of the CD1d 
protein, a glycolipid-presenting protein found on the surface of antigen presenting 
cells.68-69 The CD1 family of antigen presenting glycoproteins mediates the response 
of T-lymphocytes through the presentation of self and foreign lipids, glycolipids, 
lipopeptides, or amphipathic small molecules to TCRs on the surface of T cells.70-72 
Modulation of the immune system through presentation of endogenous and 
exogenous lipid antigens to TCRs by APCs, via CD1 molecules is reminiscent of classical 
peptide antigen presentation by MHC I and MHC II molecules.73 
1.6.1. CD1d protein and NKT cell activation 
Recently it has been shown that a minor subset of T-lymphocytes (≈0.1% of peripheral 
T lymphocytes) known as natural killer T (NKT) cells play an important role in 
regulating the progress of several diseases including cancer,74-76 malaria,77 hepatitis 
B,78 and suppression of autoimmune diseases.79 NKT cells share properties of both T 
cells (possessing TCRs) and natural killer cells (containing the common NK marker, 
NKR-P1) and can be divided into two major populations; CD1d-restricted NKT cells and 
CD1d independent NKT cells. Instead of responding to antigens presented by classical 
MHC-encoded antigen-presenting molecules, CD1d-restricted NKT cells recognize 
those presented by CD1 (including CD1d) molecules. When activated by the CD1d 
molecules on the surface of APCs, the NKT cell secretes large quantities of both pro-
inflammatory (TH1) and anti-inflammatory (TH2) cytokines.80 TH1 type cytokines such 
as IFN-γ mediate protective immune functions such as tumour rejection, whereas TH2 
type cytokines like interleukin (IL)-4 mediate regulatory immune functions to 
ameliorate autoimmune diseases. Consequently, the large release of cytokines 
induces an activation cascade of various downstream components of the immune 
system, including the key immune effector cells; DCs, NK cells, B cells, CD4+ T cells, and 
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CD8+ T cells.81-84 The best-known subset of CD1d-restricted NKT cells express an 
invariant T cell receptor α (TCR-α) chain such as mouse Vα14-Jα18 or human Vα24-
Jα26.85 These are referred to as type I or invariant NKT cells (iNKT cells) and are 
significantly better studied than their CD1d-independent counterparts. This report will 
focus on CD1d-restricted invariant NKT cells which from here on will be referred to 
simply as iNKT cells. 
 
In comparison to Figure 1.7, Figure 1.11 shows how uptake of α-GalCer by an activated 
DC/APC and subsequent presentation of α-GalCer via the CD1d molecule on the 
surface of the DC creates a CD1d/glycolipid complex that is recognized by the TCR on 
the surface of the iNKT cell. This promotes the iNKT cell to release stimulating 
cytokines such as IFN-γ, one of the key cytokines involved in DC maturation (the other 
being TNF-α). These cytokines in turn upregulate maturation of naïve T cells by 
promoting further cytokine release by the DC leading to increased proliferation of 
CD8+ T cells resulting in a stronger immune response against the tumour. Therefore, 
an iNKT cell essentially acts as a “cellular” adjuvant recruited by α-GalCer and inducing 
an artificial “danger signal” towards the co-presented TAA. 
Figure 1.11: Shows (1) presentation of α-GalCer by CD1d on an APC to the TCR of a iNKT cell; (2) INF-
γ cytokine release by iNKT cell stimulates DC to produce IL-12, CD8+ maturation stimulating cytokine; 
(3) Naïve T cell stimulation and maturation into CD8+ T cell; (4) large quantities of CD8+ T cells 
produced; (5) increased immune response against tumour. The key danger signal referenced in this 
report is the IL-12 cytokine signal released by the APC as a response to the IFN-γ released by the iNKT 
cell. Graphic produced by Nicolas Shields. 
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Glycosylceramides are presented by CD1d in a very specific manner, with the fatty acyl 
and sphingosine tails extending into the A’ and F’ pockets of the CD1d protein 
respectively. An extensive hydrogen-bonding network holds the sugar head group in 
a specific orientation for presentation to the TCR.86-87 Interestingly, glycosylceramides 
with the α anomeric configuration are mainly present in cancer cells,88 foetal89 and 
intestinal90 cell lines, having hardly been detected in normal mammalian tissue.91 This 
limited distribution should prove valuable for designing targeted delivery of anti-
cancer drugs. 
1.6.2. Biological activity of α-GalCer 
The discovery of α-GalCer/KRN-7000 provided the first evidence that glycolipids, like 
their protein counterparts, can be presented by protein complexes on the surface of 
APCs and recognized by T cells, thereby invoking an immune response. This sparked a 
“gold-rush”, with groups seeking to understand the fundamental biology and establish 
α-GalCer’s potential as an immunotheraputic agent. As a result it was observed that 
changes to the glycolipid structure can modify the immune response; either in favour 
of a pro-inflammatory (TH1-type) or an anti-inflammatory (TH2-type) response. Due to 
the high cross-reactivity of human and mouse iNKT cells and the essentially identical 
binding grooves of human and mouse CD1d/α-GalCer complex (as identified by X-ray 
structures),92 murine (mouse) models have frequently been used to determine the 
effectiveness of α-GalCer and its derivatives in activating both DCs and iNKT cells.  
 
The bioactivity discussed in this section was originally published by Silk and co-
workers93 and will demonstrate; (I) the adjuvant activity of α-GalCer in enhancing the 
priming and boosting of CD8+ T cells to coadministered antigenic peptide or protein 
fragments; and (II) coadministration of α-GalCer with a TAAs (in the form of tumour 
proteins) can provide therapeutic anti-tumour activity. Other interesting observations 
reported by the authors include (III) administration of α-GalCer and a tumour protein 
can restimulate CD8+ T cell responses in immune animals; and (IV) α-GalCer’s ability 
to affect iNKT cell stimulation after oral co-administration with a tumour protein. 
However, these findings will not be covered in further detail. 
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A CD8+ T cell immune response is triggered if a foreign antigenic peptide is detected 
and processed by an APC, with the subsequent “cross-presentation” of MHC I binding 
to naïve antigen-specific CD8+ T cells triggering the response. It has been reported that 
the CD8+ T cell response can be enhanced by co-administration of iNKT cell ligands 
such as α-GalCer.93 It has been postulated that the adjuvant effect of iNKT cell 
stimulation may arise from stimulation of DCs increasing their ability to uptake and 
process peptide antigens. Silk et al. demonstrated the adjuvant activity (iNKT cell 
stimulation) of α-GalCer on peptide vaccines (Figure 1.12).93  
 
The study involved the coadministration of α-GalCer with a protein antigen, either 
OVA257-264 or NY-ESO-1157-165 (a known tumour antigen), and the response was 
assessed 7 days later by detecting the presence of MHC I/peptide tetramers a proxy 
for the presence of either OVA257-264 specific (Figure 1.12 A) or NY-ESO-1157-165 specific 
(Figure 1.12 C) CD8+ T cells. The authors found weak T cell responses could not easily 
be detected with MHC I/peptide tetramers, therefore after priming, the response in 
mice was subsequently boosted with a vaccinia virus encoding the antigen of interest. 
The peptide-primed responses where therefore restimulated with Vac-OVA (Figure 
1.12 B) or Vac-NY-ESO-1 (Figure 1.12 D) respectively and re-evaluated 7 days later. 
The experiment  demonstrated that α-GalCer treatment could enhance peptide 
priming. While peptide-specific CD8+ T cells were detected ex vivo in mice injected 
with the peptide antigen in a vehicle, the response was significantly higher in mice 
pre-primed in the presence of α-GalCer. This result suggested the adjuvant activity of 
α-GalCer via iNKT cell stimulation can be independent of antigen processing and is 
more likely caused through stimulation of DCs increasing their immunostimulatory 
capacity. 




Figure 1.12. CD8+ T cell response to peptide antigens can be enhanced by iNKT cell stimulation with α-
GalCer. (A) OVA257-264 peptide (100 μg/mouse) was injected i.v. together with either α-GalCer or a 
vehicle, and induction of specific CD8+ T cell response was assessed in blood 7 days later. (B) One week 
after peptide priming, OVA257-264-specific CD8+ T cell responses were restimulated in vivo by i.v. injection 
of vac-OVA (5 x 105 PFU/mouse). Responses induced 7 days after restimulation are presented together 
with those observed in control animals that received vaccinia alone and those of a naïve group. (C) 
Specific CD8+ T cell responses were monitored in A2Kb-transgenic mice after i.p. injection of NY-ESO-
1157-165 (v) peptide together with either α-GalCer or a vehicle. (D) The induced responses shown in C were 
restimulated by i.v. injection of vacc-NY-ESO-1 (1 x 106 PFU/mouse) 7 days later. Figure from Silk et al., 
J. Clin. Invest. 2004, 114 (12), 1800-1811 
1.6.3. α-GalCer Clinical trials 
To date a number of Phase I and Phase II clinical trials using α-GalCer (2) have been 
reported and involved patients with tumours of various histological origins.94-98 In all 
trials the treatment was well tolerated, demonstrating the lack of acute toxicity of α-
GalCer. Unfortunately, the clinical trials have yet to demonstrate an approach with 
significant clinical benefit. It is probable the potential anti-tumour activity of α-GalCer 
in activating iNKT cells has been overestimated due to the dramatic effect observed 
in mice. This can be rationalized by the high frequency of iNKT cells in the murine liver 
and the extensive use of models with tumour metastases to that organ.85 Such activity 
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cannot be expected from humans as the frequency of iNKT cells is much lower, a fact 
highlighted in the clinical trials as patients with higher pre-treatment iNKT cell 
numbers displayed the greatest response. In addition, murine tumour models fail to 
consider the long window of silent tumour development and associated changes to 
the immune system that often occur during the natural progression of malignancy 
prior to the tumour becoming detectable. As such, α-GalCer may be a safe and 
effective addition to current regimens of cancer treatment. However, any clinical 
benefits to such regimes remain to be determined. 
1.6.4. Previous syntheses of α-GalCer 
Since its reported discovery in the 1990’s many researchers have attempted to 
synthesize α-GalCer in an effort to study its interesting biology and explore structural 
activity relationships (SARs). The hope was to unlock a potential new reservoir of 
immunologic adjuvants. Early on it was identified the difficulty in any potential 
synthesis would be generating the required 2S, 3S, 4R absolute configuration of the 
sphingosine moiety. Figure 1.13 shows retrosynthetically how α-GalCer can be 
constructed from three components, an appropriately protected galactose residue 
(blue), a fatty acid with suitable leaving group (red), and sphingosine residue with the 
desired 2S, 3S, 4R stereochemistry. 
 
Figure 1.13: Retrosynthetic analysis of α-GalCer (2). 
Takikawa et al.99 described a synthesis of α-GalCer (2) (Scheme 1.2) in which the 
stereochemistry of the C18-sphingosine 32 was generated from the chiral precursor 
(S)-serine 33 and 1-pentadecyne 34 by means of Garner’s general sphingosine 
synthesis.100 Successive orthogonal protection of the hydroxyl and amino 
functionalities as tert-butyldimethylsilyl ether and tosyl esters, respectively, gave the 
authors protected sphingosine 35. Epoxidation of 35 with DMDO afforded 36 as the 
major product in a separable mixture with its epimer (ratio = 83:17) and was isolated 
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in 69% yield. Reductive opening of epoxide 36 with diisobutylaluminum hydride 
(DIBAL) gave alcohol 37 regioselectively. Deprotection of the N-Tosyl group by 
treatment with sodium naphthalenide provided amino alcohol 38, with subsequent 
selective acetylation of the amino group by p-nitrophenyl hexacosanoate yielding 
amide 39. Protecting group manipulation and selective removal of the primary O-TBS 
group gave 40 which was used in the subsequent glycosylation with tetra-O-benzyl-α-
D-galactopyranosyl fluoride 22 under Mukaiyama’s conditions.101 Removal of the TBS 
groups from protected α-GalCer 41 and subsequent cleavage of the benzyl ethers by 
hydrogenolysis afforded α-GalCer 2 in a total of 9 steps with 8.7% overall yield. 
 
Scheme 1.2: Synthesis of α-GalCer reported by Takikawa et al. Reagents and conditions: (i) 
TBSOTf, 2,6-lutidine, DCM; (ii) TsCl, py; (iii) DMDO, acetone, 4°C; (iv) DIBAL, toluene; (v) Na, 
naphthalene, DME; (vi) p-nitrophenyl hexacosanoate, py; (vii) TBSOTf, 2,6-lutidine, DCM; (viii) 
CF3CO2H, H2O, THF; (ix) 22, SnCl2, AgClO4, MS 4Ȧ, THF; (x) TBAF, THF; (xi) 20% Pd(OH)2-C, H2, CHCl3, 
EtOH. 
Further advances have been made over the last decade in the synthesis of α-GalCer, 
especially in light of the commercial bio-synthesis of (2S,3S,4R)-2-amino-1,3,4-
octadecanetriol. However, these will be discussed in subsequent chapters. 
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1.7. The Limitations of α-GalCer 
As discussed above α-GalCer has been involved in several clinical trials with limited 
success.94-98 These have been reviewed in detail by Motohashi and Nakayama. 102 The 
first potential explanation for this lack of clinical efficacy is that α-GalCer induces iNKT 
cell anergy. For conventional T cells, anergy is characterized as impaired proliferation 
and cytokine production following chronic TCR signalling or signalling in the absence 
of co-stimulation.103 This iNKT cell impairment means iNKT cells are unable to respond 
to restimulation by α-GalCer for over a month after the initial treatment104 and 
renders multiple dose treatment regimens ineffective. Although anergy of human 
iNKT cells has not been directly addressed, some observations of reduced IFN-γ 
response in the peripheral blood over repeated doses of α-GalCer have been 
reported,105-106 and such anergy is well documented in mice studies.107-111 A second 
potential explanation, although a controversial one, is that repeated doses of α-GalCer 
skew the cytokine profile towards a TH2 response.112 Such a response would not be 
beneficial in a tumour setting, as α-GalCer requires IFN-γ (a TH1 associated cytokine) 
to induce tumour protection. A more accepted hypothesis is α-GalCer fails to induce 
a biased cytokine response, favouring neither a pro- nor anti-inflammatory cytokine 
profile which is detrimental as it causes interference in downstream cascades towards 
a particular disease state. A final possible explanation for the low efficacy in humans 
is the production of anti-bodies against α-linked sugars, as such sugars don’t naturally 
occur, whereas mice lack such anti-bodies.113 Such problems have likely contributed 
to the clinical failure of α-GalCer and its related chemical analogues.  
 
In research aimed at overcoming these issues Chi-Huey Wong and co-workers 
synthesized a number of N-acyl analogues of 2, including the biologically interesting 
fluorinated phenyl derivative 7DW8-5.114-116 They found that by introducing an 
aromatic substituent at appropriate positions along the fatty amide residue that they 
could pick up beneficial hydrophobic binding interactions within the A’ grove of the 
CD1d binding pocket thereby increasing the binding affinity of the adjuvant. This had 
two significant effects. Firstly the authors found that 7DW8-5 tended to localise within 
the draining lymph nodes of the mouse, due to the high proportion of CD1d expressive 
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APCs within this tissue. Whether or not a direct response to this they noted that 
7DW8-5 induced a weaker INF-γ cytokine response in sera of mice when compared 
with α-GalCer. However, despite this 7DW8-5 induced a stronger CD8+ T cell response 
against the co-administered antigenic peptide. The ability of 7DW8-5 to induce a 
stronger adjuvant effect despite decreased cytokine proliferation should prove 
beneficial in the context of iNKT cell anergy, though the authors did not speculate on 
this within the publication. Secondly, the authors reported that increased binding 
affinity for CD1d biased 7DW8-5’s cytokine profile towards a TH1 response, which is 
advantageous in the context of cancer treatment.  
1.8. α-GalCer glycopeptide vaccine constructs 
Despite its limited clinical success, research into therapeutic applications utilising α-
GalCer remains a hot topic. As α-GalCer is such a potent iNKT cell agonist it serves as 
a valuable model system for studying these applications within mice. It is hoped that 
lessons learned from these studies with α-GalCer can then be applied to different iNKT 
cell agonists that are equally efficacious in humans, be they analogues of α-GalCer or 
as yet undiscovered agonists. To this end Anderson et al. have exemplified a number 
of α-GalCer pro-drug strategies for use in self-adjuvanting vaccines for the treatment 
of tumour117-119 and viral infections.120  
 
While adjuvants are thought to be crucial in making cancer vaccines immunogenic 
enough to break through the immunological tolerance to tumour antigens,121 they are 
typically formulated into mixtures with the antigen. Self-adjuvanting vaccines are so 
termed as they contain both the adjuvant and antigen components within a single 
molecule and typically have an advantage over traditional formulations. Not only are 
they taken-up faster by APCs122 but it ensures that the APC activated by the adjuvant 
is the same as that exposed to the antigen.123 
 
The vaccine constructs of Anderson et al. aim to exploit this beneficial synergistic 
effect that is observed upon chemical conjugation of antigenic peptides and an iNKT 
cell agonist (adjuvant). The strategy owes its success to the fortuitous discovery of an 
acid-catalysed intra-molecular rearrangement of the fatty amide of 2 which affords an 
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in-active pro-adjuvant (pro-2) that undergoes the reverse migration, regenerating 2, 
within the biological environment (Figure 1.14). Pro-2 can then be utilized in classical 
pro-drug strategies by capping the nitrogen with a self-immolative linker, thus 
blocking the reverse-rearrangement prior to linker cleavage. 
 
Figure 1.14: Acid catalysed intra-molecular migration of the C26 acyl chain gives pro-adjuvant (Pro-2) 
which undergoes the reverse migration regenerating 2 under biological conditions 
The power of this strategy is shown in Figure 1.15, where a tumour assay 
demonstrated the effectiveness of one such conjugate, CN152 as a therapeutic agent 
for the treatment of an aggressive mouse melanoma model, B16.OVA.124 The 
construct CN152 undergoes processing within the local environment to liberate the 
antigenic peptide (SIINFEKL) and α-GalCer (2). By generating an increased antigen 
specific CD8+ T cell response within the local environment it is hoped the amount of 
adjuvant required can therefore be limited, thereby avoiding some of the detrimental 
effects described above. Figure 1.15 compares injection of admixed unconjugated 
components (Classical formulation, OVA257 peptide and α-GalCer) with the chemically 
conjugated construct CN152 (self-adjuvanting formulation). Co-administration of 
adjuvant and antigen results in a slightly delayed onset of tumour growth. However, 
once begun, growth rates mimic the negative control (PBS). For the group treated with 
vaccine construct CN152 growth mimics the negative control for the first 5 days. 
However, 5 days after treatment, tumour growth halted, and a slight reduction in 
tumour size is observed as immune cell mediated killing of the tumour occurs. After 
another 8 days tumour growth resumes until the required termination of the subjects. 
Vaccine construct CN152 provides an almost 80% increase in the time required for the 
tumours to reach lethal size over the group that received co-administered 
unconjugated adjuvant and antigen.  





Figure 1.15: Conjugated peptide vaccines stimulate potent anti-tumour activity. A single dose (500 
pmol) of conjugate vaccine CN152 was administered intravenously five days after tumour challenge 
with B16.OVA melanoma cells (n=8 per group). Control groups received admixed peptide and α-GalCer. 
Mean tumour size per group ± SEM over time are shown. Data is representitive of two separate 
experiments. Adapted from Anderson et al. Chemical Science 2015, 6 (9), 5120-5127. Copyright 2018, 
with permission from The Royal Society of Chemistry. 
Despite ongoing work with α-GalCer and analogues thereof, there is considerable 
interest in finding novel iNKT cell agonists that achieve the desired bioactivity without 
the associated limitations. 
1.9. A New Alternative 
A significant milestone was achieved earlier this decade when O’Konek and co-
workers published the surprising bioactivity of a novel iNKT cell agonist, β-
mannosylceramide (β-ManCer, 1, Figure 1.16).125 Until this point it was a widely held 
CN152 
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belief that IFN-γ induction was a critical factor for generating anti-tumour 
immunity.126 However, the authors reported β-ManCer tumour protection was an IFN-
γ-independent mechanism, instead solely dependent on nitric oxide synthase (NOS) 
and TNF-α. Such a mechanism would indicate β-ManCer was the first, in a related but 
novel class of iNKT cell agonists that displays potent anti-tumour activity via a 
completely different mechanism to the IFN-γ-dependent α-GalCer, a prospect with 
potentially exciting clinical consequences. 
 
Figure 1.16: Structure of β-ManCer, 1. 
In the initial125 and subsequent127 work detailing β-ManCer, O’Konek and colleagues 
provide details on its biology which they believe gives β-ManCer a strong potential to 
succeed as an iNKT cell agonist in settings where α-GalCer has failed. Their key findings 
are summarised below. 
 
• β-ManCer provides tumour protection via a NOS and TNF-α mechanism instead of 
IFN-γ as utilized by α-GalCer. The authors demonstrated this by showing β-ManCer 
provided protection in Ifng-/- mice, with subsequent blockading of NOS completely 
reversing the protection. NOS can also be induced by TNF-α. The authors 
demonstrated that β-ManCer was indeed inducing NOS through TNF-α, as blockade 
of TNF-α by the soluble TNF-αR-Fc fusion protein completely inhibited any protection 
by β-ManCer, but had no effect on α-GalCer protection which is INF-γ dependent. 
• β-ManCer induces comparable tumour protection to α-GalCer. However, other 
markers of cell activation such as cytokine production and upregulation of activation 
markers are substantially lower for β-ManCer. This was the first proposed evidence 
that a strong cytokine response by iNKT cells is not required for inducing tumour 
protection. 
• β-ManCer does not induce significant skewing of the cytokine profile towards a TH2 
response. 
• β-ManCer is not a target for natural anti-α-linked sugar antibodies present in humans. 
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• β-ManCer in combination with α-GalCer induces synergistic anti-tumour activity. A 
study of the two antigens at sub-therapeutic doses resulted in a significant 79% 
reduction of the median number of tumour nodules (CT26 lung metastases study).125 
This synergy further supports the conclusion that both antigens use quite distinct 
mechanisms to protect against tumours. 
• Significantly, the authors reported a complete lack in long-term functional anergy 
induced by β-ManCer, giving it the potential to be repeatedly administered with the 
same therapeutic benefits. A probable explanation for this is due to the lack of 
cytokine production and proliferation as a result of the less intense signal β-ManCer 
provides to iNKT cells, thus there is less upregulation of the molecules responsible for 
causing anergy. 
These findings hint at the possibility of an iNKT cell agonist that may succeed in a 
setting where α-GalCer has ultimately failed. In the very least, the discovery of a class 
of IFN-γ-independent iNKT cell agonists is a fundamental step forward for the area, 
one with potentially exciting ramifications; the realization of a clinically viable cancer 
immunotherapy treatment.  
1.9.1. β-ManCer: A previous synthesis 
The first reported synthesis of β-ManCer was achieved by Berzofsky and co-workers128 
who utilized a stereospecific synthesis of the difficult 1,2-cis-β glycosidic bond first 
reported by Hodosi and Kováč.129-130  
 
Traditionally the synthesis of 1,2-trans-linked glycosides is relatively easy, while the 
highly stereoselective synthesis of their 1,2-cis-linked counterparts in good yield is  
much more difficult. Especially difficult is the synthesis of 1,2-cis-linked β-
mannosides,131 due in part to the orientation of the O-2 group preventing constructive 
neighbouring group participation and providing steric hindrance along with the 
anomeric effect which favours the formation of α-linked glycosides. The method 
reported by Hodosi and Kováč utilizes a 1,2-O-cis-stannylene acetalI of sugar donors 
as a powerful nucleophile capable of displacing, via an SN2 process, good leaving 
                                                      
I Reviewed in the context of carbohydrates 132. Grindley, T. B., Applications of tin-containing 
intermediates to carbohydrate chemistry. Adv. Carbohydr. Chem. Biochem. 1998, 53, 17-142. 
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groups, with selective glycosylation of the equatorial orientated oxygen of the 
stannylene acetal (Figure 1.17). 
 
Figure 1.17: General scheme for alkylation of 1,2-dibutyl stannylene acetals of mannose with formation 
of a 1,2-cis-β glycosidic bond. 
Berzofsky and co-workers128 convergent synthesis of β-ManCer (1) (Scheme 1.3) 
began from the corresponding azide 45, of the commercially available 
phytosphingosine 46.II Protection of the vicinal diols was achieved with 2,2-
dimethoxypropane and p-toluene sulfonic acid and gave 47 in 69% yield. Conversion 
of 47 to its corresponding triflate 48 with triflic anhydride and TEA (quant. yield) gave 
a substrate with a suitable leaving group for coupling to the sugar moiety. The 1,2-O-
stannylene acetal of mannose (49) conformationally “locks” the anomeric centre of 
the sugar in the β-orientation, ensuring nucleophilic attack on 48 with displacement 
of the triflate (SN2 reaction) gives the β-linked glycoside 49 as the major product. 
Subsequent deprotection of the isopropylidene group followed by reduction of the 
azide was achieved with Ce(OTf)3 and CH3NO2 followed by H2S and pyridine 
respectively, giving compound 50. Reaction of compound 50 and an appropriate acid 
chloride via Schmidt et al.’s method134 can provide β-ManCer derivatives in good yield. 
In this synthesis reaction of 50 with hexacosanoyl chloride gave 1 in 70% yield.  
                                                      
II Manufactured using a mutant strain of the yeast Pichia ciferii. 133. Lex, D. B.; Wildt, V. D., et al. 
Microbial strains producing sphingolipid bases. US Patient 5910425, June 8, 1999. 




Scheme 1.3: Initial synthesis of β-MacCer reported by Berzofsky et al. Reagents and conditions: (i) (a) 
NaN3, Tf2O, toluene, (b) 46, CuSO4·5H2O, MeOH/toluene; (ii) 2,2-dimethoxypropane, TsOH; (iii) Tf2O, 
Et3N, DCM; (iv) 48, CsF, DMSO, MS 4Ȧ; (v) Ce(OTf)3, DCM, CH3NO2; (vi) H2S, py, H2O; (vii) C25H51COOCl, 
THF-50% NaOAc in water (2:1.5). 
1.10. Research Objectives 
As discussed in the preceding sections of this work, cancer immunotherapy is 
emerging as a viable clinical alternative to traditional anti-tumour therapies. However, 
despite cancer vaccines having the potential to induce highly specific T cell responses 
towards TAAs, they have yet to fully realize this potential, with issues remaining 
around potency, lack of clinical efficacy,135-136 manufacturing and costs. In order to 
generate a sufficient anti-tumour response it’s critical two things happen; (I) 
immunogenic peptide fragments are acquired by APC’s and presented to T cells in the 
context of MHC molecules and (II) that these APC’s are in the correct activation 
state.137 Traditionally this has been achieved using adjuvants that target pattern-
recognition receptors on APC’s, such as Toll-like receptors (TLRs)138 or C-type lectin 
receptors.139 A less explored approach to activating APCs is to stimulate accessory cells 
in the local environment. As we have shown above iNKT cell agonists such as α-GalCer, 
β-ManCer, and their synthetic analogues can serve as powerful immune adjuvants 
when co-administered with antigenic compounds in animal models, an effect which is 
further enhanced upon chemical conjugation of antigen and adjuvant.117-119, 140-141 This 
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work aims to explore the synthesis, and complications thereof for the efficient 
production of β-ManCer. It is hoped that such a synthesis can allow for the generation 
of analogues of 1 which can provide insight into possible structural activity 
relationships and provide clues as to 1’s differing bioactivity from the prototypical 
glycolipid adjuvant, α-GalCer (2). Ultimately, this work aims to exemplify β-ManCer, 
or an analogue thereof, as a self-adjuvanting glycopeptide vaccine, which upon 
targeted activation within the biological environment will result in co-release of 
immunogenic TAA peptide fragments and adjuvant 1, thereby fulfilling case I and II 
above. The strategies for each of these objectives are discussed in detail in the 
relevant chapters of this thesis. 
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Chapter II: Approaches to        
β-mannosylphytosphingosines 
This chapter reports different approaches for the synthesis of 1,2-cis-β mannosides 
related to β-mannosylceramide (β-ManCer, 1). Firstly, it outlines, the formation of the 
glycosidic linkage between a protected mannoside donor and a protected 
phytosphingosine, a key step in the synthesis of 1. Details surrounding various 
glycosylation methodologies and the synthetic complications associated with these 
reactions are then discussed. Specifically, it focuses on a systematic study of several 
chemical methodologies involved in accessing 1,2-cis-β mannosides and, ultimately, 
their applicability in efficiently and discretely accessing 1. 
2.1. A Determining factor: The glycosidic linkage 
A key consideration in the synthesis of β-ManCer (1) is the construction of the 
glycosidic linkage between the mannopyranosyl residue and the ceramide moiety. 
Figure 2.1 shows a retrosynthetic analysis of 1 highlighting two key regions, the 1,2-
cis-β glycosidic linkage and the 2S, 3S, 4R relative configuration of substituents on the 
phytosphingosine moiety. 1 can be accessed from an appropriately protected 
mannosylphytosphingosine I and commercially available cerotic acid. Amine I should 
be accessible from the corresponding azide II via chemoselective reduction. This fully 
protected mannosyl phytosphingosine II can be formed via a standard glycosylation 
reaction between appropriately protected mannosyl donor III and phytosphingosine 
acceptor IV. These two components would be obtained through protecting group 
manipulation from their commercially available starting materials; D-mannose (51) 
and (2S,3S,4R)-2-amino-1,3,4-octadecanetriol (46). 




Figure 2.1: Retrosynthetic analysis of β-mannosylceramide (1). 
2.2. Glycosylation reactions 
Generally, formation of glycosidic bonds is achieved by a nucleophilic substitution 
reaction between a glycosyl donor (the electrophile) and a glycosyl acceptor (the 
nucleophile) in the presence of a promoter (normally a Lewis acid) (Figure 2.2). 
 
Figure 2.2: Generalised glycosylation reaction between a sugar donor and alcoholic acceptor. 
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Challenges that have to be overcome include the efficiency and regioselectivity of the 
reaction, and control of the anomeric stereochemistry of the newly created glycosidic 
linkage. Regioselectivity is normally achieved by careful use of protecting groups on 
the glycosyl acceptor ensuring that only the required (desired) hydroxyl group(s) 
react. The issue of control of anomeric stereochemistry is more complex. The type of 
anomeric linkage depends on the anomeric configuration (α or β) and the relative 
stereochemistry of the C-1 and C-2 substituents. This gives rise to four different 
linkage types available for the pyranosides of common aldose sugars and these are 
shown in Figure 2.3. 
 
Figure 2.3: The 4 glycosidic linkage types avaliable in pyranosides of common aldose sugars . 
Of the four, 1,2-trans linkages have been described as “relatively easy” as participating 
groups at the C-2 position of the donor can be employed to direct the acceptor to the 
opposite face.142-144 For example, the formation of a trans-α linkage can be achieved 
when the donor I has an axial hydroxyl group at C-2 protected as an ester (Figure 2.4 
A). On activation with a promoter, loss of the leaving group gives rise to oxocarbenium 
ion II which is then intercepted by the participating group to give the more stable 
acyloxonium ion III. The nucleophilic group of the acceptor is forced to attack the 
anomeric carbon of III from the less hindered α-face, in this case, giving the 1,2-trans-
α product IV. This linkage type is commonly found in α-D-mannosides and α-L-
rhamnopyranosides. 
 
The 1,2-trans-β relative stereochemistry is achieved in a similar fashion for sugar 
donors derived from D-glucose and D-galactose. Protection of the equatorial O-2 
position of the corresponding donors results in the formation of an acyloxonium ion 
III’ where the acceptor is directed to the β-face (Figure 2.4 B). 
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Figure 2.4: Formation of 1,2-trans-α (A) and 1,2-trans-β (B) linkage types by O-2 participation. 
1,2-cis-α linkages, relevant for α-D-gluco- and galacto-pyranosides, are accessible via 
assisted halide methodologies (Figure 2.5 A).145-147 In this case, non-participating 
groups in the C-2 position, such as benzyl ethers are essential. In contrast to the 
tiresome synthesis reported in the introduction of this work, Gervay-Hague has 
developed an updated and expedient synthesis of α-galactosylceramide (α-GalCer, 2) 
utilising glycosyl iodide donors.148 Treatment of galactosyl iodide 52 with tetra-n-
butylammonium iodide (TBAI) results in isomerisation to the less stable but more 
reactive β-galactosyl iodide 53. SN2 like displacement of the anomeric iodide by 
acceptor 54 gave β-galactoside 55. This was then converted to 2 in 4 steps. Gervay-
Hague and co-workers went on to publish an improved one-pot, three step synthesis 
of 2 utilising a trimethylsilyl glycosyl iodide donor (56) and an unprotected ceramide 
residue 57 (Figure 2.5 B).149 
 
Figure 2.5: Assisted halide method for accessing 1,2-cis-α glycosides of D-gluco- and galacto-
pyranosides. Two specific examples reported by Gervay-Hague for the Synthesis of α-GalCer (2). 
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The formation of 1,2-cis-β-mannosides and rhamnosides had proven difficult until the 
development of several new methods within the last 20 years. 136, 137, 150-154 Clearly, a 
participating group at position 2 of a D-mannopyranosyl donor on reaction with an 
acceptor, would give an α-mannoside. Unfortunately, the use of a non-participating 
protecting group(s), such as a benzyl ether would also favour formation of an α-
mannoside. This is due to steric hindrance by the O-2-alkyl group, and the anomeric 
effect resulting in preferential attack from the α-face. However, selectivity is often 
lower leading to a mixture of compounds with the 1,2-trans-α and 1,2-cis-β 
configurations (Figure 2.6), which often prove difficult to separate. In some cases the 
α:β ratios are high155 and exclusive formation of the α-glycoside has also been 
reported.156 
 
Figure 2.6: General formation for glycoside products of O-2 alkyl mannopyranoside donors. 
2.2.1. 1,2-cis-β Mannosides 
A viable direct method for the synthesis of 1,2-cis-linked β-mannosides has arguably 
been one of the biggest hurdles for the synthetic carbohydrate chemist.131 The 
unfortunate combination of steric (axial O-2) and stereoelectronic (anomeric) effects 
form a formidable barrier against the formation of β-mannosides by conventional 
glycosylation protocols. As such, β-mannosides were formed by indirect methods 
involving the reduction of 2-uloses,157 inversion at C-2 of β-glucosides,158 and radical 
inversion at C-1 of α-mannosides.159  
 
The turn of the 21st century saw a seminal paper by Daniel Kahne and co-workers160 
who reported an efficient protocol for the formation of glycosides from unreactive 
donors, including the first reported direct glycosylation of an amide nitrogen. The 
method involved the reaction of a glycosyl sulfoxide donor with an acceptor in the 
presence of trifluromethanesulfonic anhydride (Tf2O) and an acid scavenger at low 
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temperature. An example is shown in Figure 2.7, where sulfoxide 58 was converted 
into aminoglycoside 59 as a 5:1 mixture of α- and β-anomers. 
 
Figure 2.7: The first reported direct glycosylation of an amide nitrogen by Kahne and co-workers 
utilizing a glucosyl sulfoxide donor (58). Figure adapted from Kahne, D., et al., JOC. 1989, 111, 
6881. 
However, it was not until significantly later that Crich and co-workers150-153 realized 
the significance of the method, reporting adaptations that provided tunable selectivity 
for either the α- or β-glycoside (Figure 2.8).  
 
Figure 2.8: Adaption of Kahne and co-workers sulfoxide glycosylation protocol reported by Crich and 
co-workers. The method allows for tunable selectivity, providing either the 1,2-trans-α (Protocol A) or 
1,2-cis-β (Protocol B) glycoside of mannose. Figure adapted from Crich, D.; Sun, S., The Journal of 
Organic Chemistry 1997, 62 (5), 1198-1199. 
Two protocols were established. The reaction of sulfoxide 60 with 
trifluromethanesulfonic anhydride (Tf2O) forms intermediate 61 which rapidly expels 
a sulfinate ester to give the oxocarbenium ion 62. In protocol A, both Tf2O and the 
alcohol acceptor (ROH) exist in the original reaction mixture leading to 62 being 
trapped by the better nucleophile (the alcohol), preferentially from the α-face leading 
predominantly to the 1,2-trans-α glycoside 63. In protocol B, delayed addition of the 
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acceptor results in formation of the β-mannoside (65) in good yield. This striking 
reversal of stereoselectivity is possible due to the in situ formation of the reactive 
glycosyl donor 64, where the oxocarbenium ion 62 has been intercepted by the triflate 
ion (OTf-). The formation of this intermediate was supported by low-temperature 1H 
and 19F NMR studies in dichloromethane-d2. Of equal importance is the O-4/6 cyclic 
protecting group which distorts the carbohydrate chair conformation of the transition 
state, allowing SN2 like displacement of the triflate group by the glycosyl acceptor. 
 
Complementary to the idea of a participating group directing the stereochemical 
outcome of a glycosylation reaction, comes the idea of a two-step tethering 
glycosylation process called intramolecular aglycon delivery (IAD)161-163 that utilizes 
the stereochemistry at C-2 to dictate a 1,2-cis outcome. The process involves covalent 
tethering of the glycosyl acceptor to the glycosyl donor at the C-2 position, with 
subsequent activation of the anomeric leaving group leading to delivery of the 
acceptor to the ‘cis face’ in an SN1 like process via a favourable cyclic transition state 
(Figure 2.9). 
 
Figure 2.9: Generalised intramolecular aglycon delivery (IAD) reaction with facial selective delivery of 
an intramolecularly tethered acceptor to give the cis configured glycoside. 
In a beneficial expansion of the IAD method the Ito/Ogawa groups reported a specific 
example utilizing the common p-methoxybenzyl (PMB) protecting group as the 
stereocontrolling element (Figure 2.10 A).154 Originally utilizing glycosyl fluorides as 
the mannosyl donor, the method was subsequently extended to more practical 
thioglycoside based systems.164 Oxidation of the PMB group with 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) gives oxycarbenium ion II that can be trapped by 
the hydroxyl group of the acceptor to give mixed acetal III. Upon activation with a 
promoter to facilitate formation of an oxocarbenium ion at the anomeric centre the 
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mixed acetal undergoes an intramolecular glycosylation, driven by the formation of a 
cyclic 5 membered transition state (IV), to give the 1,2-cis glycoside product V. 
 
Figure 2.10: A: General method for IAD reaction sequence showing teathering of the aglycon to the 
PMB protecting group followed by cis-face directed delivery. B: Ito/Ogawa utilized an IAD reaction in 
the synthesis of 68, a key intermediate in the total synthesis of Glc1Man8GlcNAc2. 
The Ito/Ogawa group went on to use their PMB-IAD in the synthesis of many large N-
linked glycans, with a key step in the total synthesis of a Glc1Man8GlcNAc2, the PMB-
IAD mediated glycosylation of a GlcNAc(β1-4)GlcNAc disaccharide 66 (Figure 2.10 B). 
 
Prior to the development of reliable direct methods for the synthesis of β-mannosides, 
a number of indirect methods were utilized. Such methods included radical inversion 
of α-mannosides,165 displacement of gluco-O-2 triflates,166-167 and facially selective 
reduction of β-keto sugars derived from β-glucosides168-169 (Figure 2.11). 
 
Such selective reductions are of interest due to the ease of generating the β-glucoside 
precursors. Glycosylation of O-2 acyl glucosyl donors readily generate the 
corresponding 1,2-trans-β glucoside in high yields with complete β-selectivity. Such 
selectivity is achieved through neighbouring group participation by the O-2 protecting 
group blocking acceptor attack on the α-face (Figure 2.12).  




Figure 2.11: Indirect formation of β-mannosides by radical inversion of α-mannosides, displacement of 
O-2 triflates, and facially selective reduction of β-keto sugars derived from β-glucosides. 
Figure 2.12: O-2 participation gives selective formation of 1,2-trans glycosides. 
Hodosi and Kováč129-130 reported a synthesis of 1,2-cis-β glycosides utilizing a glycosyl-
1,2-O-cis-stannylene acetal as a nucleophile capable of displacing good leaving groups 
on an aglycone. This method was used in the first reported synthesis of β-ManCer (1) 
by Berzofsky and co-workers128 (Scheme 1.3, Pg. 36). Although the exact mechanism 
is disputed, the general method (Figure 2.13) involves forming a key stannylene acetal 
intermediate II. Subsequent activation by addition of a halide (typically F- from CsF) 
leads to a significant increase in electron density/nucleophilicity of the equatorial 
oxygen of the acetal over the axial, which then reacts with an electrophile via an SN2 
like displacement. The result is that the 1,2-cis-β stereochemistry of the acetal is 
maintained in the reaction to provide the 1,2-cis-β glycoside configured product III. 
 
Figure 2.13: General mechanism for stanylene acetal mediated glycosylation of 1,2-diols. 
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Such chemistry was utilized by Maggi and Madsen for the regioselective 6-O-
glycosylation of unprotected phenyl 1-thioglycosides.170 Here, they utilized 4,6-
stannylene acetals of phenyl 1-thioglycosides as nucleophilic acceptors to 
regioselectively couple per-benzoylated galactopyranosyl and mannopyranosyl 
bromide donors (Figure 2.14). In the highlighted example, phenyl 1-thio-β-D-
glucopyranoside (69) was reacted with dibutyl tin oxide to form the corresponding 
4,6-O-stanylene acetal 70. Activation of mannosyl bromide 71 with silver triflate gives 
the corresponding oxocarbenium ion and subsequent acyloxonium ion, blocking the 
β-face. The stannylene acetal of 70 directs acceptor attack of the O-6 hydroxyl group, 
with coupling from the accessible α-face to give disaccharide 72. 
 
Figure 2.14: Maggi and Madsen utilized stannylene acetal mediated glycosylation in the formation of a 
1,6-α disaccharide 72 from a mannosyl bromide donor 71 and 1-thio-β-D-glucopyranoside (69). 
2.2.2. Characterisation of 1,2-cis-β Mannosides 
In order to fully characterise glycosides it is important to be able to easily distinguish 
mixtures or discrete samples of α- and β-anomers from each other. This can be 
achieved in the case of α- and β-galacto- and gluco-pyranosides using 1H NMR. In 
general, the vicinal coupling constants associated with the anomeric proton, 3J1,2, is 
normally around 8 Hz for β-anomers, reflecting a trans-diaxial relationship between 
H-1 and H-2, while those for α-anomers, an axial-equatorial relationship, have 3J1,2 
values of  ̴1-3 Hz. Unfortunately, 3J1,2 for α- and β-mannosides are very small and 
generally cannot be used to determine anomeric configuration. Fortunately, for 
mannosides, the two anomers exhibit significantly different 1JCH coupling constants for 
the anomeric centre. A 1JCH value of approximately 170 Hz is consistent with an α-
glycosidic linkage, whereas a value of approximately 160 Hz is consistent with a β-
glycosidic linkage.171 In the current work, this was initially determined via proton-
coupled 13C NMR experiments. However, these are time consuming (≥5 hours) and 
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often gave poor resolution. We later used proton coupled heteronuclear single 
quantum coherence (HSQC) experiments which provided comparable results at higher 
resolution and with significantly shorter acquisition times (60-90 min). 
2.3. General Strategy 
A key step in the synthesis of β-ManCer or any related analogue is the formation of 
the 1,2-cis β glycosidic linkage. As shown in SAR studies of α-GalCer (2) (Section 1.6) 
the configuration of this linkage is significant for bioactivity. Therefore, a 
stereoselective glycosylation protocol that allows for either complete selectivity, or 
high selectivity for the desired anomer is required. Complete selectivity is desirable as 
it avoids the tedious and potentially problematic separation of the two anomers, as 
authentic biological analysis and data interpretation requires chemically pure 
compounds. Unfortunately, unlike the 1,2-cis-α glycosidic linkage of 2, β-ManCer (1) 
involves the formation of the comparatively difficult 1,2-cis β-linkage. The aim of this 
work is to investigate several methods, including both ‘direct’ and ‘indirect’, to 
prepare 1. With the key step in such a synthesis being formation of the glycosidic bond 
(Figure 2.15), such reactions will be evaluated in terms of; I) ease of chemical 
transformations, II) number of steps and overall yield, III) α/β ratios, and IV) 
applicability to scale up synthesis.  
 
Figure 2.15: The key reaction in the total synthesis of β-ManCer is the step in which the 1,2-cis-β 
glycosidic bond is formed. Highlighted in green the glycosidic bond is formed between the 
anomeric center of a sugar donor (blue) and the hydroxyl of the phytosphingosine moeity (pink). 
The approaches to be evaluated in this work were those of Crich and co-workers’ 
sulfoxide method utilising an α-mannosyl triflate donor, Ito/Ogawas’ intramolecular 
aglycon delivery (IAD), and ‘classical’ C-2 epimerisation of a 1,2-trans β-glucoside.150-
153 All three methods use the conventional sugar donor and phytosphingosine 
acceptor reactants. However, reversal of the roles of the donor and acceptor is also 
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possible and should allow direct access to 1,2-cis-β mannosides. As such stannylene 
acetal mediated glycosylations,136, 137 where the carbohydrate component is the 
nucleophile and the phytosphingosine derivative is the electrophile, were also 
investigated. 
2.4. Crich and co-workers’ sulfoxide method 
2.4.1. Synthesis of Donor 73 and 77 
Synthesis of sulfoxide donor 73 was achieved in 5 steps using literature methods from 
commercially available D-mannose with an overall yield of 37% (Scheme 2.1).172-173 
 
Scheme 2.1: Synthesis of sulfide donor 77 and sulfoxide donor 73 from D-mannose. Reagents and 
conditions: i) (a) Ac2O, py, 0°C to rt, o/n; (b) BF3·Et2O, PhSH, anhyd. DCM. 0°C to rt, o/n, 70% over 
two steps; ii) 1M NaOMe, MeOH, rt, o/n, quant.; iii) HBF 4, PhCH(OMe)2, DMF, 50 mbar, 70°C, 3 
hrs; iv) (a) NaH, DMF, 15 min, rt; (b) BnBr, 0°C to rt, o/n, 93%; v) mCPBA, anhyd. DCM, -55°C to -
30°C, 60 min, 56%. 
Global acetylation of D-mannose under standard conditions followed by boron 
trifluoride diethyl etherate (BF3·Et2O) mediated glycosylation with thiophenol gave 
the corresponding 1-O-thiophenyl peracetylated mannose derivative 74. 
Deacetylation with catalytic sodium methoxide then gave 75 in good yield over the 
three steps. HRMS showed the expected sodiated molecular ion at m/z 295.0639 
(calcd for C12H16O5SNa [M + Na]+ m/z 295.0611).  
 
Installation of the benzylidene acetal proved problematic, due in part to the 
equilibrium nature of the reaction. Mannoside 75 is heated in DMF with stoichiometric 
tetrafluoroboric acid and benzaldehyde dimethylacetal. Formation of the desired 
product 76 results in the formation of two equivalents of MeOH which drive the 
reverse reaction. Optimization of the reaction was achieved by using benzaldehyde 
Chapter II: Approaches to β-mannosylphytosphingosines 
 
52 
dimethylacetal as the limiting reactant, carrying out the reaction at 70°C and ensuring 
that the concentration of carbohydrate reactant 75 was about 0.6 mmol·mL-1. Most 
importantly, the reaction was carried out at 50 mbar to remove the methanol. This 
gave the desired mono-benzylidine acetal 76 as the major product while minimising 
formation of the bis-benzylidine by-product. 
 
Benzylation of 76 with benzyl bromide and sodium hydride gave thiophenyl glycoside 
77 in 93% yield. Glycosyl sulfoxide donor 73 was accessed by selective oxidation of 77 
with meta-chloroperoxybenzoic acid (mCPBA). Provided the reaction was maintained 
below -28°C formation of the corresponding sulfone could be mitigated. Purification 
by precipitation with di-isopropyl ether gave analytically pure 73 in 56% yield, which 
avoided column chromatography. Sulfoxide formation was supported by elemental 
analysis and NMR spectroscopy, and was consistent with data reported in the 
literature.173 
2.4.2. Synthesis of Acceptor 78  
The first three methods to be investigated use strategies employing traditional sugar 
donors and a phytosphingosine derivative as an acceptor. Acceptor 78 was accessed 
by protection/deprotection and functional group manipulations in 4 steps from 
commercially available (2S,3S,4R)-2-amino-1,3,4-octadecanetriol 46 with a 72% 
overall yield (Scheme 2.2).149, 174-178 
 
Scheme 2.2: Synthesis of acceptor 78. Reagents and conditions: i) TfN3, MeOH/PhCH3 (1:1), 
CuSO4·5H2O, rt, o/n, 99%; ii) TIPSCl, imidazole, DMF, rt, o/n, 98%; iii) BnBr, NaH, TBAI, DMF, 0°C to rt, 
o/n; iv) TBAF, THF, rt, o/n, 75% over two steps. 
Key to the bioactivity of the resulting glycolipids is the 2S, 3S, 4R configuration of the 
appending groups on the phytosphingosine chain.179 The critical reaction in this 
sequence was formation of the azide. Typically organic azides are formed by reaction 
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of sodium azide with a molecule possessing a good leaving group. Unfortunately, this 
process results in inversion of stereochemistry at a chiral reaction centre. 
Alternatively, amines can be converted into azides with retention of stereochemistry. 
The diazo transfer reaction, which utilises triflyl azide as an electrophilic nitrogen 
source, involves transferring a diazo group to an amine in the presence of a CuII salt to 
give the corresponding azide. Other electrophilic nitrogen sources such as 81, 82, 83, 
and 84, have also been utilized in this reaction (Figure 2.16). 180-185 
 
Figure 2.16: Nonafluorobutanesulfonyl azide (82) is an efficient, shelf-stable, and cost-effective liquid 
diazo-transfer reagent.186 In 2007, imidazole-1-sulfonyl azide hydrochloride(83·HCl) was reported to be 
a crystalline diazo-transfer reagent; it is stable up to 80°C, with almost the same reactivity as TfN3 
(81).187 However, in 2011,(83·HCl) was found to be strongly impact sensitive, and 83·HBF4 and 83·H2SO4  
salts were recommended as safer and cost-effective diazo-transfer reagents.188 Benzotriazol-1-yl-
sulfonyl azide (84), which is crystalline, has also been reported to be a stable and easily available diazo-
transfer reagent.189 
Despite its importance, a clear mechanistic explanation of the ‘diazo’ transfer reaction 
remains elusive. Since the initially proposed mechanism by Anselme and co-
workers190 in 1967 the topic has remained hotly debated. Three plausible routes have 
remained largely uncontested (Figure 2.17); azide transfer via an SNi pathway (B), or 
via a diazo transfer event, though whether the amine attacked the central (C) or 
terminal (D) nitrogen of the azide remained unknown. A recent study by Pandiakumar 
and coworkers191 precluded the possibility of azide transfer via an SNi mechanism and 
provided strong supporting evidence for diazo transfer, in the presence of a metal 
catalyst, via attack on the terminal nitrogen of the azide, a mechanism originally 
proposed by Wong et al.180 However, the metal-free reaction may proceed via a 
different route. 
 
Diazo transfer followed by temporary protection of the primary hydroxyl of 45 as a 
triisopropyl silyl ether provided azide 79 (See Scheme 2.2). Benzylation under 
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standard conditions only provided partially benzylated material. However, addition of 
catalytic tetra-n-butylammonium iodide (TBAI) to the reaction mixture leading to in 
situ generation of benzyl iodide afforded derivative 80 that upon treatment with TBAF 
gave acceptor 78 in good overall yield. 
 
Figure 2.17: A: Diazotransfer reactions allow conversion of amines into azides while maintaining 
the stereochemistry about the original amine; B: A possible mechanism for diazotransfer 
involving azide transfer via an SNi pathway; C: Mechanism for azide formation via a diazo transfer 
event, with amine attack on the central nitrogen of the transfer reagent; D: Mechanism for azide 
formation via a diazo transfer event, with amine attack on the terminal nitrogen of the t ransfer 
reagent; It is now widely accepted that the metal catalysed reaction proceeds via pathway C. 
However, the metal free reaction may proceed via an alternative pathway. Figures adapted from  
Pandiakumar, A. K., et al., Tetrahedron Letters 2014, 55 (18), 2917-2920.191 
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2.4.3. Glycosylation of Donor 73 and Acceptor 78 
The reaction of sulfoxide donor 73 with phytosphingosine acceptor 78 promoted by 
triflic anhydride was repeated a number of times to optimise the reaction conditions 
(Scheme 2.3). 
Scheme 2.3: Glycosylation of sulfoxide donor 73 and phytosphingosine aceptor 78. Reagents and 
conditions: i) (a) DTBMP, 4Å MS, anhydrous DCM, 1 hr; (b) Tf2O, -78°C, 10 min; (c) 78, -78°C to -50°C, 
3hrs, α:β 5:95, 70%. 
In all cases a mixture of β- and α-glycosides were formed with ratios ranging from 
90:10 to 96:4 in favour of the β-anomer. These ratios were determined from the 
relative integrations of the discrete singlets resonating at δ5.61 and 5.64 ppm in the 
1H NMR spectrum (Figure 2.19) which correlate to the benzylidine methine (Figure 
2.18) of the β- and α-products respectively. Purification of the crude product by silica 
gel column chromatography gave 85 as an inseparable mixture of anomers with yields 
for the mixtures ranging from 62 to 73% yield. The average yield was 68%.  
 
Although integration of the resonances from the 1H NMR spectra gave the relative 
ratios of the two anomers, it could not be used to assign the configuration of each 
isomer. Derived from a proton coupled 13C NMR experiment the 1JCH coupling constant 
for the anomeric carbon provided such information. The anomeric carbon resonance 
at 102.2 ppm is split into a doublet by the single 
attached proton with a 1JCH coupling constant of 155 
Hz in the proton coupled 13C NMR spectrum, 
supporting assignment of the major glycoside 
product as a 1,2-cis-β glycoside (Figure 2.20). 
Subsequently, 1JCH coupling constants were 
obtained in shorter timeframes by proton-coupled 
heteronuclear single quantum coherence (HSQC) 
Figure 2.18: H-7, A key proton 
for identifying the relative α:β 
ratio of glycosidic products 
formed in the glycosylation 
reaction. 
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NMR experiments. 1JCH values were in good agreement +/- 2Hz despite the experiment 
used.  
 
Figure 2.19 (Above): 1H NMR spectrum of glycoside 85 recorded in CDCl3 at 500 MHz. Expansion 
highlights the benzylidine acetal proton with the relative intergration of the major and minor peaks at 
5.61 and 5.64 ppm respectively giving the relative ratio of α- and β-anomers of 85. Figure 2.20 (Below): 
Anomeric region of proton coupled 13C NMR spectrum of 85 supports assingment of the major anomer 
as β with a 1JCH of 155 Hz. Expansion shows HSQC identifying the carbon signals as C-1 and C-7 
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2.4.4. Glycosylation of Donor 77 and Acceptor 78 
Thiomannoside 77 can also be utilized as the glycosyl donor for the formation of β-
mannoside 85 using diphenyl sulfoxide and triflic anhydride as the promoter (Scheme 
2.4).192 
Scheme 2.4: Glycosylation of sulfide donor 77 and phytosphingosine aceptor 78. Reagents and 
conditions: i) (a) Ph2SO, DTBMP, 4Å MS, anhydrous DCM, 1 hr; (b) Tf2O, -60°C, 20 min; (c) 78, -78°C to -
50°C, 3hrs, α:β 1:9, 61%. 
Activation of the thiophenyl group of 77 is achieved on reaction of the triflyl ester of 
diphenyl sulfoxide. Loss of the leaving group of II produces oxocarbenium ion III which 
is trapped as the α-mannosyl triflate 86 (Figure 2.21). SN2 attack of the acceptor gives 
the 1,2-cis-β glycoside 85 in good yield and with high β selectivity. 
 
Figure 2.21: Mechanism showing the more extensive activation cycle of glycosyl donor 77. Following 
formation of α-mannosyl triflate 86 the mechanism proceeds as for sulfoxide donor 73. 
Initially the reaction was attempted using a pre-activation time of 10-15 min, as was 
the case for sulfoxide 73 above. Unfortunately, this proved detrimental to α:β ratios, 
averaging 3:7. It was reasoned that this was due to the more extensive activation 
cycle, with a significant portion of the oxocarbenium ion III present on addition of 
phytosphingosine acceptor 78. Increasing the pre-activation time to 25 min resulted 
in most of the oxocarbenium ion being trapped as the α-mannosyl triflate 86 and thus 
a significant improvement in the ratio, reliably giving glycoside 85 in ratios in excess 
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of 9:1 in favour of the β anomer. This, combined with yields in the region of 60% 
showed that this approach was as effective as that using sulfoxide donor 73. 
2.5. An intramolecular aglycon delivery (IAD) approach 
2.5.1. Synthesis of Donor 87 and 88 
Intermediate 76, used for the synthesis of sulfoxide donor 73 (Section 2.5.1) was also 
used to prepare IAD donors 87 and 88 in 38 and 39% overall yield respectively (Scheme 
2.5).  
Scheme 2.5: Synthesis of IAD donors 87 and 88. Reagents and conditions: i) (a) Bu2SnO, PhCH3, reflux, 
2 hrs; (b) CsF, BnBr, DMF, rt, o/n, 87%; ii) (a) NaH, DMF, 15 min, rt; (b) PMBCl or NAPBr, 0°C to rt, o/n, 
R=PMB 62%, R=NAP 63%. 
Selective benzylation of the 3-O-hydroxyl of 76 was achieved using stannylene acetal 
mediated alkylation. Previously reported by our group for the synthesis of 
phosphatidylinositol mannosides,193-194 the reaction proceeds via a dibutyl stannylene 
acetal intermediate. Upon activation of the acetal with fluoride (from CsF) the 
nucleophilicity of the equatorial orientated oxygen is significantly increased allowing 
alkylation via an SN2 reaction with benzyl bromide. Subsequent loss of the tin complex 
occurs on workup leading to the mono-benzylated product 89.  
 
IAD glycosyl donors 87 and 88 could be obtained by reaction of 89 with either para-
methoxybenzyl chloride (PMB-Cl) or 4-(bromomethyl)naphthalene (NAP-Br) 
respectively and sodium hydride. Chromatographic purification gave 87 and 88 in 62% 
and 63% yield respectively with compound identity supported by HRMS and NMR 
experiments.195 
2.5.2. Attempted Glycosylation of Donor 87 and Acceptor 78 
Initially, in an attempt to modify work previously reported by the Ito and Ogawa 
groups154 the para-methoxybenzyl ether of donor 87 was used as the IAD tethering 
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group (Scheme 2.6). Despite NMR indicating formation of the mixed acetal 90, 
subsequent activation of the donor always failed to yield the desired glycoside and 
gave a complex mixture of products that proved difficult to purify. Analysis of the 
literature suggested that the stability of PMB mixed acetals is a problem and for this 
reason many examples in the literature purify the mixed acetal prior to donor 
activation.196 Due to lack of stability on silica, most methods report chromographic 
purification on a type of size exclusion resin, namely SX-3 resin, which was unavailable. 
During our investigation of the literature we found a more recently reported IAD 
donor based on a 2-(methyl)naphthalene (NAP) group that exhibits higher stability, 
and where the resulting NAP mixed acetal donors are activated without prior 
purification.197-198 
 
Scheme 2.6: Attempted synthesis of glycoside 91 using donor 87. Reagents and conditions: i) (a) 78, 
anhyd. DCM, 4Å powdered MS, rt, 40 min; (b) DDQ, rt, 3 hrs; ii) (a) Ph2O, DTBMP, 4Å powdered MS, 
anhyd. DCE, 40 min; (b) Tf2O, -35°C, 15 min; (c) -35°C to rt, o/n, 0%. 
2.5.3. Glycosylation of Donor 88 and Acceptor 78. 
Oxidation of NAP-IAD donor 88 with DDQ in the presence of acceptor 78 gave mixed 
acetal 92 (Scheme 2.7). The mixed acetal was used directly in the next step where it 
was activated with diphenyl sulfoxide and trifluromethanesulfonic anhydride. After 
aqueous workup, glycoside 91 was isolated in an unoptimized yield of 46%. 
Benzylation of the 2-O-hydroxyl group gave β-85, which was identical to the β-
glycoside component of 85 formed using the methods described in Section 2.4. 




Scheme 2.7: Synthesis of glycoside 91 by IAD donor 88. Reagents and conditions: i) (a) 78, anhyd. DCM, 
4Å powdered MS, rt, 40 min; (b) DDQ, rt, 3 hrs; ii) (a) Ph2O, DTBMP, 4Å powdered MS, anhydrous DCE, 
40 min; (b) Tf2O, -35°C, 15 min; (c) -35°C to rt, o/n, 45%; iii) (a) NaH, DMF, 15 min, rt; (b) BnBr, 0°C to 
rt, o/n, 43%. 
Figure 2.22 shows a comparison of the 1H NMR spectra of 85, when formed directly 
(A) and on benzylation of 91 (B). Importantly, comparison of the resonances 
associated with the benzylidine acetal methine at 5.61 ppm for the β-anomer and 5.64 
ppm for the trace amounts of contaminating α-anomer show that synthesis of 85 
using IAD methodology generates an anomerically pure product. 
 
Each step of the reaction can be monitored by 1H NMR spectroscopy of the 
intermediate and crude product (Figure 2.23). The key resonances of IAD donor 88 (A) 
are those of H-1 at 5.51, H-7 at 5.67 and the napthyl methine protons at 4.89 ppm. 
Formation of the mixed acetal 92 (B) results in a significant downfield shift of the 
naphthyl acetal proton to 6.11 ppm. Also observed, is a slight downfield shifting of H-
1 and -7 to 5.61 and 5.78 ppm, respectively, along with added signals for the 
phytosphingosine component. Formation of glycoside 91 (C) with subsequent washing 
of the crude material with sodium bisulfite, on workup results in complete loss of the 
naphthalene signals and an upfield shift of H-7 to 5.6 ppm. A significant upfield shift 
of the H-1 signal to 4.38 ppm, which can be explained by a change in orientation of 
the anomeric proton from equatorial as in 88 and 92 to axial, was also observed. The 
Chapter II: Approaches to β-mannosylphytosphingosines 
 
61 
β-anomeric configuration of 91 was confirmed from the anomeric carbon 1JCH coupling 
constant of 163 Hz.  
 
 Figure 2.22: Comparison of the 1H NMR spectrum of 85 produced by an IAD glycosylation pathway 
(Crude material, A) and our sulfoxide glycosylation (B). Expansion of the benzylidine acetal proton show 
the trace α-anomer contamination present from the sulfoxide pathway isn’t present when using the 
completely β-selective IAD pathway. 
A 
B 
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2.6. An Indirect approach to β-mannosides: C-2 epimerisation 
of a 1,2-trans β-glucoside  
D-Glucopyranosyl donors readily form β-glycosides with complete selectivity when an 
O-2 participating protecting group is employed. Esters are the most commonly 
employed participating groups however, nitro-, azo- or cyano- substituted benzyl 
ethers have also been shown to have participating properties.142-143, 199-201 In general 
the glycosylation reactions proceed much the same with loss of a leaving group from 
the anomeric centre to form an oxocarbenium ion. This is subsequently trapped 
intramolecularly by the O-2 protecting group to give the more stable acyloxonium ion. 
In the case of a D-glucopyranosyl donor, participation by the equatorial C-2 
substituent forms the acyloxonium ion from the α-face, blocking it to nucleophilic 
attack by the acceptor. Acceptor attack therefore occurs from the accessible β-face 
yielding the β-glycoside as the major and often exclusive carbohydrate product. 
Epimerisation of the C-2 centre by methanolysis of the C-2 participating group, 
oxidation of the free alcohol, followed by stereoselective reduction of the ulose should 
then give the corresponding mannoside while maintaining the β orientation about the 
anomeric centre (Figure 2.24).157 
 
Figure 2.24: 1,2-trans-β glucosides are easily accessible, with complete selectivity, by 
glycosylation of donors with O-2 participating groups. Subsequent inversion of the C-2 hydroxyl 
group should then provide the corresponding 1,2-cis-β mannoside free of any α-anomer 
contamination. 
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2.6.1. Synthesis of Donor 93 
To trial the efficiency of accessing 1,2-cis-β mannosides via this route D-
glucopyranosyl trichloroacetimidate 93 was synthesized with an acetate participating 
group in the O-2 position from D-glucose (94) in 7 steps with an overall yield of 67% 
(Scheme 2.8). 
 
Scheme 2.8: Synthesis of trichloroacetimidate donor 93. Reagents and conditions: i) (a) HClO4, Ac2O, 
0°C; (b) red phosphorus, Br2, 10°C; (c) H2O, 30°C, 2hrs, 99%; ii) sym-collidine, TBAB, 45°C, o/n; iii) (a) 1M 
NaOMe, MeOH, rt, o/n; (b) NaH, DMF, 15 min, rt; (c) BnBr, 0°C to rt, o/n, 85% over three steps; iv) 
AcOH, rt, o/n; v) NH3 gas, 3:7 MeOH:THF, 0°C, 3 hrs, quant; vi) Cl3CCN, NaH, anhyd. DCM, 80 min, 84%. 
One-pot global acetylation and halogenation of glucose was achieved with acetic 
anhydride and perchloric acid followed by addition of red phosphorus, elemental 
bromine, and then water, to yield acetobromoglucose 95 in 99% as a white crystalline 
solid. 
 
This material was then converted into orthoester 96 using a literature procedure.202 
Subsequent deacetylation with catalytic sodium methoxide in methanol followed by 
global benzylation gave benzylated orthoester 97 in good yield. 
 
Acid mediated opening of the orthoester with glacial acetic acid gave di-acetate 98. 
Selective removal of the anomeric acetyl group was achieved on reaction of 98 with a 
solution of ammonia in THF/MeOH at 0°C.203 
 
Reaction of 99 with trichloroacetonitrile and a catalytic amount of sodium hydride 
gave trichloroacetamide 93 in high yield. The purity of the crude product was 
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sufficiently high and 93 was used in the subsequent glycosylation reaction without 
further purification. 
2.6.2. Glycosylation of Donor 93 and Acceptor 78 
Trichloroacetimidates were first introduced by Schmidt in the 1980s and have become 
popular for glycoside synthesis.204-206 Activation of donor 93 with trimethylsilyl triflate 
leads to loss of the anomeric substituent and formation of an oxocarbenium ion. 
Neighbouring group participation by the O-2 acetate generates the more stable 
acyloxonium ion and effectively blocks the α-face from acceptor attack, which occurs 
exclusively from the β-face, to generate, after purification by column 
chromatography, β-glucoside 100 in 63% yield (Scheme 2.9). 
 
Scheme 2.9: Synthesis of glycoside 100 from TCA donor 93 and acceptor 78. Reagents and conditions: 
i) (a) anhyd. tol, rt, 30 min; (b) TMSOTf, -10°C, 30 min; (c) -10°C to rt, 2 hrs, 63%. 
2.6.3. Synthesis of Donor 101 
Alternatively, thioglycoside donor 101 can be prepared from diacetate intermediate 
98 by treatment with thiophenol and boron trifluoride diethyl etherate (Scheme 2.10). 
Trituration from EtOAc with diisopropyl ether gave 101 in 94% yield on gram scale. 
 
Scheme 2.10: Synthesis of sulfide donor 101. Reagents and conditions: BF3·Et2O, PhSH, anhyd. DCM, 
0°C to rt, o/n, 94%. 
2.6.4. Glycosylation of Donor 101 and Acceptor 78 
Furthermore, β-glucoside 100 can be obtained by reaction of thioglycoside 101 with 
phytosphingosine 78. Promoted by N-iodosuccinimide and triflic acid 100 was 
obtained as the β-anomer with an improved yield of 70% (Scheme 2.11). All 
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spectroscopic data supports the proposed structure of 100 and is consistent between 
the two methods. 
Scheme 2.11: Synthesis of glycoside 100 from sulfide donor 101 and acceptor 78. Reagents and 
conditions: i) (a) NIS, 4Å MS, anhyd. DCM, -10°C, 10 min; (b) TfOH, -10°C, 3 hrs, 70%. 
2.6.5. Inversion of β-glucoside 100 
For an indirect synthesis of β-mannosides to be competitive with the corresponding 
direct approach the interconversion from glucoside to mannoside must be relatively 
high yielding. However, more importantly the conversion must give an exclusive or at 
least favourable mannoside to glucoside ratio. If not exclusive, then the mannoside 
must be easily separable from the glucoside. We proposed a 3-step interconversion 
of β-glucoside 100 to the epimerised mannoside 102 (Scheme 2.12).  
 
Scheme 2.12: Reductive inversion of β-glucoside 100 to corresponding mannoside 102. Reagents and 
conditions: i) 2.5M NaOMe, MeOH, rt, o/n, 96%; ii) Dess-Martin periodinane, anhyd. DCM, rt, 16 hrs; 
iii) L-selectride, anhyd. THF, -78°C, 10 min, 44% over two steps. 
Deacetylation of 100 under Zemplén conditions gave the corresponding alcohol 103 
which was oxidised to 2-uloside 104 using Dess-Martin periodinane (DMP). Uloside 
104 was not amenable to silica-gel chromatography and after precipitation of the DMP 
related by-products from diisopropyl ether, was used without further purification. 1H 
NMR analysis (Figure 2.25) supported formation of the ketone with a significant 
downfield shift of the resonances associated with H-1, 3, 4, 5, and loss of the proton 
resonance associated with H-2. The significant shift is a combination of the deshielding 
effect of the ketone functionality and distortional effects from the change in ring 
conformation.  




Figure 2.25: 1H NMR spetrum of 103 (A) and 104 (B) recorded in CDCl3 at 400 MHz. 
Lichtenthaler et al., and Bundle et al. have shown that reduction of the carbonyl group 
of such uloses with borohydride reagents occurs via hydride attack from the less 
hindered α-face giving rise to β-manno configured products.207 For example; Bundle 
et al. used L-Selectride for the multi-step successive synthesis of 1,2-cis-β tetra-
mannoside 105, a mannosyl polymer found within the cell walls of Candida albicans 
(Scheme 2.13).208 The synthesis involved successive coupling of ulose donor (106 or 
107) to the growing saccharide backbone. L-Selectride reduction then gave the 

















Scheme 2.13: L-selectride chemistry was used in the synthesis of mannosyl polymer 105 found within 
the cell walls of Candida albicans. Reagents and conditions: i) (a) Ag(zeolitie), DCM, 106, 78%; (b) L-
Selectride; ii) (a) AgOTf, DTBMP, MeCN, 107; (b) L-selectride, THF, -78°C, 65%. 
Reaction of uloside 104 with L-selectride occurred rapidly (1-2 min) at -78°C in THF. 
LCMS analysis of the crude reaction mixture showed that the reaction was highly 
selective for the mannosyl-configured product with the manno to gluco ratio being in 
the order of 99:1. This was also supported by NMR analysis which showed conversion 
of uloside 104 to mannoside 102 with the expected downfield shifts of H-1, 3, 4, 5, 
and re-emergence of H-2 in the NMR spectrum. The largest differences in the 1H NMR 
spectra of glucoside 103 (Figure 2.26 A) and mannoside 102 (Figure 2.26 D) are those 
resonances of H-2 and H-4. That for H-2 is expected due to its change in orientation 
from axial to equatorial (Figure 2.27). As expected, the orientation of the 
phytosphingosine substituent at the anomeric centre of mannoside 102 was 
confirmed as being equatorial from the 1JCH coupling constant which was 157 Hz, 
supporting the assignment of the anomeric configuration as β. 
 
Figure 2.27: Change in orientation of H-2 (pink) from axial to equatorial explains the downfield shift 
within the 1H NMR of the resonance associated with H-2. 
Chapter II: Approaches to β-mannosylphytosphingosines 
 69 
 







Chapter II: Approaches to β-mannosylphytosphingosines 
 
70 
The unoptimized yield for the formation of 102 was 55% over the three steps. The very 
high manno to gluco selectivity makes this an attractive alternative to the methods 
described in Sections 2.4 and 2.5 as it avoids potential contamination of the product 
with the corresponding α-glycoside. The robustness of this chemistry, where the 
donor synthesis is high yielding (67% for 93 and 74% for 101) compared with the much 
less efficient mannoside donor synthesis (around 35% overall yields) makes this an 
attractive route to the β-mannosylceramide backbone. The major drawback of this 
approach in a laboratory is the use of a highly reactive and pyrophoric reducing agent, 
L-Selectride.  
2.7. Stannylene acetal mediated glycosylation  
Traditionally glycosylations involve a glycosyl donor providing the electrophilic 
component and the acceptor acting as a nucleophile. This can be reversed where the 
donor can act as the nucleophile and the acceptor as the electrophile. This approach 
is especially powerful for forming β-mannosides as the orientation and steric bulk 
around the C-2 centre becomes irrelevant. There are several examples in the literature 
that make use of 1,2-dibutylstanylene acetals of mannose to give complete 
stereoselective formation of 1,2-cis-β-mannosides.209-213 To test the applicability of 
such a method in accessing our 1,2-cis-β-mannoside an appropriate nucleophilic 
mannose donor and electrophilic phytosphingosine acceptor were required.  
2.7.1. Synthesis of nucleophilic carbohydrate donor 105 
Precursor 105 was synthesized in five steps with an overall yield of 57% from D-
mannose using literature methods (Scheme 2.14).214-215 
 
The five step synthesis started with the preparation of acetobromomannose 106 
which was converted into ethylidene 107 on treatment with sodium borohydride in 
acetonitrile. Deacetylation and benzylation of 107 gave fully protected ethylidene 109 
in 90% yield over the two steps. A one-pot acid mediated opening of ethylidene 109 
was accomplished with 90% TFA in water to give the corresponding diol 105 in 88% 
yield.  




Scheme 2.14: Synthesis of stannylene acetal precursor 105. Reagents and conditions: i) (a) Ac2O, py, 
0°C to rt, o/n; (b) HBr in AcOH, anhyd. DCM, 0°C to rt, 4 hrs, quant; ii) NaBH4, anhyd. MeCN, o/n, 72% 
over two steps; iii) 1M NaOMe, MeOH, 30 min; iv) (a) NaH (60% in oil), DMF, 0°C, 15 min; (b) BnBr, 90% 
over two steps; v) TFA (90% in H2O), rt, o/n, α:β = 2:1 88%. 
2.7.2. Attempted synthesis of phytosphingosine acceptor 110 and 111  
It was thought that phytosphingosine acceptors 110 and 111 could be easily obtained 
by conversion of the 1-hydroxyl of phytosphingosine acceptor 78 into an appropriate 
leaving group (Scheme 2.15).  
 
Scheme 2.15: Attempted synthesis of phytosphingosne tosylate (111) and triflate (110). Reagents and 
conditions: 110-i) 2,6-lutidine, Tf2O, anhyd. DCM, 0°C to rt, 4 hrs, 0%; 111-i) TsCl, DMAP, TEA, anhyd. 
DCM, rt, o/n, 0% 
By reacting 78 with trifluromethanesulfonic anhydride or tosyl chloride and catalytic 
DMAP the corresponding phytosphingosine triflate 110 or tosylate 111 should be 
obtained. Unfortunately, attempted conversion of acceptor 78 yielded an unexpected 
product. 1H NMR analysis supported a compound with a single benzyl group and in 
the case of the tosylate none of the expected tosyl aromatic or methyl signals. It was 
postulated that introduction of an electrophilic centre at C-1 promotes an 
intramolecular nucleophilic substitution to give a cyclic ether with loss of the O-4 
benzyl substituent. Based upon the spectroscopic and HRMS data, this product was 
assigned the structure 112 (Figure 2.28). 




Figure 2.28: Attempted formation of 110 or 111 gave cyclized 2-epi-jaspin B analogue 112. 
Huang and co-workers also reported formation of the cyclized 2-epi-jaspin B analogue 
112 upon attempted formation of the corresponding triflate of 78.216 They proposed 
that key to the ring closing cyclisation is the free rotation around the C-3‒C-4 bond 
allowing O-4 to come into proximity of the electrophilic centre. Cyclisation then occurs 
via a SNi mechanism and a favourable 5-membered transition state. Therefore it was 
reasoned that replacing the benzyl protection for a 3,4-cyclic acetal would 
conformationally lock the phytosphingosine backbone and allow generation of the 
corresponding triflate. 
2.7.3. Synthesis of phytosphingosine 48 
Acetonide 113 was prepared from the TIPS protected azido phytosphingosine 
intermediate 79 (Section 2.4.2) by reaction with 2,2-dimethoxypropane catalysed by 
acid. Treatment of acetonide 113 with TBAF gave alcohol 47 in 94% over the two steps. 
Conversion of 47 to electrophilic acceptor 48 was achieved by reaction of 47 with 
trifluromethanesulfonic anhydride and 2,6-lutidine (Scheme 2.16). 
 
Scheme 2.16: Synthesis of phytosphingosine triflate 48. Reagents and conditions: i) 2,2-DPM, p-TSA, rt, 
3 hrs; ii) TBAF, THF, rt, o/n, 94% over two steps; iii) 2,6-lutidine, Tf2O, anhyd. DCM, 0°C to rt, 4 hrs, 
quant. 
No formation of the cyclic ether by-product was observed and formation of 48 was 
supported by NMR. The 1H NMR spectrum showed the expected and significant 
downfield shift of the H-1 resonances and the 19F NMR spectrum showed a strong 
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signal at -78.5 ppm. 48 was obtained in sufficient purity that it was used in the 
subsequent glycosylation without purification.  
2.7.4. Glycosylation of Donor 105 and iododecane 
A model study for the stannylene acetal mediated β-glycosylation of diol 105 using 
iododecane as the electrophilic component was undertaken to establish reaction 
conditions (Scheme 2.17). 
Scheme 2.17: Stanylene acetal mediated glycosylation of 105 with n-Decanol. Reagents and conditions: 
i) Bu2SnO, tol, reflux, 3 hrs; ii) (a) CsF, DMF, rt, 30 min; (b) n-Decanol, rt, o/n, 70%. 
Treatment of diol 105 with dibutyl tin oxide in toluene gave the intermediate 
stannylene acetal 114 which was treated with cesium fluoride and iododecane. The 
reaction proceeded cleanly to give, after workup and purification by column 
chromatography, the decyl β-mannoside 115 in yields ranging from 65-75% on 
repeated reactions. All spectroscopic data were consistent with the proposed 
structure and the 1JCH coupling constant of 157 Hz confirmed the anomeric 
configuration as β. 
2.7.5. The Glycosylation reaction of Donor 105 and Acceptor 48 
Given the success of this reaction, diol 105 was reacted with phytosphingosine 
triflate 48 under the same conditions (Scheme 2.18). β-glycoside 116 was obtained 
in 62% yield. 
Scheme 2.18: Stanylene acetal mediated glycosylation of 105 with phytosphingosine triflate 48. 
Reagents and conditions: i) Bu2SnO, tol, reflux, 3 hrs; ii) (a) CsF, DMF, rt, 30 min; (b) 43, rt, o/n, 62%. 
The 1H NMR spectrum is shown in Figure 2.29 and all spectroscopic data were 
consistent with the proposed structure. A stannylene acetal mediated glycosylation 
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route is highly attractive for a number of reasons; I) both the donor and acceptor 
components are accessible via short highly scalable synthetic routes and provide 
highly pure material in good overall yields. II) The glycosylation step works efficiently 
on a gram scale, and the target material is easily purified by standard chromographic 
techniques. III) The reaction is completely β-selective. 
 
Figure 2.29: 1H NMR specra of stannylene acetal mediated glycosylation product 116 recorded in CDCl3 
at 500 MHz. 
2.8. Summary of glycosylation methodologies  
Having evaluated the potential of several methods; Crich and co-workers’ sulfoxide 
method,150-153 Ito/Ogawa’s intramolecular aglycon delivery (IAD), C-2 epimerisation of 
a 1,2-trans-β glucoside, and stannylene acetal mediated glycosylation,136, 137 for the 
synthesis of β-ManCer (1), a comparison with the protocol currently used for the 
commercial synthesis of 1 was required.  
2.8.1. Glycosylation of Donor 117 and Acceptor 78III 
The synthesis of β-ManCer (1) employed by our collaborators involves the 
glycosylation of a trichloroacetimidate donor 117 with phytosphingosine acceptor 78 
(Scheme 2.19). The coupling is mediated by trimethylsilyl triflate which following 
                                                      
III This work was undertaken by the Ferrier Research Institute, Victoria University of Wellington, New 
Zealand. 
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work-up and purification by silica gel chromatography yields glycoside 85 as an 
inseparable mixture of α and β anomers with a ratio of 15:85 in 97% yield. 
 
Scheme 2.19: Glycosylation protocol currently employed by the Ferrier Research Institute in the total 
synthesis of 1. Reagents and conditions: i) TMSOTf, anhyd. DCM, 0°C, 4 hrs, α:β 15:85 97%. 
The β-selectivity is rationalised by the C-4/6 cyclic acetal distorting the carbohydrate 
ring conformation, minimising the steric bulk of the axial C-2 substituent and allowing 
acceptor attack from the β-face. However, unlike Crich’s method (which relies on in-
situ generation of the reactive α-mannosyl triflate glycosyl donor) acceptor attack 
occurs on an oxocarbenium ion intermediate, allowing attack from either face. As 
such, the selectivity for the desired β anomer is decreased. This method also suffers 
from the requisite formation of TCA donor 117, which, due to its high reactivity, is 
unsuitable for long-term storage. Furthermore, formation of 117 requires two extra 
synthetic steps from D-mannosyl thioglycoside 77. 
2.8.2. Method comparisons 
Our systematic analysis of the methodologies available for the synthesis of β-
mannosides has led to the discovery of several synthetic protocols that hold some 
significant advantages over the current method utilized for the synthesis of 1. 
 
One significant downside to the trichloroacetimidate based synthesis currently 
employed is the relatively high percentage of undesirable α-anomer that is generated 
during the glycosylation reaction. This is problematic for two major reasons. Firstly, 
the two anomers can’t be separated until later in the synthesis of β-ManCer (1), 
minimising the applicability of the route for the divergent synthesis of late stage 
analogues. Secondly, once separated it can prove difficult to quantify and/or identify 
residual trace contamination of the undesirable anomer, which presents a problem in 
biological evaluation of the compound and batch potency control.  




Of all the methods evaluated Ito/Ogawas’ intramolecular aglycon delivery (IAD) 
showed the least promise for our system in both overall yield, ease of reactions, and 
applicability to scale up synthesis (Table 2.1 and 2.2). 
 
Interestingly, the indirect approach relying on C-2 epimerisation of a 1,2-trans-β-
glucoside to generate the equivalent β-mannoside showed promise with its ability to 
generate the desired β-glycoside with complete selectivity and in good overall yields. 
However, despite being an effective method for accessing β-mannosides on a research 
scale synthesis, its reliance on the highly pyrophoric reagent, L-Selectride to reduce 
the uloses intermediate to the desired mannoside limits its applicability to commercial 
scale up.  
 
Of the methods studied, the two that showed the most promise over the current 
commercial synthesis were those methods based on Crich and co-workers 
methodology and the stannylene acetal mediated glycosylation method. 
 
Crich and co-workers methodology involving the glycosylation of thiomannoside 
donor 77 with phytosphingosine acceptor 78 proceeds efficiently to give glycoside 85 
in 29% overall yield. With a total of 9 steps for both components (from commercially 
available D-mannose and (2S,3S,4R)-2-amino-1,3,4-octadecanetriol) the synthetic 
route is 20% shorter than the current TCA-mediated synthesis. Like the current 
method, the glycosylation is not completely β-selective instead generating a mixture 
of anomers. However, it does so with a modest improvement to the ratio, ≥9:1 in 
favour of the desired β-glycoside vs 85:15. Alternatively, adding an extra step by 
utilising sulfoxide donor 73 in the glycosylation reaction the β selectivity can be 
improved to >95:5 (Table 2.1). 
 
By overcoming the major shortcoming of Crich’s methodology, mixed selectivity, the 
stannylene acetal mediated glycosylation method shows huge promise. By reversing 
the typical glycosylation roles (electrophilic donor, nucleophilic acceptor) and utilising 
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a conformationally locked sugar 114, glycoside 116 is generated in 32% overall yield 
with total β-selectivity. With a total of 11 steps, the sequence is the same length as 
the current method and is highly scalable to commercial synthesis. The only downside 
is any residual tin residues would need to be quantified prior to biological evaluation.  
 
The key glycosylation step of the four methods studied are summarised and compared 
to the current synthetic method in Table 2.1, with the overall sequence summarised 
in Table 2.2. 
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i) DTBMP, Tf2O, 4Ȧ MS, DCM, 







i) DTBMP, Ph2SO, Tf2O, 4Ȧ MS,DCM, 

















TfOH, DCM, -10°C 
 
70 0:100 
Stannylene Acetal 2.7.5 
  
i) Bu2SnO, Toluene, reflux 
ii) 48, CsF, DMF, 4Ȧ MS, 60° C 
 
62 0:100 
Ito/Ogawas’ IAD 2.5.4 
  









TMSOTf, DCM, 0°C 
 
97 15:85 
Table 2.1: Summary of the various glycosylation methodologies reported in this chapter.  
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71 5:95 Multi-Gram 
Applicable, requires 
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danger of L-Selectride 
required in inversion step 









Applicability limited due to 
danger of L-Selectride 
required in inversion step 





62 0:100 Multi-Gram 
Tin residues would need 
to be quantified 
11 32 
Ito/Ogawas’ IAD 2.5.4 
  











Table 2.2: Summary of the reaction sequences reported in this chapter, highlighted is the key glycosylation step of each sequence 
                                                      
IV Scale reaction carried out on 
V X+Y: X represents steps up to/including glycosylation, Y represents steps required to convert to corresponding β-mannoside 
VI X: (Y) X overall yield to glycosylation, Y overall yield including inversion to corresponding β-mannoside 
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2.9. A new commercial synthesis 
The sulfide glycosylation method described in this work and shown in Scheme 2.20, 
has since been exemplified at the Ferrier Research Institute and is likely to replace 
their current trichloroacetimidate based glycosylation for the commercial synthesis of 
β-ManCer (1). 
Scheme 2.20: Summary of the synthesis of 1 developed in this work and adopted by the Ferrier 
Research institute for the commercial synthesis of β-ManCer. Reagents and conditions: i) (a) Ac2O, 
py, 0°C to rt, o/n; (b) BF3·Et2O, PhSH, anhyd. DCM. 0°C to rt, o/n, 70% over two steps; ii) 1M 
NaOMe, MeOH, rt, o/n, quant.; iii) HBF4, PhCH(OMe)2, DMF, 50 mbar, 70°C, 3 hrs; iv) (a) NaH, 
DMF, 15 min, rt; (b) BnBr, 0°C to rt, o/n, 93%; v) (a) Ph2SO, DTBMP, 4Å MS, anhydrous DCM, 1 hr; 
(b) Tf2O, -60°C, 20 min; (c) 78, -78°C to -50°C, 3hrs, α:β 7:93, 70%. 
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Chapter III: Synthesis of Mannosylceramides 
This chapter discusses the biological ramifications of the non-stereospecific 
glycosylation protocols reported in the previous chapter. A detailed synthesis of α-
mannosylceramide (α-ManCer, 118) and β-mannosylceramide (β-ManCer, 1) follows. 
This chapter then reports on the findings of structural activity relationship (SAR) 
studies of α-GalCer (2) and several analogues thereof before reporting on the 
synthesis and characterisation of several biologically relevant N-acyl analogues of 1. 
3.1. Synthesis of Mannosylceramides  
Having investigated different methods for accessing 1,2-cis-β-mannosyl 
phytosphingosines the next step was to complete the synthesis of the adjuvant β-
ManCer (1). Although our synthetic routes have provided β-glycosides of varying 
structures, they all possess the same core motif shown in Figure 3.1 A. 
 
Figure 3.1: A; Generalised core moteif of all glycoside products from the proceeding chapter. B; 
Glycoside product of method chosen for commercial synthesis of 1 by the Ferrier Research Institute. 
Although it is possible to produce 1 from any of the glycoside intermediates shown in 
the previous chapter, discussions with our collaborators at the Ferrier Research 
Institute, indicated that glycoside 85 (Figure 3.1 B) was the best substrate to achieve 
this. 
3.2. Synthesis of α-Mannosylceramide (118) 
It is well known that isomeric compounds exhibit markedly different pharmacological 
effects, thus it is important that isomerically pure compounds are used for biological 
testing.217 α- (118) and β-ManCer (1) fall into this category (Structures shown Figure 
3.2). 




Figure 3.2: Structures of α- (118) and β-mannosylceramide (1). 
As discussed in the introduction of this work, NKT cells are defined as lymphocytes 
bearing both the common NK marker NKR-P1 and T cell receptors (TCRs) and can be 
divided into two major populations.218, 219 CD1d-restricted NKT cells are further 
divided into two sub-populations, with type 1 CD1d-restricted NKT cells characterised 
by the expression of invariant TCR α chains such as mouse Vα14-Jα18 and human 
Vα24-Jα26 and are typically referred to as iNKT (Vα14 NKT) cells. Vα14 NKT cells have 
been extensively studied and are strongly activated by glycolipids such as α-GalCer (2), 
and to a lesser extent, β-ManCer (1).85, 93, 127, 219-220 In contrast, CD1d-independent NKT 
cells (Vα19 NKT cells) are characterised by expression of the Vα19-Jα26 invariant TCR 
α chain and are less well studied. Vα19 NKT cells are known to be activated by α-
ManCer (118) (which is inactive towards CD1d-restricted NKT cells) and, like Vα14 NKT 
cells, are capable of producing both proinflammatory and anti-inflammatory 
cytokines.221 It has been suggested that both Vα14 and Vα19 NKT cells share roles in 
the regulation of the immune system despite being activated by different agonists.222 
As such, mixtures of α- and β-ManCer are undesirable as they can potentially activate 
both subsets of NKT cells. As many glycosylation reactions give mixtures of anomers, 
an authentic sample of 118 would serve as a reference in determining the anomeric 
purity of 1 (Synthesized via different routes). Thus, a synthesis of 118 was undertaken.  
3.2.1. Synthesis of Donor 119  
As discussed in the preceeding chapter the synthesis of 1,2-trans glycosides is 
considered to be “relatively easy” with exclusive formation of 1,2-trans-α mannosides 
reported when starting from mannopyranosyl donors possessing a participating group 
at O-2. Mannopyranosyl donor 119 was synthesized in 2 steps from 3,4,6-tri-O-benzyl-
D-mannose (105, Section 2.7.1) in 75% overall yield (Scheme 3.1). 




Scheme 3.1: Synthesis of glycosyl donor 119 from D-mannose. Reagents and conditions: i) (a) Ac2O, py, 
0°C to rt, o/n; (b) HBr in AcOH, anhyd. DCM, 0°C to rt, 4 hrs, quant; ii) NaBH4, anhyd. MeCN, o/n, 72% 
over steps i & ii; iii) 1M NaOMe, MeOH, 30 min; iv) (a) NaH (60% in oil), DMF, 0°C, 15 min; (b) BnBr, 90% 
over two steps; v) TFA (90% in H2O), rt, o/n, α:β=2:1 88%; vi) Ac2O, py, rt, o/n, quant.; vii) BF3·Et2O, 
PhSH, anhyd. DCM, rt, o/n, α:β=2:1 75%. 
Acetylation of 105 with acetic anhydride and pyridine gave diacetate 120, which upon 
isolation by aqueous workup, was used directly in the subsequent reaction. Boron 
trifluoride diethyl etherate mediated glycosylation of 120 with thiophenol gave 
mannopyranosyl donor 119 in 75% over the two steps. 1H NMR and all other 
spectroscopic data were in agreement with the proposed structure. 
3.2.2. Attempted glycosylation of Donor 119 and Acceptor 78 
Attempted glycosylation of mannopyranosyl donor 119 with phytosphingosine 
acceptor 78 promoted by triflic acid and N-iodosuccinimide failed to afford any 
glycoside products (Scheme 3.2). 
 
Scheme 3.2: Attempted formation of α-mannoside 121 from glycosyl donor 119 and phytosphingosine 
acceptor 78. Reagents and conditions: i) TfOH, NIS, anhyd. DCM, 4Å MS, -10°C to rt, 0%. 
3.2.3. Synthesis of Donor 122 
It is well known that acetates can cause problems in glycosylation reactions, as they 
are prone to migration and orthoester formation. As such the benzoyl protected donor 
122 was synthesized in two steps from intermediate 119 with a 79% overall yield 
(Scheme 3.3).  




Scheme 3.3: Synthesis of glycosyl donor 122 from donor 119. Reagents and conditions: i) 2.5M NaOMe, 
MeOH, rt, o/n; ii) BzCl, DMAP, py, 0°C to rt, o/n, α-122 = 54% and β-122 = 25%, over two steps. 
Alcohol 123 was obtained on treatment of donor 119 with sodium methoxide, 
subsequent treatment with benzoyl chloride and DMAP gave, after isolation and 
purification, donor 122 as its discrete anomers α-122 and β-122 in 54% and 25% 
respectively. NMR and HRMS analyses were in total agreement with the proposed 
structures of the α- and β-anomers of 122. 
3.2.4. Glycosylation of Donor 122 and Acceptor 78 
Glycosylation of mannosyl donor α-122 with protected phytosphingosine 78, 
promoted by triflic acid and N-iodosuccinimide (NIS) proceeded efficiently to give, 
after workup, glycoside 124 in 74% yield (Scheme 3.4). 
 
Scheme 3.4: Synthesis of glycoside 124 from donor α-122 and acceptor 78. Reagents and conditions: i) 
TfOH, NIS, anhyd. DCM, 4Å MS, -10°C to rt, 74%. 
NIS provides an electrophilic iodine source to thiomannoside 122, which upon loss of 
the anomeric substituent forms oxocarbenium ion I. An intramolecular rearrangement 
gives acyloxonium ion II, and blocks the β-face from acceptor attack, resulting in 
exclusive formation of 124 (Figure 3.3). 
 
The 1H NMR spectrum along with an extraction of the anomeric cross peaks from a 
proton coupled HSQC experiment is shown in Figure 3.4. All spectroscopic data 
supported the proposed structure of 124 and a 1JCH coupling constant of 171 Hz is 
consistent with its assignment as α. 
 




Figure 3.3: Mechanism for the formation of glycoside 124. Benzoyl participation with oxocarbenium ion 
I, gives acyloxonium ion II, blocking the β-face and leading to exclusive formation of the α-glycoside. 
 
Figure 3.4: 1H NMR spectrum of 124 recorded at 500MHz in CDCl3. Expansion shows the proton-coupled 
HSQC resonances associated with the anomeric proton signal, 171 Hz (2554-2383) supporting the α-
anomer assignment. 
3.2.5. Global deprotection of glycoside 124 
α-Mannosylphytosphingosine (α-ManPhyt, 125) was formed in two steps from α-
glycoside 124 (Scheme 3.5). Catalytic sodium methoxide in methanol was used for 
methanolysis of the benzoyl ester. The crude material was then subjected to standard 
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hydrogenolysis conditions. Following workup, purification by reverse phase silica gel 
chromatography, and lyophilisation, 125 was obtained in 50% yield over the two steps. 
 
Scheme 3.5: Formation of 125 by global deprotection of glycoside 124. Reagents and conditions: i) 2.5M 
NaOMe, MeOH, rt, 3 hrs; ii) Pd/C, H2, HCl, 1:1 DCM:MeOH, o/n, 50% over two steps. 
Both 1H and 13C NMR (Figure 3.5) supported the proposed structure of 125 and HRMS 
was consistent with the protonated molecular ion at m/z 480.3515. As evident from 
the 1H NMR spectrum, 125 clearly contains an impurity, with differences centred 
around H-1 and H-1’ (minor peaks at 4.77 and 4.10 ppm respectively). An additional 
peak at 2.71 ppm with an HSQC cross peak correlation to a methyl carbon at 33.83 
ppm, suggests the impurity is an N-methyl analogue (126, Structure shown in Figure 
3.6). Such a structure can be rationalised by in-situ oxidation of the hydrogenation 
solvent (methanol) to formaldehyde, which reacts with the amine of 125 to give an 
imine (127), subsequent reductive amination would then give 126, which is supported 
by HRMS. 
 
Figure 3.5: 1H (Bottom) and 13C (Top) NMR spectra of 125 recorded at 500 and 125 MHz respectively in 
2:1 CDCl3:CD3OD. 




Figure 3.6: Structure and proposed method of formation of N-methyl impurity 126. 
3.2.6. N-acylation of α-ManPhyt (125) with cerotic acid 
Regioselective coupling of cerotic acid with 125 afforded α-ManCer (118) in good 
yield (Scheme 3.6). 
 
Scheme 3.6: Formation of α-mannosylceramide (118) by N-acylation of 125 with cerotic acid. Reagents 
and conditions: i) (a) C25H51COOH, TEA, isopropyl chloroformate (1M in tol), anhyd. DCM, rt, 2 hrs; (b) 
rt to 0°C; (c) 125, 1:0.2 DCM:DMF, 0°C to rt, o/n, 83%. 
Pre-activation of cerotic acid as a mixed carbonic anhydride was achieved on 
treatment with isopropyl chloroformate solution and base, with subsequent addition 
of 125 providing the crude amide 118 (Figure 3.7).  
 
Figure 3.7: Mechanism for the isopropyl chloroformate activation of cerotic acid and subseqent N-
acylation of 125. 
Purification, firstly by trituration with water to remove any salts, followed by 
precipitation from hot ethanol, provided, after centrifugation, the clean glycolipid. 
Fatty acid coupling was supported by 1H NMR (Figure 3.8) which showed the amide 
NH resonance at 7.3 ppm, a new triplet at 2.16 ppm (2H) pertaining to the alpha 
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protons on the fatty amide, and an increase in the integral of the CH3 triplet at 0.84 
from 3 to 6 protons (relatively). 13C NMR and HRMS further supported the proposed 
structure of 118. 
 
Figure 3.8: 1H NMR spectrum of 118 recorded at 500 MHz in 2:1 CDCl3:CD3OD. 
3.3. Synthesis of β-Mannosylceramide – Pathway A  
With a discrete reference sample of α-ManCer (118) in hand, we turned our attention 
towards employing glycoside 85 for the synthesis β-ManCer (1). Although, 85 was 
isolated as a 95:5 inseparable mixture of β- and α-anomers, it was envisioned that 
removal of the undesired anomer might be achieved at an intermediary stage in the 
synthesis of 1. Initially two routes to 1 were investigated; firstly, a more direct route 
via hydrogenolysis of 85 would provide mainly β-mannosylphytosphingosine (β-
ManPhyt, 50) (Figure 3.9). A route to 50 (which is also of biological interest) could also 
start from glycosides 91, 102 and 116, prepared by the other methods described in 
Chapter II. Subsequent selective N-acylation with cerotic acid would afford 1 (Pathway 
A, Figure 3.9). Alternatively, a chemoselective reduction of the azide functionality of 
85 to give amine 128 would provide a late stage intermediate for the synthesis of 1 
and accommodate the synthesis of various N-acyl analogues (Pathway B, Figure 3.9). 
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N-acylation of 128 with cerotic acid would afford 129, a fully protected derivative of 
1. Subsequent global hydrogenolysis would then provide the synthetic adjuvant 1.  
 
Figure 3.9: Overview of the two proposed pathways for accessing β-mannosylceramide (1). 
3.3.1. Global deprotection of glycoside 85 
Global deprotection of azide 85 was achieved by hydrogenolysis on treatment with 
catalytic palladium on carbon and hydrogen under acidic conditions (Scheme 3.7) 
 
Scheme 3.7: Synthesis of β-mannosylphytosphingosine (50·TFA) by global deprotection of azide 85. 
Reagents and conditions: i) Pd/C, HCl, H2, 1:1 DCM:MeOH, 18 hrs, 90%. 
The product was purified by reverse phase silica gel using Isolute C-18(EC) cartridges 
and a gradient of TFA water and acetonitrile, to give, after lyophilization 50·TFA in 90% 
yield. Unfortunately the 5:95 α:β anomeric ratio of 85 was maintained in 50·TFA. The 
1H NMR, Figure 3.10 clearly shows the impurity with both anomeric proton resonances 
visible at 4.76 and 4.51 ppm for the α- and β-anomer respectively. 
 




Figure 3.10: 1H NMR spectrum of 50·TFA recorded in 2:1 CDCl3:CD3OD at 500 MHz. Expansion of the 
anomeric proton resonance higlights the 95:5 β:α ratio of anomers. 
3.3.2. N-acylation of β-mannosylphytosphingosine (50) with cerotic acid 
N-Acylation of 50 with cerotic acid mediated by isopropyl chloroformate provided 1 
in 72% yield (Scheme 3.8). No ester by-products were observed by HPLC. 
 
Scheme 3.8: N-acylation of 50·TFA with cerotic acid to afford a 95:5 inseprable mixture of the β:α 
anomers of 1. Reagents and conditions: i) (a) C25H51COOH, TEA, isopropyl chloroformate (1M in tol), 
anhyd. DCM, rt, 2 hrs; (b) rt to 0°C; (c) 50·TFA, 1:0.2 DCM:DMF, 0°C to rt, o/n, 81%. 
The 1H NMR spectrum, shown in Figure 3.11 B, supported the incorporation of the 
fatty acid from the triplet (2H) at 2.15 ppm associated with the alpha methylene of 
the fatty amide. Unfortunately, when the spectra were stacked with our α-ManCer 
standard (Figure 3.11 A) it was clear that the α-anomer contamination of starting 
material 85 had been maintained in 1 produced by this sequence. 





Figure 3.11: Comparison of the 1H NMR spectra of α-mannosylceramide (118, Top) with 1 (bottom) 
recorded at 400 MHz in 2:1 CDCl3:CD3OD. Clearly visible in the spectrum of 1 is the 5% α-contamination 
3.3.3. Purification of 1 formed by Pathway A 
Global acetylation of impure 1 provided per-acetylated β-ManCer 130 (Scheme 3.9). 
Purification of 130 by silica gel allowed separation of α-130 and β-130. Isolated in 
86% yield, β-130 was subjected to global deacetylation under Zemplén conditions to 
provide, after trituration with water followed by precipitation from hot ethanol then 
centrifugation, β-1 in 95% yield. 
 
Scheme 3.9: Anomeric purification of 1 by global acetylation, separation, and global deprotection. 
Reagents and conditions: i) Ac2O, py, rt, o/n, 81%; ii) 2.5M NaOMe, MeOH, rt, o/n, quant. 
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Comparison of the 1H NMR spectra of α/β-1 prior to, and subsequent to, purification 
using this process is shown in Figure 3.12. The 1H and 13C NMR spectra of β-1 are 




Figure 3.12: : Comparison of the 1H NMR spectra of 1 prior (Top) and subsequent (Bottom) seperation 
of the α- and β-anomers, recorded at 400 MHz in 2:1 CDCl3:CD3OD. The triplet at 1.15ppm is associated 
with residual EtOH from the purification process. 
The identity of 1 was confirmed by high resolution mass spectrometry which found an 
ion at m/z 880.7227 consistent with the sodiated molecular ion (M+Na+) of 1. The 
analytical purity of 1 was supported by high performance liquid chromatography 
(HPLC) using an evaporative light scattering detector (ELSD) (Figure 3.14) and 
elemental analysis, (Calculated for 1; C50H99NO9·H2O: C, 68.53; H, 11.62; N, 1.60. Found 
C, 68.41; H, 11.75; N, 1.59). 
 









Figure 3.14: HPLC-ELSD chromatograms of β-ManCer (1) and β-ManPhyt (50) showing the difference in 

























































Comparison of 1 and 50
Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9]
50 1 Solvent Gradient
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3.3.4. Summary of Pathway A 
In summary; Pathway A was able to provide access to anomerically pure β-ManCer. 
However, when starting from 85 with a 95:5 mixture of β and α anomers, the minor 
anomer was retained throughout the synthesis. To overcome this a global acetylation, 
purification and deprotection sequence was utilized to afford the adjuvant 1 in high 
purity. 
3.4. Synthesis of β-Mannosylceramide – Pathway B  
An alternative N-acylation approach that preserves the hydroxyl protecting group 
strategy might allow anomeric separation, prior to global hydrogenolysis and 
generation of 1. 
3.4.1. Chemoselective reduction of azide 85 
Initial attempts to selectively reduce azide 85 using Staudinger reaction conditions 
with triphenylphosphine as the reductant failed to yield amine 128, even after 
prolonged reaction times and/or heating. Further attempts utilising triethylphosphine 
or zinc as the reducing agent also failed, instead giving highly complex mixtures of 
products. Finally, treatment of azide 85 with trimethylphosphine in THF followed by 
addition of water afforded a crude product containing mostly iminophosphorane 131 
(Scheme 3.10), which was supported by 31P NMR with a strong resonance at 44.7ppm. 
Replacing the water for 2M sodium hydroxide solution gave, after workup, amine 128 
with sufficient purity that it was used in the subsequent acylation reaction without 
purification.  
 
Scheme 3.10: Synthesis of amine 128 by chemoselective reduction of azide 85. Reaction proceeds via 
an intermediate, iminophosphorane 131. Reagents and conditions: i) (a) Me3P (1M in THF), anhyd. THF, 
0°C to rt, 5 hr; (b) NaOH (2M), o/n, quant. 
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3.4.2. N-acylation of amine 128 with cerotic acid 
N-Acylation of amine 128 was achieved upon treatment with N,N-
diisopropylethylamine (DIPEA) and cerotic acid, which had been pre-activated with N-
hydroxybenzotriazole (HOBt) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (EDCI·HCl) (Scheme 3.11). 
 
Scheme 3.11: N-acylation of amine 128 with cerotic acid to afford fully protected β-ManCer derivative 
129. Reagents and conditions: i) (a) EDCI·HCl, HOBt, C25H51COOH, 10:4 DCM:DMF, rt, 30 min; (b) 128, 
DIPEA, anhyd. DCM, rt, o/n, α-129 1% over two steps, β-129 81% over two steps. 
The reaction proceeds by deprotonation of cerotic acid to generate carboxylate 132 
which on attack of protonated carbodiimide 133 gives O-acylisourea 134 (Figure 3.15). 
Formation of the active ester with hydroxybenzotriazole 135 gives 136 and the urea 
by-product 137. Addition of amine 128 results in coupling of the activated fatty acid 
residue, formation of amide 129 and regeneration of 135.  
 
Following workup and purification by silica gel column 
chromatography, separation of α- and β-129 was achieved in 1 
and 81% yields respectively. Figure 3.16 shows a TLC of some 
of the column fractions which highlights the difference in Rf of 
the two anomers, with the α being higher than the β. 
 
The 1H NMR spectra of both α-129 and β-129 are shown in 
Figure 3.17. Clearly, α-129 contains an impurity. Nevertheless, 
analysis of all NMR data supported the structures of both 
products. Resonances of note in the 1H NMR spectra include 
Figure 3.16: TLC of 
column fractions 
showing α (left) and 
β (right) seperation. 
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those associated with the anomeric proton and the NH amide proton doublet at 4.75 
and 5.50 ppm respectively for α-129 and 4.38 and 5.66 ppm for β-129. The 13C NMR 
spectrum of β-129 also supported the structure proposed. A coupled HSQC spectrum 
showed a 1JCH coupling constant for the anomeric carbon of 155 Hz confirming the β-
anomeric configuration. Similarly that of α-129 was measured as 169 Hz. HRMS for β-
129 was consistent with the sodiated molecular ion at m/z 1328.9420 and elemental 
analysis supported the purity of β-129. 
 
Figure 3.15 (Above): Mechanism for the pre-activation of cerotic acid by EDCI and subsequent 
formation of the major anomer, amide β-129. Figure 3.17 (Below): Comparison of the 1H NMR of α-129 
(Top) and β-129 (Bottom). The α-fraction contain some of the β-anomer. However, the β-fractions 
contains no trace of the α-anomer. Recorded at 500 MHz in CDCl3. 
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3.4.3. Global deprotection of β-129 
Global deprotection of β-129 was achieved by hydrogenolysis mediated by catalytic 
palladium on carbon under an atmosphere of hydrogen (Scheme 3.12). 1 was purified 
by trituration with water then precipitation from hot ethanol to afford, after isolation 
by centrifugation, 1 in 92% yield. All spectroscopic data supported the formation of 1 
and were consistent with the data obtained for the formation of 1 by global 
deacetylation of β-130 (Section 3.3.3). 
 
Scheme 3.12: Hydrogenolysis of derivative β-129 to afford the synthetic adjuvant 1. Reagents and 
conditions: i) Pd/C, DCM/MeOH H2, rt, o/n, 92%. 
3.4.4. Summary of Pathway B 
Pathway B provided access to pure β-ManCer (1) in 3 steps and 75% overall yield from 
glycoside intermediate 85, or in 12 steps and 22% overall yield from D-mannose, 
(2S,3S,4R)-2-amino-1,3,4-octadecanetriol and cerotic acid. 
3.5. Synthesis of β-Mannosylceramide (1) – Pathway C 
Both pathway A and B are capable of producing pure 1. Unfortunately, they do not 
provide access to pure β-ManPhyt (50), which is also of biological interest. It was 
apparent that the α- and β-anomers of intermediates in these syntheses were only 
separable when fully protected. As a result a new route, Pathway C (Scheme 3.13), 
was developed. It was reasoned that chemoselective reduction of azide 85 to give 
amine 128 (Section 3.4.1) and subsequent temporary protection of the amine as a 
carbamate (138) might provide a molecule suitably protected such that is would allow 
separation of the two anomers, ultimately providing β-50. 




Scheme 3.13: Proposed Pathway C, for the synthesis of anomerically pure β-mannosylphytosphingosine 
(β-ManPhyt, 50). 
3.5.1. Boc protection of amine 128 
Treatment of crude amine 128 with Boc anhydride and DIPEA afforded, after workup 
and purification, α-138 and β-138 as discrete compounds in 5 and 78% yields 
respectively over the two steps (Scheme 3.14). All spectroscopic data were in 
agreement with the proposed structures and 1JCH coupling constants of 170 and 156 
Hz supported their assignment as α and β respectively. 
 
Scheme 3.14: Boc protection of amine 50 allowing seperation of the anomers of 138. Reagents and 
conditions: i) (a) Me3P (1M in THF), anhyd. THF, 0°C to rt, 5 hr; (b) NaOH (2M), o/n; ii) Boc2O, DIPEA, 
DMF, 50°C, o/n, α-138 5% over two steps, β-138 78% over two steps. 
3.5.2. Deprotection of Boc derivative β-138 
Hydrogenolysis of the benzyl ether protecting groups and benzylidine acetal followed 
by treatment with trifluoroacetic acid, afforded, after reverse phase silica gel 
purification, β-50 in 77% yield (Scheme 3.15). The 1H, 13C and 19F NMR spectra are 
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shown in Figure 3.18 and all other spectroscopic data were in agreement with the 
proposed structure. 
 
Scheme 3.15: Two step global deprotection of Boc derivative β-138 affording β-50. Reagents and 
conditions: i) Pd/C, H2, 1:1 DCM:MeOH, rt, o/n; ii) TFA, DCM, rt, o/n, 77% over two steps. 
Importantly, comparison of the 1H NMR spectrum of β-50 (Figure 3.18 C) with our α-
ManPhyt (125) standard (Figure 3.18 D) shows no contamination by the α-anomer 
within the product. Worth noting is as the Boc protection of the amine was maintained 
during the hydrogenolysis conditions, no N-methyl by-product was observed. N-
acylation of β-50 with cerotic acid provides 1 in 4 steps and 69% yield or in 13 steps 
and 20% overall yield from commercial D-mannose, (2S,3S,4R)-2-amino-1,3,4-




Figure 3.18: 19F (A), 13C NMR (B), and 1H (C) spectra of β-50 recorded in 2:1 CDCl3:CD3OD at 376, 125, 
and 500 MHz respectively. Compared with the  1H NMR spectrum of α-mannosylphytosphingosine (α-
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3.5.3. One-pot global deprotection of glycoside 116 
Alternatively, β-ManPhyt β-50 can be prepared directly (Scheme 3.16) using 
anomerically pure azides such as 116, the glycoside product of the stannylene acetal 
mediated glycosylation (Section 2.7.5). 
 
Scheme 3.16: Direct synthesis of β-ManCer (1) when starting from anomerically pure starting materials 
like glycoside 116. Reagents and Conditions: i) Pd/C, HCl, H2, 1:1 DCM:MeOH, rt, o/n, 87%; ii) (a) 
C25H51COOH, TEA, isopropyl chloroformate (1M in tol), anhyd. DCM, rt, 2 hrs; (b) rt to 0°C; (c) 50·TFA, 
1:0.2 DCM:DMF, 0°C to rt, o/n, 92%. 
Concomitant reduction of azide 116 was achieved by hydrogenolysis of the benzyl 
ethers under acidic condition resulting in simultaneous loss of the isopropylidene 
residue. Following workup, purification on C18 silica gel, then lyophilization, gave β-
50·TFA in 87% yield. Subsequent selective N-acylation of β-50 with cerotic acid, 
mediated by isopropyl chloroformate, afforded 1 in two steps from azide 116 in 70% 
overall yield (Scheme 3.16). This sequence provides the synthetic adjuvant 1 in an 
expeditious 13 steps and 22% overall yield from D-mannose, (2S,3S,4R)-2-amino-1,3,4-
octadecanetriol and cerotic acid.  
3.6. Biologically relevant analogues 
3.6.1. Analogues: An introduction. 
The identification and synthesis of immuno-active agents for clinical and mechanistic 
applications is a rapidly growing area of research. In this vein, analogues of the 
prototypical CD1d agonist α-GalCer (2) have attracted considerable attention. In an 
effort to develop such analogues, there have been numerous structure activity 
relationship (SAR) studies with the goal of determining how tolerable the iNKT cell 
agonist 2 is to change. These studies focused on the effect of modifying the structure 
of α-GalCer with respect to five categories; I) substitution or functionalization of the 
hydroxyl groups of the sugar moiety, II) modification of the phytosphingosine chain, 
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III) substitution of the pyranosyl or glycosyl oxygen atoms, IV) functionalization or 
substitution of the amide moiety, and V) modification of the acyl chain (summarised 
in Figure 3.19). There are several reviews detailing the SAR studies based on these five 
categories,33, 62, 79, 91, 93, 223-226 and a summary of the findings is detailed in Table 3.1.  
 
Figure 3.19: The five modifiable substructures of α-GalCer (2). 
SUMMARY OF SAR STUDIES OF 2 
The 2-, 3-, and 4-hydroxy groups of the sugar moiety, which participate in the hydrogen-bonding 
network with CD1d and/or TCR, should be intact or exchanged to a functional group which can 
make polar interaction. 
Modification of the 6-hydroxy group of the galactose is acceptable. 
The 3S-hydroxy group of the sphingosine chain is essential. Existence of the 3-hydroxy group is 
necessary to make a stable complex with CD1d, and to stimulate NKT cells. The 4-hydroxy group is 
important for the glycolipid to be recognized by human NKT-TCR. 
The cyclohexanol analogue possessing an ether linkage instead of the acetal bond can stimulate NK 
cells via NKT cell activation and induce a large production of IFN-γ. 
The 2-amide bond has high tolerability to be modified. The S absolute configuration is important 
for immunostimulatory potency. 
Modification of the acyl chain is also acceptable. To improve binding affinity to CD1d, introduction 
of aromatic ring(s) at the proper position is more effective than chain elongation. 
The glycolipids possessing higher binding affinity for CD1d than α-GalCer tend to induce more TH1 
biased cytokine production. 
The glycolipids binding to CD1d with low affinity tend to cause TH2 type immune responses. 
 
Table 3.1: Summary of findings from SAR studies of α-GalCer and analogues. From T. Tashiro; Mori, K., 
Glycosphingolipid Ligands for Invariant Natural Killer T Cells as Immunostimulants. In Studies in Natural 
Products Chemistry, 2014; Vol. 42. 
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As discussed in the introduction of this work, iNKT cells play an important role in cell 
immunology with their ability to induce both pro-inflammatory and anti-inflammatory 
immune responses. CD1d mediated presentation of glycolipids to TCRs on the surface 
of CD1d-restricted (Vα14) iNKT cells induces the release of cytokines, with the 
cytokine profile governed by the structure227 and/or dose228 of the presented 
glycolipid antigen. These cytokines, as well as trans-activating APCs, 229-230 can have 
downstream effects on B cells,231-232 CD4+, and CD8+ T cells233-234 thereby bridging the 
gap between innate and adaptive immunity.235-237 TH1 dominant cytokines such as IFN-
γ, TNF-α and IL-2 are beneficial for the treatment of tumours,238-239 and bacterial or 
viral infections.240-241 Whereas a TH2 cytokine profile (e.g. IL-4, IL-6) are well suited for 
the control of autoimmune diseases,242 such as type I diabetes243-244 and lupus.245 An 
unbiased response, neither TH1 or TH2 favoured, is potentially problematic as it may 
lead to opposing effects against a particular disease condition.246 Likewise, the 
potency of cytokine release may also present clinical challenges with upregulation of 
a single pathway potentially inducing iNKT cell hyporesponsiveness or anergy.104, 247-
248 As discussed previously α-GalCer (2) is a potent Vα14 iNKT cell agonist.249-254 
However, 2 has performed poorly in human trials.95-96, 255-256 The widely believed 
consensus of the immunology community is α-GalCer (2) is handicapped by its inability 
to induce a clearly biased cytokine response.115-116, 174, 220, 257-258 It was reasoned that 
with 2 serving as a template, combined with SAR knowledge, that analogues could be 
developed with a biased cytokine profile whilst maintaining or improving on α-
GalCer’s potent activity.  
Figure 3.20: (a) Side view of α-GalCer (2) bound within human CD1d. The hydrophobic antigen-binding 
groove, with pockets labeled A′ and C′, is gray; 2 is orange; residues of CD1d are blue. (b) Top view of 
the TCR recognition surface formed by presentation of α-GalCer in CD1d. Adapted from Koch, M., et al., 
Nat. Immunol. 2005, 6 (8), 819-826; Copyright 2018, with permision from Springer Nature.  
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It is known from the crystal structure of human CD1d bound α-GalCer (Figure 3.20)259 
that the two acyl chains of the glycolipid are bound into two pockets within the 
quaternary structure of CD1d leaving the sugar head group exposed on the surface for 
interaction with TCRs on the surface of iNKT cells. Analogues of 2 can be broadly 
divided into two groups, those with modifications to the acyl chains and those that 
modify the head group.259-260 Of the many variants of 2, the most potent analogues 
reported differ in the nature of the fatty amide and of the many N-acyl analogues of 2 
known, the analogues 7DW8-5 and C34 reported by Chi-Huey Wong and co-
workers261-264 and C20:2 originally published by Yu et al (Figure 3.21)265 are most 
notable. Another site of variation that appears well tolerated by CD1d/NKT cell binding 
is the O-6 position of the galactose head group. Although the immunology of 
compounds bearing O-6 substituents is not quite as compelling as those with N-acyl 
modifications, certain variations at this position are reported to have favourable 
solubility profiles. However, due to the synthetic ease of modifying the amino 
functionality of a late-stage intermediate coupled with the remarkable immunology 
attained by some α-GalCer analogues, we focussed our efforts on creating N-acyl 
analogues of 1. 
 
Figure 3.21: Chemical structures of α-GalCer (2), 7DW8-5, C34, and C20:2. 
Recent studies have shown that increasing the binding affinity of a glycolipid for CD1d 
shifts the cytokine release profile towards a stronger TH1 response.261, 266 Both 7DW8-
5 and C34 were designed to exploit this by increasing favourable interactions with the 
lipid binding moiety of CD1d.267 The fluorinated phenyl ring-modified analogue of α-
GalCer (2), 7DW8-5 exemplified this idea displaying nearly a 100-fold stronger CD1d 
binding affinity over the parent molecule.268 Although both glycolipid adjuvants were 
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found to induce a similar cytokine response in sera of mice injected intravenously (i.v.), 
it was quite different on intramuscular (i.m.) administration (Figure 3.22).268 The 
authors rationalised this by identifying different bio-distribution patterns for 2 and 
7DW8-5. Following i.m. administration 2 induced a systemic cytokine response, 
whereas, 7DW8-5 with a much higher CD1d binding affinity was locally trapped by DCs 
expressing CD1d within draining lymph nodes (dLN).  
 
Figure 3.22: The levels of mouse IFN-γ and glycolipids in the sera of glycolipid-administered mice. (A 
and B) After BALB/c mice (n= 5 per group) were administered 1 μg α-GalCer or 7DW8-5 by i.v. (A) or 
i.m. (B) injection. Sera were obtained at indicated time points, and the concentrations of murine IFN-γ 
in the sera were determined with ELISA. Figure adapted from Li, et al., J. Immunol. 2015, 195 (6), 2710-
2721. Copyright 2018, with permision from Elsevier. 
Although this resulted in decreased in sera levels of INF-γ, 7DW8-5 induced a highly 
potent adjuvant effect resulting in increased CD8+ T cell response against the co-
administered antigen, and increased protection against malaria parasites (Figure 
3.23). These findings have led to 7DW8-5 being taken forward into human clinical trials 
for malaria and HIV vaccines.114, 269 
 
Conversely, C20:2 induces a TH2 bias, triggering IL-4 production without inducing a 
strong INF-γ response.270 Perhaps more importantly Denkberg et al. have shown C20:2 
loads preferentially onto cell surface CD1d without the need for endosomal 
internalisation by APCs which may prove useful in immunotherapeutic applications.265, 
271 
  




Figure 3.23: Colocalization of 7DW8-5 and IrPySpz in dLN-resident DCs facilitates activation and 
recruitment of DCs and enhances T cell immunogenicity and efficacy of IrPySpz vaccine. (A) BALB/c mice 
(n= 25 per group) were immunized i.m. with 1 × 105 IrPySpz(GFP-Luc) alone or together with 1 μg of 
each glycolipid. Sixteen hours later, PLNs-resident DCs were isolated and then 7.5 × 105 DCs/mouse 
were adoptively transferred i.v. to naive BALB/c mice (n= 5 per group). (B) Ten days later, blood was 
collected and the PyCS-specific CD8+ T cell response determined by an IFN-γ ELISpot assay. (C) Two days 
later, the same transferred mice and naive BALB/c mice as controls were challenged i.v. with 2 × 104 
PySpz; 42 h later, the parasite burden in liver was determined by quantifying the amount of parasite-
specific rRNA with real-time quantitative RT-PCR. Mean ± SD for five mice in each group is shown. Figure 
adapted from Li, X., et al., J. Immunol. 2015, 195 (6), 2710-2721. Copyright 2018, with permision from 
Elsevier. 
Altiti et al. Synthesized a series of C-glycoside analogues of α-GalCer including 7DW8-
5 variant 139 (Figure 3.24).272 Given the high cytokine potency of phenyl terminated 
alkanoyl derivatives of 2 (e.g. C34 and 7DW8-5) it was surprising that analogue 139 
was completely inactive.  
A 
B C 




Figure 3.24: Chemical structure of 139, a C-glycoside analogue of 7DW8-5. First reported by Altiti, A. S., 
et al., Carbohydr. Res. 2017, 443-444, 73-77. 
The unexpected loss of activity for the 11-phenylundecanoyl C-glycoside (139) 
reported reinforces the emerging idea that activity enhancements through structural 
changes at different loci of the parent O-glycoside are not necessarily additive.272 
Given the contradictory findings and multi-factorial nature of cytokine stimulation, 
speculation on whether equivalent modifications to β-ManCer (1) will be 
advantageous or destructive is premature. As such any new N-acyl analogues of 1 that 
helps develop an understanding of how subtle structural changes impact on cytokine 
activity are advantageous, either as potent new adjuvants or in providing critical SAR 
data. With this in mind our attention turned towards the synthesis of three N-acyl 
analogues of 1 (Structures shown Figure 3.25) comparable to the α-
galactosylceramide analogues 7DW8-5, C34, and C20:2. 
 
Figure 3.25: Chemical structure of 1, and our three N-acyl analogue targets, 140, 141, and 142. 
3.6.2. Fatty acid synthesis 
11-(Fluorophenyl)- and 11-((fluorophenoxy)phenyl)-undecanoic acid, (143) and (144) 
respectively, were Synthesized in 6-steps from 1,10-decanediol (145) in 11 and 13% 
overall yields (Scheme 3.17).  




Scheme 3.17: Synthesis of fatty acids 143 and 144 from 1,10-decanediol (145). Reagents and conditions: 
i) (a) NaH, DMF, 0°C, 30 min; (b) BnBr, 0°C to rt, 4 hrs, 50%; ii) DIAD, MBT, Ph3P, anhyd THF, 0°C to rt, 4 
hrs, 75%; iii) mCPBA, anhyd. DCM, 0°C to rt, o/n, 78%; iv) (a) HCOC6H4-R, LiHMDS, anhyd THF, -78°C , 1 
hr; (b) -78°C to rt, o/n, 149 = 53% (E:Z = 8:1), 150 = 55% (E:Z = 45:1); v) Pd/C, HCl, H2, EtOH, 151 = 81%, 
152 = 82%; vi) NMO, TPAP, MeCN, rt, 3 hrs, 143 = 95%, 144 = 95%. 
Mono-benzylation of 1,10-decandiol (145) was achieved on treatment with benzyl 
bromide and sodium hydride under dilute conditions to give 146 in 50% yield. 146 was 
converted into mercaptobenzothiazole derivative 147 using standard Mitsunobu 
conditions. Oxidation of 147 with mCPBA gave sulfone 148 in 78% yield. 1H and 13C 
NMR were in agreement with the proposed structure of 148 and HRMS gave the 
expected sodiated molecular ion at m/z 468.1613.  
 
Benzothiazolyl sulfones can be used for the efficient preparation of alkenes on 
reaction with aldehydes in a single step using the modified Julia olefination 
reaction.273-275 The reaction proceeds on activation of the benzothiazole sulfone with 
LiHMDS to give the metalated derivative II, which rapidly reacts with aldehydes (or 
ketones) to give alkoxide intermediate III (Figure 3.26 A). The alkoxide intermediate 
then undergoes an intramolecular Smiles rearrangement276-277 to give a sulfinate salt 
IV, which spontaneously eliminates sulfur dioxide and hydroxybenzothiazole to afford 
the alkene product. Addition of the metalated derivative II to the aldehyde can occur 
from either face, giving rise to the anti or syn configuration of alkoxide III, shown in 
Figure 3.26 B and C respectively. This ultimately gives rise to either the E- or Z-alkene, 
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where the selectivity can be tuned based on the sulfone used. Benzothiazolyl sulfones 
tends to favour E-alkenes, with an increase in selectivity observed on using 1-phenyl-
1H-tetrazol-5-yl sulfones. Whereas the selectivity can be reversed on use of pyridinyl 
sulfones, which exhibit high Z-selectivity.  
 
Figure 3.26: Mechanism of modified Julia olefination; (A) formation of alkoxide III on reaction of sulfone 
with LiHMDS; (B) Smiles rearangement of anti-alkoxide to afford E-configured alkene; (C) Smiles 
rearangement of syn-alkoxide to afford Z-configured alkene. 
Treatment of sulfone 148 with LiHMDS and para-fluorobenzaldehyde afforded, after 
work-up and purification by column chromatography, alkene 149 in 53% yield with an 
E:Z ratio of 8:1. Likewise, treatment with para-fluorophenoxyphenyl benzaldehyde 
gave alkene 150 in 55% yield with an improved selectivity of 45:1 in favour of the E-
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isomer. All spectroscopic data were in agreement with the proposed structures of 149 
and 150.  
 
Concomitant reduction of the double bond and hydrogenolysis of the benzyl ether of 
149 and 150 was achieved on treatment with palladium on carbon under a hydrogen 
atmosphere. Reduction of the alkene occurred rapidly; however, cleavage of the 
benzyl ether proved sluggish and required addition of acid and prolonged reaction 
times (48 hrs). Alcohols 151 and 152 were obtained after purification by column 
chromatography in 81 and 82% yield respectively. 
 
 
Figure 3.27: 1H NMR spectra of 143 (top) and 144 (bottom) recorded at 500 MHz in CDCl3. 
One pot oxidation of the alcohol to the carboxylic acid was performed on treatment 
of 151 and 152 with catalytic tetrapropylammonium perruthenate (TPAP) and N-
methylmorpholine N-oxide to serve as a co-oxidant. The reactions proceeded 
efficiently to give after isolation and purification of the fatty acid in excellent yields. 
The 1H NMR spectra (shown in Figure 3.27) along with the 13C and 19F NMR data and 
HRMS were consistent with the proposed structures of 143 and 144 and consistent 
with data previously reported in the literature.278 




3.6.3. N-acylation of amine 128 with fatty acid 143 or 144 
Fully protected amide derivatives 153 and 154 were synthesized in two steps from 
glycoside intermediate 85 (Scheme 3.18) using an identical procedure to the 
formation of protected β-ManCer (129) as described in Section 3.4.2. Chemoselective 
reduction of the azide functionality of 85 with trimethylphosphine and sodium 
hydroxide provided amine 128 with a handle for selective N-acylation. Fatty acid 143 
or 144 was pre-activated with EDCI and HOBt, and reacted with crude amine 128 to 
afford amide 153 or 154 respectively.  
 
Scheme 3.18: Synthesis of fully protected β-mannosylceramide analogues 153 and 154. Reagents and 
conditions: i) (a) Me3P (1M in THF), anhyd. THF, 0°C to rt, 5 hr; (b) NaOH (2M), o/n, quant; ii) (a) EDCI·HCl, 
HOBt, 143 or 144, 10:4 DCM:DMF, rt, 30 min; (b) 128, DIPEA, anhyd. DCM, rt, o/n; 153 = α-153 1% & β-
153 70% over two steps; 154 = α:β 3:97 65% over two steps. 
Amide 153 was isolated as its discrete α- and β-anomers in 1 and 70% yields 
respectively. The anomeric configuration of each product was determined by proton-
coupled HSQC experiments which gave 1JCH values of 172 and 156 Hz, supporting their 
assignments of α-153 and β-153 respectively. The 1H NMR spectrum of each anomer 
is shown in Figure 3.28 and all other spectroscopic data were consistent with the 
proposed structures of α- and β-153.  
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Figure 3.28: 1H NMR spectrum of α-153 (Top) and β-153 (Bottom) recorded in CDCl3 at 500 MHz. 
Expansion shows NH amide and benzylidene acetal protons. 
Unfortunately, 154 gave poor separation on silica gel chromatography and was 
isolated as an α-enriched and β-enriched mixture. The β-enriched fraction was 
isolated in 65% yield with an improved α:β ratio of 3:97. The 1H NMR spectrum of each 
fraction is shown in Figure 3.29, with contamination by the α-anomer clearly visible in 
the β-enriched fraction. 
Figure 3.29: 1H NMR spectrum of α-enriched (Top) and β-enriched (Bottom) 154 recorded in CDCl3 at 
500 MHz. Expansion shows NH amide and benzylidene acetal protons and shows the presence of a 
minor amount of its α-anomer. 
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3.6.4. Global deprotection of β-153 
Catalytic hydrogenolysis of β-153 provided, after purification by trituration, β-
ManCer 7DW8-5 analogue 140 in 83% yield (Scheme 3.19). 
 
Scheme 3.19: Synthesis of β-mannosylceramide 7DW8-5 analogue 72. Reagents and conditions: i) Pd/C, 
H2, rt, o/n, 83%. 
The 1H, 13C, and 19F NMR spectrum of 140 are shown in Figure 3.30 and all other 
spectroscopic data supported the proposed structure. The purity of 140 was assessed 
by HPLC and elemental analysis, and deemed sufficient for biological evaluation. 
 
Figure 3.30: 1H (Top), 13C (Bottom right), and 19F (Bottom left) NMR spectrum of 140 recorded in 2:1 
CDCl3:CD3OD at 500, 125, and 376 MHz respectively. 
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3.6.5. Purification of 154 and subsequent global deprotection 
Given the contamination of 154 with the corresponding α-anomer (α:β 3:97), global 
deprotection by treatment with palladium under a hydrogen atmosphere was 
subsequently followed by global acetylation of the crude mixture to afford 
peracetylated derivative 155 (Scheme 3.20). 
 
Scheme 3.20: Synthesis of β-mannosylceramide C34 analogue 141. Reagents and conditions: i) Pd/C, 
H2, rt, o/n; ii) Ac2O, py, rt, o/n, α-155 5%, β-155 74%; iii) 2.5M NaOMe, MeOH, rt, 3 hrs, 85%. 
Acetylation provided a less polar substrate which gave better separation of the 
anomers upon silica gel column chromatography. Here, 155 was isolated as discrete 
anomers in 5 and 74% yields respectively for α-155 and β-155. Proton-coupled HSQC 
experiments supported assignment of the anomeric configuration of the minor and 
major components with 1JCH values of 164 and 158 Hz for α-155 and β-155 
respectively. 
 
Deacetylation of β-155 under Zemplén conditions, followed by isolation and 
purification by trituration, afforded pure β-ManCer C34 analogue 141 in 85% yield. 
The 1H, 13C, and 19F NMR spectrum of 141, shown in Figure 3.31 supported the 
proposed structure, and HRMS found the expected sodiated molecular ion at m/z 
856.5348. As for 140 above, the purity of 141 was assessed by HPLC and elemental 
analysis. 
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Figure 3.31: 1H (Top), 13C (Bottom right), and 19F (Bottom left) NMR spectra of 141 recorded in 2:1 
CDCl3:CD3OD at 500, 125, and 376 MHz respectively. 
3.6.6. N-acylation of β-mannosylphytosphingosine (50) with elicosadienoic 
acid and subsequent global acetylation 
β-ManPhyt (50) was selectively N-acylated with commercially available 
elicosadienoic acid (Scheme 3.21) as for the synthesis of α- or β-ManCer (Section 
3.2.6 and 3.4.2). 
 
Scheme 3.21: Synthesis of protected β-mannosylceramide C20:2 analogue 156. Reagents and 
conditions: i) (a) Elicosadienoic acid, TEA, isopropyl chloroformate (1M in tol), anhyd. DCM, rt, 50 min; 
(b) rt to 0°C; (c) 50, DMF, 0°C to rt, 3 hrs; (d) Ac2O, DMAP, o/n, 86% 
Elicosadienoic acid was activated as a mixed anhydride upon treatment with isopropyl 
chloroformate prior to addition of 50. After ca. 3 hrs TLC indicated complete 
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consumption of 50 at which point acetic anhydride and a single crystal of DMAP was 
added to the reaction mixture. Following isolation and purification by column 
chromatography acetylated β-ManCer C20:2 analogue 156 was isolated in 86% yield. 
All spectroscopic techniques supported the proposed structure of 156. 
3.6.7. Deacetylation of protected β-mannosylceramide C20:2 analogue 156 
Deacetylation of 156 was performed on treatment with catalytic sodium methoxide 
solution to give, after purification by precipitation and isolation by centrifugation, β-
ManCer C20:2 analogue 142 in 88% yield (Scheme 3.22). 
 
Scheme 3.22: Synthesis of β-mannosylceramide C20:2 analogue 142. Reagents and conditions: i) 2.5M 
NaOMe, MeOH, rt, 3 hrs, 88%. 
HRMS found the expected sodiated molecular ion at m/z 792.5940 and the 1H and 13C 
NMR spectra, shown in Figure 3.32, supported the proposed structure of 142. 
 
Figure 3.32: 1H (Top) and 13C (Bottom) NMR spectrum of 142 recorded in 2:1 CDCl3:CD3OD at 500 and 
125 MHz respectively. 
Chapter III: Synthesis of Mannosylceramides 
 
117 
3.7. Formulation and Biological evaluation 
The purity of α-ManPhyt (125), α-ManCer (118), β-ManPhyt (50), β-ManCer (1), and 
β-ManCer analogues 140, 141, and 142 (which are to be submitted for biological 
evaluation) was assessed by HPLC using a charged aerosol detector (CAD), with the 
peak identity confirmed by liquid chromatography mass spectrometry (LCMS). The 
chromatograms can be found in the Section 6.4 of this work, with the results 
summarised in Table 3.2. 
 
Compound Number CI Number CAD Purity (%) Peak Parent ion (M/z) 
125 CI168 91.27 480 
118 CI164 96.62 881 
50 CI120 87.25 480 
1 CN138 95.06 881 
140 CI121 96.18 765 
141 CI122 94.82 857 
142 CI123 94.68 793 
Table 3.2: Summary of HPLC-CAD purity of glycolipids submitted for biological evaluation. 
As some of the free glycolipids have poor solubility in water (and most other solvents) 
they require a degree of preparation before undergoing immunological testing. One 
method that permits their solubilizing in water or PBS is lyophilizing small amounts 
into non-immunogenic matrix. Here, 200 µg of the compounds listed above were 
formulated with sucrose (56 mg), L-histidine (7.5mg), and tween-20 (5 mg) and 
provided to collaborators at the National Institute of Health (NIH) for biological 
evaluation.  
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Chapter IV: β-ManCer Vaccines: A Prodrug Approach 
This chapter provides a brief introduction to prodrug strategies and some of the 
immunological advantages they provide. It then goes onto describe several examples 
of α-GalCer prodrugs and their use in glycopeptide self-adjuvanting vaccines. After 
detailing the synergistic effects such vaccines provide, the synthesis and 
characterisation of a β-ManCer (1) prodrug is discussed. Ultimately, this chapter 
reports the exemplification of two novel self-adjuvanting glycopeptide vaccine 
constructs of 1 for use in immuno-therapeutic research. 
4.1. Introduction –Antigen Adjuvant Vaccine constructs 
As discussed in the introduction of this work, α-GalCer (2) displays clinically interesting 
adjuvant activity with its ability to activate APCs via CD1d mediated presentation to 
TCRs on the surface of Vα14 iNKT cells. In the context of vaccine development, 
adjuvants serve as stimulating agents that enhance antigen-specific immune 
responses and pleasing results have been obtained from co-administration 
experiments utilizing the prototypical iNKT cell ligand α-GalCer and peptide 
antigens.279 
4.1.1. Synergistic effects 
A milestone in the field of synthetic vaccines was achieved in 2007 when Boons et al. 
reported the superior properties of a vaccine candidate featuring chemical ligation of 
three individual components, a TLR ligand, T-epitope, and B-epitope.280 The authors 
attributed an increase in the local production of cytokines, upregulation of co-
stimulatory proteins, and the enhanced uptake by macrophages and dendritic cells to 
the chemical ligation strategy with massive uplifts in IgG antibody titers of the 
conjugated vaccine when compared with doses of the admixed components.  
 
Vecchi and co-workers later demonstrated that direct conjugation of a toll-like 
receptor agonist TLR7aR to the streptococcus pneumonia specific antigen RrgB, 
through a cleavable covalent linker improved the immunogenicity of the antigen.141 
The authors found that the RrgB-TLR7aR conjugate showed a 10-fold increase in the 
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survival rate of the animals after lethal challenge with Pneumococcal disease 
compared with treatment utilizing; (I) native unconjugated adjuvant and antigen, and 
(II) antigen alone (Figure 4.1).  
 
The authors proposed that the increased immunogenicity was a result of co-
localization of the adjuvant and antigen, as it would result in a single APC receiving 
synchronized exposure to both. Their hypothesis was supported by mechanistic 
studies on DC’s and showed that the efficiency of antigen presentation was highly 
dependent on whether the DC had received prior stimulation. 
 
Figure 4.1: Kaplan–Meier plot for survival estimation of the immunized groups for 10 days after lethal 
challenge. 8 mice were immunized per group for the conjugate RrgB-TLR7aR in comparison to the non-
conjugated (RrgB+TLR7aNR) and the native unconjugated adjuvant. Adapted from Vecchi et al. Eur J 
Pharm Biopharm 2014, 87 (2), 310-317. Copyright 2018, with permission from Elsevier. 
4.1.2. An α-Galactosylceramide prodrug 
A similar strategy by Anderson et al. reported conjugation of minimal peptide epitopes 
to an α-GalCer derivative, where the C-26 fatty acid (FA) is deliberately misorientated, 
for the production of vaccines with enhanced T cell responses and efficacies in 
allergy117 and cancer118 models. They demonstrated that by inducing an acid mediated 
N- to O-acyl migration of the fatty acid of α-GalCer (2), they could create a “pro-
adjuvant” 157 that rapidly underwent the reverse O- to N-acyl migration under 
physiological conditions (Figure 4.2 B). Not unexpectedly, they found that the ability 
of 157 to generate an adjuvant response was similar to that of 2. However, capping 
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the amine of 157 as an N-acetate (158), which would block the reverse acyl migration, 
resulted in complete loss of activity (Figure 4.2 C). Therefore, access to an interesting 
new class of α-GalCer prodrugs was possible by reacting the free amine, generated by 
the acyl migration, with an enzymatically cleavable linker, rendering such constructs 
inactive until processed in vivo. Furthermore, they realised that conjugation of an 
MHC class I-binding peptide (via such a linker) should provide a vaccine construct 
where it is possible to control release of both adjuvant and antigen by enzymatic 
processing. This would exploit the synergistic advantage derived from co-delivery of 
adjuvant and antigen to a single APC in a similar manner to that reported by Vecchi et 
al.141 
 
Figure 4.2: (a) Chemical structures of 2, 157, and 158. (b)HPLC traces showing the reverse migration of 
157 to α-GalCer (2) over time under buffer conditions. (c) Assessment of NKT cell activity in response 
to i.v. administration of the indicated compounds into C57BL/6 mice, as determined by assessing up-
regulation of CD86 as a marker of APC activation in the spleen by flow cytometry. Graphs represent the 
mean ± SEM of fluorescence intensity for CD86 on DCs (CD11c+ cells) in groups of three animals. Data 
are representative of two separate experiments. p< 0.05. Copyright 2018, with permission from 
Springer Nature.  
4.1.3. An Esterase cleavable linker 
One of the constructs presented by Anderson et al., CN152 shown in Figure 4.3, 
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by an acyloxymethyl carbamate. Acyloxymethyl carbamates are well-known amine 
capping groups that release the free amine through in vivo esterase activity.281 The 
peptide antigen was attached to the acyloxymethyl carbamate though an oxime 
linkage.  
 
Figure 4.3:  Mechanism of adjuvant/antigen release from misorientated prodrug CN152 via in vivo 
esterase activity. Adapted from Anderson et al. Nat. Chem. Biol. 2014, 10 (11), 943-949. 
4.1.4. A Protease cleavable linker 
Having described the first example of an adjuvant-antigen vaccine construct with the 
two components linked through an esterase cleavable linker,117 Anderson et al. 
described a similar vaccine construct based on a protease cleavable linker.120 
Protease-sensitive valine-citrulline-p-amino-benzyl (VC-PAB) carbamates are known 
substrates for lysosomal proteases,282-283 including Cathepsin B which is abundant in 
APCs.284 Vaccine construct CN175, shown Figure 4.4, was formed by capping the 
amine of migrated α-GalCer (MaGC, 157) with a VC-PAB self-immolative linker 
terminated in an alkyl azide. The azide was then reacted with an alkyne terminated 
MHC class I-binding peptide using a copper-catalysed azide alkyne click (CuAAC) 
reaction to provide construct CN175. 
 
Given vaccine construct CN175 showed comparable anti-tumour activity to construct 
CN152 it was chosen as the lead candidate by the authors due to the convenience of 
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the chemistry used along with the superior chemical stability of the VC-PAB carbamate 
linkage compare to the acyloxymethyl carbamate of CN152. 
 
Figure 4.4: Structure of vaccine construct CN175 reported by Anderson et al. containing the protease 
cleavable Cit-Val linker sequence. Chemical Science 2015, 6 (9), 5120-5127.  
4.1.5. The current generation 
To date Anderson et al. have shown that iNKT cell-dependent antigen-specific T-cell 
responses can be boosted, enhancing antitumor activity upon conjugation of MHC 
class I-binding CD8+ T cell epitopes to a misorientated α-GalCer derivative through a 
cleavable linker.117-118 Unfortunately, due to the high polymorphism of human 
leukocyte antigen (HLA) molecules, vaccines that rely on minimal MHC-binding 
sequences, would require patient selection or vaccine tailoring, based on appropriate 
HLA expression.120 One method that avoids the need to stratify patients is to use 
synthetic long peptides (SLPs) of the target protein, which cover the entire sequence. 
This ensures both CD4+ and CD8+ T cell epitopes are presented in all patients.285 The 
authors found that in attempting to conjugate SLPs to CN175 (Figure 4.4) using the 
aforementioned CuAAC reaction significant product degradation occurred. Whereas, 
strain-promoted alkyne-azide cycloaddition (SPAAC) methodology which utilises a 
bicyclo[6.1.0]nonyne (BCN) scaffold286 provided very clean products with rapid 
coupling of SLPs to migrated α-galactosylceramide prodrug scaffolds, such as 160 
(Figure 4.5).120 




Figure 4.5: Structure of migrated α-galactosylceramide prodrug scaffold 160 reported by Anderson et 
al. containing the SPAAC BCN handle. ACS Chemical Biology 2017, 12 (11), 2898-2905. 
Figure 4.6 shows how a prodrug scaffold I, analogous to 160 above, containing the 
protease cleavable valine-citrulline motif can undergo enzyme catalysed hydrolysis to 
give an antigenic peptide fragment and a substituted electron rich aromatic fragment 
II featuring a free electron-donating substituent. II then undergoes a rapid and 
spontaneous self-immolative 1,6-elimination to give the free drug III and azaquinone 
methide derivative IV. The self-immolative elimination is driven by an increase of 
entropy coupled with the irreversible formation of thermodynamically stable carbon 
dioxide.287 
Figure 4.6: Highlights the Cathepsin B enzymatic cleavage point on a PAB-CV linker and shows the 
subsequent spontaneous 1,6-self-elimination to give the free drug III and azaquinone methide residue 
IV. 
4.2. Rearrangement of β-Mannosylceramide  
Key to the glycopeptide vaccine approach detailed above is the ability to induce an N- 
to O-acyl migration within the glycolipid adjuvant affording a misorientated derivative 
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or pro-adjuvant. In the hopes of applying such a strategy to β-ManCer (1) attention 
turned towards inducing such a shift of the acyl chain of 1 and a comprehensive 
structural analysis of the resulting migrated β-ManCer (MbMC, 161). 
4.2.1. Migration of β-mannosylceramide 
Scheme 4.1: Migration of β-ManCer (1) generates a misorientated pro-adjuvant MbMC (161). Reagents 
and conditions: i) Dioxane, HCl, 65°C, 25 min, quant. 
Treatment of 1 with HCl in freshly distilled dioxane, upon heating, induced the desired 
N- to O-migration of the C-26 acyl chain to afford MbMC (161, Scheme 4.1). Although 
161 is shown as a discrete product, a mixture of ester constitutional isomers is 
assumed with the O-4’ isomer as the major product (This is discussed in detail in 
Section 4.2.2). Analysis of the crude material by HPLC, shown in Figure 4.7, supports 
the migration of the acyl chain with a significant decrease in the retention time of 
amine 161 (6.16 min) relative to the amide starting material (7.40 min). Both peaks 
share the same sodiated parent molecular ion at m/z 880 when analysed by LCMS. 
Comparison of the 1H NMR spectra of 1 and 161 shown in Figure 4.8 further supported 
migration of the acyl chain. As esters are more electron withdrawing than amides a 
downfield shift in the resonance of adjacent protons would be expected. A shift in the 
CH2 triplet, adjacent to the carbonyl of the acyl chain, from 2.16 ppm to 2.32 ppm 
supports this change from an amide to ester. An upfield shift of H-2’ (4.17 to 3.35 ppm) 
and significant downfield shift of H-4’ (3.53 to 4.85 ppm) also support a migration of 
the acyl functionality from the 2’- to 4’- position of the phytosphingosine. 
 
The hydrochloride salt of 161 was stable and in this form did not undergo the reverse 
migration in organic solvents. Migration of the acyl group of β-ManCer (1) to both O-
3’ and O-4’ can occur. However, it was assumed that the O-4’ ester was the major 
product. 
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Figure 4.7: Comparison of the HPLC chromatograms of 1 (Red) and 161 (Blue). Analysis was conducted 
on an analytical HPLC on an Agilent 1260 Infinity Quaternary HPLC equipped with a Dionex Corona Ultra 
RS charged aerosol detector (CAD) and peak identity was confirmed on an Agilent 6130 single 
quadrupole mass spectroscopic detector using a Phenomenex Kinetex 100Å C18 (2.6 µm, 3.0 x 50 mm) 
functionalized silica column and the following method:[T15, AW-BM, TFA2, F0.50, 30-100B G7H5].VII 
 
Figure 4.8: Comparision of the 1H NMR spectra of β-ManCer (1, top) with MbMC (161, bottom) recorded 
in 2:1 CD3OD:CDCl3 at 500 MHz. 
                                                      
VII Descriptions of the method can be found in the general experimental, Chapter 6  
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4.2.2. Structural analysis of migrated β-mannosylceramide 
To investigate this, β-ManCer (1) was migrated as before and the crude MbMC 161 
was acetylated to give a mixture of products (Scheme 4.2). It was hoped that analysis 
of the 2D NMR data would provide traceable connections, and allow determination of 
the position of the C-26 acyl chain within the different isomers.  
 
Scheme 4.2: Migration of β-mannosylceramide and subsequent capping by global acetylation provided 
per-acetates 162 and 163 in a 93:7 ratio. Reagents and conditions: i) Dioxane, HCl, 65°C, 25 min; ii) 
Ac2O, py, TEA, rt, o/n, 162:163 = 93:7, 79% over two steps. 
Comparison of the 1H NMR spectra of acetylated β-ManCer (130) and acetylated 
MbMC (162+163) indicated that no reverse ester to amide isomerisation had occurred 
under the reaction conditions, as all products contained an N-acetamide motif. The 
relative integrations of the anomeric proton signals at 4.55 and 4.51 ppm, gave the 
93:7 ratio of major to minor products and the position of the C-26 acyl residue was 
determined by HSQC and HMBC NMR experiments. The major product 162 was 
confirmed to be the O-4’ isomer and the minor product 163 as the O-3’ isomer. Figure 
4.9 shows the HSQC interactions (red) with the easily identified anomeric carbon 
signal at 98.3 ppm. Sequential HMBC correlations (blue) then give C-1’, H-2’, C-3’, H-
4’, and the carbonyl carbon of the cerotic acid residue respectively. The HMBC 
spectrum shows a correlation between H-4’ and a carbonyl carbon signal at δ173.94 
ppm. The latter signal also shows a cross peak with the α-methylene of the acyl chain 
confirming that the major isomer is the O-4’ ester (162). The structure of the minor O-
3’ ester (163) is supported by similar HMBC and HSQC interactions.  
 




Figure 4.9: Structure of 162 showing HSQC interactions in red and HMBC interactions in blue. 
4.2.3. Regeneration of β-mannosylceramide under biological conditions 
The reverse O- to N-migration of MbMC (161) in PBS buffer at pH = 7.4 was monitored 
by HPLC using both ELSD and MS detection to follow the course of the reaction. MbMC 
(161) was dissolved in DMSO at 1 mg·mL-1 and the resulting solution was then diluted 
5% into phosphate buffered saline (PBS) and monitored over time for the formation 
of 1. Figure 4.10 shows the HPLC chromatograms of the total ion current for all SIM 
channels (m/z 859 [1/161+H]+ and 881 [1/161+Na]+) at 2, 30, 60, and 120 minutes 
respectively. As evident from the chromatograms, there was an increase in the 
relative peak area for β-ManCer (1, 6.59 min) with respect to that of MbMC (161, 5.12 
min) over time. This would indicate that the reverse migration is taking place under 
the buffer conditions and supported our hypothesis that our pro-adjuvant 161 will 
regenerate the active adjuvant β-ManCer (1). Unfortunately, monitoring the 
migration beyond 120 minutes proved problematic due to the limited solubility of 1, 
which precipitates out of the DMSO-buffer solution. This is further supported by HPLC 
analysis using ELSD detection, which showed an increase in peak area of 1 over ca. 3 
hrs after which it remained constant. However, the absolute intensity of the peak 
corresponding to 161 continued to decrease. This would suggest that the reverse 
migration of 161 still occurred after 3 hrs, but the 1 which is subsequently formed then 
precipitated out of solution, which is noted by a decrease in the opacity of the 
solution.  



























HPLC migration study in PBS buffer at pH=7.4.
2 Min 30 Min 60 min 120 Min
Figure 4.10: LCMS chromatograms of 161 in PBS buffer at the indicated timepoints, showing the reverse O- to N-acyl migration which regenerates the 
active adjuvant 1 under biological conditions. Analysis using the following method:[T15, AW-BM, TFA2, F0.50, 30-100B G7H5]. 
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4.3. A self-immolative linker for adjuvant-antigen conjugation 
4.3.1. Synthesis of pNP-PAB-CV-Fmoc linker 
A self-immolative linker scaffold (164) containing the protease-sensitive L-valine-L-
citrulline peptide sequence was synthesized in three steps from Fmoc-valine (165), 
citrulline (166) and p-aminobenzyl alcohol (167) using literature procedures (Scheme 
4.3).288-290  
 
Scheme 4.3: Synthesis of protease sensitive self-immolitive linker backbone Fmoc-Val-Cit-PAB-pNP 
(164). Reagents and conditions: i) (a) Fmoc-Val, TEA, isopropyl chloroformate, THF, 1 hr, rt; (b) Cit, 
NaHCO3, H2O, 0°C to rt, 3hrs, 82%; ii) HOCH2C6H4NH2, EEDQ, DCM/MeOH, 40°C, o/n, 50%; iii) 
CO(OC6H4NO2)2, DIPEA, DMF, rt, o/n, 35%. 
The synthesis began with the isopropyl chloroformate mediated coupling of pre-
activated Fmoc-L-valine (Fmoc-Val) and L-citrulline (Cit) to give the N-terminal 
protected dipeptide Fmoc-Val-Cit (168) in 82% yield. Coupling of the p-aminobenzyl 
(PAB) alcohol unit was achieved on treatment with the reagent, N-ethoxycarbonyl-2-
ethoxy-1,2-dihydroquinoline (EEDQ) to give, after isolation and purification, the linker 
backbone Fmoc-Val-Cit-PAB (169) in 50% yield. To give a scaffold suitable for coupling 
to MbMC (161), linker 169 was activated as its p-nitrophenyl carbonate derivative 164 
upon treatment with bis(4-nitrophenyl) carbonate under basic conditions. 164 was 
isolated after precipitation then purification by C18 reverse phase silica gel 
chromatography in 35% yield for the reaction, or 14% overall yield from Fmoc-L-valine. 
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HRMS gave the expected protonated (M+H+), and sodiated (M+Na+) molecular ions at 
m/z 767.3035 and m/z 789.2862, respectively. All other spectroscopic data were in 
accordance with those previously reported in the literature.291 
4.3.2. Synthesis of pNP-BCN 
The second linker component Synthesized was a bicyclo[6.1.0]nonyne (BCN) scaffold 
(170) which would be used as a handle for selective bioorthogonal conjugation of SLP 
antigens to our vaccine construct via strain-promoted alkyne-azide cycloaddition 
(SPAAC) reactions. p-Nitrophenyl carbonate BCN 170 was Synthesized in five steps 
from commercially available 1,5-cyclooctadiene (171) using literature methods in 4% 
overall yield (Scheme 4.4).292-295  
 
Scheme 4.4: Synthesis of BCN-pNP 170. Reagents and conditions: i) N2CHCOOEt, 1,5-COD, Rh2OAc4, 
DCM, 48 hrs, endo-172 = 18%, exo-172 = 35%; ii) LiAlH4, Et2O, reflux, o/n; iii) Br2, DCM; iv) KOt-Bu, THF, 
reflux, 2 hrs, 26% over three steps; v) CO(OC6H4NO2)2, DIPEA, DCM, 30°C, o/n, 54%. 
Initially, intermolecular ruthenium-catalysed carbenoid cyclopropanation of 171 with 
ethyl diazoacetate gave 172, which upon purification by silica gel chromatography was 
isolated as its discrete endo- and exo-isomers in 18 and 35% yield, respectively. 
Lithium aluminum hydride reduction of the ester of exo-172 gave alcohol 173. 
Subsequent dibromination of the alkene followed by potassium tert-butoxide induced 
bis-elimination gave, after purification by column chromatography, BCN 175 in 26% 
over the three steps. To give a derivative suitable for coupling to our vaccine construct, 
175 was activated as its p-nitrophenyl carbonate derivative 170 upon treatment with 
bis(4-nitrophenyl)carbonate under basic conditions. Purification by silica gel column 
chromatography gave 170 in 54% yield. All spectroscopic data supported the proposed 
structure of 170 and were in full agreement with those previously reported in the 
literature.295 
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4.4. A β-mannosylceramide prodrug 
4.4.1. Coupling of MbMC (161) and pNP-PAB-CV-Fmoc (164) linker 
Crude MbMC (161) was coupled with activated pNP-PAB-CV-Fmoc linker 164 under 
basic conditions to afford, the crude pro-adjuvant, MbMC-PAB-CV-Fmoc (176, 
Scheme 4.5). Purification was achieved by reverse phase silica gel chromatography 
using a binary gradient of water methanol followed by methanol chloroform as the 
eluent to provide 176 in 58% yield. 
 
Scheme 4.5: Synthesis of MbMC-PAB-CV-Fmoc (176). Reagents and conditions: i) Anhyd. py, anhyd. 
TEA, rt, o/n, 58%. 
The structure of 176 was supported by 1H NMR (Shown in Figure 4.11) with inclusion 
of the PAB methylene resonance at 5.06 ppm and the distinct 6 proton double doublet 
resonance of the valine methyl groups at 0.91 ppm. Aromatic resonances associated 
with the PAB and Fmoc moieties were also present. The 13C NMR and HRMS, which 
found the expected sodiated molecular ion at m/z 1507.9894, further supported the 
proposed structure of 176. 
Figure 4.11: 1H NMR spectrum of MbMC-PAB-CV-Fmoc (176) recorded in 2:1 CD3OD:CDCl3 at 500 MHz. 
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4.4.2. Fmoc deprotection of 176 
Fluorenylmethyloxycarbonyl (Fmoc) deprotection of 176 was achieved on treatment 
with piperidine (10 vol% in DMF), to afford after isolation and purification by reverse 
phase silica gel chromatography, 177 in 70% yield (Scheme 4.6). 1H NMR supported 
deprotection of 176 with loss of the resonances associated with the Fmoc aromatic 
protons at 7.72, 7.52, and 7.35 ppm and a downfield shift of the valine CH3 signals 
from 0.91 to 1.00 ppm. All other data were in agreement with the proposed structure 
of 177. 
 
Scheme 4.6: Synthesis of MbMC-PAB-CV-NH2 (177). Reagents and conditions: i) (a) DMF, piperidine, 
0°C, 5 min; (b) rt, 30 min, 70%. 
4.4.3. Coupling of MbMC-PAB-CV-NH2 (177) and pNP-BCN (170) 
Coupling of the p-nitrophenyl activated BCN residue 170 was achieved on treatment 
with amine 177 under basic conditions (Scheme 4.7). Pro-adjuvant construct 178 was 
obtained, after purification by C18 column chromatography, in 72% yield. HRMS found 
the expected sodiated molecular ion (M+Na+) of 178 at m/z 1462.0033 and the 1H and 
13C NMR spectra (shown Figure 4.12) were in full agreement with the proposed 
structure. Key resonances within the 13C NMR spectrum were the anomeric carbon 
signal at 100.01 ppm and the quaternary carbon signal at 99.08 ppm. With no HSQC 
correlation and an HMBC correlation to H-3/6’’’ at 2.28 ppm, this quaternary carbon 
signal was assigned as the alkyne carbons, supporting coupling of the BCN unit. This 
was further evident in the 1H NMR spectrum with BCN proton resonances associated 
with H-2’’’, -3’’’, -6’’’, and -7’’’ present at 2.28 ppm and the BCN methine signals 
present in a 3 proton multiplet at 0.73-0.59 ppm. 
 





Scheme 4.7: Synthesis of adjuvant prodrug scaffold, MbMC-PAB-CV-BCN (178). Reagents and 
conditions: i) DMF, anhyd. TEA, rt, o/n, 72%.  
 
Figure 4.12: 1H (bottom) and 13C (Top) NMR spectra of MbMC-PAB-CV-BCN (178) recorded in 2:1 
CD3OD:CDCl3 at 500 and 125 MHz respectively.  
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4.5. Glycopeptide vaccines 
4.5.1. Coupling of MbMC-PAB-CV-BCN (178) and Peptide 179 
Strain promoted azide alkyne cycloaddition mediated conjugation of pro-adjuvant 
construct 178 with ISA Peptide HPV16 E7 (179, N3(CH2)4CO-FFRK-
GQAEPDRAHYNIVTFCCKCDS)VIII gave, following purification by semi-preparative 
HPLC, glycopeptide vaccine construct CI207 (MbMC-PAB-CV-BCN-FFRK-GQAE 
PDRAHYNIVTFCCKCDS) in 32% yield (Scheme 4.8). 
 
Scheme 4.8: Synthesis of glycopeptide vaccine construct, CI207, MbMC-PAB-CV-BCN-FFRK-
GQAEPDRAHYNIVTFCCKCDS . Reagents and conditions: i) deoxygenated DMSO, rt, o/n, 32%.  
HPLC analysis (Figure 4.13 A) showed a single peak for the purified vaccine 
construct at 8.10 min with a purity of 98.5%. Although compound 178 contains the 
isomerically pure exo-BCN cyclooctyne, peptide conjugation is expected to give rise to 
a mixture of diastereoisomers about the newly formed triazole group. While these 
diastereoisomers could not be resolved by HPLC we reasoned that, should they form, 
the spatial arrangement of the BCN unit should not affect vaccine processing given 
                                                      
VIII Provided by the Ferrier Research Institute, Victoria University of Wellington, New Zealand. 
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this functionality is remote to both the citrulline-para-amino-benzyl and peptidic FFRK 
residues. Peak identity was supported by LCMS (Figure 4.13 B) with the extracted 
mass spectrum (Figure 4.13 C) giving the M+3H+, M+4H+, and M+5H+ multiply 
charged ions of CI207 at m/z 1501, 1126, and 901 respectively. HRMS was further 
used to support the proposed structure of CI207 with fits for the 2+, 3+, 4+, and 5+ 
protonated molecular ions at m/z 2250.2479, 1500.4808, 1125.6194, and 
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Figure 4.13: HPLC analysis was conducted on an analytical RP-HPLC on an Agilent 1260 Infinity 
Quaternary HPLC equipped with a Dionex Corona Ultra RS charged aerosol detecter (CAD) and an 
Agilent 6130 single quadrupole mass spectroscopic detector using a Phenomenex Kinetex 100Å C18 
(2.6 µm, 3.0 x 50 mm) functionalized silica column and the following method:[T15, AW-BM, TFA2, F0.50, 
30-100B G7H5]; (A) HPLC-CAD chromatogram of purified vaccine construct CI207. (B) LCMS-SIM 
chromatogram of m/z 1501, 1126, 901, and 724. (C) Extracted mass spectrum from the TIC for the peak 
at 8.10 min. 
4.5.2. Coupling of MbMC-PAB-CV-BCN (178) and Peptide 180 
In a similar manner, pro-adjuvant construct 178 was conjugated to ovalbumin (OVA) 
synthetic long peptide (SLP) 180 (N3(CH2)4CO-FFRK-KISQAVHAAHAEINEAGRESIIN 
FEKLTEWT)IX, containing both CD4+ and CD8+ peptide epitopes, to afford following 
purification by semi-preparative HPLC and isolation by lyophilization, glycopeptide 
vaccine construct CI243 (MbMC-PAB-CV-BCN-FFRK-KISQAVHAAHAEINEAGRESII 
NFEKLTEWT) in 64% yield (Scheme 4.9).  
 
Scheme 4.9: Synthesis of glycopeptide vaccine construct, CI243, MbMC-PAB-CV-BCN-FFRK-
KISQAVHAAHAEINEAGRESIINFEKLTEWT . Reagents and conditions: i) deoxygenated DMSO, rt, o/n, 64%.  
                                                      
IX Provided by the Ferrier Research Institute, Victoria University of Wellington, New Zealand. 
Chapter IV: β-ManCer Vaccines: A Prodrug Approach 
 
139 
The proposed structure of CI243 was supported by HPLC (98.1% purity), LCMS, and 
HRMS which found the expected protonated 3+, 4+, 5+, and 6+ molecular ions at m/z 
1879.0727, 1409.5601, 1127.8468, and 940.0439 respectively. 
4.5.3. Formulation of CI207 and CI243 
Solubilisation of CI207 and CI243 was achieved by freeze-drying the samples (50 µg) 
in the presence of sucrose (56 mg), L-histidine (7.5mg), and tween-20 (5 mg) as 
previously described for the solubilisation of β-ManCer, and were provided to 
collaborators at the National Institute of Health (NIH) for biological evaluation.  
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Chapter V: Future Work – The Next Steps 
5.1. Summary of work completed 
Herein we have reported a number of efficient methods for the synthesis of 1,2-cis- 
mannosides, a key step in the total synthesis of the synthetic adjuvant -ManCer (1). 
At the inception of this work the current synthesis of 1 within our group utilized a TCA 
mediated glycosylation of a protected mannoside donor 117 and a phytosphingosine 
acceptor 78 to afford the key glycoside intermediate 85 (Scheme 5.1 A). Although 
highly efficient, the reaction yielded a 15:85 mixture of the  and  anomers of 85, 
which are difficult to separate. As discussed in the preceding chapters of this work -
ManCer (118) is a V19 (CD1d-independent) iNKT cell agonist whereas -ManCer (1) 
is a V14 (CD1d-restricted) iNKT cell agonist. As such it is imperative that discrete 
samples of - or -ManCer be studied, thereby avoiding activation of multiple iNKT 
cell subtypes. This work presented four methods for the synthesis of 1,2-cis- 
glycosides with improved stereoselectivity over the current method, of which three 
have significant methodological value. C-2 epimerisation of a 1,2-trans- glucoside 
was able to provide the corresponding -mannoside with complete selectivity and in 
good overall yield. However, the requisite use of the highly pyrophoric reducing agent, 
L-Selectride limits its potential for scale up applications. Alternatively a sulfoxide 
glycosylation approach based on methodology originally reported by Crich and co-
workers was able to provide the same glycoside intermediate 85 as the current 
commercial synthesis in high yield and with a modest improvement to the : ratios 
(Scheme 5.1 B, 5:95 vs 15:85). Combined with a 20% shorter synthetic sequence this 
method has subsequently been adopted by the Ferrier Research Institutes as a 
replacement for the TCA based synthesis. Of the methods investigated the most 
effective was the stannylene acetal mediated glycosylation of a 1,2-diol 105 with 
phytosphingosine triflate 48 (Scheme 5.1 C). This method afforded glycoside 
intermediate 116 in high yield and with complete selectivity for the β-anomer. The 
only limitations of the stannylene acetal method appear to be donor substrate scope, 
which requires further investigation, and the need to quantify residual tin residues 
before biological administration. 




Scheme 5.1: A: The key glycosylation step currently utilised by the Ferrier Research Institute in their 
total Synthesis of 1. Reagents and conditions: i) TMSOTf, anhyd. DCM, 0°C, 4 hrs, α:β 15:85 97%. B: 
Sulfoxide glycosylation protocol reported in Chapter II of this work. Reagents and conditions: i) (a) 
DTBMP, 4Å MS, anhydrous DCM, 1 hr; (b) Tf2O, -78°C, 10 min; (c) 78, -78°C to -50°C, 3hrs, α:β 5:95, 70%. 
C: Stanylene acetal mediated glycosylation protocol reported in Chapter II of this work. Reagents and 
conditions: i) Bu2SnO, tol, reflux, 3 hrs; ii) (a) CsF, DMF, rt, 30 min; (b) 48, rt, o/n, 62%. 
Having developed an efficient synthesis of 1,2-cis- mannosides we utilized these key 
glycoside intermediates in the total synthesis of 1, and a number of N-acyl analogues 
thereof: 50, 140, 141, and 142 (Figure 5.1). It is planned that biological evaluation of 
these compounds can provide insights into the structural activity relationships of this 
important class of adjuvants. Furthermore, should these evaluations show an activity 
advantage for 140, 141, or 142 over 1, then it is envisioned that adjuvant would be 
utilised in the aforementioned rearrangement pro-drug approach. 
 
In a similar manner to that reported for -GalCer (2) by Anderson et al.117, 140 we 
investigated the acid-catalysed intra-molecular rearrangement of the C26 acyl chain 
of 1. Having found that an N- to O-acyl migration of 1 afforded a misorientated 
derivative, MbMC (161) that underwent the reverse O- to N-acyl migration under 
physiological buffer conditions, regenerating the active adjuvant -ManCer (1), the 
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amine of 161 was utilized as a handle to develop pro-adjuvant vaccine scaffolds. These 
scaffolds were exemplified in the synthesis of two novel self-adjuvanting vaccines, 
CI207 bearing a HPV16 E7 antigenic peptide sequence and CI243 which bears a model 
SLP OVA sequence containing both CD4+ and CD8+ epitopes (Scheme 5.2). It is hoped 
these self adjuvanting vaccines will provide, following processing in the local 
environment, both adjuvant 1 and antigenic peptide fragments to the same APC, 
thereby exploiting the synergistic effect reported by Vecchi and co-workers.141  
 
Figure 5.1: Structure of β-ManCer (1) and its N-acyl analogues, 50, 140, 141, and 142. 
The proposed mechanism of release is detailed in Figure 5.2 and involves Cathepsin B 
mediated cleavage of the para-aminobenzyl citrulline amide bond of the self-
adjuvanting vaccine construct I. Such derivatives, II, are known to rapidly undergo a 
spontaneous 1,6-self immolative elimination to afford, in this case, the misorientated 
pro-adjuvant 161 and quinone methide IV. 161 would then undergo an intramolecular 
rearrangement to regenerate the active adjuvant β-ManCer (1). Concurrently linker 
fragment III undergoes protease cleavage at the FFRK peptidic sequence, followed by 
antigen processing to afford the active antigenic peptide V.  
 
Although this work has largely focused on the chemical synthesis of such compounds, 
biological evaluation is underway and will be reported in subsequent publications.  
 
  




Scheme 5.2: Complete synthetic scheme for the total synthesis of self-adjuvanting vaccine constructs 
CI207 and CI243 starting from D-mannose (51) and (2S,3S,4R)-2-amino-1,3,4-octadecanetriol (46). 
  




Figure 5.2: Proposed mechanism of vaccine congugate cleavage mediated by Cathepsin B, to yield 
Antigen (V) and the adjuvant β-ManCer (1). 
5.2. Improving the synthesis of β-ManCer 
The utilisation of boronic esters have also been exemplified for the highly 
stereoselective addition of alcohols to the β-face of 1,2-anhydromannose donors. This 
methodology requires an aryl borinic acid (181) to bind reversibly to the acceptor 
alcohol (I) which then activates the 1,2-anhydromannose (182), generating a reactive 
cationic oxonium species. Intramolecular addition of the appended acceptor then 
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provides the desired β-mannoside (III) with regeneration of the borinic ester catalyst. 
(Figure 5.3).296 
 
Figure 5.3: Arylboronic esters have also been exemplified for the stereoselective glycosylation of 1,2-
anhydromannose donors. Figure adapted from Tanaka, M., et al., Org. Lett. 2016, 2288-2291. 
Unfortunately, synthesis of the β-epoxide (182) requires harsh conditions and/or 
expensive reagents, with most classical oxidations of D-glucal providing favourable 
formation of the α-epoxide. The two known methods for the stereoselective synthesis 
of 1,2-anhydromannose β-epoxides involve Me3SiCl mediated opening of a 1,2-
orthoester of mannose to give the 2-acetyl α-chloride (184), with subsequent 
potassium tert-butoxide mediated removal of the acetate group, forming via an O-2 
alkoxide, the β-epoxide (182).297 The second method utilizes stereoselective oxidation 
of D-glucal (185) with dibenzothiophene oxide (DBTO) and trifluromethanesulfonic 
anhydride, and is summarised in Scheme 5.5.298 
 
Scheme 5.5: The only two examples of stereoselective formation of β-epoxide 182 reported in the 
literature. 
With the non-trivial synthesis of 1,2-anhydromannose β-epoxides, their use for the 
stereoselective synthesis of 1,2-cis-β mannosides was not explored within this work. 
However, such a method should be evaluated in future work, as an improved protocol 
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for the synthesis of α-GalCer (2). It can be envisioned that oxidation of 3,4,6-tri-O-
benzyl-D-galactal (186) with mCPBA or DMDO would afford the corresponding α-
epoxide 187. Glycosylation with an appropriate glycosyl-acceptor-derived boronic 
ester should then afford the desired 1,2-cis-α galactoside 188 (Figure 5.4 A). Such work 
has been exemplified by Nakagawa et al. for the synthesis of many 1,2-cis-α glycosidic 
bonds of glucose, which he used in the synthesis of a number of disaccharides 
including formation of the key 1,4-α glycosidic bond of isoflavone glycoside 189 
(Figure 5.4 B).299 
 
Figure 5.4: A: Proposed expedious formation of α-GalCer (2) from 3,4,6-tri-O-benzyl-D-galactal (186). 
B: Structure of isoflavone glycoside 189. 
5.3. Insights learned from α-galactosylceramide glycopeptide 
vaccine constructs 
It has long been known that prodrugs designed for enzymatic release often prove to 
be poor substrates for their targeted enzyme due to the steric hindrance of the “drug” 
around the masksed enzymatic cleavage site. This has been successfully overcome by 
utilizing self-immolative spacer/linker groups, which separate the pro-drug trigger site 
from the drug moiety. Such linkers are well known, have been extensively reviewed in 
the context of tumour-activated prodrug therapies,300-303 and are abundant scaffolds 
in clinically approved drugs.304  
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Initial results from biological studies of α-GalCer glycopeptide vaccines, analogous to 
CI207 and CI243, appear to show poor turnover in respect to enzymatic linker 
cleavage. The study involved incubating the vaccine construct I with Cathepsin B, 
which should recognise the linkers’ citrulline-valine sequence and hydrolyse the N-
terminal citrulline peptidic bond to give amine II and fragment III. The residual linker 
of amine II then undergoes a spontaneous 1,6-elimination, with subsequent 
rearrangement of the C26 acyl chain regenerating 2 which can be detected by LCMS 
analysis (Figure 5.5).  
 
Figure 5.5: Vaccine construct cleavage by Cathepsin B affords α-GalCer (2) and fragment III which can 
be detected by LCMS, allowing determination of the rate of linker cleavage (enzyme turnover). 
It is known, from similar studies of analogous structures lacking the BCN-peptide 
component that linker cleavage occurs, with the regenerated adjuvant 2 forming in 
appreciable quantities. It has therefore been postulated that structures such as I, and 
likely CI207 and CI243, are too sterically bulky around the Cathepsin B cleavage site to 
allow sufficient turnover. To investigate this two additional β-ManCer glycopeptide 
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vaccine constructs, CI209 and CI210 were synthesized containing an additional C12 
spacer between the citrulline-valine protease sequence and the BCN moiety 
(Structures Figure 5.6).X It is expected that future comparisons of CI207 and CI243, as 
well as CI209 and CI210 will provide evidence to support this hypothesis. Should 
incorporation of the spacer unit prove beneficial it is envisioned that additional 
analogues be synthesized where the length and type of spacer unit is varied. 
 
Figure 5.6: Structures of vaccine constructs CI207 and CI243 and their C12 linker analogues CI209 and 
CI210. 
5.4. A different class of conjugates. 
It is known from SAR studies of α-GalCer (2) that the 6-O hydroxyl group of the sugar 
residue is solvent accessible within the binding site of CD1d. Because of this, chemical 
modification at this position retains the iNKT cell agonist activity of the parent 
glycolipid.305 For example, Compton and co-workers have exemplified a 6-deoxy 6-thio 
derivative of α-GalCer for use in self-adjuvanting cancer vaccines (Figure 5.7 A).119 
Compounds such as CN222 and CN212 favour intracellular release of the glycolipid 
                                                      
X These compounds have been synthesized by me (Sage Robinson, University of Otago). However, are 
not detailed in this thesis beyond mention in the experimental (Section 6.3). 
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and antigen with the activation strategy exploiting the endogenous reductant 
glutathione (GSH).306 Typically, the extracellular concentration of GSH is low (approx. 
1-20 μM in plasma) compared with the relatively high intracellular concentration 
(approx. 0.5-10 mM). This gradient can be exploited providing a level of stability for 
“thiol-reactive” conjugates outside of the cell, with rapid degradation upon 
internalization. 
 
Figure 5.7: A: Structures of 6-deoxy 6-thio α-GalCer constructs CN222 and CN212 reported by Compton 
and co-workers. B: A generalised structure of a β-ManCer equivalent construct. 
While such a strategy does not necessarily hold for β-ManCer (1) it warrants further 
investigation as it would allow for a different attachment site of the peptidic antigen, 
yielding a motif such as I (Figure 5.7 B). It can be envisioned that such substrates could 
be easily accessed using our stannylene acetal mediated glycosylation methodology 
where the 6-hydroxyl of the sugar moiety is orthogonally protected. Benzylation of 
the 2-hydroxyl group of the intermediate glycoside followed by selective deprotection 
of the 6-position would provide a molecule such as 190 (Figure 5.8 A). Subsequent 
tosylation of 190 followed by displacement with potassium thioacetate or sodium 
azide should then afford 191 or 192 respectively. Such compounds, possessing masked 
thio or amino groups, would, on deprotection and N-acylation with cerotic acid, afford 
6-deoxy 6-thio or 6-deoxy 6-amino β-ManCer and provide a handle for antigenic 
peptide ligation techniques.  




Figure 5.8: A: Tosylation of 190 followed by displacement with thio acetate or azide would afford 
protected 6-deoxy 6-thio (191) or 6-deoxy 6-amino (192) β-ManCer analogues. B: Stanylene acetal 
mediated glycosylation donor substrate scope.  
As mentioned in the summary of this work, further investigation into the substrate 
scope of the stannylene acetal “diol” is required. Attempts to utilise triol 193, or silyl 
protected compounds 194 and 195 as the donor in such glycosylation reactions have 
proven unsuccessful (Figure 5.8 B). It is anticipated that 196 with a para-bromobenzyl 
protecting group in the 6-position, which is analogous to the benzyl ether of 105 will 
be a suitable donor. However, this remains to be investigated. Subsequent benzylation 
of 197 (the glycoside product of stannylene acetal mediated glycosylation of donor 
196 and acceptor 48), followed by selective removal of the para-bromobenzyl 
protecting group would afford 198, a suitable substrate for tosylation, and 
displacement with either potassium thioacetate or sodium azide (Figure 5.9). Para-
bromobenzyl ethers have been utilized as protecting groups in organic chemistry, 
bearing similar stability to their unsubstituted parents, which can be easily and 
selectively removed under mild conditions. Removal is achieved through palladium-
catalysed amination of the aryl halide which generates a labile intermediate that is 
cleaved on brief exposure to Lewis acids, protic acids, or oxidants.307 




Figure 5.9: Proposed stanylene acetal mediated glycosylation of donor 196 possesing orthoganal 
protection in the 6 position should provide 198, a sutible substrate for tosylation and displacement with 
thio acetate or azide affording protected 6-deoxy 6-thio or 6-deoxy 6-amino β-ManCer derivatives. 
Highlighted is the para-bromobenzyl protecting group selective deprotection protocol. 
This work has made several notable advances towards our original goal of 
glycopeptide vaccine development. Of note, the synthesis of two unique self- 
adjuvanting glycopeptide vaccines constructs utilising the adjuvant β-ManCer provide 
the potential for a potent cancer specific immune response without inducing T cell 
anergy, the crippling limitation of vaccines utilising α-GalCer. Should these vaccines 
prove effective a significant step towards the realisation of an effective cancer 
immunotherapeutic treatment will have been made. 
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Chapter VI: Experimental 
6.1 General Experimental 
6.1.1. Nuclear Magnetic Resonance (NMR) spectroscopy 
1H NMR spectra where recorded at either 400 MHz on a Varian 400-MR NMR system 
or at 500 MHz on a Varian 500 MHz AR Premium Shielded Spectrometer. All spectra 
were recorded from samples at 25°C in 5 mm diameter NMR tubes. Chemical shifts 
are referenced to the residual solvent peak (CHCl3 7.26 ppm, CHD2OD 3.31 ppm, 
CHD2(SO)CD3 2.50 ppm, CHD2(CO)CD3 2.05 ppm, HDO 4.79 ppm). CDCl3-CD3OD solvent 
mixtures were always referenced to the methanol residual solvent peak. Chemical 
shifts are reported to the nearest 0.01 ppm and coupling constants (J) have been 
rounded to the nearest 0.1 Hz. Resonances were assigned as follows: chemical shift 
(number of protons, multiplicity, coupling constant(s), assigned proton(s)). Multiplicity 
abbreviations are reported using the standard ACS conventions. CH indicates an 
unspecified methine proton, CH2 an unspecified methylene proton, and CH3 (or Me) 
an unspecified methyl proton. 
 
13C NMR spectra where recorded at either 100 MHz on a Varian 400-MR NMR system 
or at 125 MHz on a Varian 500 MHz AR Premium Shielded Spectrometer under the 
same conditions as for the 1H NMR spectra. Chemical shifts are referenced to the 
deuterated solvent peak (CDCl3 77.0 ppm, CD3OD 49.0 ppm, (CD3)2SO 39.5 ppm, 
(CD3)2CO 29.8 ppm). CDCl3-CD3OD solvent mixtures were always referenced to the 
methanol deuterated solvent peak. Spectra recorded in D2O were referenced to an 
external reference of dioxane at 67.19 ppm. Chemical shifts have been rounded to the 
nearest 0.01 ppm. Resonances were assigned as follows: chemical shift (assignment). 
 
19F NMR spectra where recorded at 376 MHz on a Varian 400-MR NMR system under 
the same conditions as for the 1H NMR spectra. Chemical shifts are reported relative 
to an external reference of trifluoroacetic acid at -76.55 ppm using the δ scale and 
have been rounded to the nearest 0.01 ppm. Coupling constants (J) have been 
rounded to the nearest 0.1 Hz. Resonances were assigned as follows: chemical shift 
Chapter VI: Experimental 
 
158 
(multiplicity, coupling constant(s)) and multiplicity abbreviations are reported using 
the standard ACS conventions. 
 
31P NMR spectra where recorded at 161 MHz on a Varian 400-MR NMR system under 
the same conditions as for the 1H NMR spectra. Chemical shifts are reported relative 
to an external reference of triphenylphosphine oxide at 25.50 ppm using the δ scale 
and have been rounded to the nearest 0.01 ppm. 
 
2-Dimensional correlation spectra (gCOSY, gHSQC, gHMBC, NOSEY, ASAPHMQC) were 
used to assign peaks in both the 1H- and 13C-NMR spectra. 
6.1.2. Infrared Spectroscopy 
Infrared spectra were recorded on a Bruker Optics Alpha FT-IR spectrometer with a 
diamond Attenuated Total Reflectance (ATR) top plate. No preparations where 
required for sample analysis. Values are reported in wavenumbers, ν (cm-1). 
6.1.3. High Resolution Mass Spectrometry 
HRMS analysis was conducted on a Bruker microTOFQ mass spectrometer using an 
electrospray ionization (ESI) source in either the positive or the negative mode as 
indicated. 
6.1.4. Chromatography  
Thin Layer chromatography (TLC) was performed on aluminum-backed Merck sorbent 
silica gel plates. Compounds were visualized using a UV lamp and stained using a 
Vanillin (Vanillin in ethanol and 0.01% H2SO4) or phosphomolybdic acid (10 wt% in 
EtOH) stain with subsequent charring.  
 
Normal phase column chromatography was performed using silica gel (230-400 mesh) 
and the specified elutent. 
 
Reverse phase column chromatography was preformed using Isolute® C18(EC) column 
cartridges purchased from Biotage, using the specified gradient and elutents. When 
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required due to lack of solubility in the starting solvent ratio the compound was 
concentrated onto Octadecylsilyl-functionalized silica gel (200-400 mesh, 20-22% 
loading) from the specified solvents and dry loaded onto the Isolute® cartridge. 
6.1.5. Melting Points 
Melting points were determined using a Metler Toledo FP62 automatic melting point 
apparatus, and are uncorrected. 
6.1.6. Semi-Preparative HPLC 
Semi-preparative HPLC purification employed a Agilent 1100 HPLC system fitted with 
a Phenomenex Luna C18(2), 5 μm, 250 x 21.2mm column, with H2O/0.05% TFA as 
eluent A and MeOH/0.05% TFA as eluent B. Runs were conducted using approx. 200 
µL of a 10 mg mL-1 crude reaction solution and the target material was eluted using 
the specified flow and solvent gradient. Monitored at 254 nm fractions were collected 
based on slope (up slope = 0.3, down slope = 0.3). The fractions were analysed by 
HPLC, with those containing the desired material at sufficient purity being pooled and 
lyophilized. 
6.1.7. HPLC analysis 
Synthetic purity HPLC analyses were conducted on an analytical RP-HPLC (Shimadzu 
LC-20AD equipped with both a SPD-20A UV [210 and 254 nm] and ELSD-LTII [350 kPa, 
nebulizer 60°C] detector). Peak identity was confirmed by LCMS on an analytical RP-
HPLC (Shimadzu LC-20AD equipped with both a SPD-20A UV [210 and 254 nm] and 
Shimadzu LCMS-2020 single quadrupole mass spectroscopic detector using ESI or 
DUIS). Using the specified column, solvents, flow rate and conditions.  
 
Unless otherwise stated operational values for the LCMS-2020 single quadrupole mass 
spectroscopic detector were as follows: Interface Voltage: +4.5 kV (ESI-Positive), -3.5 
kV (ESI-Negative); Detector Voltage: 1.1 kV; Nebulizing gas flow: 1.5 L min-1; Drying 
Gas Flow: 15 L min-1; DL Temperature: 250°C; Block Heater Temperature: 400°C; DL 
and Q-Array Voltages: default values. 
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HPLC columns were as follows: Column A; Phenomenex Prodigy 5u ODS3 100Å C18 (5 
µm, 3.00 x 250 mm) functionalized silica. Column B: Phenomenex Prodigy 5u ODS3 
100Å C8 (5 µm, 3.00 x 250 mm) functionalized silica. Column C: VisionHT C18 HL (3 
µm, 2.10 x 50 mm) functionalized silica. Column D: Phenomenex Gemini-NX C18 110Å 
(3 µm, 2.00 x 150 mm) functionalized silica. Column E: Phenomenex Luna 100Å C8(2) 
(3 µm, 2.00 x 250 mm) functionalized silica. Column F: Phenomenex Luna 200Å HILIC 
(3 µm, 4.60 x 150 mm). Unless otherwise stated all columns were used at 40°C. 
 
Unless otherwise stated, the solvent system for all reverse phase analytical LC 
purposes was a mixture H2O (containing 0.05% TFA or FA) and either MeCN 
(containing 0.05% TFA or FA) or MeOH (containing 0.05% TFA or FA). HPLC grade 
acetonitrile (CH3CN) and methanol (MeOH) was purchased from Merck Chemicals. 
MilliQ grade H2O was obtained from a Millipore purification system. LCMS grade H2O, 
acetonitrile, and methanol was purchased from Fisher Scientific. HPLC grade 
trifluroacetic acid (TFA) and HPLC grade Formic Acid (FA) was purchased from 
Scharlau. 
 
HPLC data were reported using the following convention. Column Time Solvents Acid 
Modifier Flow Gradient Mass range [Column X, TXX, AX-BX XXX2, FXX, XX-XXXB GXHX, 
XX-XXXPos/Neg]. 
Column X: Referes to the column used, as listed above. 
Time: Refers to the method time in minutes. 
Solvents: Identifies the solvents used for line A and line B, solvents are: W=Water, 
A=Acetonitrile, M=Methanol. 
Acid Modifier: Indicates the acid additive in line A and B, either trifluroacetic acid (TFA) 
or formic acid (FA). 
Flow: The total solvent flow rate in mL min-1 
Gradient: Indicates the starting and final percentages of solvent B. Followed by the 
time taken in min to transverse this gradient, then the time taken in min that the 
maximum percentage of B is held constant. All methods then include a return to the 
starting percentage of B over 1 min and a hold at that percentage for 2 min. 
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Mass range: LCMS only, Refers to the spectra window of the TIC in hundreds of m/z 
and whether positive or negative is used  
 
For example: Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.6, 60-100B G4H9] 
would refer to a method that used a VisionHT C18 HL (3 µm, 2.10 x 50 mm) 
functionalized silica column for a 16 minute run. The solvent for line A was H2O and 
line B was Methanol, both solvents contained TFA as the acid modifier. The solvent 
flow was 0.6 mL·min-1 and there was a gradient of line B (methanol) of 60% to 100% 
over 4 minutes (G4) with a 100% methanol hold for 9 minutes (H9) before returning 
to 60% methanol over 1 minute and a hold of 60% methanol for 2 minutes. A similar 
LCMS method: Analytical LCMS [Column C, T16, AWBM, TFA2, F0.6, 60-100B G4H9 22-
200Pos] would mean the same where the TIC spectra window was 220-2000 m/z in 
positive ion mode. 
6.1.8. Microanalyses 
Microanalyses were carried out by the Campbell Microanalytical Laboratory, 
University of Otago using a Carlo Erba 1108 CHNS combustion analyzer. The error in 
the quoted values is ± 0.3%. 
6.1.9. Reaction Conditions 
All experiments requiring anhydrous conditions were performed under a dry nitrogen 
or argon atmosphere using apparatus flame heated and dried under vacuum 
immediately prior to use. Reactions carried out at room temperature (rt) were 
conducted at 20°C and baths of the following type were used to reach the following 
temperatures: 25°C (Sand), 0°C (ice and water), -41°C (dry ice and acetonitrile), -78°C 
(dry ice and acetone), -196°C (liquid nitrogen).   
6.1.10. Reagents and Solvents 
Anhydrous acetonitrile (CH3CN), dichloromethane (CH2Cl2), tetrahydrofuran (THF), 
diethyl ether (Et2O), methanol (MeOH), and toluene were dried using the PURE SOLV 
MD-6 purification system. Anhydrous N,N-dimethylforamide (DMF) was purchased in 
Sure/SealTM bottles. All other solvents and reagents were used as received.  
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6.1.11. Resin, beads and solid supports 
4Ȧ Molecular sieves (4Ȧ MS) were freshly activated prior to use using the following 
method; Placed inside a tube furnace at 320°C for 1 hour and then cooled to room 
temperature under high vacuum for approximately 30 min before being flushed with 
argon. Molecular sieves where considered freshly activated if used within 72 hrs of 
this process. Unless otherwise stated bead like molecular sieves were used. 
 
Amberlite® IRA 400 (OH-) exchange resin refers to beads of Standard Amberlite® IRA 
400 that has been converted to the hydroxide form by extensive treatment with 
sodium hydroxide and was purchased from Sigma-Aldrich®. 
 
Amberlite® IRA 120 (H+) is a strongly acidic cation exchange resin which is used for a 
wide variety of water demineralization, dealkalization and deionization applications. 
6.1.12. Work-up and Yields  
Unless otherwise stated aqueous solutions used in work-up procedures were 
saturated and the organic extracts dried with anhydrous magnesium sulfate, filtered 
and concentrated on a rotary evaporator. 
 
A standard aqueous workup involved extracting into the specified organic solvent, 
back extracting the aqueous layer three times, washing the combined organic layers 
with water, then brine, drying the combined organic extracts with anhydrous MgSO4 
and evaporating to dryness.  
 
Unless otherwise stated it can be assumed that all purified compounds are dried to a 
constant weight on a high vacuum system before recording of the final weight for yield 
calculations and obtaining spectral data. 
6.1.13. New Compounds 
New compounds are indicated by the term ‘title compound(s)’ (italicized font) whereas 
known compounds are indicated by the term ‘title compound(s)’ (plain font). 
Chapter VI: Experimental 
 
163 
6.1.14. Numbering of Compounds 
Mannosyl derivatives were numbered using the standard convention for 
carbohydrates. In pseudo-oligosaccharides the numbering of the mannosyl residues 




6.2 Preparation of special reagents 
6.2.1. Sodium methoxide solution (2.5M in MeOH):  
Was prepared by washing 575 mg of elemental sodium in 3 successive baths of 
petroleum ether (PE) to remove any oil coating. The elemental sodium was then 
dissolved in 10 mL of MeOH to afford an approx. 2.5M solution of NaOMe that was 
used immediately. 
6.2.2. Lithium bis(trimethylsilyl)amide (LHMDS) solution (0.5M in THF): 
Was prepared by dropwise addition of nBuLi (1.7 M in hexane, 4.41 mL, 7.50 mmol) to 
a stirred solution of freshly distilled Hexamethyldisilazane (HMDS, 1.588 mL, 7.50 
mmol) in THF (9 mL) at 0 °C under argon in a flame dried Schlenk tube. The reaction 
was stirred for 30 min at zero degrees before being allowed to warm to rt and stirred 
for an additional 60 min prior to use. 
 
The concentration of nBuLi was determined by titration of nBuLi against N-
benzylbenzamide (100 mg) in 1 mL (THF) at -40°C (dry ice/acetonitrile) with a blue 
endpoint. 
6.2.3. Ethyl diazoacetate (Approx. 15 wt% in toluene): 
Thionyl chloride (12 mL, 165 mmol) was added dropwise to a stirred solution of glycine 
(10 g, 133 mmol) in absolute ethanol (100 mL, 1713 mmol) at -10 °C. The mixture was 
then stirred at reflux for 2 hrs, before being cooled to rt where the solvents were 
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removed in vacuo. The white solid obtained was treated twice with ethanol and 
concentrated in vacuo to remove any adhering thionyl chloride. The residue was 
recrystallized from ethanol to afford glycine ethyl ester hydrochloride as a white solid. 
 
Sodium nitrite (2.379 g, 34.5 mmol) in water (15 mL) was added to glycine ethyl ester 
hydrochloride (4.01 g, 28.7 mmol) and sodium acetate (1.131 g, 13.79 mmol) in 15 mL 
water at 0 °C. Allowed to warm to rt over 5 min the reaction was stirred for an 
additional 120 min. 2 mL of 10 % H2SO4 was added (reaction exothermed) and after 
stirring at rt for 30 min the mixture was extracted into toluene (22 mL). The organic 
layer was washed with sodium carbonate, dried, filtered and collected in a flask to give 
an approx. 15 wt% yellow solution of ethyl diazoacetate in toluene. 
6.2.4. Dimethyldioxirane (DMDO) solution: 
An anhydrous solution of DMDO was prepared following a modified method based on 
Adam & Hadjiarapoglou (1993). A mixture of 190 mL acetone, 58 g sodium bicarbonate 
and 250 mL water were cooled to 15°C (ice/water bath) in a 1 L three-necked round-
bottomed flask. Oxone® (2KHSO5·K2SO4·KHSO4) was added in four 30 g portions over 
15 min while stirring using a strong magnetic follower. The DMDO solution in acetone 
was produced by vacuum distillation (200 mbar) of the slurry at room temperature 
into a two necked receiver flask (cooled to -78°C, dry ice/acetone). After 15 min the 
pressure was reduced to 100 mbar and distillate collected for another 15 min. Approx. 
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The solution was dried by three storages over 10 g of ground MgSO4 at -20°C, which 
had been vacuum furnace dried at 250°C, and allowing 12-16 hrs for each period of 
drying before decanting the solution to a fresh flame dried flask and replacing the 
MgSO4. The DMDO solution remained active over a period of one to two months while 
stored under argon at -20°C.  
 
The concentration of the obtained DMDO solution was determined iodometrically by 
addition of 1 mL of the DMDO solution to a mixture of 0.25 mL saturated KI-solution 
and 1.0 mL glacial acetic acid. The resulting dark-red solution was titrated with a 
freshly prepared aqueous Na2S2O3 solution (0.05 M), indicating a typical concentration 
of 50–100 mM. 
6.2.5. Cyclohexanone dimethyl ketal 
To a solution of cyclohexanone (5 mL, 48.3 mmol) in methanol (12 mL, 297 mmol) at 
room temperature was added Trimethyl orthoformate (6.4 mL, 58.5 mmol) and 
sulphuric acid (2 drops). The solution was refluxed for 12 hours, after which the 
solution was concentrated in vacuo and cooled in an ice bath. The cold solution was 
poured into an aqueous KOH solution (0.05M, 120 mg, 2.13 mmol) and extracted with 
ethyl acetate (2 x 50 mL) and washed with brine (50 mL). The solution was 
concentrated in vacuo to afford cyclohexanone dimethyl ketal as an orange crude 
liquid, which was used without further purification. 
6.3 Experimental Protocols  
6.3.1. Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-mannopyranoside [74]308 
Acetic anhydride (126 mL, 1332 mmol) was added dropwise to a 
stirred solution of D-mannose 51 (20 g, 111 mmol) in pyridine (80 mL) 
at 0 °C. The reaction was stirred at rt overnight, after which a standard 
aqueous workup was performed using DCM as the organic solvent. Additional washes 
of the organic extract was performed with 10% aqueous HCl and 5% aqueous NaHCO3. 
The solvents were removed in vacuo to afford crude peracetate 202 as a thick syrup 
that was used directly for the next step. Rf = 0.35 (3:1 EtOAc/PE); HRMS (ESI-pos): calcd 
for C16H22O11Na [M + Na]+ m/z 413.3399, found m/z 413.3322. 




Boron trifluoride diethyl etherate (27 mL, 219 mmol) was added dropwise to a stirred 
solution of crude per-acetate 202 (54 g) and thiophenol (20 mL, 196 mmol) in 
anhydrous DCM (80.0 mL) at 0 °C and allowed to warm to rt overnight. The reaction 
was diluted with DCM and washed with 0.5 M NaOH after which a standard aqueous 
workup was preformed using DCM as the organic solvent. The solvents were removed 
in vacuo to give the residue which was purified by crystallisation from Et2O and PE, 
filtered, and dried to a constant weight to afford the title compound 74 (34 g, 78 mmol, 
70 % over two steps) as white crystals. 
 
Data for 74: Rf = 0.66 (1:1 EtOAc/PE); δH(500 MHz, CDCl3): 7.52 – 7.45 (2H, m, 
Ph), 7.35 – 7.28 (3H, m, Ph), 5.50 (1H, dd, J= 3.0, 1.6 Hz, H-2), 5.49 (1H, d, J= 1.5 Hz, H-
1), 5.38 – 5.29 (2H, m, H-3, H-4), 4.59 – 4.49 (1H, m, H-5), 4.30 (1H, dd, J= 12.2, 6.0 Hz, 
H-6), 4.10 (1H, dd, J= 12.3, 2.4 Hz, H-6), 2.15 (3H, s, OAc), 2.07 (3H, s, OAc), 2.05 (3H, 
s, OAc), 2.01 (3H, s, OAc); δC(126 MHz, CDCl3): 170.66 (C=O), 170.03 (C=O), 169.93 
(C=O), 169.86 (C=O), 132.73 (ipso-C), 132.18 (Ph), 129.32 (Ph), 128.24 (Ph), 85.81 (C-
1), 71.03 (C-2), 69.64 (C-5), 69.50 (C-3), 66.50 (C-4), 62.57 (C-6), 21.01 (OAc), 20.85 
(OAc), 20.82 (OAc), 20.77 (OAc); HRMS (ESI-pos): calcd for C20H29O9SNa [M + Na]+ m/z 
463.1033 found m/z 463.1063; Anal. Calcd for C20H24O9S: C, 54.54; H, 5.49; S, 7.28. 
Found C, 53.97; H, 5.53; S, 6.76. 
6.3.2. Phenyl 1-thio-α-D-mannopyranoside [75]309 
Sodium methoxide solution (1M, 50 mL, 50.0 mmol) was added 
dropwise to a solution of thio glycoside 74 (10 g, 22.66 mmol) in MeOH 
(50 mL), then left to stir at rt overnight. The reaction was neutralised 
with amberlite IR-120 (H+ form), then filtered through Celite and the solvent removed 
in vacuo to give the title compound 75 (22.66 mmol, quant) as a white solid which was 
used without further purification. 
 
Data for 75: δH(500 MHz, D2O): 7.65 – 7.58 (2H, m, Ph), 7.49 – 7.40 (3H, m, Ph), 
5.54 (1H, d, J= 1.5 Hz, H-1), 4.24 (1H, dd, J= 3.4, 1.6 Hz, H-2), 4.18 (1H, ddd, J= 9.9, 5.8, 
2.3 Hz, H-5), 3.88 (1H, dd, J= 9.5, 3.4 Hz, , H-3), 3.86 (1H, dd, J= 12.4, 2.4 Hz, , H-6), 3.78 
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(1H, dd, J= 12.5, 5.9 Hz, H-6), 3.74 (1H, t, J= 9.8 Hz, , H-4); δC(126 MHz, D2O): 132.64 
(ipso-C), 129.47 (Ph), 128.38 (Ph), 88.24 (C-1), 73.65 (C-5), 71.54 (C-2), 71.09 (C-3), 
67.06 (C-4), 60.76 z; HRMS (ESI-pos): calcd for C12H16O5SNa [M + Na]+ m/z 295.0611 
found m/z 295.0639; Analytical HPLC [Column A, T18, AW-BA, TFA2, F0.5, 10-100B 
G12H3] tR =6.610 min. 
6.3.3. Phenyl 4,6-O-benzylidene-1-thio-α-D-mannopyranoside [76]310 
A solution of crude tetraol 75 (5.94 g, 21.8 mmol) in DMF (36 mL, 
1.6 mL per mmol of 75) was heated to 70 °C and degassed by 
evacuation to 50 mbar. The flask was returned to atmospheric 
pressure and tetrafluoroboric acid (54% w/v in Et2O, 2.68 mL, 19.62 mmol) followed 
by benzaldehyde dimethylacetal (4.35 mL, 28.3 mmol) were added dropwise. The flask 
was re-evacuated to 50 mbar and maintained at this pressure by a regulator for the 
course of the reaction. The solution was stirred at 70 °C for 3 hours then quenched by 
the addition of TEA (3 mL). The DMF was removed by vacuum distillation (0.1 mbar, 
70 °C) before the addition of ice-cold water. The resulting precipitate was filtered and 
dried to a constant weight to give a complex mixture containing mainly the crude title 
compound 76 (6 g) which was used without further purification. A small sample of 76 
was recrystallized from hot EtOAc to give a fluffy white solid used for data collection. 
The unreacted starting material (1.1 g) was recovered by EtOAc extractions of the 
water layer. 
 
Data for 76: δH(500 MHz, Acetone-d6): 7.64 – 7.47 (4H, m, Ph), 7.44 – 7.25 (6H, 
m, Ph), 5.64 (1H, s, H-7), 5.57 (1H, d, J= 1.2 Hz, H-1), 4.49 (2H, b, J= 3.6 Hz, OH), 4.27 – 
4.16 (2H, m, H-2, H-5), 4.12 (1H, dd, J= 10.1, 4.9 Hz, H-6), 4.03 (1H, t, J= 9.5 Hz, H-4), 
3.96 (1H, dd, J= 9.7, 3.5 Hz, H-3), 3.81 (1H, t, J= 10.2 Hz, H-6); δC(126 MHz, Acetone-
d6): 139.27 (ipso-C), 135.00 (ipso-C), 132.64 (Ph), 130.02 (Ph), 129.54 (Ph), 128.78 (Ph), 
128.38 (Ph), 127.31 (Ph), 102.61 (C-7), 90.14 (C-1), 80.09 (C-3), 73.75 (C-2), 69.71 (C-
3), 68.98 (C-6), 65.92 (C-5); HRMS (ESI-pos): calcd for C19H20O5SNa [M + Na]+ m/z 
383.0924 found m/z 383.0949; Analytical HPLC [Column A, T18, AW-BA, TFA2, F0.5, 
10-100B G12H3] tR =11.302 min; Analytical HPLC [Column C, T13, AW-BM, TFA2, F0.4, 
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10-100B G8H2] tR =6.610 min; Anal. Calcd for C19H20O5S: C, 63.32; H, 5.59; S, 8.90. 
Found C, 62.61; H, 5.59; S, 8.65. 
6.3.4. Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-α-D-
mannopyranoside [77]311 
Sodium hydride (60 % in oil, 445 mg, 11.13 mmol) was added to a 
solution of benzylidine acetal 76 (816 mg, 2.264 mmol) in 
anhydrous DMF (5 mL) at 0 °C under argon and left to stir for 15 
min. Benzyl bromide (1.7 mL, 14.31 mmol) was added dropwise and the resulting 
mixture allowed to warm to rt. After stirring overnight the reaction was quenched with 
MeOH and a standard aqueous workup preformed using EtOAc as the organic solvent. 
The solvents were removed in vacuo and the crude residue purified by column 
chromatography (PE to 5:1 PE:EtOAc) to give the title compound 77 (1.14 g, 2.108 
mmol, 93 %) as white solid. 
 
Data for 77: Rf = 0.72 (1:4 EtOAc/PE); δH(500 MHz, CDCl3): 7.57 – 7.50 (2H, m, 
Ph), 7.41 – 7.27 (18H, m, Ph), 5.65 (1H, s, H-7), 5.50 (1H, d, J= 1.4 Hz, H-1), 4.82 (1H, d, 
J= 12.2 Hz, PhCH2), 4.72 (2H, s, PhCH2), 4.66 (1H, d, J= 12.2 Hz, PhCH2), 4.32 (1H, t, J= 
9.3 Hz, H-4), 4.27 (1H, dd, J= 9.4, 4.7 Hz, H-5), 4.22 (1H, dd, J= 10.2, 4.4 Hz, H-6), 4.04 
(1H, dd, J= 3.3, 1.5 Hz, H-2), 3.97 (1H, dd, J= 9.4, 3.2 Hz, H-3), 3.89 (1H, t, J= 9.8 Hz, H-
6); δC(126 MHz, CDCl3): 138.49 (ipso-C), 137.86 (ipso-C), 137.71 (ipso-C), 133.89 (ipso-
C), 131.79 (Ph), 129.27 (Ph), 129.02 (Ph), 128.58 (Ph), 128.50 (Ph), 128.34 (Ph), 128.26 
(Ph), 128.01 (Ph), 127.81 (Ph), 127.78 (Ph), 126.24 (Ph), 101.67 (C-7), 87.27 (C-1), 79.23 
(C-4), 78.23 (C-2), 76.36 (C-3), 73.24 (PhCH2), 73.21 (PhCH2), 68.66 (C-6), 65.59 (C-5); 
HRMS (ESI-pos): calcd for C33H32O5SNa [M + Na]+ m/z 563.1863 found m/z 563.1878. 
6.3.5. Phenyl 2,3-di-O-dibenzyl-4,6-O-benzylidene-1-thio-α-D-
mannopyranoside S-oxide [73]152, 312 
mCPBA (1.58 g, 4.59 mmol) was added to a stirred solution of thio 
glycoside 77 (2.48 g, 4.59 mmol) in anhydrous DCM (20 mL) at -55 
°C, and the reaction mixture stirred for 60 min, warming to -30°C 
over this time. The reaction was quenched at -30°C by addition of 50:50 aqueous 
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sodium thiosulfate-sodium hydrogen carbonate. The solution was warmed to rt and a 
standard aqueous workup preformed using DCM as the organic solvent. The solvent 
was removed in vacuo to give the residue as an orange syrup. The product was 
precipitated on addition of di-isopropyl ether and filtered to give the title compound 
73 (1.44 g, 2.58 mmol, 56%) as a white solid. Unreacted starting material was 
recovered by concentrating the filtrate. No sulfone was observed provided the 
reaction remained below approx. -28°C. 
 
Data for 73: Rf = 0.57 (1:2 EtOAc/PE); δH(500 MHz, CDCl3): 7.56 – 7.26 (18H, m, 
Ph), 7.22 (2H, dd, J= 6.7, 3.0 Hz, Ph), 5.64 (1H, s, H-7), 4.83 (1H, d, J= 12.1 Hz, PhCH2), 
4.67 (1H, d, J= 12.0 Hz, PhCH2), 4.60 (1H, d, J= 11.9 Hz, PhCH2), 4.56 (1H, d, J= 11.9 Hz, 
PhCH2), 4.50 (1H, d, J= 1.3 Hz, H-1), 4.40 (1H, dd, J= 3.4, 1.3 Hz, H-2), 4.32 (1H, t, J= 9.3 
Hz, H-4), 4.28 (1H, dd, J= 10.0, 3.2 Hz, H-3), 4.22 (1H, dd, J= 10.3, 4.8 Hz, H-6), 4.10 (1H, 
td, J= 9.4, 4.8 Hz, H-5), 3.76 (1H, t, J= 10.2 Hz, H-6); δC(126 MHz, CDCl3): 138.40 (ipso-
C), 137.46 (ipso-C), 137.40 (ipso-C), 131.79 (ipso-C), 129.57 (Ph), 129.14 (Ph), 128.52 
(Ph), 128.50 (Ph), 128.39 (Ph), 128.04 (Ph), 127.93 (Ph), 127.79 (Ph), 126.22 (Ph), 
124.50 (Ph), 101.77 (C-7), 97.76 (C-1), 78.17 (C-4), 76.45 (C-7), 73.69 (PhCH2), 73.40 
(PhCH2), 73.04 (C-2), 70.24 (C-5), 68.35 (C-6); RP-HPLC (C-8, Method IV), tR =10.735 
min; HRMS (ESI-pos): calcd for C33H32O6SNa [M + Na]+ m/z 579.1812 found m/z 
579.1796; Anal. Calcd for C33H32O6S: C, 71.20; H, 5.79; S, 5.76. Found C, 70.61; H, 5.89; 
S, 5.41. 
6.3.6. (2S,3S,4R)-2-Azido-1,3,4-octadecanetriol [45]313-314 
Sodium azide (5.22 g, 80.0 mmol) was dissolved in water (10 mL) and 
cooled to 0 °C before the addition of toluene (15 mL). With vigorous 
stirring Tf2O (3 mL, 17.54 mmol) in anhydrous toluene (5 mL) was 
added dropwise over 30 min. The solution was stirred at 0 °C for a further 60 min 
before being warmed to rt. Stirred for an additional 10 min, the layers were separated 
and the organic layer washed with sat aq NaHCO3 to give a solution of 
trifluoromethanesulfonyl azide that was used immediately. 
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A solution of triflic azide in toluene was added dropwise to a suspension of (2S,3S,4R)-
2-amino-1,3,4-octadecanetriol 46 (3.0 g, 9.45 mmol), [Analytical HPLC [Column C, T16, 
AW-BA, TFA2, F0. 25, 10-100B G8H5] tR =6.613 min (>99%)] in MeOH/toluene (1:1, 10 
mL). Copper(II) sulfate pentahydrate (20 mg, 0.080 mmol) was added and the reaction 
stirred at rt for 3 hrs. The volatiles were removed in vacuo to give a blue/grey solid, 
which was crystallised from EtOAc to afford the title compound 45 (3.24 g, 9.44 mmol, 
99 %) as a white solid which was used without further purification. 
 
Data for 45: Rf = 0.42 (10 % MeOH in CHCl3); δH(500 MHz, Acetone-d6): 4.14 
(1H, dd, J= 14.3, 5.1 Hz, OH-1), 3.99 (1H, ddd, J= 11.6, 5.4, 3.5 Hz, H-1a), 3.90 – 3.76 
(1H, m, H-1b), 3.67 – 3.57 (3H, m, H-2, H-3, H-4), 2.81 (2H, d, J= 1.1 Hz, OH), 1.77 – 
1.50 (2H, m, CH2), 1.29 (24H, s, 12 x CH2), 0.96 – 0.80 (3H, m, CH3-18); δC(126 MHz, 
Acetone-d6): 75.90 (C-3/C-4), 72.52 (C-3/C-4), 65.79 (C-2), 62.29 (C-1), 33.67 (CH2), 
32.64 (CH2), 30.49 (CH2), 30.37 (CH2), 30.08 (CH2), 29.89 (CH2), 29.69 (CH2), 26.37 (CH2), 
23.33 (CH2), 14.36 (C-18); ṽmax (cm-1) 3279 (alcohol OH), 2915 (alkane C-H stretch), 
2846 (alkane C-H stretch), 2116 (N3 stretch), 2094 (N3 stretch), 1461 (C-H bend), 1246 
(C-N stretch), 1058, 1009, 722; HRMS (ESI-pos): calcd for C18H37N3O3Na [M + Na]+ m/z 
366.2727 found m/z 366.2730; Analytical HPLC [Column C, T16, AW-BA, TFA2, F0. 25, 
10-100B G8H5] tR =9.254 min (98.2%). 
6.3.7. (2S,3S,4R)-2-Azido-1-O-triisopropylsilyl-3,4-octadecanediol [79] 
To a suspension of triol 45 (2.164 mg, 6.3 mmol), imidazole (860 
mg, 12.6 mmol) and DMAP (1 crystal) in DMF (8 mL) under argon 
was added triisopropylsilyl chloride (2.1 mL, 9.52 mmol) and the 
solution was stirred at rt overnight. The reaction mixture was quenched with Et2O and 
a standard aqueous workup preformed using Et2O as the organic solvent. The solvents 
were removed in vacuo to give the crude title compound 79 as a colourless oil that 
was used without further purification. 
 
Data for 79: Rf =0.88 (10 % MeOH in CHCl3); δH(400 MHz, CDCl3): 4.11 (1H, dd, 
J= 10.7, 4.6 Hz, H-1a), 3.99 (1H, dd, J= 10.5, 5.3 Hz, H-1b), 3.78 – 3.67 (2H, m, H-3, H-
4), 3.55 (1H, q, J= 5.0 Hz, H-2), 2.50 (2H, b, OH), 1.66 – 1.41 (3H, m, CH2), 1.25 (23H, s, 
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CH2), 1.09 (21H, d, J= 6.1 Hz, 3 x iPr), 0.87 (3H, t, J= 6.7 Hz, CH3-18); δC(101 MHz, CDCl3): 
74.78 (C-3/C-4), 72.70 (C-3/C-4), 64.02 (C-1), 63.06 (C-2), 32.29 (CH2), 32.07 (CH2), 
29.85 (CH2), 29.84 (CH2), 29.83 (CH2), 29.80 (CH2), 29.77 (CH2), 29.73 (CH2), 29.73 (CH2), 
29.51 (CH2), 25.86 (CH2), 22.83 (CH2), 18.02 (iPr), 18.01 (iPr), 14.25 (C-18), 11.93 (iPr); 
HRMS (ESI-pos): calcd for C27H57N3O3SiNa [M + Na]+ m/z 522.4061 found m/z 
522.4052; Analytical HPLC [Column C, T16, AW-BA, TFA2, F0. 25, 10-100B G8H5] tR 
=12.170 min (99.4%). 
6.3.8. (2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1-O-triisopropylsilyl-octadecane 
[80] 
Sodium hydride (60 % in oil, 1.4 g, 35.0 mmol) was added to a 
solution of diol 79 (3.15 g, 6.3 mmol) and vacuum dried TBAI (650 
mg, 1.760 mmol) in DMF ( 25 mL) at 0 °C under argon and left to 
stir for 15 min. Benzyl bromide (3.1 mL, 25.6 mmol) was added dropwise and resulting 
mixture allowed to warm to rt overnight. The reaction was quenched with the careful 
addition of water and a standard aqueous workup preformed using EtOAc as the 
organic solvent. The solvents were removed in vacuo and then on high vacuum (0.1 
mbar) to give the crude title compound 80 that was used directly in the next step. 
 
Data for 80: Rf =0.72 (10:1 PE:EtOAc); δH(500 MHz, CDCl3): 7.39 – 7.27 (10H, m, 
Ph), 4.75 (1H, d, J= 11.4 Hz, PhCH2), 4.62 (1H, d, J= 11.5 Hz, PhCH2), 4.61 (1H, d, J= 11.5 
Hz, PhCH2), 4.54 (1H, d, J= 11.4 Hz, PhCH2), 4.09 (1H, dd, J= 10.4, 2.8 Hz, H-1a), 3.85 
(1H, dd, J= 10.4, 7.4 Hz, H-1b), 3.69 – 3.59 (3H, m, H-2, H-3, H-4), 1.71 (1H, dddd, J= 
14.5, 10.2, 7.7, 4.7 Hz, CH2), 1.63 – 1.53 (1H, m, CH2), 1.51 – 1.41 (1H, m, CH2), 1.27 
(23H, d, J= 3.1 Hz, CH2), 1.14 – 1.01 (21H, m, 3 x iPr), 0.89 (3H, t, J= 6.8 Hz, CH3-18); 
δC(126 MHz, CDCl3): 138.59 (ipso-C), 138.33 (ipso-C), 128.48 (Ph), 128.47 (Ph), 128.13 
(Ph), 127.98 (Ph), 127.85 (Ph), 127.72 (Ph), 79.91 (C-3/C-4), 78.71 (C-3/C-4), 73.79 
(PhCH2), 72.23 (PhCH2), 64.84 (C-1), 64.67 (C-2), 32.09 (CH2), 29.94 (CH2), 29.92 (CH2), 
29.87 (CH2), 29.86 (CH2), 29.84 (CH2), 29.79 (CH2), 29.77 (CH2), 29.53 (CH2), 25.68 (CH2), 
22.86 (CH2), 18.11 (iPr), 18.10 (iPr), 14.28 (C-18), 12.05 (iPr); HRMS (ESI-pos): calcd for 
C41H69N3O3SiNa [M + Na]+ m/z 702.5000 found m/z 702.5015; Analytical HPLC [Column 
C, T23, AW-BA, TFA2, F0. 25, 10-100B G8H12] tR =18.147 min. 
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6.3.9. (2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1-octadecanol [78]315 
To a solution of phytosphingosine 80 (4.28 g, 6.3 mmol) in dry THF 
(30 mL) under argon was added TBAF (1M in THF, 12.6 mL, 12.6 
mmol) and the reaction stirred at rt overnight. The volatiles were 
removed in vacuo to afford the residue which was purified by column chromatography 
(PE to 10:1 PE:EtOAc) to give the title compound 78 (2.58 g, 4.92 mmol, 78% over four 
steps) as a colourless oil. 
 
Data for 78: Rf = 0.37 (5:1 PE:EtOAc); δH(500 MHz, CDCl3): 7.39 – 7.27 (10H, m, 
Ph), 4.71 (1H, d, J= 11.3 Hz, PhCH2), 4.67 (1H, d, J= 11.2 Hz, PhCH2), 4.63 (1H, d, J= 11.4 
Hz, PhCH2), 4.57 (1H, d, J= 11.4 Hz, PhCH2), 3.89 (1H, dd, J= 11.7, 5.1 Hz, H-1a), 3.79 
(1H, dd, J= 11.7, 5.1 Hz, H-1b), 3.73 – 3.61 (3H, m, H-2, H-3, H-4), 2.54 (1H, t, J= 6.3 Hz, 
OH), 1.69 (1H, dddd, J= 14.5, 10.3, 7.3, 4.9 Hz, CH2), 1.61 – 1.52 (1H, m, CH2), 1.47 – 
1.37 (1H, m, CH2), 1.26 (24H, d, J= 3.5 Hz, CH2), 0.88 (3H, t, J= 6.9 Hz, CH3-18); δC(126 
MHz, CDCl3): 138.10 (ipso-C), 137.77 (ipso-C), 128.67 (Ph), 128.59 (Ph), 128.25 (Ph), 
128.16 (Ph), 128.14 (Ph), 128.00 (Ph), 80.71 (C-3/C-4), 79.18 (C-3/C-4), 73.78 (PhCH2), 
72.72 (PhCH2), 63.19 (C-2), 62.31 (C-1), 32.08 (CH2), 30.40 (CH2), 29.86 (CH2), 29.84 
(CH2), 29.81 (CH2), 29.76 (CH2), 29.72 (CH2), 29.52 (CH2), 25.63 (CH2), 22.84 (CH2), 14.27 
(C-18); HRMS (ESI-pos): calcd for C32H49N3O3Na [M + Na]+ m/z 546.3666 found m/z 




Method A: A mixture of sulfoxide 73 (445 mg, 0.800 
mmol), DTBMP (422 mg, 2.012 mmol), and activated 4Ȧ 
molecular sieves (10 mg mL-1) was stirred in dry DCM 
(13 mL·mmol-1 of donor) for 1 hr at rt before it was 
cooled to -78 °C. Tf2O (150 µL, 0.888 mmol) was added and after being stirred at the 
same temperature for 10 min, a solution of alcohol 78 (503 mg, 0.961 mmol) in dry 
DCM (4.4 mL per·mmol-1 acceptor) was added dropwise. The resulting mixture was 
allowed to warm to -50 °C over 3 hr before being quenched with the addition of 
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saturated aqueous NaHCO3. After being warmed to rt, the mixture was filtered and 
the filtrate was extracted with DCM, the combined organic layers were washed with 
saturated aqueous NaHCO3 and brine, and the solvents removed in vacuo to give the 
residue which was purified by column chromatography (PE to 8:1 PE:EtOAc). The title 
compound 85 was obtained as an inseparable mixture of anomers (α:β= 5:95, 504.5 
mg, 0.529 mmol, 66%) as a colourless oil. 
 
Data for 85: Rf = 0.50 (5:1 PE:EtOAc); δH(500 MHz, CDCl3): 7.49 (4H, ddt, J= 17.4, 
5.8, 1.6 Hz, Ph), 7.42 – 7.35 (3H, m, Ph), 7.35 – 7.21 (18H, m, Ph), 5.61 (1H, s, H-7), 4.99 
(1H, d, J= 12.1 Hz, PhCH2), 4.85 (1H, d, J= 12.1 Hz, PhCH2), 4.69 (1H, d, J= 12.6 Hz, 
PhCH2), 4.67 (1H, s, PhCH2), 4.67 (1H, s, PhCH2), 4.60 (1H, d, J= 12.5 Hz, PhCH2), 4.56 
(1H, d, J= 11.6 Hz, PhCH2), 4.53 (1H, d, J= 11.5 Hz, PhCH2), 4.38 (1H, d, J= 0.9 Hz, H-1), 
4.24 (1H, dd, J= 10.4, 4.8 Hz, H-6), 4.22 – 4.11 (2H, m, H-1’, H-4), 3.94 (1H, dd, J= 3.1, 
0.8 Hz, H-2), 3.88 (1H, t, J= 10.3 Hz, H-6), 3.79 – 3.72 (2H, m, H-1’, H-3’/H-4’), 3.69 (1H, 
td, J= 6.5, 3.0 Hz, H-2’), 3.64 (1H, dt, J= 7.7, 3.9 Hz, H-3’/H-4’), 3.55 (1H, dd, J= 9.9, 3.1 
Hz, H-3), 3.23 (1H, td, J= 9.7, 4.9 Hz, H-5), 1.70 (1H, dddd, J= 14.5, 10.4, 7.5, 4.9 Hz, 
CH2), 1.62 – 1.51 (1H, m, CH2), 1.48 – 1.36 (1H, m, CH2), 1.26 (23H, s, CH2), 0.88 (3H, t, 
J= 7.1 Hz, CH3-18’); δC(126 MHz, CDCl3): 138.70 (ipso-C), 138.49 (ipso-C), 138.43 (ipso-
C), 138.15 (ipso-C), 137.71 (ipso-C), 129.01 (Ph), 128.58 (Ph), 128.52 (Ph), 128.47 (Ph), 
128.45 (Ph), 128.33 (Ph), 128.28 (Ph), 128.24 (Ph), 128.21 (Ph), 128.06 (Ph), 128.02 
(Ph), 127.97 (Ph), 127.84 (Ph), 127.72 (Ph), 127.69 (Ph), 127.62 (Ph), 126.21 (Ph), 
102.26 (d, 1JCH = 155.29 Hz C-1), 101.56 (C-7), 79.30 (C-3’/C-4’), 79.11 (C-3’/C-4’), 78.68 
(C-4), 77.81 (C-3), 76.41 (C-2), 75.18 (PhCH2), 74.08 (PhCH2), 72.41 (PhCH2), 72.10 
(PhCH2), 69.63 (C-1’), 68.68 (C-6), 67.80 (C-5), 62.00 (C-2’), 32.08 (CH2), 30.05 (CH2), 
29.95 (CH2), 29.86 (CH2), 29.84 (CH2), 29.82 (CH2), 29.80 (CH2), 29.78 (CH2), 29.52 (CH2), 
25.53 (CH2), 22.85 (CH2), 14.28 (C-18’); ṽmax (cm-1) 2920 (C-H stretch), 2850 (C-H 
stretch), 2127 (N3 stretch), 2100 (N3 stretch), 1453 (C-H bend), 1375 (C-H bend), 1215 
(C-O stretch), 1184 (C-O stretch), 1093 (C-O stretch), 1074 (C-O stretch), 745 (C-H 
stretch mono substituted benzene derivative), 693 (C-H stretch mono substituted 
benzene derivative); Analytical HPLC [Column B, T19, AW-BA, TFA2, F0.50, 10-100B 
G8H8] tR =15.928 min; HRMS (ESI-pos): calcd for C59H75N3O8Na [M + Na]+ m/z 976.5446 
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found m/z 976.5441; Anal. Calcd for C59H75N3O8: C, 74.26; H, 7.92; N, 4.40. Found C, 
74.03; H, 7.97; N, 4.38. 
 
Method B: To a stirred solution of alcohol 91 (36 mg, 0.042 mmol) in DMF (2 mL) at 0 
°C was added sodium hydride (60% in oil, 10 mg, 0.250 mmol). The reaction was stirred 
at this temperature for 15 min prior to the addition of benzyl bromide (15 µL, 0.124 
mmol). Warmed to rt the reaction was stirred overnight before being quenched with 
the careful addition of water. The reaction was diluted with EtOAc and washed with 
saturated aqueous NH4Cl. The organic layer was concentrated in vacuo to afford the 
residue which was purified by flash column chromatography (PE to 5:1 PE/EtOAc) to 
afford only the β-anomer of the title compound 85 (17 mg, 0.018 mmol, 42.8%) as a 
colourless oil. 
 
1H NMR and all other analytical data were the same as that of 85 synthesized using 
Method A and Method C. 
 
Method C: Thio glycoside 77 (100 mg, 0.185 mmol), diphenyl sulfoxide (62 mg, 0.308 
mmol), DMAP (104 mg, 0.496 mmol), and activated powdered 4Ȧ molecular sieves (4 
mg mg-1 of donor) was stirred in anhydrous DCM (13 mL·mmol-1 of donor) for 40 min 
at rt under Ar before being cooled to -60°C. Tf2O (42 µL, 0.249 mmol) was added and 
after being stirred at the same temperature for 20 min a solution of alcohol 78 (105 
mg, 0.200 mmol) in anhydrous DCM (2 mL) was added dropwise. The reaction was 
stirred at -78°C for an additional 2.5 hrs before being warmed slowly to rt where it was 
quenched on addition of TEA. Filtered through Celite, the organic filtrate was washed 
with saturated aqueous NH4Cl, dried filtered and concentrated in vacuo to afford the 
residue which was purified by flash column chromatography (PE to 5:1 PE/EtOAc) to 
give the title compound 85 as an inseparable mixture of anomers (α:β= 1:9, 107 mg, 
0.112 mmol, 61%) as a colourless oil. 
 
1H NMR and all other analytical data were consistent with those of 85 synthesized 
using Method B and Method C. 





Sulfoxide 73 (92 mg, 0.165 mmol) and DTBMP (80 mg, 
0.382 mmol) were azeotroped together from anhydrous 
toluene. 4Ȧ powdered molecular sieves and anhydrous 
DCM (2.5 mL) were added at rt under argon before the solution was cooled to -78 °C. 
Stirred for 30 min, Tf2O (38 µL, 0.225 mmol) was then added dropwise. Alcohol 47 (75 
mg, 0.195 mmol) in anhydrous DCM (2.5 mL) was added 15 min later and the reaction 
mixture was stirred at -78 °C for an hour before being warmed slowly to rt. After 
stirring for 1 hr. the reaction was quenched on addition of NaHCO3 and the crude 
reaction mixture was diluted with DCM. A standard aqueous workup was preformed 
using DCM as the organic solvent. The solvents were removed in vacuo to give the 
residue which was purified by column chromatography (PE to 3:1 PE:EtOAc) to give 
the title compound 203 as an inseparable mixture of anomers (α:β= 19:81, 84.2 mg, 
0.103 mmol, 63 %) as a colourless oil.  
 
Data for 203: Rf = 0.46 (5:1 PE:EtOAc); δH(500 MHz, CDCl3): 7.53 – 7.26 (15H, 
m, Ph), 5.63 (1H, s, H-7), 5.01 (1H, d, J= 12.1 Hz, PhCH2), 4.83 (1H, d, J= 12.1 Hz, PhCH2), 
4.69 (1H, d, J= 12.5 Hz, PhCH2), 4.59 (1H, d, J= 12.6 Hz, PhCH2), 4.55 (1H, d, J= 0.77, H-
1), 4.31 (1H, dd, J= 10.4, 4.8 Hz, H-6), 4.23 (1H, t, J= 9.6 Hz, H-4), 4.16 (2H, tt, J= 10.8, 
6.3 Hz, H-1’, H-3’/H-4’), 4.00 (1H, d, J= 3.1 Hz, H-2), 3.96 (1H, t, J= 10.3 Hz, H-6), 3.92 – 
3.87 (2H, m, H-1’, H-3’/H-4’), 3.62 (1H, dd, J= 9.9, 3.1 Hz, H-3), 3.54 (1H, ddd, J= 10.0, 
7.6, 2.8 Hz, H-2’), 3.34 (1H, td, J= 9.7, 4.9 Hz, H-5), 1.71 – 1.52 (4H, m, 2 x CH2), 1.41 
(3H, s, C(CH3)2), 1.32 (3H, s, C(CH3)2), 1.26 (22H, s, 11 x CH2), 0.88 (3H, t, J= 6.8 Hz, CH3-
18’); δC(126 MHz, CDCl3): 138.67 (ipso-C), 138.44 (ipso-C), 137.69 (ipso-C), 129.00 (Ph), 
128.60 (Ph), 128.46 (Ph), 128.33 (Ph), 128.26 (Ph), 127.69 (Ph), 127.64 (Ph), 126.20 
(Ph), 108.53 (C(CH3)2), 102.55 (d, 1JCH = 154.76 Hz C-1), 101.57 (C-7), 78.62 (C-4), 78.59 
(C-3’/C-4’), 77.91 (C-2), 76.42 (C-3), 75.68 (C-3’/C-4’), 75.28 (PhCH2), 72.43 (PhCH2), 
70.95 (C-1’), 68.66 (C-6), 67.99 (C-5), 60.04 (C-2’), 32.08 (CH2), 29.85 (CH2), 29.81 (CH2), 
29.79 (CH2), 29.76 (CH2), 29.72 (CH2), 29.58 (CH2), 29.52 (CH2), 28.39 (C(CH3)2), 26.61 
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(CH2), 25.82 (C(CH3)2), 22.85, 14.28 (C-18’); HRMS (ESI-pos): calcd for C48H67N3O8Na [M 
+ Na]+ m/z 836.4820 found m/z 836.4837. 
6.3.12. Phenyl 3-O-benzyl-4,6-O-benzylidene-1-thio-α-D-mannopyranoside 
[89]316 
Method A: Benzylidine acetal 76 (870 mg, 2.415 mmol) and 
dibutyltin oxide (665 mg, 2.67 mmol) were dried under high 
vacuum for 1 hour to insure dryness. Toluene (20 mL) was added 
and the reaction was refluxed for 2 hrs. under an argon atmosphere. The resulting 
clear solution was allowed to cool to rt and the solvent removed in vacuo. The residue 
was placed under high vacuum for 30 min then under argon. Cesium fluoride (380 mg, 
2.502 mmol) was added, then anhydrous DMF was cannulated into the mixture. 
Benzyl bromide (330 µL, 2.78 mmol) was added and the reaction stirred at rt 
overnight. The reaction was diluted with Et2O and washed with saturated aqueous KF 
solution, and brine. The organic layer was concentrated in vacuo and the residue re-
dissolved in DCM and absorbed onto silica gel then purified by column 
chromatography (PE to 3:1 PE/EtOAc) to give the title compound 89 (945 mg, 2.098 
mmol, 87%) as a colourless foam. 
 
Data for 89: δH(500 MHz, CDCl3): 7.55 – 7.27 (15H, m, Ph), 5.63 (1H, s, H-7), 
5.60 (1H, d, J= 1.2 Hz, H-1), 4.90 (1H, d, J= 11.8 Hz, PhCH2), 4.75 (1H, d, J= 11.8 Hz, 
PhCH2), 4.34 (1H, td, J= 9.8, 4.9 Hz, H-5), 4.29 (1H, dt, J= 2.9, 1.3 Hz, H-2), 4.21 (1H, dd, 
J= 10.4, 4.9 Hz, H-6), 4.18 (1H, t, J= 9.5 Hz, H-4), 3.97 (1H, dd, J= 9.5, 3.4 Hz, H-3), 3.86 
(1H, t, J= 10.3 Hz, H-6), 2.85 (1H, d, J= 1.4 Hz, OH); δC(126 MHz, CDCl3): 137.88 (ipso-
C), 137.58 (ipso-C), 133.41 (ipso-C), 131.89 (Ph), 129.29 (Ph), 129.13 (Ph), 128.70 (Ph), 
128.39 (Ph), 128.21 (Ph), 128.04 (Ph), 127.86 (Ph), 126.22 (Ph), 101.79 (C-7), 87.94 (C-
1), 79.17 (C-4), 75.86 (C-3), 73.37 (PhCH2), 71.58 (C-2), 68.69 (C-6), 64.73 (C-5); HRMS 
(ESI-pos): calcd for C26H26O5SNa [M + Na]+ m/z 473.1393 found m/z 473.1364. 
 
Method B: A solution of crude triol 204 (1.1 g, 2.94 mmol) in DMF (10 mL) was heated 
to 70 °C and degassed by evacuation to 50 mbar. The flask was returned to 
atmospheric pressure and tetrafluoroboric acid (54% w/v in Et2O, 0.45 mL, 3.29 mmol) 
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followed by benzaldehyde dimethylacetal (0.75 mL, 4.90 mmol) were added. The flask 
was re-evacuated to 50 mbar and maintained at this pressure by a regulator for the 
course of the reaction. The solution was stirred at 70 °C for 5 hours, and then 
quenched with the addition of TEA (3 mL). The reaction was diluted with EtOAc and 
washed with brine. The organic layer was concentrated in vacuo to afford the residue 
that was purified by column chromatography (PE to 2:1 PE/EtOAc) to afford the title 
compound 89 (690 mg, 1.532 mmol, 52% over two steps) as a pale orange oil. 
 
1H NMR and all other analytical data were consistent with those of 89 synthesized 
using Method A. 
6.3.13. Phenyl 2-O-methoxybenzyl-3-O-benzyl-4,6-O-benzylidene-1-thio-α-
D-mannopyranoside [87]311 
To a solution of alcohol 89 (935 mg, 2.075 mmol) in anhydrous DMF 
(10 mL) at 0 °C under Ar was added sodium hydride (60% in oil, 128 
mg, 3.20 mmol) and the reaction was stirred for 20 min. 4-
Methoxybenzyl chloride (315 µL, 2.408 mmol) was added and the reaction was 
allowed to warm to rt overnight. The reaction was quenched with the careful addition 
of water and a standard aqueous workup was preformed using EtOAc as the organic 
solvent. The solvents were removed in vacuo and the residue was purified by column 
chromatography (PE to 4:1 PE/EtOAc) to afford the title compound 87 (732 mg, 1.282 
mmol, 62%) as a colourless oil. 
 
Data for 87: δH(500 MHz, CDCl3): 7.52 (2H, dd, J= 7.8, 1.8 Hz, o-Ph), 7.43 – 7.25 
(15H, m, PH), 6.88 – 6.81 (2H, m, m-Ph), 5.65 (1H, s, H-7), 5.46 (1H, d, J= 1.4 Hz, H-1), 
4.82 (1H, d, J= 12.2 Hz, PhCH2), 4.66 (2H, s, PhCH2), 4.64 (1H, d, J= 12.7 Hz, PhCH2), 
4.34 – 4.18 (3H, m, H-4, H-5, H-6), 4.03 (1H, dd, J= 3.3, 1.4 Hz, H-2), 3.95 (1H, dd, J= 
9.4, 3.2 Hz, H-3), 3.88 (1H, t, J= 9.7 Hz, H-6), 3.80 (3H, s, OMe); δC(126 MHz, CDCl3): 
159.53 (ipso-C), 138.53 (ipso-C), 137.72 (ipso-C), 133.94 (ipso-C), 131.77 (Ph), 129.95 
(Ph), 129.88 (Ph), 129.25 (Ph), 129.00 (Ph), 128.48 (Ph), 128.33 (Ph), 127.78 (Ph), 
127.75 (Ph), 126.23 (o-Ph), 113.98 (m-Ph), 101.64 (C-7), 87.35 (C-1), 79.21 (C-4), 77.69 
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(C-2), 76.32 (C-3), 73.18 (PhCH2), 72.84 (PhCH2), 68.65 (C-6), 65.60 (C-5), 55.42 (OMe); 
HRMS (ESI-pos): calcd for C34H34O6SNa [M + Na]+ m/z 593.1968 found m/z 593.1943. 
6.3.14. Phenyl 3-O-benzyl-1-thio-α-D-mannopyranoside [204] 
Tetraol 75 (802 mg, 2.94 mmol) and dibutyltin oxide (828 mg, 3.33 
mmol) were dried under high vacuum for 1 hour to insure dryness. 
Toluene (10 mL) was added and the reaction was refluxed for 2 hrs 
under an argon atmosphere. After 2 hrs the resulting yellow/orange solution was 
allowed to cool to rt and the solvent removed in vacuo. The residue was placed under 
high vacuum then under argon. Cesium fluoride (476 mg, 3.13 mmol) was added then 
dry DMF (10 mL) was cannulated into the mixture. Benzyl bromide (405 µL, 3.41 mmol) 
was added and the reaction allowed to stir at rt overnight. The reaction was diluted 
with Et2O and washed with water, saturated aqueous KF soln, and brine. The organic 
layer was concentrated in vacuo to afford the crude title compound 204 that was used 
without further purification. 
 
Data for 204: Analytical HPLC [Column C, T13, AW-BM, TFA2, F0. 5, 10-100B 
G8H2] tR =8.057 min. 
6.3.15. Phenyl 2-O-(2-napthalenylmethyl)-3-O-Benzyl-4,6-O-benzylidene-1-
thio-α-D-mannopyranoside [88]317 
To a stirred solution of alcohol 89 (670 mg, 1.488 mmol) in DMF 
at 0 °C was added sodium hydride (60% in oil, 81 mg, 2.025 mmol) 
and the reaction was stirred at 0°C for 15 min before 2-
(bromomethyl)naphthalene (418 mg, 1.853 mmol) was added. 
The reaction was allowed to warm to rt overnight before being 
quenched with the careful addition of water. Diluted with EtOAc 
and washed with brine the organic layer was concentrated in vacuo to afford the 
residue which was purified by column chromatography (PE to 2:1 PE/EtOAc) to afford 
the title compound 88 (549 mg, 0.929 mmol, 63%) as a colourless oil. 
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 Data for 88: δH(500 MHz, CDCl3): 7.87 – 7.76 (4H, m, Ph), 7.54 – 7.47 
(5H, m, Ph), 7.42 – 7.36 (3H, m, Ph), 7.36 – 7.28 (7H, m, Ph), 7.24 – 7.21 (3H, m, Ph), 
5.67 (1H, s, H-7), 5.51 (1H, d, J= 1.4 Hz, H-1), 4.89 (2H, t, J= 1.0 Hz, NAPCH2), 4.85 (1H, 
d, J= 12.1 Hz, PhCH2), 4.66 (1H, d, J= 12.2 Hz, PhCH2), 4.36 (1H, t, J= 9.5 Hz, H-4), 4.32 
– 4.21 (2H, m, H-5, H-6), 4.09 (1H, dd, J= 3.3, 1.4 Hz, H-2), 3.99 (1H, dd, J= 9.8, 3.2 Hz, 
H-3), 3.91 (1H, t, J= 9.9 Hz, H-6); δC(126 MHz, CDCl3): 138.52 (ipso-C), 137.73 (ipso-C), 
135.27 (ipso-C), 133.81 (ipso-C), 133.35 (ipso-C), 133.25 (ipso-C), 131.84 (Ph), 129.23 
(Ph), 129.02 (Ph), 128.51 (Ph), 128.45 (Ph), 128.35 (Ph), 128.11 (Ph), 127.85 (Ph), 
127.83 (Ph), 127.78 (Ph), 127.18 (Ph), 126.30 (Ph), 126.28 (Ph), 126.24 (Ph), 126.17 
(Ph), 101.67 (C-7), 87.43 (C-1), 79.30 (C-4), 78.13 (C-2), 76.38 (C-3), 73.39 (PhCH2), 
73.31 (PhCH2), 68.69 (C-6), 65.69 (C-5); HRMS (ESI-pos): calcd for C37H35O5S [M + H]+ 
m/z 591.2200 found m/z 591.2184; calcd for C37H34O5SNa [M + Na]+ m/z 613.2019 




To a mixture of IAD donor 88 (102 mg, 0.173 mmol) and 
alcohol 78 (113 mg, 0.217 mmol) in anhydrous DCM (20 
mL·mmol-1) was added freshly activated 4Å powdered 
molecular sieves (4 mg mg-1 of donor). The mixture was 
stirred at rt for 40 min under Ar. Then DDQ (53 mg, 
0.233 mmol) was added, the resulting mixture was stirred for 3 hrs at rt under Ar. The 
reaction was quenched with aqueous ascorbic acid buffer (0.7% ascorbic acid, 1.3% 
citric acid, 0.9% NaOH), and filtered through Celite. The filtrate was extracted with 
DCM and washed with saturated aqueous NaHCO3 soln and brine. The combined 
organic layers were dried, filtered and concentrated in vacuo to give the crude mixed 
acetal 92 that was used directly in the next step 
 
Data for 92: Rf = 0.51 (1:1 EtOAc/PE); δH(400 MHz, Acetone-d6): 7.99 – 7.14 
(32H, m, Ph), 6.11 (1H, s, NAPCH(OR)2), 5.78 (1H, s, H-7), 5.61 (1H, d, J= 1.4 Hz, H-
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1), 4.90 – 4.76 (2H, m), 4.71 – 4.54 (4H, m), 4.46 (1H, d, J= 11.5 Hz), 4.35 – 4.24 (2H, 
m), 4.17 – 4.08 (1H, m), 4.03 (2H, dt, J= 10.3, 2.9 Hz), 3.91 – 3.72 (4H, m), 3.70 – 3.62 




Mixed acetal 92 (102 mg, 0.092 mmol), 
diphenylsulfoxide (28 mg, 0.133 mmol), DTBMP (50 mg, 
0.239 mmol) and freshly activated 4Å powdered 
molecular sieves (4 mg mg-1 of acetal) in anhydrous DCE (5mL) was stirred at rt under 
Ar for 40 min prior to being cooled to -35 °C. Tf2O (20 µL, 0.117 mmol) was added and 
the mixture was allowed to stir at the same temperature for 15 min, before being 
warmed slowly to rt. The reaction was stirred overnight and then quenched with the 
addition of a few drops of TEA, before being filtered through Celite. The reaction was 
diluted with aqueous NH4Cl and extracted into DCM. The organic layer was washed 
with brine, dried filtered and concentrated in vacuo to afford the residue which was 
purified by column chromatography (dry loaded from toluene, run PE to 5:1 PE/EtOAc) 
to afford the title compound 91 (36 mg, 0.042 mmol, 45%) as a colourless oil. 
 
Data for 91: δH(400 MHz, CDCl3): 7.53 – 7.27 (20H, m, Ph), 5.60 (1H, s, H-7), 
4.86 (1H, d, J= 12.4 Hz, PhCH2), 4.79 (1H, d, J= 12.4 Hz, PhCH2), 4.69 (1H, d, J= 11.4 Hz, 
PhCH2), 4.65 (1H, d, J= 11.3 Hz, PhCH2), 4.56 (2H, s, PhCH2), 4.38 (1H, d, J= 1.1 Hz, H-
1), 4.26 (1H, dd, J= 10.5, 4.9 Hz, H-6), 4.21 – 4.07 (3H, m, H-2, H-4, H-1’), 3.89 – 3.78 
(3H, m, H-1’, H-2’, H-6), 3.67 – 3.61 (2H, m, H-3’, H-4’), 3.59 (1H, dd, J= 9.5, 3.3 Hz, H-
3), 3.24 (1H, td, J= 9.8, 4.9 Hz, H-5), 2.46 (1H, bs, OH), 1.75 – 1.50 (4H, m, CH2), 1.26 
(22H, s, CH2), 0.92 – 0.84 (3H, m, CH3-18’); δC(101 MHz, CDCl3): 138.41 (ipso-C), 138.12 
(ipso-C), 137.99 (ipso-C), 137.58 (ipso-C), 131.19 (Ph), 129.46 (Ph), 129.09 (Ph), 128.58 
(Ph), 128.54 (Ph), 128.54 (Ph), 128.38 (Ph), 128.33 (Ph), 128.22  (Ph), 128.09 (Ph), 
128.04 (Ph), 128.02 (Ph), 127.97 (Ph), 127.88 (Ph), 126.18 (Ph), 124.94 (Ph), 101.67 (C-
7), 100.32 (d, 1JCH = 162.89 Hz, C-1), 79.43 (C-3’/C-4’), 79.12 (C-3’/C-4’), 78.45 (C-4), 
76.61 (C-3), 73.87 (PhCH2), 72.60 (PhCH2), 72.19 (PhCH2), 69.93 (C-2), 69.84 (C-1’), 
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68.69 (C-6), 67.09 (C-5), 61.94 (C-2’), 32.08 (CH2), 30.12 (CH2), 29.95 (CH2), 29.86 (CH2), 
29.85 (CH2), 29.83 (CH2), 29.82 (CH2), 29.78 (CH2), 29.76 (CH2), 29.52 (CH2), 25.34 (CH2), 
22.84 (CH2), 14.28 (C-18’); HRMS (ESI-pos): calcd for C52H69O8N3Na [M + Na]+ m/z 
886.4977 found m/z 886.5003. 
6.3.18. 1,2,3,4,6-Penta-O-acetyl-α-D-glucopyranose [205] 
D-Glucose 94 (10 g, 55.6 mmol) was dissolved in py (30 mL) and cooled 
to 0 °C, before the dropwise addition of acetic anhydride (70 mL, 741 
mmol). After warming to rt over 1 hour the reaction was stirred 
overnight before being diluted with EtOAc. The organic layer was washed successively 
with 1M HCl, water, saturated aqueous sodium bicarbonate, and brine. The solvent 
was removed in vacuo to afford the title compound 205 (α:β 3.5:1, 22 g, 55.6 mmol, 
quant.) as a white crystalline solid which was used without further purification. 
 
Data for 205: Rf = 0.51 (1:1 EtOAc/PE); δH(400 MHz, CDCl3): 6.33 (1H, d, J= 3.7 
Hz, H-1), 5.47 (1H, t, J= 9.9 Hz, H-3), 5.14 (1H, t, J= 10.1 Hz, H-4), 5.09 (1H, dd, J= 10.3, 
3.4 Hz, H-2), 4.31 – 4.22 (1H, m, H-6), 4.14 – 4.05 (2H, m, H-5, H-6), 2.18 (3H, s, OAc), 
2.09 (3H, s, OAc), 2.04 (3H, s, OAc), 2.02 (3H, s, OAc), 2.01 (3H, s, OAc); δC(101 MHz, 
CDCl3): 170.78 (C=O), 170.37 (C=O), 169.80 (C=O), 169.53 (C=O), 168.90 (C=O), 89.18 
(C-1), 69.94 (C-3/C-5), 69.93 (C-3/C-5), 69.30 (C-2), 67.98 (C-4), 61.57 (C-6), 21.04 
(OAc), 20.85 (OAc), 20.82 (OAc), 20.72 (OAc), 20.60 (OAc); HRMS (ESI-pos): calcd for 
C16H22O11Na [M + Na]+ m/z 413.1054 found m/z 413.1082. 
6.3.19. 2,3,4,6-Tetra-O-acetyl-1-bromo-α-D-glucopyranose [95]318 
Method A: Perchloric acid (72%, 4 drops) was added dropwise to a 
stirred solution of acetic anhydride (50 mL, 533 mmol) pre cooled to 
0°C. Anhydrous D-glucose 94 (12 g, 66.6 mmol) was added to the stirred 
solution at such a rate that the temperature remained below 40°C. After cooling to 
10°C, red phosphorus (4.13 g, 133 mmol) was added in one portion before bromine 
(6.2 mL, 120 mmol) was added dropwise at such a rate that the temperature remained 
below 40°C, followed by dropwise addition of water (6 mL) over a period of 10 min, 
again maintaining the temperature bellow 40°C. After stirring for a further 2 hrs, the 
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reaction mixture was diluted with DCM, and the filtrate collected in a flask filled with 
ice water. A standard aqueous workup was preformed using DCM as the organic 
solvent to give the crude material as an impure syrup which was recrystallized from 
Et2O/PE to give the title compound 95 (27 g, 66 mmol, 99%) as a white crystalline solid.  
 
Data for 95: Rf = 0.59 (1:1 EtOAc/PE); m.p. 78 °C (lit319 mp 77-79 °C); [𝛼]𝐷
20 =
+182.0 (𝑐 = 1.0, CHCl3); δH(400 MHz, CDCl3): 6.61 (1H, d, J= 4.0 Hz, H-1), 5.56 (1H, t, 
J= 9.7 Hz, H-3), 5.16 (1H, t, J= 9.7 Hz, H-4), 4.84 (1H, dd, J= 10.0, 4.0 Hz, H-2), 4.37 – 
4.26 (2H, m, H-5, H-6), 4.13 (1H, dd, J= 12.5, 1.7 Hz, H-6), 2.10 (3H, s, OAc), 2.10 (3H, 
s, OAc), 2.05 (3H, s, OAc), 2.03 (3H, s, OAc); δC(101 MHz, CDCl3): 170.65 (C=O), 169.99 
(C=O), 169.93 (C=O), 169.60 (C=O), 86.69 (C-1), 72.28 (C-5), 70.75 (C-2), 70.31 (C-3), 
67.32 (C-4), 61.10 (C-6), 20.82 (OAc), 20.80 (OAc), 20.77 (OAc), 20.70 (OAc); HRMS 
(ESI-pos): calcd for C14H19BrO9Na [M + Na]+ m/z 433.0105 found m/z 433.0083. 
 
Method B: Hydrogen bromide in AcOH (30%, 35 mL, 474 mmol) was added dropwise 
to a stirred solution of peracetate 205 (18 g, 44.3 mmol) in anhydrous DCM (15 mL) at 
0 °C. The resulting solution was stirred at rt overnight. After completion, the reaction 
mixture was poured into ice water and a standard aqueous workup was performed 
with DCM as the organic solvent. The solvents where removed in vacuo to afford the 
residue which was recrystallized from Et2O/PE to give the title compound 95 (15 g, 
36.7 mmol, 83%) as a white solid. 
 
1H NMR and all other analytical data were consistent with those of 95 synthesized 
using Method A. 
6.3.20. Ethyl 3,4,6-tri-O-acetyl-α-D-glucopyranosyl-1,2-O-ortho-acetate 
[206]318 
To a solution of bromide 95 (15 g, 36.5 mmol) in sym-collidine (25 mL) 
was added absolute ethanol (6 mL, 103 mmol) and TBAB (118 mg, 0.365 
mmol) and the mixture stirred at 50°C for 3 days. From the homogenous 
solution initially obtained, crystals of sym-collidinium bromide began to 
gradually separate. Chloroform (60 mL) was then added, and the clear solution 
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washed with 0.5M HCl (caution: it is necessary the organic solution remain slightly 
basic), saturated aqueous NaHCO3 and brine. The solvents were removed in vacuo to 
give the title compound 206 (13 g) which was used without further purification. A 
small sample of 206 was recrystallized from hot EtOH to give a single diastereomer as 
a white crystalline solid that was used for data collection. 
 
Data for 206: δH(500 MHz, CDCl3): 5.71 (1H, d, J= 5.2 Hz, H-1), 5.19 (1H, t, J= 2.8 
Hz, H-3), 4.90 (1H, ddd, J= 9.6, 2.7, 0.9 Hz, H-4), 4.32 (1H, ddd, J= 5.2, 3.0, 0.9 Hz, H-2), 
4.23 – 4.14 (2H, m, H-6), 3.95 (1H, ddd, J= 9.6, 5.0, 3.2 Hz, H-5), 3.54 (2H, qd, J= 7.0, 
1.5 Hz, OCH2CH3), 2.11 (3H, s, OAc), 2.10 (3H, s, OAc), 2.09 (3H, s, OAc), 1.72 (3H, s, 
CH3), 1.18 (3H, t, J= 7.0 Hz, OCH2CH3); δC(126 MHz, CDCl3): 170.85 (C=O), 169.82 (C=O), 
169.34 (C=O), 121.42 (CH3COEt), 97.06 (C-1), 73.22 (C-2), 70.32 (C-3), 68.39 (C-4), 
67.09 (C-5), 63.24 (C-6), 59.34 (OCH2CH3), 20.96 (CCH3), 20.92 (OAc), 20.92 (OAc), 
20.92 (OAc), 15.44 (OCH2CH3); HRMS (ESI-pos): calcd for C16H24O10Na [M + Na]+ m/z 
399.1262 found m/z 399.1248. 
6.3.21. Ethyl α-D-glucopyranosyl-1,2-O-ortho-acetate [207] 
Sodium methoxide solution (1M, 20 mL, 20.00 mmol) was added 
dropwise to a solution of ortho-acetate 206 (2.8 g, 7.23 mmol) in MeOH 
(15 mL), then left to stir at rt overnight. The reaction was neutralised 
with amberlite IR-120 (H+ form), then filtered through Celite and the 
solvent removed in vacuo to give the title compound 207 (1.8 g, 7.16 mmol, 99%) as a 
white solid that was used without further purification.  
 
Data for 207: δH(500 MHz, D2O): 5.82 (1H, d, J= 5.2 Hz, H-1), 4.42 (1H, t, J= 4.6 
Hz), 3.99 (1H, t, J= 4.1 Hz), 3.85 (1H, dd, J= 12.2, 2.3 Hz, H-6), 3.72 (1H, dd, J= 12.3, 6.1 
Hz, H-6), 3.68 – 3.62 (3H, m, H-5 OCH2CH3), 3.59 (1H, dd, J= 9.1, 3.9 Hz), 1.74 (3H, s, 
CH3), 1.19 (3H, t, J= 7.0 Hz, OCH2CH3); δC(126 MHz, D2O): 121.70 (CH3COEt), 97.94 (C-
1), 76.82, 73.83, 72.37, 69.20, 62.12 (C-6), 60.15 (OCH2CH3), 21.45 (CH3), 14.94 
(OCH2CH3); HRMS (ESI-pos): calcd for C10H18O7Na [M + Na]+ m/z 273.0945 found m/z 
273.0932. 
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6.3.22. Ethyl 3,4,6-tri-O-benzyl-α-D-glucopyranosyl-1,2-O-ortho-acetate 
[208] 
Sodium hydride (60% in oil, 1.5 g, 35.8 mmol) was added to a solution 
of crude triol 207 (1.8 g, 7.16 mmol) in DMF (5 mL) at 0 °C under argon 
and left to stir for 15 min. Benzyl bromide (4.25 mL, 35.8 mmol) was 
added dropwise and the resulting mixture warmed to rt. After stirring 
overnight, the reaction was quenched with water and a standard aqueous workup 
preformed using EtOAc as the organic solvent. The solvents were removed in vacuo 
and the residue purified by column chromatography (PE to 3:1 PE:EtOAc) to give the 
title compound 208 (1.94 g, 3.73 mmol, 52 % over three steps) as a colourless oil. 
 
Data for 208: δH(500 MHz, CDl3): 7.41 – 7.26 (13H, m, Ph), 7.18 (2H, dd, J= 7.5, 
1.9 Hz, Ph), 5.77 (1H, d, J= 5.2 Hz, H-1), 4.71 (1H, d, J= 11.8 Hz, PhCH2), 4.64 – 4.55 (3H, 
m, PhCH2), 4.51 (1H, d, J= 12.1 Hz, PhCH2), 4.42 (1H, ddd, J= 5.3, 3.6, 0.8 Hz, H-2), 4.39 
(1H, d, J= 11.4 Hz, PhCH2), 3.88 (1H, dd, J= 4.6, 3.6 Hz, H-3), 3.80 (1H, ddd, J= 9.6, 4.0, 
2.4 Hz, H-5), 3.71 (1H, dd, J= 9.5, 4.5 Hz, H-4), 3.71 – 3.61 (2H, m, H-6), 3.55 (2H, qq, J= 
9.1, 7.0 Hz, OCH2CH3), 1.67 (3H, s, CH3), 1.20 (3H, t, J= 7.1 Hz, OCH2CH3); δC(126 MHz, 
CDCl3): 138.23 (ipso-C), 138.08 (ipso-C), 137.88 (ipso-C), 128.58 (Ph), 128.48 (Ph), 
128.47 (Ph), 128.16 (Ph), 128.14 (Ph), 128.02 (Ph), 127.99 (Ph), 127.91 (Ph), 127.73 
(Ph), 121.11 (CH3COEt), 97.93 (C-1), 78.95 (C-3), 75.92 (C-2), 75.07 (C-4), 73.54 
(PhCH2), 73.08 (PhCH2), 72.05 (PhCH2), 70.62 (C-2), 69.28 (C-6), 58.83 (OCH2CH3), 22.00 
(CH3), 15.48 (OCH2CH3); HRMS (ESI-pos): calcd for C31H36O7Na [M + Na]+ m/z 543.2353 
found m/z 543.2344. 
6.3.23. Methyl 3,4,6-tri-O-acetyl-α-D-glucopyranosyl-1,2-O-ortho-acetate 
[96]320 
Bromide 95 (15 g, 36.7 mmol) was dissolved under an argon 
atmosphere in sym-collidine (35 mL) and warmed to 45 °C. TBAB (5.9 
g, 18.35 mmol) and anhydrous MeOH (8 mL, 198 mmol) were added. 
And the reaction stirred at rt overnight. The reaction was diluted with 
DCM, washed with water and the solvents removed in vacuo. The remaining sym-
collidine was then removed by vacuum distillation (cryogen trap, 0.1 mbar, 70 °C) to 
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give the residue which solidified on standing to give the title compound 96 (15 g) as 
an off white solid and was used without further purification. A small sample of 96 was 
recrystallized from hot MeOH to give a single diastereomer as a white crystalline solid 
that was used for data collection. 
 
 Data for 96: δH(400 MHz, CDCl3): 5.71 (1H, d, J= 5.2 Hz, H-1), 5.19 (1H, t, J= 2.9 
Hz, H-3), 4.89 (1H, dd, J= 9.5, 2.6 Hz, H-4), 4.31 (1H, dd, J= 5.2, 3.0 Hz, H-2), 4.25 – 4.11 
(2H, m, H-6), 3.94 (1H, ddd, J= 9.5, 4.8, 3.4 Hz, H-5), 3.28 (3H, s, OMe), 2.10 (3H, s, 
OAc), 2.09 (3H, s, OAc), 2.09 (3H, s, OAc), 1.70 (3H, s, CCH3); δC(101 MHz, CDCl3): 
170.86 (C=O), 169.81 (C=O), 169.32 (C=O), 121.71 (CH3COMe), 97.03 (C-1), 73.14 (C-
2), 70.18 (C-3), 68.28 (C-4), 67.06 (C-5), 63.20 (C-6), 51.20 (OCH3), 20.95 (OAc), 20.93 
(OAc), 20.89 (OAc), 20.16 (CCH3); HRMS (ESI-pos): calcd for C15H22O10Na [M + Na]+ m/z 
385.1105 found m/z 385.1079. 
6.3.24. Methyl 3,4,6-tri-O-acetyl-α-D-glucopyranosyl-1,2-O-ortho-acetate 
[97] 
Sodium methoxide solution (1M, 50 mL, 50.0 mmol) was added 
dropwise to a solution of ortho-acetate 96 (13 g, 36.7 mmol) in 
methanol (50 mL), then left to stir at rt overnight. After completion, 
the solvent was removed in vacuo to give crude triol 209 (8.8 g) as a 
yellow foam which was used directly in the next step. 
 
Sodium hydride (60% in oil, 7.38 g, 185 mmol) was added to a solution of crude triol 
209 (8.7 g, 36.7 mmol) in DMF (15 mL) at 0 °C under argon and left to stir for 15 min. 
Benzyl bromide (22 mL, 185 mmol) was added dropwise and the resulting mixture 
warmed to rt over an hour. After stirring at rt overnight the reaction was quenched on 
the careful addition of water and a standard aqueous workup preformed using EtOAc 
as the organic solvent. The solvents were removed in vacuo and the residue purified 
by column chromatography (PE to 6:1 PE:EtOAc) to give the title compound 97 (15.8 
g, 31.2 mmol, 85% over three steps) as a yellow oil. 
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Data for 97: δH(400 MHz, CDCl3): 7.39 – 7.27 (13H, m, Ph), 7.18 (2H, dd, J= 7.3, 
2.2 Hz, Ph), 5.79 (1H, d, J= 5.3 Hz, H-1), 4.72 (1H, d, J= 11.8 Hz, PhCH2), 4.64 – 4.56 (3H, 
m, PhCH2), 4.51 (1H, d, J= 12.2 Hz, PhCH2), 4.43 (1H, ddd, J= 5.3, 3.6, 0.7 Hz, H-2), 4.39 
(1H, d, J= 11.4 Hz, PhCH2), 3.88 (1H, dd, J= 4.6, 3.6 Hz, H-3), 3.82 – 3.77 (1H, m, H-5), 
3.71 (1H, dd, J= 9.6, 4.6 Hz, H-4), 3.66 (2H, t, J= 3.3 Hz, H-6), 3.29 (3H, s, OMe), 1.66 
(3H, s, CH3); δC(101 MHz, CDCl3): 138.18 (ipso-C), 138.02 (ipso-C), 137.80 (ipso-C), 
128.58 (Ph), 128.48 (Ph), 128.46 (Ph), 128.16 (Ph), 128.15 (Ph), 128.04 (Ph), 127.98 
(Ph), 127.92 (Ph), 127.73 (Ph), 121.31 (CH3COMe), 97.95 (C-1), 78.85 (C-3), 76.01 (C-
2), 74.97 (C-4), 73.53 (PhCH2), 73.08 (PhCH2), 72.02 (PhCH2), 70.62 (C-2), 69.24 (C-6), 
50.72 (OCH3), 21.42 (CCH3);HRMS (ESI-pos): calcd for C30H34O7Na [M + Na]+ m/z 
529.2197 found m/z 529.2167. 
6.3.25. 2-O-Acetyl-3,4,6-tri-O-benzyl-D-glucopyranose [99]321 
Method A: To ortho-acetate 208 (1.94 g, 3.73 mmol) was added 
glacial acetic acid (15 mL, 262 mmol) and the reaction was stirred at 
rt overnight. After completion the solvent was removed in vacuo to 
afford crude bisacetate 98 (1.95 g, 3.65 mmol) as a colourless oil that was used directly 
in the next step. Rf = 0.35 (1:2 EtOAc/PE); HRMS (ESI-pos): calcd for C31H34O8Na [M + 
Na]+ m/z 557.2146, found m/z 557.2155. 
 
Bisacetate 98 (1.95 g, 3.65 mmol) was dissolved in a solution of MeOH:THF (3:7, 100 
mL) and cooled to 0 °C. Ammonia gas was bubbled through the solution to the point 
of saturation and the reaction was stirred at 0 °C until TLC indicated loss of starting 
material (ca. 3 hrs). The ammonia was removed by bubbling N2 through the solution 
and the solvents were removed in vacuo to afford the title compound 99 (α:β = 12:1, 
1.8 g, 3.65 mmol, quant.) as a white solid that was used without further purification. 
 
Data for 99: Rf = 0.40 (1:2 EtOAc/PE); δH(500 MHz, CDCl3): 7.45 – 7.27 (13H, m, 
Ph), 7.23 – 7.08 (2H, m, Ph), 5.40 (1H, d, J= 3.6 Hz, H-1), 4.89 (1H, dd, J= 10.0, 3.6 Hz, 
H-2), 4.85 – 4.69 (3H, m, PhCH2), 4.63 – 4.48 (3H, m, PhCH2), 4.16 – 4.04 (2H, m, H-3, 
H-4), 3.74 – 3.57 (3H, m, H-5, H-6), 2.03 (3H, s, OAc); δC(126 MHz, CDCl3): 170.47 (C=O), 
138.60 (ipso-C), 138.06 (ipso-C), 137.83 (ipso-C), 128.57 (Ph), 128.55 (Ph), 128.52 (Ph), 
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128.09 (Ph), 128.07 (Ph), 128.06 (Ph), 128.01 (Ph), 127.94 (Ph), 127.91 (Ph), 127.83 
(Ph), 127.77 (Ph), 127.74 (Ph), 90.55 (C-1), 79.92, (C-3/ C-4), 78.25 (C-5), 75.58 (PhCH2), 
75.19 (PhCH2), 73.74 (C-2), 73.56 (PhCH2), 70.31 (C-3/ C-4), 68.97 (C-6), 21.05 (OAc); 
HRMS (ESI-pos): calcd for C29H32O7Na [M + Na]+ m/z 515.2040, found m/z 515.2024; 
Analytical HPLC [Column C, T16, AW-BA, TFA2, F0. 25, 10-100B G8H5] tR =8.106 min 
(99.3%). 
 
Method B: 99 was also prepared from ortho-acetate 97 (5.0 g, 9.88 mmol) using an 
identical procedure to Method A. The crude residue was purified by crystallisation 
from PE/EtOAc to afford the title compound 99 (4.1 g, 8.26 mmol, 84%) as a white 
solid. 
 
1H NMR and all other analytical data were consistent with those of 99 synthesized 
using Method A. 
6.3.26. 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-glucopyranosyl 
trichloroacetimidate [93] 
Trichloroacetonitrile (500 µL, 4.99 mmol) and sodium hydride 
(60% in oil, 12.0 mg, 0.300 mmol) was added to a solution of 
alcohol 99 (397.5 mg, 0.807 mmol) in anhydrous DCM (4 mL) under 
argon. The solution was stirred at rt for 80 min after which the 
solvent removed was in vacuo to afford the title compound 93 (433.2 mg, 0.680 mmol, 
84%) as a colourless oil, which was used directly in the next step. 
 
Data for 93: Rf = 0.61 (1:2 EtOAc/PE); δH(500 MHz, CDCl3): 8.56 (1H, s, NH), 7.49 
– 7.27 (13H, m, Ph), 7.21 – 7.11 (2H, m, Ph), 6.52 (1H, d, J= 3.5 Hz, H-1), 5.07 (1H, dd, 
J= 10.0, 3.6 Hz, H-2), 4.85 (2H, t, J= 10.8 Hz, PhCH2), 4.77 (1H, d, J= 11.5 Hz, PhCH2), 
4.63 (1H, d, J= 12.1 Hz, PhCH2), 4.57 (1H, d, J= 10.6 Hz, PhCH2), 4.50 (1H, d, J= 12.1 Hz, 
PhCH2), 4.09 (1H, t, J= 9.5 Hz, H-3), 4.01 (1H, ddd, J= 10.1, 3.5, 2.0 Hz, H-5), 3.88 (1H, 
dd, J= 10.1, 9.2 Hz, H-4), 3.81 (1H, dd, J= 11.1, 3.4 Hz, H-6), 3.70 (1H, dd, J= 11.1, 2.0 
Hz, H-6), 1.93 (3H, s, OAc); δC(126 MHz, CDCl3): 170.19 (COCH3), 161.16 (COCCl3), 
138.41 (ipso-C), 137.98 (ipso-C), 137.95 (ipso-C), 128.60 (Ph), 128.58 (Ph), 128.54 (Ph), 
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128.28 (Ph), 128.08 (Ph), 128.03 (Ph), 127.93 (Ph), 127.88 (Ph), 94.19 (C-1), 79.64 (C-
3), 77.16 (C-4), 75.57 (PhCH2), 75.54 (PhCH2), 73.66 (C-5), 73.60 (PhCH2), 72.54 (C-2), 
68.05 (C-6), 20.74 (OAc); HRMS (ESI-pos): calcd for C31H32O7NCl3Na [M + Na]+ m/z 
658.1137, found m/z 658.1167; Analytical HPLC [Column C, T16, AW-BA, TFA2, F0. 25, 
10-100B G8H5] tR =7.318 min (98.5%). 
6.3.27. Phenyl 2-O-acetyl-3,4,6-tri-O-benzyl-1-thio-α-D-glucopyranose [101] 
BF3·Et2O (370 μL, 2.99 mmol) was added dropwise to a stirred solution 
of crude bisacetate 98 (1.6 g, 2.99 mmol) and thiophenol (315 μL, 2.99 
mmol) in anhydrous DCM (5 mL) at 0 °C. Allowed to warm to rt 
overnight after which the reaction was diluted with DCM and washed with 0.5M 
NaOH. A standard aqueous workup was performed using DCM as the organic solvent. 
The solvents were removed in vacuo to give the residue which was dissolved in 
minimal EtOAc and titrated out with di-isopropyl ether to afford the title compound 
101 (1.65 g, 2.82 mmol, 94%) as a white solid. 
 
Data for 101: δH(400 MHz, CDCl3): 7.57 – 7.47 (2H, m, Ph), 7.37 – 7.16 (18H, m, 
Ph), 5.07 – 4.97 (1H, m, H-2), 4.78 (2H, dd, J= 11.1, 5.0 Hz, PhCH2), 4.66 (1H, d, J= 11.4 
Hz, PhCH2), 4.63 – 4.55 (3H, m, PhCH2, H-1), 4.53 (1H, d, J= 11.9 Hz, PhCH2), 3.78 (1H, 
dd, J= 11.0, 2.0 Hz, H-6), 3.72 (1H, dd, J= 11.0, 4.9 Hz, H-6), 3.69 – 3.65 (2H, m, H-3, H-
4), 3.54 (1H, ddd, J= 9.8, 4.8, 1.9 Hz, H-5), 1.99 (3H, s); δC(101 MHz, CDCl3): 169.65 
(C=O), 138.34 (ipso-C), 138.21 (ipso-C), 138.00 (ipso-C), 133.14 (Ph), 132.41 (Ph), 
128.97 (Ph), 128.59 (Ph), 128.49 (Ph), 128.16 (Ph), 128.03 (Ph), 127.99 (Ph), 127.92 
(Ph), 127.86 (Ph), 127.80 (Ph), 127.72 (Ph), 86.15 (C-1), 84.57 (C-3/C-4), 79.54 (C-5), 
77.94 (C-3/C-4), 75.45 (PhCH2), 75.25 (PhCH2), 73.62 (PhCH2), 71.95 (C-2), 69.06 (C-6), 
21.16 (CH3); HRMS (ESI-pos): calcd for C35H36O6SNa [M + Na]+ m/z 607.2125, found 
m/z 607.2149. 
  





Method A: Trichloroacetimidate 93 (287 mg, 0.451 mmol) 
and alcohol 78 (182.6 mg, 0.349 mmol) were azeotroped 
together from toluene before being dissolved in 
anhydrous toluene (4 mL) under an argon atmosphere. The solution was stirred at rt 
for 30 min to ensure dryness before being cooled to -10 °C. TMSOTf (13 µL, 0.070 
mmol) in toluene (70 μL) was added dropwise and the reaction stirred at -10 °C for 30 
min. Warmed to rt over an hour the reaction was quenched when TLC showed 
consumption of the starting material by addition of a few drops of TEA. The solvents 
were removed in vacuo to afford the crude material which was purified by column 
chromatography (PE to 10:1 PE/EtOAc) to afford the title compound 100 (220 mg, 
0.221 mmol, 63%) as a colourless oil. 
 
Data for 100: δH(500 MHz, CDCl3): 7.44 – 7.27 (23H, m, Ph), 7.23 – 7.10 (2H, m, 
Ph), 5.06 (1H, t, J= 8.6 Hz, H-2), 4.80 (2H, dd, J= 11.1, 6.1 Hz, PhCH2), 4.69 (3H, dd, J= 
11.0, 5.5 Hz, PhCH2), 4.59 (3H, dd, J= 17.9, 11.4 Hz, PhCH2), 4.51 (2H, dd, J= 11.9, 5.6 
Hz, PhCH2), 4.40 (1H, d, J= 7.9 Hz, H-1), 4.16 (1H, dd, J= 10.6, 6.2 Hz, H-1’), 3.83 (1H, 
dd, J= 10.6, 3.3 Hz, H-1’), 3.78 – 3.59 (7H, m, H-2’, H-3’, H-4’, H-3, H-4, H-6, H-6), 3.46 
(1H, dd, J= 9.6, 3.3 Hz, H-5), 1.96 (3H, s, OAc), 1.68 (1H, dtd, J= 13.8, 9.0, 4.8 Hz, CH2), 
1.54 (1H, tdt, J= 14.2, 9.3, 4.7 Hz, CH2), 1.43 (1H, dq, J= 10.6, 5.3 Hz, CH2), 1.26 (23H, s, 
CH2), 0.89 (3H, t, J= 6.8 Hz, CH3-18); δC(126 MHz, CDCl3): 169.58 (C=O), 138.59 (ipso-
C), 138.33 (ipso-C), 138.32 (ipso-C), 138.23 (ipso-C), 138.04 (ipso-C), 128.57 (Ph), 
128.51 (Ph), 128.47 (Ph), 128.27 (Ph), 128.16 (Ph), 128.05 (Ph), 128.00 (Ph), 127.92 
(Ph), 127.86 (Ph), 127.83 (Ph), 127.74 (Ph), 127.72 (Ph), 100.77 (C-1), 83.08 (C-3), 79.48 
(C-4’), 78.63 (C-3’/C-4), 78.06 (C-3’/C-4), 75.44 (C-3), 75.20 (PhCH2), 75.16 (PhCH2), 
74.12 (PhCH2), 73.63 (PhCH2), 73.13 (C-2), 72.06 (PhCH2), 68.82 (C-6), 68.75 (C-1’), 
61.55 (C-2’), 32.08 (CH2), 30.01 (CH2), 29.91 (CH2), 29.86 (CH2), 29.83 (CH2), 29.82 
(CH2), 29.79 (CH2), 29.77 (CH2), 29.52 (CH2), 25.61 (CH2), 22.85 (CH2), 21.14 (OAc), 
14.28 (C-18’); HRMS (ESI-pos): calcd for C61H79O9N3Na [M + Na]+ m/z 1020.5709, found 
m/z 1020.5736. 




Method B: Triflic Acid (15 µL, 0.170 mmol) was added to a mixture of thio glycoside 
101 (240 mg, 0.458 mmol), alcohol 78 (322.6 mg, 0.552 mmol), and NIS (190 mg, 0.802 
mmol) in anhydrous DCM (5 mL) containing pre-activated 4Ȧ MS at -10°C under argon. 
When TLC indicated completion (ca. 3 hrs), the reaction was diluted with DCM and 
filtered through Celite. The filtrate was washed with NaHCO3 and concentrated in 
vacuo to afford the residue which was purified by column chromatography (PE to 8:1 
PE/EtOAc) to afford the title compound 100 (258 mg, 0.258 mmol, 70%) as a white 
solid. 
 
1H NMR and all other analytical data were consistent with those of 100 synthesized 
using Method A. 
6.3.29. 1-((2'S,3'S,4'R)-2'-Azido-3',4'-di-O-benzyl-1'-octadecanyl) 3,4,6-tri-O-
benzyl-β-D-glucopyranoside [103] 
Sodium methoxide solution (2.5M, 5 mL, 12.5 mmol) was 
added dropwise to a solution of glycoside 100 (346 mg, 
0.347 mmol) in methanol (10 mL). The reaction was 
stirred overnight at rt then neutralised with amberlite IR-120 (H+ form). The solution 
was filtered through Celite washed with methanol and the solvent removed in vacuo 
to give the residue. The residue was diluted with EtOAc and washed with 50% aqueous 
NaHCO3 and the organic concentrated in vacuo to afford an analytically pure sample 
of the title compound 103 (318 mg, 0.333 mmol, 96%) as a white solid that was used 
without further purification. 
 
Data for 103: δH(400 MHz, CDCl3): 7.44 – 7.27 (23H, m, Ph), 7.18 (2H, dd, J= 7.2, 
2.3 Hz, Ph), 4.95 (1H, d, J= 11.3 Hz, PhCH2), 4.84 (2H, d, J= 11.2 Hz, PhCH2), 4.72 – 4.65 
(2H, m, PhCH2), 4.61 – 4.52 (4H, m, PhCH2), 4.49 (1H, d, J= 12.2 Hz, PhCH2), 4.26 – 4.22 
(1H, m, H-1), 4.19 (1H, dd, J= 10.5, 6.6 Hz, H-6), 3.88 (1H, dd, J= 10.6, 3.2 Hz, H-6), 3.79 
– 3.69 (4H, m, H-2’, H-1’, H-3’/H-4’), 3.64 (2H, td, J= 6.8, 5.5, 3.0 Hz, H-3’/H-4’, H-4), 
3.60 – 3.56 (2H, m, H-2, H-3), 3.42 (1H, dt, J= 9.6, 3.2 Hz, H-5), 2.41 (1H, b, OH), 1.69 
(2H, td, J= 13.2, 11.2, 7.4 Hz, CH2), 1.56 (1H, ddt, J= 14.3, 9.8, 4.4 Hz, CH2), 1.42 (1H, h, 
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J= 5.0, 4.5 Hz, CH2), 1.26 (22H, d, J= 4.2 Hz, CH2), 0.89 (3H, t, J= 6.6 Hz, CH3-18); δC(101 
MHz, CDCl3): 138.80 (ipso-C), 138.42 (ipso-C), 138.26 (ipso-C), 138.25 (ipso-C), 138.09 
(ipso-C), 128.59 (Ph), 128.57 (Ph), 128.53 (Ph), 128.51 (Ph), 128.48 (Ph), 128.26 (Ph), 
128.25 (Ph), 128.13 (Ph), 128.10 (Ph), 128.06 (Ph), 127.93 (Ph), 127.89 (Ph), 127.88 
(Ph), 127.82 (Ph), 127.72 (Ph), 102.80 (d, 1JCH = 162.54 Hz, C-1), 84.53 (C-2), 79.37 (C-
3’/C-4’), 78.96 (C-3’/C-4’), 77.56 (C-4), 75.42 (C-5), 75.26 (PhCH2), 75.15 (PhCH2), 74.89 
(C-2), 73.93 (PhCH2), 73.61 (PhCH2), 72.20 (PhCH2), 69.54 (C-6), 68.90 (C-1), 61.82 (C-
2’), 32.08 (CH2), 30.02 (CH2), 29.92 (CH2), 29.86 (CH2), 29.85 (CH2), 29.83 (CH2), 29.82 
(CH2), 29.78 (CH2), 29.76 (CH2), 29.52 (CH2), 25.49 (CH2), 22.85 (CH2), 14.28 (C-18’); 
HRMS (ESI-pos): calcd for C59H77O8N3Na [M + Na]+ m/z 978.5603, found m/z 978.5626; 




A solution of glucoside 103 (318 mg, 0.333 mmol) in 
anhydrous DCM (5 mL) at rt under Ar was treated with 
Dess-Martin periodinane (460 mg, 1.030 mmol) in one 
portion. The resulting suspension was stirred for 16 hrs then diluted with DCM and 
filtered through Celite. The filtrate was washed with 50% sat. aqueous NaHCO3. The 
combined organic layers were dried and concentrated in vacuo to give the residue 
which was triturated with di-isopropyl ether to remove excess Dess-Martin related 
materials and filtered. The filtrate was concentrated in vacuo to afford the 
intermediate ulose 104 that was used directly in the next step. 
 
To a solution of 104 (318 mg, 0.333 mmol) in anhydrous THF (1 mL, 3 mL per mmol) at 
-78 °C under Ar was added L-Selectride (1M in THF, 700 µL, 0.700 mmol). After 10 min 
the reaction was stopped by the addition of acetic acid. The reaction was warmed to 
rt, diluted with DCM and washed with 2M HCl, followed by sat. aq. NaHCO3. The 
combined organic extracts were concentrated in vacuo to afford the crude residue 
which was purified by column chromatography (PE to 7:1 PE/EtOAc) to afford a single 
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diastereomer of the title compound 102 (140 mg, 0.146 mmol, 44% over two steps) as 
a colourless oil. 
 
 Data for 102: δH(500 MHz, CDCl3): 7.42 – 7.25 (22H, m, Ph), 7.23 (3H, ddd, J= 
9.5, 7.0, 3.1 Hz, Ph), 4.90 (1H, d, J= 10.8 Hz, PhCH2), 4.78 (1H, d, J= 11.9 Hz, PhCH2), 
4.70 – 4.65 (3H, m, PhCH2), 4.60 (1H, d, J= 12.2 Hz, PhCH2), 4.57 – 4.50 (4H, m, PhCH2), 
4.33 (1H, s, H-1), 4.16 (1H, dd, J= 10.5, 7.4 Hz, H-1’), 4.08 (1H, d, J= 3.1 Hz, H-2), 3.91 
(1H, t, J= 9.4 Hz, H-4), 3.85 (1H, dd, J= 10.5, 3.4 Hz, H-1’), 3.81 (1H, ddd, J= 7.5, 5.4, 3.4 
Hz, H-2’), 3.74 – 3.71 (2H, m, H-6), 3.65 (1H, t, J= 5.0 Hz, H-3’), 3.61 (1H, dt, J= 7.0, 4.1 
Hz, H-4’), 3.52 (1H, dd, J= 9.0, 3.1 Hz, H-3), 3.36 (1H, ddd, J= 9.7, 4.3, 2.8 Hz, H-5), 2.34 
(1H, b, OH), 1.67 (1H, dddd, J= 14.6, 10.3, 7.0, 5.0 Hz, CH2), 1.62 – 1.53 (1H, m, CH2), 
1.40 (1H, dq, J= 9.9, 5.2, 4.8 Hz, CH2), 1.26 (23H, d, J= 5.0 Hz, CH2), 0.89 (3H, t, J= 6.9 
Hz, CH3-18’); δC(126 MHz, CDCl3): 138.46 (ipso-C), 138.41 (ipso-C), 138.05 (ipso-C), 
138.01 (ipso-C), 128.68 (Ph), 128.62 (Ph), 128.56 (Ph), 128.52 (Ph), 128.51 (Ph), 128.47 
(Ph), 128.42 (Ph), 128.36 (Ph), 128.25 (Ph), 128.21 (Ph), 128.08 (Ph), 128.05 (Ph), 
128.00 (Ph), 127.98 (Ph), 127.95 (Ph), 127.90 (Ph), 127.86 (Ph), 127.80 (Ph), 127.67 
(Ph), 99.73 (d, 1JCH = 157.18 Hz, C-1), 81.44 (C-3), 79.25 (C-3’/C-4’), 79.21 (C-3’/C-4’), 
75.62 (C-5), 75.31 (CH2Ph), 74.27 (C-4), 73.89 (CH2Ph), 73.60 (CH2Ph), 72.15 (CH2Ph), 
71.47 (CH2Ph), 69.45 (C-1’), 69.21 (C-6), 68.26 (C-2), 61.93 (C-2’), 32.08 (CH2), 30.09 
(CH2), 29.95 (CH2), 29.86 (CH2), 29.83 (CH2), 29.82 (CH2), 29.79 (CH2), 29.76 (CH2), 29.52 
(CH2), 25.39 (CH2), 22.85 (CH2), 14.28 (C-18’); HRMS (ESI-pos): calcd for C59H77O8N3Na 
[M + Na]+ m/z 978.5603, found m/z 978.5619; Analytical LCMS [Column C, T23, AW-
BA, TFA2, F0. 15, 10-100B G8H12, 50-165Pos] tR =17.027 min. 
6.3.31. 3,4,6-Tri-O-acetyl-1,2-ethylidene-β-D-mannopyranoside [107]322-326 
Acetic anhydride (28 mL) was added to a stirred solution of D-
mannose (5.1 g, 28.3 mmol) in py (10 mL) at 0 °C. The reaction was 
stirred at rt overnight, after which a standard aqueous workup was 
performed using EtOAc as the organic solvent. Additional washes of 
the aqueous extract was performed with 10% aqueous HCl and 5% aqueous NaHCO3. 
The solvents where removed in vacuo to afford crude penta-O-acetyl-D-mannose 202 
(α:β = 3:1, 28.2 mmol, quant.) which was used without further purification. Rf = 0.35 
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(3:1 EtOAc/PE); HRMS (ESI-pos): calcd for C16H22O11Na [M + Na]+ m/z 413.3399, found 
m/z 413.3322. 
 
Hydrogen bromide in AcOH (33%, 5 mL, 67.7 mmol) was added dropwise to a stirred 
solution of crude peracetate 202 (1.95 g, 5.00 mmol) in dry DCM (5 mL) at 0 °C. The 
resulting solution was stirred at rt for 4 hr. and monitored by TLC. After completion, 
the reaction mixture was poured into ice water and a standard aqueous workup was 
performed with DCM as the organic solvent. The solvents where removed in vacuo to 
afford crude bromide 106 (5.00 mmol, quant.) as a foam which was used without 
further purification. Rf = 0.56 (1:1 EtOAc/PE); HRMS (ESI-pos): calcd for C14H19O9BrNa 
[M + Na]+ m/z 433.0105, found m/z 433.0091. 
 
Crude bromide 106 (2 g, 4.86 mmol) was dissolved in dry acetonitrile (5 mL) under an 
argon atmosphere. Sodium borohydride (1.2 g, 31.7 mmol) was added and the 
reaction stirred at rt overnight. After completion, a standard aqueous workup was 
preformed using EtOAc as the organic solvent. The solution was filtered through a bed 
of Celite and the solvents removed in vacuo to afford the crude product. Purification 
by column chromatography (EtOAc:PE = 3:1 to 1:1) afforded the title compound 107 
as an inseparable mixture of endo/exo isomers (Major/Minor =7:1, 1.16 g, 3.50 mmol, 
72%, over 3 steps) as a white solid.  
 
Data for 107: Rf = 0.53 (1:1 EtOAc/PE); δH(500 MHz, CDCl3): 5.35 (1H, t, J= 9.7 
Hz, H-4), 5.31 (1H, d, J= 0.6 Hz, H-1), 5.30 (1H, q, J= 4.9 Hz, H-7), 5.22 (1H, dd, J= 9.9, 
4.0 Hz, H-3), 4.27 (1H, dd, J= 4.0, 2.4 Hz, H-2), 4.22 (1H, dd, J= 12.1, 5.3 Hz, H-6), 4.15 
(1H, dd, J= 12.1, 2.7 Hz, H-6), 3.69 (1H, ddd, J= 9.6, 5.2, 2.7 Hz, H-5), 2.12 (3H, s, OAc), 
2.07 (3H, s, OAc), 2.05 (3H, s, OAc), 1.54 (3H, d, J= 5.0 Hz, CH3-8); δC(126 MHz, CDCl3): 
170.86 (C=O), 170.51 (C=O), 169.67 (C=O), 104.98 (C-7), 96.69 (C-1), 77.49 (C-2), 71.77 
(C-5), 70.75 (C-3), 66.18 (C-4), 62.68 (C-6), 21.73 (C-8), 20.92 (OAc), 20.90 (OAc), 20.85 
(OAc); HRMS (ESI-pos): calcd for C14H20O9Na [M + Na]+ m/z 355.1000, found m/z 
355.0983. 
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6.3.32. 1,2-Ethylidene-β-D-mannopyranoside [108]323, 327-340 
Method A: IRA 400 (OH-) exchange resin (2 g) was added to a solution 
of ethylidene 107 (1.9 g, 5.85 mmol) in MeOH (25 mL) and stirred at 
rt overnight. The reaction was monitored by TLC, after completion the 
mixture was filtered and the solvent removed in vacuo to afford the 
crude titled product 108 as an inseparable mixture of endo/exo isomers (major/minor 
=7:1, 5.85 mmol, quant.) as a white foam which was used without further purification. 
 
Data for 108: Rf = 0.33 (10% methanol in DCM); δH(500 MHz, D2O): 5.41 (1H, 
dd, J= 2.2 Hz, H-1), 5.33 (1H, q, J= 4.9 Hz, H-7), 4.27 (1H, dd, J= 4.3, 2.3 Hz, H-2), 3.98 
(1H, dd, J= 9.5, 4.3 Hz, H-3), 3.89 (1H, dd, J= 12.2, 2.5 Hz, H-6), 3.74 (1H, dd, J= 12.4, 
6.1 Hz, H-6), 3.71 (1H, t, J= 9.7 Hz, H-4), 3.49 – 3.41 (1H, m, H-5), 3.36 (3H, s, 3x OH), 
1.49 (3H, dd, J= 4.7, 0.9 Hz, CH3-8); δC(126 MHz, D2O): 104.20 (C-7), 96.38 (C-1), 79.86 
(C-2), 75.21 (C-5), 70.71 (C-3), 67.12 (C-4), 60.83 (C-6), 20.33 (C-8); HRMS (ESI-pos): 
calcd for C8H14O6Na [M + Na]+ m/z 229.0683, found m/z 229.0670. 
 
Method B: Sodium methoxide solution (1M in MeOH, 2 mL, 2.000 mmol) was added 
to a solution of ethylidene 107 (800 mg, 2.407 mmol) in MeOH (10 mL) and stirred at 
rt for 30 min. The reaction mixture was diluted with MeOH and the solvent removed 
in vacuo to afford the crude titled product 108 as an inseparable mixture of endo/exo 
isomers (Major/Minor =7:1, 2.407 mmol, quant.) as a white foam which was used 
without further purification. 
 
1H NMR and all other analytical data were consistent with those of 108 synthesized 
using Method A. 
6.3.33. 3,4,6-Tri-O-benzyl-1,2-ethylidene-β-D-mannopyranoside [109]341-342 
Sodium hydride (60% in oil, 1.5 g, 36.2 mmol) was added to a solution 
of crude triol 108 (1.2 g, 5.85 mmol) in DMF (5 mL) at 0 °C under argon 
and left to stir for 15 min. Benzyl bromide (6.5 mL, 54.7 mmol) was 
added dropwise and the resulting mixture allowed to warm to rt. After stirring 
overnight the reaction was quenched with MeOH and a standard aqueous workup 
Chapter VI: Experimental 
 
195 
preformed using diethyl ether as the organic solvent. The solvents were removed in 
vacuo and the crude residue purified by column chromatography (PE to 4:1 PE/EtOAc) 
to give the title compound 109 (major/minor =7:1, 2.50 g, 5.24 mmol, 90 % over two 
steps) as a white solid. 
 
Data for 109: Rf = 0.85 (1:1 EtOAc/PE); δH(500 MHz, CDCl3): 7.41 – 7.27 (13H, 
m, Ph), 7.24 (2H, dd, J= 7.5, 1.7 Hz, Ph), 5.32 (1H, q, J= 4.9 Hz, H-7), 5.19 (1H, d, J= 2.3 
Hz, H-1), 4.90 (1H, d, J= 10.7 Hz, PhCH2), 4.83 (1H, d, J= 12.0 Hz, PhCH2), 4.77 (1H, d, J= 
12.0 Hz, PhCH2), 4.63 (2H, d, J= 10.2 Hz, PhCH2), 4.57 (1H, d, J= 12.2 Hz, PhCH2), 4.15 
(1H, dd, J= 3.9, 2.3 Hz, H-2), 3.99 (1H, t, J= 9.3 Hz, H-4), 3.80 (1H, dd, J= 9.3, 3.9 Hz, H-
3), 3.77 – 3.72 (2H, m, H-6), 3.46 (1H, ddd, J= 9.4, 4.6, 2.3 Hz, H-5), 1.55 (2H, d, J= 5.0 
Hz, CH3-8); δC(126 MHz, CDCl3): 138.46 (ipso-C), 138.40 (ipso-C), 137.92 (ipso-C), 
128.57 (Ph), 128.51 (Ph), 128.49 (Ph), 128.43 (Ph), 128.40 (Ph), 128.15 (Ph), 128.02 
(Ph), 127.84 (Ph), 127.71 (Ph), 127.58 (Ph), 104.45 (C-7), 96.84 (C-1), 78.83 (C-3), 77.96 
(C-2), 75.28 (CH2Ph), 74.99 (C-4), 74.78 (C-5), 73.53 (CH2Ph), 72.25 (CH2Ph), 69.32 (C-
6), 21.87 (C-8); HRMS (ESI-pos): calcd for C29H32O6Na [M + Na]+ m/z 499.2091, found 
m/z 499.2066. 
6.3.34. 3,4,6-Tri-O-benzyl-D-mannopyranoside [105]343-348 
Ethylidene 109 (743 mg, 1.560 mmol) was suspended in a solution of 
9:1 TFA:water (15 mL, 176 mmol) and stirred at rt overnight, 
monitored by TLC. Following completion, the reaction mixture was 
diluted with toluene (10 mL) and concentrated in vacuo to give the crude material. 
This was purified by column chromatography (isocratic EtOAc: PE = 1:2) to give the 
title compound 105 (α:β = 2:1, 616 mg, 1.369 mmol, 88%) as a white solid. 
 
Data for 105: Rf = 0.31 (1:1 EtOAc/PE); δH(500 MHz, CDCl3): 7.40 – 7.26 (12H, 
m, Ph), 7.18 (3H, dd, J= 7.1, 2.1 Hz, Ph), 5.28 (1H, d, J= 1.7 Hz, H-1), 4.83 (1H, d, J= 11.0 
Hz, PhCH2), 4.72 – 4.65 (2H, m, PhCH2), 4.59 (1H, d, J= 12.3 Hz, PhCH2), 4.52 (2H, d, J= 
12.6 Hz, PhCH2), 4.10 – 4.02 (1H, m, H-5), 4.06 – 4.01 (1H, m, H-2), 3.94 (2H, m, H-3, 
H-6), 3.74 (1H, t, J= 9.0 Hz, H-4), 3.67 (1H, dd, J= 7.1, 3.9 Hz, H-6), 2.72 (2H, s, 2x OH); 
δC(126 MHz, CDCl3): 138.34 (ipso-C), 138.07 (ipso-C), 138.01 (ipso-C), 128.67 (Ph), 
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128.50 (Ph), 128.49 (Ph), 128.15 (Ph), 128.08 (Ph), 128.07 (Ph), 128.01 (Ph), 127.82 
(Ph), 94.05 (C-1), 79.83 (C-3), 75.20 (CH2Ph), 74.63 (C-4), 73.56 (CH2Ph), 72.16 (CH2Ph), 
71.02 (C-5), 69.46 (C-6), 68.64 (C-2); ); Analytical HPLC [Column C, T16, AW-BM, TFA2, 
F0.25, 10-100B G8H5] tR =8.827 min (98.050%); HRMS (ESI-pos): calcd for C27H30O6Na 
[M + Na]+ m/z 473.1935, found m/z 473.1952. 
6.3.35.  (2S,3S,4R)-2-Azido-3,4-O-isopropylidine-1-O-triisopropylsilyl-
octadecane [113] 
p-TSA (≈200 mg, added portionwise in 40 mg lots till the pH of the 
solution was slightly acidic ≈pH 5-6) was added to a stirred solution 
of crude diol 79 (2.95 g, 5.91 mmol) in 2,2-dimethoxypropane (40 
mL, 326 mmol) at rt. The reaction was monitored by HPLC for loss of the starting 
material: analytical HPLC [Column C, T23, AW-BA, TFA2, F0. 25, 10-100B G8H12] tR 
=12.170 min. When the reaction was complete (ca. 3 hrs) the solution was poured into 
10% aqueous NaHCO3 and extracted with EtOAc. The organic layer was concentrated 
in vacuo to give the title compound 113 as a colourless oil that was used without 
further purification. 
 
Data for 113: δH(400 MHz, CDCl3): 4.14 (2H, dd, J= 10.5, 2.8 Hz, H-1), 3.92 (1H, 
dd, J= 9.8, 5.5 Hz, H-3/H-4), 3.88 (1H, dd, J= 10.4, 7.1 Hz, H-3/H-4), 3.39 (1H, ddd, J= 
9.7, 7.1, 2.7 Hz, H-2), 1.54 (8H, s, CH2), 1.41 (3H, s, CH3), 1.31 (3H, s, CH3), 1.26 (18H, s, 
CH2), 1.09 (21H, d, J= 5.5 Hz, 3 x iPr), 0.96 – 0.80 (3H, t, J= 7.0 Hz, CH3-18); Analytical 
HPLC [Column C, T23, AW-BA, TFA2, F0. 25, 10-100B G8H12] tR =17.349 min (99.5%). 
6.3.36. (2S,3S,4R)-2-Azido-3,4-O-isopropylidine-octadecanol [47] 
To a solution of phytosphingosine 113 (3.2 g, 5.91 mmol) in dry THF 
(15 mL) under argon was added TBAF (1M in THF, 9 mL, 9.0 mmol) 
and the reaction stirred at rt overnight. The volatiles were removed 
in vacuo to afford the residue which was purified by column chromatography (PE to 
5:1 PE:EtOAc) to give the title compound 47 (2.18 g, 5.61 mmol, 94% over four steps) 
as a colourless oil that solidified on standing. 
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Data for 47: δH(400 MHz, CDCl3): 4.18 (1H, ddd, J= 9.3, 5.6, 3.0 Hz, H-3/4), 3.98 
(2H, td, J= 10.6, 9.8, 5.0 Hz, H-3/4, H-1a), 3.87 (1H, dd, J= 11.6, 5.5 Hz, H-1b), 3.47 (1H, 
ddd, J= 9.6, 5.5, 4.3 Hz, H-2), 1.67 – 1.51 (4H, m, CH2), 1.43 (3H, s, C(CH3)2), 1.34 (3H, 
s, C(CH3)2), 1.26 (22H, s, CH2), 0.88 (3H, t, J= 7.0 Hz, CH3-18); δC(101 MHz, CDCl3): 
108.59 (C(CH3)2), 77.89 (C-3/C-4), 76.84 (C-3/C-4), 64.13 (C-1), 61.32 (C-2), 32.08 (CH2), 
29.85 (CH2), 29.84 (CH2), 29.83 (CH2), 29.81 (CH2), 29.80 (CH2), 29.75 (CH2), 29.74 (CH2), 
29.69 (CH2), 29.55 (CH2), 29.51 (CH2), 28.18 (C(CH3)2), 26.67 (CH2), 25.71 (C(CH3)2), 
22.85 (CH2), 14.28 (C-18); Analytical HPLC [Column C, T23, AW-BA, TFA2, F0. 25, 10-
100B G8H12] tR =10.815 min; HRMS (ESI-pos): calcd for C21H41O3N3Na [M + Na]+ m/z 
406.3040 found m/z 406.3016. 
6.3.37.  (2S,3S,4R)-2-Azido-3,4-O- isopropylidine-1-O-
trifluoromethanesulfonyl-octadecane [48] 
2,6-Lutidine (2.5 mL, 21.58 mmol) and Tf2O (510 µL, 2.94 mmol) were 
added successively to a solution of alcohol 47 (760 mg, 1.979 mmol) 
in anhydrous DCM (4 mL) at 0°C under argon. The reaction mixture 
was stirred at 0°C for 5 min then at rt for an hour. Following 
completion the reaction was diluted with DCM and concentrated in vacuo to give an 
oil residue. Pentane was added and the resulting suspension filtered to remove any 
lutidine salts. The filtrate was concentrated in vacuo to give the title compound 48 
(1.979 mmol, quant.) as a yellow/orange oil that was used immediately. 
 
Data for 48: δH(400 MHz, CDCl3): 4.86 (1H, dd, J= 10.6, 2.6 Hz, H-1a), 4.58 (1H, 
dd, J= 10.6, 7.6 Hz, H-1b), 4.20 (1H, ddd, J= 9.0, 5.5, 3.4 Hz, H-4), 3.85 (1H, dd, J= 9.3, 
5.5 Hz, H-3), 3.72 (1H, ddd, J= 9.6, 7.6, 2.6 Hz, H-2), 1.64 – 1.49 (4H, m), 1.41 (3H, s), 
1.31 (3H, s), 1.25 (22H, s), 0.87 (3H, t, J= 6.3 Hz); δC(101 MHz, CDCl3): 83.13, 76.35, 
69.52, 63.16, 33.31, 32.06, 31.06, 29.80, 29.49, 25.84, 22.83, 14.25; δF(376 MHz, 
CDCl3): -78.47 (d, J= 8.9 Hz, OSO2CF3). 
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6.3.38. 1-O-Decyl 3,4,6-Tri-O-benzyl-β-D-mannopyranoside [115] 
Diol 105 (153 mg, 0.340 mmol) and dibutyltin 
oxide (95 mg, 0.380 mmol) were dried together 
under high vacuum for 30 min, then flushed 
with argon. To this was added anhydrous 
toluene (10 mL) and the reaction mixture was heated to reflux (80 °C) for 3 h, with 
water excluded using a Dean and Stark apparatus, forming a clear, yellow solution. 
Cooled to rt the solvent was removed in vacuo to give the crude stannylene acetal 
114. Caesium fluoride (61 mg, 0.403 mmol) (pre-dried in a furnace at 110 °C for 4 hr.) 
was added and the combined solids were dried for 30 min under high vacuum. The 
flask was flushed with argon and anhydrous DMF (5 mL) was added. After 60 min, 1-
Iododecane (150 µL, 0.685 mmol) was added and the reaction heated to 60°C 
overnight. Following completion the DMF was removed using a high vac cryogen setup 
(modified vacuum distillation, 60°C, 0.1 mbar) to give the residue which was purified 
by column chromatography (3:1,PE:EtOAc) to give the title compound 115 (126 mg, 
0.213 mmol, 63 %, 95 % brsm) as a colourless oil. 
 
Data for 115: Rf = 0.75 (1:2 EtOAc/PE); δH(500 MHz, CDCl3): 7.42 – 7.28 (13H, 
m, Ph), 7.24 – 7.20 (2H, m, Ph), 4.91 (1H, d, J= 10.8 Hz, PhCH2), 4.79 (1H, d, J= 11.9 Hz, 
PhCH2), 4.68 (1H, d, J= 12.0 Hz, PhCH2), 4.63 (1H, d, J= 12.1 Hz, PhCH2), 4.58 (1H, d, J= 
12.0 Hz, PhCH2), 4.55 (1H, d, J= 11.2 Hz, PhCH2), 4.42 (1H, d, J= 1.0 Hz, H-1), 4.12 (1H, 
d, J= 3.1 Hz, H-2), 3.95 (1H, dt, J= 8.9, 6.8 Hz, H-1’), 3.88 (1H, t, J= 9.3 Hz, H-4), 3.79 
(1H, dd, J= 11.0, 2.0 Hz, H-6), 3.72 (1H, dd, J= 10.8, 5.3 Hz, H-6), 3.58 (1H, dd, J= 9.1, 
3.0 Hz, H-3), 3.51 (1H, dt, J= 8.9, 6.8 Hz, H-1’), 3.44 (1H, ddd, J= 9.7, 5.4, 2.0 Hz, H-5), 
2.20 (1H, s, OH), 1.64 (2H, p, J= 7.0 Hz, H-2’), 1.29 (14H, s, CH2), 0.91 (3H, t, J= 6.8 Hz, 
CH3-10’); δC(126 MHz, CDCl3): 138.35 (ipso-C), 138.32 (ipso-C), 137.96 (ipso-C), 128.60 
(Ph), 128.56 (Ph), 128.44 (Ph), 128.41 (Ph), 128.18 (Ph), 127.99 (Ph), 127.91 (Ph), 
127.89 (Ph), 127.80 (Ph), 127.65 (Ph), 127.04 (Ph), 99.83 (d, 1JCH = 157.37 Hz, C-1), 
81.69 (C-3), 75.37 (C-5), 75.26 (CH2Ph), 74.40 (C-4), 73.59 (CH2Ph), 71.42 (CH2Ph), 
69.95 (C-1’), 69.37 (C-6), 68.45 (C-2), 31.99 (CH2), 29.67 (CH2), 29.66 (C-2’), 29.64 (CH2), 
29.54 (CH2), 29.42 (CH2), 26.11 (CH2), 22.78 (CH2), 14.22 (C-10’); HRMS (ESI-pos): calcd 
for C37H50O6Na [M + Na]+ m/z 613.3500, found m/z 613.3477; Anal. Calcd for C37H50O6: 
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C, 75.22; H, 8.53. Found C, 73.44; H, 8.54; Analytical HPLC [Column A, T18, AW-BA, TFA2, 
F0.75, 10-100B G13H2] tR =15.798 min. 
6.3.39. 1-((2'S,3'S,4'R)-2’-azido-3’,4’-O-isopropylidene-1’-octadecanyl) 3,4,6-
tri-O-benzyl-β-D-mannopyranoside [116] 
Diol 105 (706 mg, 1.567 mmol) and dibutyl tin oxide (550 
mg, 2.209 mmol) were dried together under high vacuum. 
The flask was backfilled with argon and toluene (15 mL) 
was added. The reaction was refluxed at 135°C for 3 hrs before the resulting 
yellow/orange solution was allowed to cool to rt and the solvent removed in vacuo to 
give the intermediate dibutyl tin acetal 114 as a yellow oil. The residue was placed 
under high vacuum for 30 min then under argon. Cesium fluoride (340 mg, 2.238 
mmol) was added and anhydrous DMF (6 mL) was cannulated into the mixture. 
Allowed to stir at rt for 30 min before the addition of triflate 48 (1020 mg, 1.979 mmol) 
as a solution in DMF (1 mL). The reaction was stirred overnight at rt under argon 
before being concentrated in vacuo. The residue was re-dissolved in EtOAc and 
washed with saturated aqueous KF solution. The organic layer was concentrated in 
vacuo and the residue purified by flash column chromatography (PE to 3:1 PE/EtOAc) 
to afford the title compound 116 (793 mg, 0.972 mmol, 62%) as a colourless oil. 
 
Data for 116: δH(500 MHz, CDCl3): 7.45 – 7.27 (13H, m, Ph), 7.21 (2H, dd, J= 7.7, 
1.9 Hz, Ph), 4.89 (1H, d, J= 10.9 Hz, PhCH2), 4.78 (1H, d, J= 11.9 Hz, PhCH2), 4.67 (1H, 
d, J= 11.9 Hz, PhCH2), 4.63 (1H, d, J= 12.2 Hz, PhCH2), 4.57 (1H, d, J= 10.3 Hz, PhCH2), 
4.55 (1H, d, J= 9.7 Hz, PhCH2), 4.50 (1H, d, J= 1.1 Hz, H-1), 4.23 – 4.08 (3H, m, H-1’, H-
3’, H-4’), 3.99 (1H, dd, J= 10.6, 2.8 Hz, H-1’), 3.91 (1H, t, J= 9.2 Hz, H-4), 3.86 (1H, dd, 
J= 9.6, 5.5 Hz, H-3), 3.78 (1H, dd, J= 10.9, 2.3 Hz, H-6), 3.73 (1H, dd, J= 10.9, 5.2 Hz, H-
6), 3.64 – 3.55 (2H, m, H-2, H-2’), 3.45 (1H, ddd, J= 9.6, 5.2, 2.3 Hz, H-5), 1.80 (1H, b, 
OH), 1.69 – 1.47 (2H, m, CH2), 1.39 (3H, s, C(CH3)2), 1.37 – 1.31 (2H, m, CH2), 1.30 (3H, 
s, C(CH3)2), 1.26 (22H, s, CH2), 0.88 (3H, t, J= 6.9 Hz, CH3-18’); δC(126 MHz, CDCl3): 
138.44 (ipso-C), 138.36 (ipso-C), 137.98 (ipso-C), 128.61 (Ph), 128.52 (Ph), 128.49 (Ph), 
128.23 (Ph), 128.06 (Ph), 127.97 (Ph), 127.92 (Ph), 127.88 (Ph), 127.70 (Ph), 108.50 
(C(CH3)2), 99.73 (d, 1JCH = 157.87 Hz C-1), 81.39 (C-2), 77.94 (C-3’), 75.76 (C-3), 75.71 
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(C-5), 75.27 (PhCH2), 74.25 (C-4), 73.64 (PhCH2), 71.53 (PhCH2), 70.66 (C-1’), 69.29 (C-
6), 68.21 (C-4’), 59.83 (C-2’), 32.08 (CH2), 29.85 (CH2), 29.81 (CH2), 29.77 (CH2), 29.75 
(CH2), 29.71 (CH2), 29.57 (CH2), 29.51 (CH2), 28.33 (C(CH3)2), 26.59 (CH2), 25.80 
(C(CH3)2), 22.85 (CH2), 14.28 (C-18’); Analytical HPLC [Column C, T16, AW-BM, TFA2, 
F0. 25, 10-100B G8H5] tR =11.669 min; Analytical LCMS [Column C, T16, AW-BM, TFA2, 
F0. 25, 10-100B G8H5, 30-180Pos] tR =12.018 min (838.8 m/z); HRMS (ESI-pos): calcd 
for C48H69O8N3Na [M + Na]+ m/z 838.4977 found m/z 838.4970. 
6.3.40. Phenyl 2-O-acetyl-3,4,6-tri-O-benzyl-1-thio-D-mannopyranoside 
[119] 
Acetic anhydride (2 mL) was added to a stirred solution of diol 105 
(260 mg, 0.578 mmol) in pyridine (1 mL). The reaction was stirred at 
rt overnight after which a standard aqueous workup was performed 
using EtOAc as the organic solvent. Additional washes of the organic extract was 
performed with 10% aqueous HCl and 5% aqueous NaHCO3. The solvents were 
removed in vacuo to afford crude bisacetate 120 as a colourless oil that was used 
directly in the next step. HRMS (ESI-pos): calcd for C33H34O5SNa [M + Na]+ m/z 
565.2019, found m/z 565.1999. 
 
BF3·Et2O (120 µL, 0.972 mmol) was added dropwise to a stirred solution of crude 
bisacetate 120 and thiophenol (100 µL, 0.951 mmol) in anhydrous DCM (5 mL) and 
stirred at rt overnight. The reaction was diluted with DCM and washed with 0.5 M 
NaOH solution. The organic layer was concentrated in vacuo to give the residue which 
was purified by column chromatography (PE to 4:1 PE/EtOAc) to afford the title 
compound 119 (α:β = 2:1, 255 mg, 0.436 mmol, 75%) as a colourless oil. 
 
 Data for 119: δH(400 MHz, CDCl3): 7.61 – 7.17 (20H, m, Ph), 5.81 (dd, J= 3.4, 1.1 
Hz, H-2β), 5.63 – 5.59 (1H, m, H-2α), 5.54 (1H, d, J= 1.6 Hz, H-1α), 4.88 (1H, dd, J= 10.7, 
5.6 Hz), 4.86 (d, J= 1.2 Hz, H-1β), 4.82 – 4.44 (6H, m, PhCH2), 4.34 (1H, ddd, J= 9.4, 4.7, 
1.7 Hz, H-5α), 4.02 – 3.92 (1H, m), 3.86 (1H, ddd, J= 11.4, 8.2, 3.2 Hz), 3.79 – 3.67 (1H, 
m), 3.56 (ddd, J= 9.7, 5.9, 1.9 Hz, H-5β), 2.23 (s, OAc-β), 2.15 (3H, s, OAc-α); HRMS (ESI-
pos): calcd for C35H36O6SNa [M + Na]+ m/z 607.2125, found m/z 607.2152. 
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6.3.41. Phenyl 2-O-benzoyl-3,4,6-tri-O-benzyl-1-thio-α-D-mannopyranoside 
[122] 
Sodium methoxide solution (2.5M in MeOH, 25 mL, 62.5 mmol) was 
added dropwise to a stirred solution of acetate 119 (872 mg, 1.491 
mmol) in MeOH (25 mL) at rt. The reaction was stirred overnight at 
rt then neutralised with amberlite IR-120 (H+ form). The solution was filtered through 
Celite washed with methanol and the solvent removed in vacuo to give the residue. 
The residue was diluted with EtOAc and washed with 50% aqueous NaHCO3 and the 
organic layer concentrated in vacuo to afford alcohol 123 as a yellowish solid that was 
used directly in the next step. HRMS (ESI-pos): calcd for C33H34O5SNa [M + Na]+ m/z 
565.2019, found m/z 565.1999. 
 
Benzoyl chloride (200 µL, 1.670 mmol) was added dropwise to a stirred solution of 
alcohol 123 (195 mg, 0.360 mmol) and DMAP (1 crystal) in py (4 mL) at 0 °C. The 
reaction was warmed to rt and stirred overnight. The reaction was diluted with EtOAc 
and washed with saturated aqueous NaHCO3 solution. The organic layer was 
concentrated in vacuo then on high vacuum to give the residue which was purified by 
column chromatography (PE to 6:1 PE/EtOAc) to afford the title compound 122 as its 
discrete anomers α-122 (124 mg, 0.192 mmol, 54%) and β-122 (59 mg, 0.092 mmol, 
26%) both as white solids. 
 
 Data for α-122: δH(400 MHz, CDCl3): 8.06 (2H, d, J= 7.7 Hz, Ph), 7.55 (1H, t, J= 
7.5 Hz, Ph), 7.50 (2H, dd, J= 6.6, 2.9 Hz, Ph), 7.41 – 7.18 (20H, m, Ph), 5.87 (1H, t, J= 2.3 
Hz, H-2), 5.65 (1H, s, H-1), 4.91 (1H, d, J= 10.8 Hz, PhCH2), 4.82 (1H, d, J= 11.3 Hz, 
PhCH2), 4.71 (1H, d, J= 11.9 Hz, PhCH2), 4.61 (1H, d, J= 11.4 Hz, PhCH2), 4.58 (1H, d, J= 
10.9 Hz, PhCH2), 4.51 (1H, d, J= 11.8 Hz, PhCH2), 4.39 (1H, dd, J= 10.4, 3.6 Hz, H-1), 4.17 
(1H, t, J= 9.5 Hz, H-4), 4.06 (1H, dd, J= 9.3, 3.0 Hz, H-3), 3.95 (1H, dd, J= 10.9, 4.1 Hz, H-
6), 3.79 (1H, dd, J= 10.9, 1.8 Hz, H-6); δC(101 MHz, CDCl3): 165.74 (C=O), 138.50 (ipso-
C), 138.41 (ipso-C), 137.77 (ipso-C), 133.83 (ipso-C), 133.35 (ipso-C), 132.01 (Ph), 
130.09 (Ph), 129.90 (Ph), 129.20 (Ph), 128.55 (Ph), 128.54 (Ph), 128.49 (Ph), 128.46 
(Ph), 128.30 (Ph), 128.14 (Ph), 127.94 (Ph), 127.84 (Ph), 127.67 (Ph), 127.63 (Ph), 86.53 
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(C-1), 78.71 (C-3), 75.51 (PhCH2), 74.64 (C-4), 73.52 (PhCH2), 72.77 (C-5), 71.83 
(PhCH2), 70.76 (C-2), 69.16 (C-6); HRMS (ESI-pos): calcd for C40H38O6SNa [M + Na]+ m/z 
669.2279 found m/z 669.2266. 
 
 Data for β-122: δH(400 MHz, CDCl3): 8.22 – 8.03 (2H, m, Ph), 7.63 – 7.55 (1H, 
m, Ph), 7.55 – 7.49 (2H, m, Ph), 7.46 – 7.15 (20H, m, Ph), 6.03 (1H, dd, J= 3.3, 1.0 Hz, 
H-2), 4.96 (1H, d, J= 1.0 Hz, H-1), 4.87 (2H, t, J= 10.5 Hz, PhCH2), 4.76 (1H, d, J= 11.8 
Hz, PhCH2), 4.62 (1H, d, J= 11.9 Hz, PhCH2), 4.56 (2H, dd, J= 11.1, 7.0 Hz, PhCH2), 3.96 
(1H, t, J= 9.5 Hz, H-4), 3.92 – 3.85 (2H, m, H-6), 3.79 (1H, dd, J= 9.3, 3.3 Hz, H-3), 3.63 
(1H, ddd, J= 9.8, 4.3, 2.7 Hz, H-5); δC(101 MHz, CDCl3): 165.92 (C=O), 138.66 (ipso-C), 
138.30 (ipso-C), 137.66 (ipso-C), 134.39 (ipso-C), 133.33(ipso-C), 131.28 (Ph), 130.32 
(Ph), 129.82 (Ph), 129.13 (Ph), 128.54 (Ph), 128.49 (Ph), 128.47 (Ph), 128.37 (Ph), 
128.15 (Ph), 127.90 (Ph), 127.85 (Ph), 127.67 (Ph), 127.60 (Ph), 127.57 (Ph), 85.60 (C-
1), 81.63 (C-3), 80.00 (C-5), 75.45 (PhCH2), 74.20 (C-4), 73.60 (PhCH2), 71.80 (PhCH2), 
70.87 (C-2), 69.60 (C-6); HRMS (ESI-pos): calcd for C40H38O6SNa [M + Na]+ m/z 669.2279 
found m/z 669.2282. 
6.3.42. 1-((2'S,3'S,4'R)-2’-azido-3’,4’-di-O-benzyl-1’-octadecanyl) 2-O-
benzoyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside [124] 
Triflic acid (5 µL, 0.057 mmol) was added to a mixture of 
alcohol 78 (80 mg, 0.153 mmol), thio glycoside α-122 (121 
mg, 0.186 mmol), and NIS (60 mg, 0.253 mmol) in 
anhydrous DCM (5 mL) containing pre-activated 4Ȧ MS at -
10°C under argon. The reaction was warmed slowly to rt and after ca. 4 hours was 
diluted with DCM. The organic layer was washed with saturated aqueous NaHCO3 and 
Na2S2O3 solutions then concentrated in vacuo to give the crude material which was 
purified by column chromatography (PE to 6:1 PE/EtOAc) to afford the title compound 
124 (120 mg, 0.113 mmol, 74%) as a colourless oil. 
 
 Data for 124: δH(500 MHz, CDCl3): 8.14 – 7.98 (2H, m, Ph), 7.56 (1H, td, J= 7.4, 
1.3 Hz, Ph), 7.43 – 7.16 (27H, m, Ph), 5.65 (1H, d, J= 2.0 Hz, H-2), 4.96 (1H, d, J= 1.9 Hz, 
H-1), 4.88 (1H, d, J= 10.8 Hz, PhCH2), 4.78 (1H, d, J= 11.4 Hz, PhCH2), 4.69 (2H, dd, J= 
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11.6, 4.8 Hz, PhCH2), 4.64 – 4.45 (6H, m, PhCH2), 4.14 – 4.08 (3H, m, H-3, H-4, H-5), 
3.86 – 3.80 (2H, m), 3.78 (1H, ddd, J= 8.3, 5.4, 2.8 Hz, H-2’), 3.65 (2H, dd, J= 9.5, 2.1 
Hz), 3.60 (2H, td, J= 10.3, 9.5, 6.0 Hz, H-3’, H-4’), 1.72 – 1.62 (1H, m, CH2), 1.55 (3H, dq, 
J= 15.0, 5.5, 3.8 Hz, CH2), 1.40 (1H, ddd, J= 13.1, 9.2, 4.4 Hz, CH2), 1.26 (21H, d, J= 3.8 
Hz, CH2), 0.89 (3H, t, J= 6.6 Hz, CH3-18’); δC(126 MHz, CDCl3): 165.77 (C=O), 138.55 
(ipso-C), 138.41 (ipso-C), 138.11 (ipso-C), 137.95 (ipso-C), 133.27 (Ph), 130.12 (Ph), 
130.01 (Ph), 128.56 (Ph), 128.55 (Ph), 128.53 (Ph), 128.47 (Ph), 128.43 (Ph), 128.25 
(Ph), 128.20 (Ph), 128.11 (Ph), 127.98 (Ph), 127.82 (Ph), 127.74 (Ph), 127.66 (Ph), 
127.62 (Ph), 98.54 (d, 1JCH = 166.32 Hz, C-1), 79.39 (C-3/C-4), 79.27 (C-3/C-4), 78.17, 
75.40 (PhCH2), 74.26, 73.87 (PhCH2), 73.57 (PhCH2), 72.29, 72.09 (PhCH2), 71.71 
(PhCH2), 68.97, 68.90 (C-2), 62.15 (C-2’), 32.08 (CH2), 30.08 (CH2), 29.93 (CH2), 29.86 
(CH2), 29.83 (CH2), 29.82 (CH2), 29.80 (CH2), 29.76 (CH2), 29.52 (CH2), 25.48 (CH2), 22.85 
(CH2), 14.28 (C-18’); HRMS (ESI-pos): calcd for C66H81O9N3Na [M + Na]+ m/z 1082.5865, 
found m/z 1082.5837. 
6.3.43. 1-((2'S,3'S,4'R)-2'-Amino-1',3',4'-octadecantriyl) α-D-
mannopyranoside 2,2,2-trifluoroacatate, CI168 [α-ManPhyt, 125] 
To a solution of glycoside 124 (120 mg, 0.113 mmol) in 
MeOH (10 mL) was added freshly prepared sodium 
methoxide solution (2.5M in MeOH, 80 µL, 0.100 mmol) 
and the reaction mixture was stirred at rt for 3 hours. The 
reaction was diluted with DCM and concentrated in vacuo. The resulting white solid 
was dissolved in DCM and washed with brine. The solvent was removed in vacuo to 
give crude alcohol 210 as a white solid which was used directly in the next step. HRMS 
(ESI-pos): calcd for C59H77O8N3Na [M + Na]+ m/z 978.5603 found m/z 978.5630. 
 
To crude alcohol 210 was added 10% palladium on carbon (11 mg, 0.100 mmol) and 
placed under an N2 atm. DCM/MeOH (1:1, 6 mL) was added along with 1M 
hydrochloric acid (400 µL, 0.400 mmol). The reaction mixture was evacuated and 
replaced with an atmosphere of H2 (3x) and stirred at rt under a balloon of H2 
overnight. The hydrogen atmosphere was removed, the reaction diluted with hot 
EtOH, and filtered through Celite. The solvents were removed in vacuo to give the 
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crude material as its hydrochloride salt. The residue was purified by C18 reverse phase 
chromatography (Isolute C-18(EC) with a gradient of H2O (0.05% TFA) and MeCN 80:20 
to 0:100 eluting around 60:40). The fractions containing the target molecule were 
combined and freeze-dried overnight to give the title compound 125 (33 mg, 0.055 
mmol, 49%) as a lyophilized white solid. 
 
Data for 125: δH(500 MHz, 2:1, CDCl3:CD3OD): 4.75 (1H, d, J= 1.7 Hz, H-1), 4.13 
– 3.95 (1H, m, H-1’), 3.88 – 3.79 (2H, m, H-1’, H-6), 3.68 (2H, ddd, J= 11.4, 5.7, 2.4 Hz, 
H-6, H-3), 3.63 – 3.53 (3H, m, H-2’, H-3’, H-4), 3.53 – 3.45 (2H, m, H-2, H-4’), 3.42 – 
3.35 (1H, m, H-5), 1.75 (1H, t, J= 10.0 Hz, CH2), 1.57 – 1.45 (1H, m, CH2), 1.22 (24H, s, 
CH2), 0.84 (3H, t, J= 6.8 Hz, CH3-18’); δC(126 MHz, 2:1, CDCl3:CD3OD): 101.00 (d, 1JCH = 
171.36 Hz C-1), 73.67 (C-2), 72.70 (C-5), 71.99 (C-4’), 71.43 (C-3), 70.41 (C-4), 67.73 (C-
3’), 64.00 (C-1’), 62.12 (C-6), 54.04 (C-2’), 34.64 (CH2), 32.22 (CH2), 29.98 (CH2), 29.94 
(CH2), 29.65 (CH2), 25.54 (CH2), 22.95 (CH2), 14.20 (C-18’); δF(376 MHz, 2:1, 
CDCl3:CD3OD): -75.98; Analytical HPLC [Column A, T18, AW-BA, TFA2, F0.50, 10-100B 
G12H3] tR =10.461 min; Analytical HPLC [Column C, T14, AW-BM, TFA2, F0.50, 10-100B 
G9H2] tR =8.049 min; Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =2.708 min; HRMS (ESI-pos): calcd for C24H50O8N [M + H]+ m/z 480.3531 found 
m/z 480.3515. 
6.3.44. N-[(1S,2S,3R)-2,3-dihydroxy-1-[(α-D-mannopyranosyloxy)methyl] 
heptadecyl] Hexacosanamide, CI164 [α-ManCer, 118] 
Method A: To a solution of glycolipid α-129 (79 mg, 0.060 mmol) in DCM/MeOH (1:1, 
6 mL) was added 10% palladium on carbon (64 mg, 0.060 mmol). The stirred reaction 
mixture was degassed under vacuum and backfilled with hydrogen three times then 
left to stir overnight under a balloon of hydrogen. The hydrogen atmosphere was 
removed and the grey precipitate that formed during the reaction was dissolves on 
dilution with hot EtOH. The solution was then filtered through Celite and washed 
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excess hot EtOH. The solvents were removed in vacuo to give the crude material which 
was precipitated by dissolving in hot ethanol and triturating out of solution with the 
dropwise addition of water. The mixture was heated to re-dissolve and the resulting 
solution was transferred to a 14 mL centrifuge tube and allowed to cool to rt forming 
a suspended white precipitate. The tube was spun at 5200 rpm for 25 min before the 
aqueous-organic layer was decanted leaving behind a white solid. The solid was re-
suspended in 10 mL water and spun again to further wash the solid, again decanting 
the aqueous layer. The solid was dissolved in hot ethanol, transferred to a round 
bottom flask, concentrated in vacuo, and dried to a constant weight to afford the title 
compound 118 (43 mg, 0.050 mmol, 83%) as a white solid. 
 
Data for 118: δH(500 MHz, 2:1 CDCl3:CD3OD): 7.29 (1H, d, J= 8.8 Hz, NH), 4.73 
(1H, d, J= 1.7 Hz, H-1), 4.18 – 4.11 (1H, m, H-2’), 3.87 – 3.75 (3H, m, H-2, H-6, H-1’), 
3.70 (1H, dd, J= 11.9, 5.1 Hz, H-6), 3.66 (1H, dd, J= 9.3, 3.2 Hz, H-3), 3.64 – 3.56 (2H, m, 
H-1’, H-4), 3.53 – 3.42 (3H, m, H-3’, H-4’, H-5), 2.16 (2H, t, J= 7.6 Hz, H-2’’), 1.73 – 1.42 
(5H, m, CH2), 1.22 (67H, s, CH2), 0.84 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’); δC(126 MHz, 
2:1 CDCl3:CD3OD): 175.07 (C=O), 100.90 (d, 1JCH = 170.57 Hz, C-1), 74.93 (C-3’/C-4’), 
73.24 (C-3’/C-4’), 72.49 (C-5), 71.57 (C-3), 70.85 (C-2), 67.68 (C-4), 67.06 (C-1’), 61.97 
(C-6), 51.37 (C-2’), 36.73 (C-2’’), 32.70 (CH2), 32.21 (CH2), 30.04 (CH2), 30.00 (CH2), 
29.96 (CH2), 29.92 (CH2), 29.85 (CH2), 29.71 (CH2), 29.64 (CH2), 26.21 (CH2), 26.14 (CH2), 
22.94 (CH2), 14.21 (C-18’ & C-26’’); HRMS (ESI-pos): calcd for C50H99O9NNa [M + Na]+ 
m/z 880.7212 found m/z 880.7194; Analytical HPLC [Column C, T16, AW-BM, TFA2, 
F0.60, 60-100B G4H9] tR =6.391 min (99.9%); Analytical LCMS [Column C, T16, AW-BM, 
TFA2, F0.60, 60-100B G4H9, 60-120Pos] tR =6.751 min (880.90 m/z). 
 
Method B: To a mixture of hexanoic acid (21 mg, 0.066 mmol) in anhydrous DCM (5mL) 
under an argon atmosphere, was added TEA (200 µL, 1.424 mmol) then Isopropyl 
chloroformate solution (70 µL, 0.070 mmol) and the resulting solution was stirred at 
rt for 50 min to give the crude mixed carbonic anhydride. 
 
To a solution of α-ManPhyt 125 (31 mg, 0.052 mmol) in anhydrous DMF (5 mL) at 0 °C 
under argon and with the exclusion of light was added the mixed carbonic anhydride 
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solution. After 5 min the ice bath was removed and the reaction was warmed to rt 
overnight. The reaction was diluted with MeOH and the solvents were removed in 
vacuo to give the residue which was absorbed onto silica gel from a mixture of warm 
MeOH:CHCl3 and purified by column chromatography (CHCl3 to 40% MeOH:CHCl3) to 
give the title compound 118 (42 mg, 0.049 mmol, 94%) as a white solid. 
 
1H NMR and all other analytical data were consistent with those of 118 synthesized 
using Method A. 
6.3.45. 1-((2'S,3'S,4'R)-2'-Amino-1',3',4'-octadecantriyl) β-D-
mannopyranoside 2,2,2-trifluoroacatate, CI120 [β-ManPhyt, 50] 
Method A: To azide 85 (184 mg, 0.193 mmol) was added 
10% Pd on carbon (42 mg, 0.040 mmol) and 
DCM/MeOH (1:1, 6 mL) was added, followed by 1M 
hydrochloric acid (380 µL, 0.380 mmol). The nitrogen atmosphere was evacuated and 
replaced with an atmosphere of H2 (3x) and stirred at rt under a balloon of H2 for 18 
hr. The hydrogen atmosphere was removed, the solution filtered through Celite and 
the solvents removed in vacuo to give crude material. The crude material was purified 
by C18 reverse phase chromatography (Isolute C-18(EC) with a gradient of H2O and 
MeCN 80:20 to 0:100 eluting around 60:40). The fractions containing the target 
molecule were combined and lyophilized overnight to give the title compound 50 (α:β= 
5:95, 83 mg, 0.174 mmol, 90%) as a white solid. 
 
Data for 50: δH(500 MHz, 2:1, CDCl3:CD3OD): 4.54 (1H, d, J= 0.9 Hz, H-1), 4.11 – 
3.96 (2H, m, H-1’), 3.93 (1H, d, J= 3.1 Hz, H-2), 3.90 (1H, dd, J= 11.9, 2.4 Hz, H-6), 3.71 
(1H, dd, J= 11.9, 5.8 Hz, H-6), 3.62 (1H, dt, J= 8.7, 4.0 Hz, H-2’), 3.58 – 3.52 (2H, m, H-
4, H-3’), 3.47 (1H, dd, J= 9.4, 3.2 Hz, H-3), 3.42 (1H, td, J= 8.4, 2.7 Hz, H-4’), 3.23 (1H, 
ddd, J= 9.6, 5.8, 2.4 Hz, H-5), 1.76 (1H, ddd, J= 13.5, 7.1, 2.9 Hz, CH2), 1.52 (1H, dd, J= 
13.6, 5.1 Hz, CH2), 1.42 – 1.15 (26H, m, CH2), 0.85 (3H, t, J= 6.9 Hz, CH3-18’); δC(126 
MHz, 2:1, CDCl3:CD3OD): 100.24 (d, 1JCH = 158.29 Hz C-1), 77.38 (C-5), 74.15 (C-3), 72.95 
(C-4’), 72.30 (C-3’), 71.42 (C-2), 67.56 (C-4), 65.77 (C-1’), 61.90 (C-6), 54.42 (C-2’), 34.79 
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(CH2), 32.45 (CH2), 30.23 (CH2), 30.20 (CH2), 30.19 (CH2), 30.16 (CH2), 29.86 (CH2), 25.74 
(CH2), 23.16 (CH2), 14.29 (C-18’); δF(376 MHz, 2:1, CDCl3:CD3OD): -76.15; Analytical 
HPLC [Column A, T18, AW-BA, TFA2, F0.50, 10-100B G12H3] tR =10.398 min; Analytical 
HPLC [Column C, T14, AW-BM, TFA2, F0.50, 10-100B G9H2] tR =8.035 min; Analytical 
HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR =2.766 min; HRMS (ESI-
pos): calcd for C24H50O8N [M + H]+ m/z 480.3531 found m/z 480.3508.  
 
Method B: To a solution of Boc glycoside β-138 (199 mg, 0.194 mmol) in 
DCM/MeOH (1:1, 20 mL) was added 10% palladium on carbon (60 mg, 0.056 mmol). 
The stirred reaction mixture was degassed under vacuum and backfilled with 
hydrogen three times then left to stir overnight under a balloon of hydrogen. After 
dilution with hot EtOH the solution was filtered through Celite and washed with hot 
EtOH (50 mL). The solvents were removed in vacuo to give Boc-β-ManPhyto 211 that 
was used without further purification. HRMS (ESI-pos): calcd for C29H57O10NNa [M + 
Na]+ m/z 602.3875 found m/z 602.3844. 
 
Trifluoroacetic acid (1 mL, 13.07 mmol) was added to a stirred solution of 211 (112 
mg, 0.193 mmol) in DCM (5 mL). The reaction was stirred at rt overnight before being 
diluted with DCM. The solvents removed in vacuo to give a residue which was purified 
by C18 reverse phase chromatography (Isolute C-18(EC) with a gradient of H2O and 
MeCN 80:20 to 0:100 eluting around 60:40). The fractions containing the target 
molecule were combined and lyophilized to give the title compound 50 (β only, 89 mg, 
0.147 mmol, 77% over two steps) as a white solid. 
 
1H NMR and all other analytical data were consistent with those of 50 synthesized 
using Method A. 
 
Method C: To glycoside 116 (β only, 188 mg, 0.230 mmol) was added 10% Pd on 
carbon (22 mg, 0.021 mmol) and placed under an N2 atm. DCM/MeOH (1:1, 6 mL) was 
added followed by a few drops of concentrated hydrochloric acid. The nitrogen 
atmosphere was evacuated and replaced with an atmosphere of H2 (3x) and the 
reaction mixture was stirred at rt under a balloon of H2 for 12 hr. The hydrogen 
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atmosphere was removed, the solution filtered through Celite and the solvents 
removed in vacuo to give the crude material as its hydrochloride salt. The crude 
residue was purified by C18 reverse phase chromatography (Isolute C-18(EC) with a 
gradient of H2O and MeCN 80:20 to 0:100 eluting around 60:40). The fractions 
containing the target molecule were combined and lyophilized overnight to give the 
title compound 50 (104 mg, 0.201 mmol, 87%) as a fluffy white solid. 
 
1H NMR and all other analytical data were consistent with those of 50 synthesized 
using Method A and B. 
6.3.46. N-[(1S,2S,3R)-2,3-dihydroxy-1-[(β-D-mannopyranosyloxy)methyl] 
heptadecyl] Hexacosanamide, CN138 [β-ManCer, 1] 
To a solution of glycolipid β-129 (251 mg, 0.192 mmol) in DCM/MeOH (1:1, 20 mL) was 
added 10% palladium on carbon (52 mg, 0.049 mmol). The stirred reaction mixture 
was degassed under vacuum and backfilled with hydrogen three times then left to stir 
overnight under a balloon of hydrogen. The hydrogen atmosphere was removed and 
the grey precipitate that formed during the reaction was dissolves on dilution with hot 
EtOH. The solution was then filtered through Celite and washed with excess hot EtOH. 
The solvents were removed in vacuo to give the crude material which was precipitated 
by dissolving in hot ethanol and triturating out of solution with dropwise addition of 
water, once the precipitate formed the mixture was heated to re-dissolve. The 
resulting solution was allowed to cool slowly to rt and then cooled in the freezer (-
20°C), the resulting precipitate was filtered through a Hirsch funnel and dried to a 
constant weight affording the title compound 1 (151 mg, 0.176 mmol, 92%) as a white 
solid. 
 
Data for 1: Rf = 0.41 (15% MeOH:CHCl3); δH(500 MHz, 2:1 CDCl3:CD3OD): 4.47 
(1H, s, H-1), 4.17 (1H, dt, J= 7.1, 4.1 Hz, H-2’), 4.04 (1H, dd, J= 10.3, 3.9 Hz, H-1’), 3.86 
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(2H, dd, J= 12.3, 2.7 Hz, H-2, H-6), 3.71 (2H, td, J= 11.9, 11.0, 5.0 Hz, H-1’, H-6), 3.62 – 
3.50 (3H, m, H-4, H-3’, H-4’), 3.43 (1H, dd, J= 9.4, 3.3 Hz, H-3), 3.20 (1H, ddd, J= 8.9, 
5.9, 2.5 Hz, H-5), 2.16 (2H, t, J= 7.6 Hz, H-2’’), 1.65 – 1.46 (4H, m, CH2), 1.23 (75H, s, 
CH2), 0.84 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’); δC(126 MHz, 2:1 CDCl3:CD3OD): 174.82 
(C=O), 100.49 (d, 1JCH = 158.16 Hz, C-1), 77.02 (C-5), 74.47 (C-4), 74.25 (C-3), 72.40 (C-
3’/C-4’), 71.23 (C-2), 68.53 (C-1’), 67.71 (C-3’/C-4’), 62.04 (C-6), 50.66 (C-2’), 36.88 (C-
2’’), 32.43 (CH2), 32.32 (CH2), 30.18 (CH2), 30.16 (CH2), 30.12 (CH2), 30.10 (CH2), 30.08 
(CH2), 30.06 (CH2), 30.03 (CH2), 29.96 (CH2), 29.83 (CH2), 29.77 (CH2), 29.76 (CH2), 29.74 
(CH2), 26.34 (CH2), 26.31 (CH2), 23.05 (CH2), 14.26 (C-18’ & C-26’’); HRMS (ESI-pos): 
calcd for C50H99O9NNa [M + Na]+ m/z 880.7212 found m/z 880.7227; analytical HPLC 
[Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR =6.444 min (99.9%); analytical 
LCMS [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9, 60-120Pos] tR =6.801 min 
(m/z 880.90); Anal. Calcd for C50H99NO9·H2O: C, 68.53; H, 11.62; N, 1.60. Found C, 
68.41; H, 11.75; N, 1.59. 
 
Method B: To a mixture of hexacosanoic acid (25 mg, 0.059 mmol) in anhydrous DCM 
(1 mL) under Ar was added triethylamine (25 µL, 0.180 mmol) followed by isopropyl 
chloroformate solution (1M in toluene, 60 µL, 0.060 mmol). After 2 hr the solution was 
cooled to 0 °C then a solution of β-ManPhyt 50 (19 mg, 0.039 mmol) in anhydrous 
DCM:DMF (1.2 mL, 1:0.2) was added. After 5 min the ice bath was removed and the 
reaction was allowed to warm to rt overnight. The reaction was diluted with MeOH 
and the solvents were removed in vacuo to give the residue which was absorbed onto 
silica gel from a mixture of warm MeOH:CHCl3 and purified by column chromatography 
(CHCl3 to 40% MeOH:CHCl3) to give the title compound 1 (39 mg, 0.043 mmol, 73%) as 
a white solid. 
 
1H NMR and all other analytical data were consistent with those of 1 synthesized using 
Method A. 
 
Method C: To a solution of glycolipid β-130 (32 mg, 0.032 mmol) in DCM/MeOH (2:4, 
10 mL) under argon was added sodium methoxide solution (2.5M in MeOH, 30.0 µL, 
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0.075 mmol) and the reaction mixture was stirred at rt for 3 hours. The reaction was 
diluted with DCM/MeOH (1:1, 20 mL) and the volatiles removed in vacuo. The residue 
was dissolved in minimal ethanol and transferred to a 14 mL centrifuge tube and 10 
mL water was added causing a milky white suspension to form. The tube was spun at 
5200 rpm for 25 min before the aqueous layer was decanted leaving behind a white 
solid. The solid was re-suspended in 10 mL water and spun again to further wash the 
solid, again decanting the aqueous layer. The combined aqueous layers were 
evaporated to dryness and the procedure repeated to obtain further solid. The solids 
were dissolved in ethanol, transferred to a round bottom flask, concentrated in vacuo, 
and dried to a constant weight to afford the title compound 142 (23 mg, 0.028 mmol, 
87%) as a white solid. 
 
1H NMR and all other analytical data were consistent with those of 1 synthesized using 
Method A and Method B. 
6.3.47. 1-[(2'S,3'S,4'R)-2'-N-hexacosanamide-3',4'-di-O-acetyl-1'-
octadecanyl] 2,3, 4,6-tetra-O-acetyl-β-D-mannopyranoside [130] 
To a mixture of hexacosanoic acid (25 mg, 0.059 mmol) in anhydrous DCM (1 mL) 
under Ar was added triethylamine (25 µL, 0.180 mmol) followed by isopropyl 
chloroformate solution (1M in toluene, 60 µL, 0.060 mmol). After 2 hr the solution was 
cooled to 0 °C then a solution of β-ManPhyt α/β-50 (19 mg, 0.039 mmol) in anhydrous 
DCM:DMF (1.2 mL, 1:0.2) was added. After 5 min the ice bath was removed and the 
reaction was allowed to warm to rt overnight. The reaction was diluted with MeOH 
and the solvents were removed in vacuo to give the residue which was absorbed onto 
silica gel from a mixture of warm MeOH:CHCl3 and purified by column chromatography 
(CHCl3 to 40% MeOH:CHCl3) to give β-ManCer (1) as an inseparable mixture of 
anomers (α:β= 5:95, 20 mg) as a white solid. Rf = 0.41 (15% MeOH:CHCl3); HRMS (ESI-
pos): calcd for C50H99O9NNa [M + Na]+ m/z 880.7212 found m/z 880.7207. 




Acetic anhydride (1 mL, 10.58 mmol) was added dropwise to a stirred solution of 1 
(α:β= 5:95, 20 mg) in pyridine (1 mL, 12.41 mmol) at rt. The reaction was stirred at rt 
overnight, after which a standard aqueous workup was performed using EtOAc as the 
organic solvent. Additional washes of the organic layer was performed with 2M 
aqueous HCl and sat. aqueous NaHCO3 solutions. The solvents where removed in 
vacuo to give the residue which was purified by column chromatography (PE to 2:1 
PE/EtOAc) to afford the title compound 130 as its β-anomer β-130 (5 mg, 0.004 mmol) 
as a white film. A trace amount of α-130 was evident by TLC but was not isolated. 
 
Data for β-130: δH(500 MHz, CDCl3): 6.19 (1H, d, J= 9.5 Hz, NH), 5.40 (1H, d, J= 
3.4 Hz, H-2), 5.22 (1H, t, J= 9.9 Hz, H-4), 5.03 (2H, ddd, J= 9.8, 6.2, 2.9 Hz, H-3’, H-4’), 
4.83 (1H, dt, J= 10.3, 2.9 Hz, H-3), 4.55 (1H, s, H-1), 4.36 (1H, tt, J= 9.5, 2.9 Hz, H-2’), 
4.22 (1H, dd, J= 12.2, 5.4 Hz, H-6), 4.16 (1H, dd, J= 12.2, 2.7 Hz, H-6), 3.96 (1H, dd, J= 
9.5, 2.9 Hz, H-1’), 3.61 (1H, ddd, J= 9.9, 5.4, 2.7 Hz, H-5), 3.45 (1H, dd, J= 9.5, 2.8 Hz, H-
1’), 2.22 (2H, t, J= 7.0 Hz, H-2’’), 2.21 (3H, s, CH3), 2.08 (3H, s, CH3), 2.05 (3H, s, CH3), 
2.04 (3H, s, CH3), 2.00 (6H, s, CH3), 1.74 – 1.54 (8H, m, CH2), 1.25 (64H, d, J= 2.7 Hz, 
CH2), 0.88 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’); δC(126 MHz, CDCl3): 173.24 (C=O), 
171.32 (C=O), 171.13 (C=O), 170.67 (C=O), 170.11 (C=O), 169.75 (C=O), 169.69 (C=O), 
98.30 (d, 1JCH = 158.5 Hz, C-1), 73.50 (C-3), 72.53 (C-5), 71.36 (C-3’), 70.78 (C-4’), 68.64 
(C-2), 68.20 (C-1’), 66.22 (C-4), 62.59 (C-6), 47.43 (C-2’), 36.83 (C-2’’), 32.08 (CH2), 
29.89 (CH2), 29.87 (CH2), 29.85 (CH2), 29.81 (CH2), 29.77 (CH2), 29.73 (CH2), 29.54 (CH2), 
29.51 (CH2), 29.50 (CH2), 29.48 (CH2), 27.81 (CH2), 25.80 (CH2), 25.79 (CH2), 22.84 (CH2), 
21.16 (OAc), 20.85 (OAc), 20.83 (OAc), 20.79 (OAc), 20.75 (OAc), 14.27 (C-18’, C-26’’); 
HRMS (ESI-pos): calcd for C62H111O15NNa [M + Na]+ m/z 1132.7846 found m/z 
1132.7868. 






To a solution of azide α/β-85 (160 mg, 0.168 mmol) in anhydrous THF (5 mL) at 0 °C 
under argon was added trimethylphosphine (1M in THF, 1100 µL, 1.100 mmol). After 
warming to rt over 1 hr. the solution was then stirred at rt for 4 hrs before the addition 
of NaOH (2M, 4 mL). The mixture was stirred at rt overnight to hydrolyse the imino-
phosphorane, then the reaction was diluted with DCM, washed with water and the 
volatiles were removed in vacuo to give the crude amine intermediate 128 as a 
colourless oil. Rf = 0.55 (10% MeOH in CHCl3); HRMS (ESI-pos): calcd for C59H78O8N [M 
+ H]+ m/z 928.5722, found m/z 928.5728. 
 
EDCI·HCl (100 mg, 0.518 mmol) and HOBt (80 mg, 0.579 mmol) were added to a stirred 
suspension of hexacosanoic acid (99 mg, 0.236 mmol) in DCM/DMF (10:4, 14 mL) at 
rt. After 30 min a solution of crude amine 128 (0.168 mmol) in anhydrous DCM (5 mL) 
was added followed by DIPEA (200 µL, 1.142 mmol) and the reaction stirred at rt 
overnight. The reaction was diluted with DCM, washed with water and the aqueous 
layer re-extracted with EtOAc. The combined organic extracts were concentrated in 
vacuo to give the crude material which was purified by column chromatography (PE, 
to 5:1 PE:EtOAc) to give the title compound 129 as its discrete anomers, α-129 (7.4 
mg, 0.005 mmol, 1.1 % over two steps) and β-129 (178 mg, 0.136 mmol, 81% over two 
steps) both as white solids. 
 
Data for α-129: Rf = 0.45 (5:1 PE/EtOAc); δH(500 MHz, CDCl3): 7.54 – 7.26 (25H, 
m), 5.63 (1H, s), 5.51 (1H, d, J= 9.0 Hz), 4.84 (1H, d, J= 12.2 Hz), 4.78 – 4.73 (2H, m), 
4.72 – 4.63 (3H, m), 4.53 (2H, s), 4.40 (1H, d, J= 11.7 Hz), 4.30 – 4.20 (2H, m), 4.16 (1H, 
dd, J= 10.2, 4.7 Hz), 3.88 (1H, dd, J= 10.0, 3.3 Hz), 3.84 (1H, t, J= 10.4 Hz), 3.79 – 3.68 
(4H, m), 3.63 (1H, dd, J= 10.1, 5.0 Hz), 3.58 (1H, dd, J= 6.2, 3.4 Hz), 3.54 – 3.48 (2H, m), 
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1.94 (2H, h, J= 7.2 Hz), 1.53 – 1.40 (2H, m), 1.24 (68H, d, J= 11.4 Hz), 0.88 (6H, t, J= 6.8 
Hz); δC(126 MHz, CDCl3): 172.68, 138.80, 138.51, 138.48, 138.17, 137.81, 128.94, 
128.60, 128.54, 128.45, 128.28, 128.11, 127.99, 127.94, 127.67, 127.59, 126.42, 
101.60, 100.06 (d, 1JCH = 169.07 Hz C-1), 79.98, 79.29, 79.10, 76.62, 76.35, 73.69, 73.28, 
73.23, 72.16, 68.88, 67.59, 64.73, 51.04, 49.63, 36.97, 32.09, 30.15, 30.02, 29.89, 
29.86, 29.82, 29.74, 29.54, 29.52, 25.95, 25.87, 22.85, 14.28; HRMS (ESI-pos): calcd for 
C85H127O9NNa [M + Na]+ m/z 1328.9403 found m/z 1328.9373 
 
Data for β-129: Rf = 0.36 (5:1 PE/EtOAc); δH(500 MHz, CDCl3): 7.55 – 7.27 (25H, 
m, Ph), 5.67 (1H, d, J= 8.3 Hz, NH), 5.62 (1H, s, H-7), 4.91 (1H, d, J= 12.2 Hz, PhCH2), 
4.82 (1H, d, J= 12.3 Hz, PhCH2), 4.77 (1H, d, J= 11.5 Hz, PhCH2), 4.71 (1H, d, J= 12.4 Hz, 
PhCH2), 4.65 – 4.52 (4H, m, PhCH2), 4.45 – 4.35 (2H, m, H-1, H-2’), 4.26 (1H, dd, J= 10.4, 
4.8 Hz, H-6), 4.19 (1H, t, J= 9.6 Hz, H-4), 4.08 (1H, dd, J= 10.3, 7.8 Hz, H-1’), 3.96 – 3.84 
(2H, m, H-2, H-6), 3.83 – 3.74 (2H, m, H-1’, H-3’/H-4’), 3.57 (2H, m, H-3, H-3’/H-4’), 3.26 
(1H, td, J= 9.7, 4.8 Hz, H-5), 1.95 (2H, qt, J= 14.8, 7.1 Hz, CH2), 1.67 (2H, tdd, J= 21.9, 
11.3, 6.4 Hz, CH2), 1.28 (70H, s, CH2), 0.90 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’); δC(126 
MHz, CDCl3): 172.91 (C=O), 138.63 (ipso-C), 138.61 (ipso-C), 138.57 (ipso-C), 138.42 
(ipso-C), 137.66 (ipso-C), 128.98 (Ph), 128.55 (Ph), 128.50 (Ph), 128.43 (Ph), 128.41 
(Ph), 128.29 (Ph), 128.03 (Ph), 127.96 (Ph), 127.90 (Ph), 127.79 (Ph), 127.69 (Ph), 
127.67 (Ph), 126.18 (Ph), 102.17 (d, 1JCH = 155.29 Hz C-1), 101.56 (C-7), 80.57 (C-3’/C-
4’), 79.72 (C-3’/C-4’), 78.76 (C-4), 77.95 (C-3), 76.06 (C-2), 74.81 (PhCH2), 73.69 
(PhCH2), 72.55 (PhCH2), 72.17 (PhCH2), 68.71 (C-1’), 68.67 (C-6), 67.66 (C-5), 49.88 (C-
2’), 36.89 (CH2), 32.06 (CH2), 30.52 (CH2), 29.94 (CH2), 29.86 (CH2), 29.83 (CH2), 29.79 
(CH2), 29.69 (CH2), 29.54 (CH2), 29.52 (CH2), 29.51 (CH2), 29.49 (CH2), 26.04 (CH2), 25.76 
(CH2), 22.83 (CH2), 14.26 (C-18’, C-26’’); HRMS (ESI-pos): calcd for C85H127O9NNa [M + 
Na]+ m/z 1328.9403 found m/z 1328.9420; Anal. Calcd for C85H127NO9: C, 78.12; H, 
9.80; N, 1.07. Found C, 78.06; H, 9.99; N, 1.15. 






To a solution of azide 85 (237 mg, 0.249 mmol) in 
anhydrous THF (10 mL) at 0 °C under argon was added 
trimethylphosphine (1M in THF, 1.100 mL, 1.100 
mmol). Allowed to warm to rt over 1 hr. the solution was then stirred at rt for 4 hrs. 
NaOH (2M, 4 mL) was added to the reaction and the resulting solution stirred at rt 
overnight to hydrolyse the imino-phosphorane. The reaction was diluted with DCM, 
washed with water and the volatiles were removed in vacuo to give the crude amine 
intermediate 128 as a colourless oil. Rf = 0.55 (10% MeOH in CHCl3); HRMS (ESI-pos): 
calcd for C59H78O8N [M + H]+ m/z 928.5722, found m/z 928.5728. 
 
Di-tert-butyl dicarbonate (70 mg, 0.321 mmol) was added to a stirred solution of 
amine intermediate 128 (231 mg, 0.249 mmol) and DIPEA (260 µL, 1.493 mmol) in 
DMF (5mL) at rt. The reaction was heated to 50 °C overnight then allowed to cool to 
rt. The reaction was diluted with EtOAc and a standard aqueous workup was 
preformed using EtOAc as the organic solvent. The solvents were removed in vacuo to 
afford a residue that was purified by column chromatography (PE, to 4:1 PE:EtOAc) to 
give the title compound 138 as its discrete anomers, α-138 (15 mg, 0.014 mmol, 6% 
over two steps) and β-138 199 mg, 0.194 mmol, 78% over two steps) both as 
colourless oils. 
 
Data for α-138: δH(500 MHz, CDCl3): 7.55 – 7.26 (25H, m), 5.64 (1H, s), 4.86 
(1H, d, J= 12.1 Hz), 4.77 (1H, d, J= 9.5 Hz), 4.74 (2H, d, J= 10.4 Hz), 4.65 (2H, d, J= 12.1 
Hz), 4.57 (1H, d, J= 11.5 Hz), 4.51 (1H, d, J= 11.6 Hz), 4.38 (1H, d, J= 11.5 Hz), 4.24 (1H, 
t, J= 9.6 Hz), 4.19 (1H, dd, J= 9.9, 4.5 Hz), 3.91 (1H, dd, J= 10.0, 3.3 Hz), 3.84 (1H, t, J= 
10.1 Hz), 3.79 – 3.72 (2H, m), 3.69 – 3.64 (1H, m), 3.54 (2H, s), 1.56 (2H, s), 1.43 (9H, 
s), 1.29 – 1.22 (14H, m), 0.88 (3H, t, J= 6.9 Hz); δC(126 MHz, CDCl3): 138.83, 138.18, 
137.83, 128.93, 128.54, 128.52, 128.49, 128.47, 128.45, 128.28, 128.15, 128.11, 
127.91, 127.86, 127.83, 127.67, 127.66, 126.22, 101.58, 100.17 (d, 1JCH = 170.23 Hz C-
Chapter VI: Experimental 
 
215 
1), 79.32, 76.72, 76.45, 73.68, 73.40, 72.30, 68.87, 67.98, 64.62, 51.21, 32.08, 29.87, 
29.85, 29.82, 29.52, 28.52, 28.50, 26.05, 22.85, 14.28; HRMS (ESI-pos): calcd for 
C64H85O10NNa [M + Na]+ m/z 1050.6066 found m/z 1050.6052. 
 
Data for β-138: δH(500 MHz, CDCl3): 7.56 – 7.44 (4H, m, Ph), 7.42 – 7.26 (21H, 
m, Ph), 5.61 (1H, s, H-7), 4.96 (1H, d, J= 12.2 Hz, PhCH2), 4.86 (1H, d, J= 12.2 Hz, PhCH2), 
4.80 (1H, d, J= 11.1 Hz, PhCH2), 4.71 (1H, d, J= 12.5 Hz, PhCH2), 4.66 – 4.58 (3H, m, 
PhCH2), 4.51 (1H, d, J= 11.6 Hz, PhCH2), 4.39 (1H, s, H-1), 4.25 (1H, dd, J= 10.4, 4.8 Hz, 
H-6), 4.19 (1H, t, J= 9.6 Hz, H-4), 4.11 (1H, dd, J= 9.9, 6.5 Hz, H-1’), 4.03 – 3.95 (1H, m, 
H-2’), 3.92 (1H, d, J= 3.0 Hz, H-2), 3.87 (1H, t, J= 10.3 Hz, H-6), 3.77 (1H, dd, J= 7.0, 3.0 
Hz, H-3’/H-4’), 3.66 (1H, dd, J= 10.1, 3.5 Hz, H-1’), 3.56 (2H, td, J= 8.2, 7.0, 3.2 Hz, H-3, 
H-3’/H-4’), 3.26 (1H, td, J= 9.7, 4.8 Hz, H-5), 1.75 – 1.63 (2H, m, CH2), 1.43 (9H, s, 3x 
CH3), 1.27 (24H, d, J= 4.5 Hz, CH2), 0.90 (3H, t, J= 6.8 Hz, CH3-18’); δC(126 MHz, CDCl3): 
155.44 (C=O), 138.68 (ipso-C), 138.66 (ipso-C), 138.57 (ipso-C), 138.47 (ipso-C), 137.71 
(ipso-C), 128.99 (Ph), 128.60 (Ph), 128.53 (Ph), 128.48 (Ph), 128.46 (Ph), 128.33 (Ph), 
128.31 (Ph), 128.28 (Ph), 128.26 (Ph), 128.13 (Ph), 128.06 (Ph), 127.79 (Ph), 127.74 
(Ph), 127.71 (Ph), 127.69 (Ph), 126.20 (Ph), 102.16 (d, 1JCH = 155.94 Hz C-1), 101.56 (C-
7), 79.92 (C-3’/C-4’), 79.80 (C-3’/C-4’), 79.46 (C(CH3)3), 78.81 (C-4), 77.97 (C-3), 75.83 
(C-2), 74.80 (PhCH2), 74.06 (PhCH2), 72.57 (PhCH2), 71.99 (PhCH2), 69.14 (C-1’), 68.70 
(C-6), 67.72 (C-5), 51.16 (C-2’), 32.07 (CH2), 29.88 (CH2), 29.86 (CH2), 29.84 (CH2), 29.81 
(CH2), 29.51 (CH2), 28.54 (CH3), 26.05 (CH2), 22.84 (CH2), 14.27 (C-18’); HRMS (ESI-pos): 
calcd for C64H85O10NNa [M + Na]+ m/z 1050.6066 found m/z 1050.6088. 
6.3.50. 10-(Benzyloxy)-1-Decanol [146] 
Sodium hydride (60% in oil, 790 mg, 19.75 mmol) was 
added to a solution of 1,10-decanediol 145 (2.65 g, 
15.02 mmol) in anhydrous DMF (10 mL) at 0 °C under argon and stirred for 30 min. At 
that temperature benzyl bromide (2 mL, 16.50 mmol) was added dropwise and the 
reaction was allowed to warm to rt before being stirred for an additional 4 hrs. The 
reaction was quenched with the careful addition of water, diluted with EtOAc and the 
organic layer washed with water and brine. The solvents were removed in vacuo and 
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the residue purified by column chromatography (PE to 4:1 PE/EtOAc) to give the title 
compound 146 (1.97 g, 7.47, 50%) as a colourless oil. 
 
 Data for 146: δH(400 MHz, CDCl3): 7.41 – 7.26 (5H, m, Ph), 4.50 (2H, s, PhCH2), 
3.62 (2H, t, J= 6.7 Hz, H-1), 3.46 (2H, t, J= 6.6 Hz, H-10), 1.70 – 1.47 (4H, m, H-2, H-9), 
1.45 – 1.27 (12H, m, CH2); δC(101 MHz, CDCl3): 138.82 (ipso-C), 128.45 (Ph), 127.73 
(Ph), 127.58 (Ph), 72.97 (PhCH2), 70.64 (C-10), 63.17 (C-1), 32.92 (CH2), 29.89 (CH2), 
29.66 (CH2), 29.63 (CH2), 29.58 (CH2), 29.53 (CH2), 26.31 (CH2), 25.86 (CH2); HRMS (ESI-
pos): calcd for C17H28O2Na [M + Na]+ m/z 287.1982 found m/z 287.1999. 
6.3.51. 2-(10’-benzyloxydecyl)mercaptobenzothiazole [147] 
DIAD (1.8 mL, 9.14 mmol) was added dropwise 
over a period of 2 min to a stirred solution of 
alcohol 146 (1.93 g, 7.29 mmol), 2-
mercaptobenzothiazole (1.57 g, 9.12 mmol), and triphenylphosphine (2.32 g, 8.85 
mmol) in anhydrous THF (15 mL) at 0 °C under argon. The reaction mixture was 
allowed to warm to rt over 2 hours then quenched with brine. The aqueous layer was 
extracted with DCM and the organic layer washed with brine. The solvents were 
removed in vacuo and the residue purified by column chromatography (PE to 8:1 
PE:EtOAc) to afford the title compound 147 (2.25 g, 5.43 mmol, 75%) as a pale yellow 
oil. 
 
Data for 147: δH(400 MHz, CDCl3): 7.93 – 7.84 (1H, m, H-4), 7.76 (1H, dd, J= 8.1, 
1.2 Hz, H-7), 7.42 (1H, ddd, J= 8.3, 7.3, 1.2 Hz, H-5), 7.35 (4H, d, J= 4.4 Hz, Ph), 7.32 – 
7.27 (2H, m, H-6, Ph), 4.51 (2H, s, PhCH2), 3.47 (2H, t, J= 6.6 Hz, H-1’), 3.35 (2H, t, J= 
7.3 Hz, H-10’), 1.83 (2H, p, J= 7.4 Hz, H-2’), 1.68 – 1.56 (2H, m, H-9’), 1.48 (2H, p, J= 6.7 
Hz, CH2), 1.43 – 1.26 (10H, m, CH2); δC(101 MHz, CDCl3): 167.53 (C-2), 153.51 (C-3a), 
138.85 (ipso-C), 135.29 (C-7a), 128.46 (Ph), 127.74 (Ph), 127.59 (Ph), 126.11 (C-5), 
124.22 (C-6), 121.58 (C-4), 121.03 (C-7), 72.99 (PhCH2), 70.64 (C-1’), 33.78 (C-10’), 
29.90 (CH2), 29.62 (CH2), 29.57 (CH2), 29.52 (CH2), 29.33 (CH2), 29.19 (CH2), 28.89 (CH2), 
26.32 (CH2); HRMS (ESI-pos): calcd for C24H31NOS2Na [M + Na]+ m/z 436.1739 found 
m/z 436.1715. 
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6.3.52. 2-(10’-benzyloxydecylsulfonyl)benzothiazole [148] 
mCPBA (7.51 g, 21.76 mmol) was added to a 
stirred solution of mercaptobenzothiazole 147 
(2.25 g, 5.43 mmol) in anhydrous DCM (15 mL) 
at 0 °C under argon. The resulting suspension 
was allowed to warm to rt and stirred overnight. The reaction was quenched with 
aqueous sodium thiosulfate solution, extracted into DCM and washed with saturated 
aqueous sodium bicarbonate then brine. The solvents were removed in vacuo and the 
residue purified by column chromatography (PE to 3:1 PE/EtOAc) to afford the title 
compound 148 (1.89 g, 4.25 mmol, 78%) as a crystalline white solid. 
 
Data for 148: δH(400 MHz, CDCl3): 8.26 – 8.17 (1H, m, H-4), 8.13 – 7.93 (1H, m, 
H-7), 7.68 – 7.55 (2H, m, H-6, H-5), 7.36 – 7.27 (5H, m, Ph), 4.49 (2H, s, PhCH2), 3.55 – 
3.48 (2H, m, H-1’), 3.45 (2H, t, J= 6.6 Hz, H-10’), 1.93 – 1.82 (2H, m, H-2’), 1.64 – 1.54 
(2H, m, H-9’), 1.42 (2H, p, J= 7.3 Hz, CH2), 1.36 – 1.22 (10H, m, CH2); δC(101 MHz, 
CDCl3): 166.08 (C-2), 152.89 (C-3a), 138.83 (ipso-C), 136.91 (C-7a), 128.47 (Ph), 128.12 
(Ph), 127.77 (C-5), 127.75 (Ph), 127.60 (C-6), 125.60 (C-4), 122.48 (C-7), 73.00 (PhCH2), 
70.60 (C-10’), 54.86 (C-1’), 29.88 (CH2), 29.50 (CH2), 29.49 (CH2), 29.26 (CH2), 29.02 
(CH2), 28.36 (CH2), 26.28 (CH2), 22.39 (CH2); HRMS (ESI-pos): calcd for C24H31NO3S2Na 
[M + Na]+ m/z 468.1638 found m/z 468.1613. 
6.3.53. p-fluro-1-[(1E/Z)-11-benzyloxyundecen-1-yl]-benzene [149] 
LiHMDS (0.5M in THF, 4.75 mL, 2.375 mmol) was 
added dropwise via cannula to a stirred solution 
of sulfone 148 (780 mg, 1.748 mmol) and para-
flurobenzaldehyde (150 µL, 1.370 mmol) in anhydrous THF (10 mL) at -78 °C under 
argon. The resulting mixture was stirred for 1 hr at -78 °C before being warmed to rt 
slowly overnight. The reaction was quenched with brine, extracted into DCM, washed 
thrice with saturated aqueous NaHSO3. The solvents were removed in vacuo and the 
residue was purified by column chromatography (PE to 8:1 PE:EtOAc) to give an 
inseparable mixture of the E and Z isomers of the title compound 149 (E:Z= 8:1, 258 
mg, 0.728 mmol, 53%) as a colourless oil. 




Data for 149: δH(400 MHz, CDCl3): 7.34 (4H, d, J= 4.3 Hz, Ph), 7.32 – 7.27 (2H, 
m, Ph), 7.03 – 6.92 (2H, m, Ph), 6.33 (1H, dt, J= 15.7, 1.3 Hz, H-1), 6.13 (1H, dt, J= 15.8, 
6.9 Hz, H-2), 4.51 (2H, s, PhCH2), 3.47 (2H, t, J= 6.6 Hz, H-11), 2.19 (2H, qd, J= 7.0, 1.4 
Hz, H-3), 1.62 (2H, dq, J= 8.3, 6.6 Hz, H-10), 1.45 (2H, p, J= 7.3 Hz, H-4), 1.40 – 1.25 
(10H, m, CH2); δC(101 MHz, CDCl3): 161.98 (d, 1JCF = 245.5 Hz, F ipso-C), 138.87 (ipso-
C), 134.23 (d, 4JCF = 3.2 Hz, ipso-C), 131.10 (d, J= 2.3 Hz, C-2) 128.65 (C-1), 128.48 (Ph), 
127.75 (Ph), 127.60 (Ph), 127.41 (d, 3JCF = 7.8 Hz, o-Ph), 115.41 (d, 2JCF = 21.4 Hz, m-Ph), 
73.00 (PhCH2), 70.67 (C-11), 33.13 (C-3), 29.93 (CH2), 29.68 (CH2), 29.62 (CH2), 29.60 
(CH2), 29.51 (CH2), 29.35 (CH2), 26.34 (CH2); δF(376 MHz, CDCl3): -116.02 (tt, J= 8.7, 5.5 
Hz);HRMS (ESI-pos): calcd for C24H31FONa [M + Na]+ m/z 377.2251 found m/z 
377.2258. 
6.3.54. 11-(p-flurophenyl)-undecan-1-ol [151] 
To a solution of alkene 149 (466 mg, 1.314 mmol) 
in abs ethanol (10 mL) was added 10% palladium 
on carbon (243 mg, 0.228 mmol) and 4 drops of 
conc. HCl. The stirred reaction mixture was degassed under vacuum and backfilled 
with hydrogen three times then left to stir overnight under a balloon of hydrogen. The 
hydrogen atmosphere was removed and after dilution with EtOAc the solution was 
filtered through Celite and washed with EtOAc. The solvents were removed in vacuo 
to give the residue which was purified by column chromatography (PE to 5:1 PE:EtOAc) 
to afford the title compound 151 (285 mg, 1.069 mmol, 81%) as a crystalline white 
solid. 
 
Data for 151: δH(400 MHz, CDCl3): 7.15 – 7.08 (2H, m, o-Ph), 7.00 – 6.90 (2H, 
m, m-Ph), 3.64 (2H, t, J= 6.6 Hz, H-1), 2.66 – 2.44 (2H, m, H-11), 1.57 (4H, dq, J= 13.7, 
6.7 Hz, H-2, H-10), 1.38 – 1.22 (14H, m, CH2); δC(101 MHz, CDCl3): 161.25 (d, 1JCF = 242.8 
Hz, F ipso-C), 138.60 (d, 4JCF = 3.4 Hz, ipso-C), 129.77 (d, 3JCF = 7.8 Hz, o-Ph), 115.02 (d, 
2JCF = 21.1 Hz, m-Ph); 63.23 (C-1), 35.27 (C-11), 32.95 (CH2), 31.76 (CH2), 31.75 (CH2), 
29.73 (CH2), 29.70 (CH2), 29.69 (CH2), 29.61 (CH2), 29.56 (CH2), 29.33 (CH2), 25.88 (CH2); 
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δF(376 MHz, CDCl3): -118.32 (tt, J= 9.0, 5.5 Hz); HRMS (ESI-pos): calcd for C17H27FONa 
[M + Na]+ m/z 289.1938 found m/z 289.1959. 
6.3.55. 11-(p-Fluorophenyl)-undecanoic acid [143] 
Alcohol 151 (215 mg, 0.805 mmol) NMO 
monohydrate (1.15 g, 8.30 mmol) were dissolved 
in MeCN (3.3 mL) under a nitrogen atmosphere. 
TPAP (38 mg, 0.105 mmol) was added and the reaction was stirred at rt. for 3 hrs. The 
reaction was quenched with an excess of 2-propanol (IPA) and concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc containing 1% AcOH to 
CHCl3 containing 1% AcOH) to afford the title compound 143 (214 mg, 0.763 mmol, 
95%) as a white crystalline solid. 
 
 Data for 143: δH(500 MHz, CDCl3): 7.15 – 7.07 (2H, m, o-Ph), 6.95 (2H, tt, J= 8.8, 
2.3 Hz, m-Ph), 2.56 (2H, t, J= 7.8 Hz, H-11), 2.34 (2H, t, J= 7.5 Hz, H-2), 1.68 – 1.52 (4H, 
m, H-3, H-10), 1.36 – 1.22 (12H, m, CH2); δC(126 MHz, CDCl3): 179.36 (C=O), 161.26 (d, 
1JCF = 242.7 Hz, F ipso-C), 138.60 (d, 4JCF = 3.0 Hz, ipso-C), 129.77 (d, 3JCF = 7.6 Hz, o-Ph), 
115.03 (d, 2JCF = 21.0 Hz, m-Ph); 35.27 (C-11), 34.07 (C-2), 31.74 (CH2), 29.62 (CH2), 
29.57 (CH2), 29.53 (CH2), 29.36 (CH2), 29.31 (CH2), 29.19 (CH2), 24.83 (CH2); δF(376 
MHz, CDCl3): -118.70 (tt, J= 8.9, 5.5 Hz); HRMS (ESI-neg): calcd for C17H24FO2 [M]- m/z 
279.1766 found m/z 279.1780; Anal. Calcd for C17H25FO2: C, 72.82; H, 8.99. Found C, 
72.52; H, 9.32. 
6.3.56. p-(4-Fluorophenoxy)-1-[(1E/Z)-11-benzyloxyundecen-1-yl]-benzene 
[150] 
LiHMDS (0.5M in THF, 6 mL, 3.00 mmol) 
was added dropwise via cannula to a 
stirred solution of sulfone 148 (750 mg, 
1.683 mmol) and 4-(4-fluorophenoxy)benzaldehyde (355 mg, 1.608 mmol) in 
anhydrous THF (10 mL) at -78 °C under argon. The resulting mixture was stirred for 1 
hr at -78 °C before being warmed to rt slowly overnight. The reaction was quenched 
with brine, extracted into EtOAc, and washed thrice with saturated aqueous NaHSO3. 
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The solvents were removed in vacuo and the residue was purified by column 
chromatography (PE to 12:1 PE:EtOAc) to give an inseparable mixture of the E and Z 
isomers of the title compound 150 (E:Z= 45:1, 370 mg, 0.828 mmol, 55%) as a 
colourless oil. 
 
Data for 150: δH(400 MHz, CDCl3): 7.36 – 7.26 (7H, m, Ph), 7.05 – 6.94 (4H, m, 
Ph), 6.92 – 6.87 (2H, m, Ph), 6.34 (1H, dt, J= 15.9, 1.4 Hz, H-1), 6.14 (1H, dt, J= 15.8, 6.9 
Hz, H-2), 4.50 (2H, s, PhCH2), 3.47 (2H, t, J= 6.6 Hz, H-11), 2.19 (2H, qd, J= 7.0, 1.4 Hz, 
H-3), 1.61 (2H, dt, J= 8.1, 6.6 Hz, H-10), 1.44 (2H, q, J= 6.7 Hz, CH2), 1.41 – 1.27 (10H, 
m, CH2); δC(101 MHz, CDCl3): 158.86 (d, 1JCF = 241.5 Hz, F ipso-C), 156.55 (ipso-C), 
153.22 (d, 4JCF = 2.5 Hz, ipso-C), 138.86 (ipso-C), 133.44 (ipso-C), 130.63 (C-2), 128.89 
(C-1), 128.48 (Ph), 127.76 (Ph), 127.60 (Ph), 127.33 (Ph), 120.40 (d, 3JCF = 8.2 Hz, o-Ph), 
118.60 (Ph), 116.37 (d, 2JCF = 23.3 Hz, m-Ph), 73.00 (PhCH2), 70.67 (C-11), 33.17 (C-3), 
29.92 (CH2), 29.69 (CH2), 29.62 (CH2), 29.60 (CH2), 29.57 (CH2), 29.35 (CH2), 26.34 (CH2); 
δF(376 MHz, CDCl3): -120.38 (tt, J= 8.1, 4.6 Hz); HRMS (ESI-pos): calcd for C30H35FO2Na 
[M + Na]+ m/z 469.2513 found m/z 469.2531. 
6.3.57. 11-(p-(4-Fluorophenoxy)phenyl)-undecan-1-ol [152] 
To a solution of alkene 150 (674 mg, 
1.510 mmol) in abs ethanol (10 mL) was 
added 10% palladium on carbon (261 mg, 
0.246 mmol) and 4 drops of conc. HCl. The stirred reaction mixture was degassed 
under vacuum and backfilled with hydrogen three times then left to stir overnight 
under a balloon of hydrogen. After dilution with EtOAc the solution was filtered 
through Celite and washed with EtOAc, the solvents were removed in vacuo to give 
the crude material which was purified by column chromatography (PE to 5:1 PE:EtOAc) 
to afford the title compound 152 (446 mg, 1.244 mmol, 82%) as a white solid. 
 
Data for 152: δH(400 MHz, CDCl3): 7.16 – 7.10 (2H, m, Ph), 7.04 – 6.93 (4H, m, 
o-Ph, m-Ph), 6.91 – 6.86 (2H, m, Ph), 3.64 (2H, t, J= 6.6 Hz, H-1), 2.58 (2H, t, J= 7.9 Hz, 
H-11), 1.66 – 1.49 (4H, m, H-2, H-10), 1.41 – 1.24 (14H, m, CH2); δC(101 MHz, CDCl3): 
158.73 (d, 1JCF = 241.0 Hz, F ipso-C), 155.50 (ipso-C), 153.53 (d, 4JCF = 2.6 Hz, ipso-C), 
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138.05 (ipso-C), 129.72 (Ph), 120.20 (d, 3JCF = 8.2 Hz, o-Ph), 118.48 (Ph), 116.29 (d, 2JCF 
= 23.3 Hz, m-Ph), 63.24 (C-1), 35.35 (C-11), 32.96 (CH2), 31.77 (CH2), 29.74 (CH2), 29.72 
(CH2), 29.64 (CH2), 29.57 (CH2), 29.42 (CH2), 25.89 (CH2); δF(376 MHz, CDCl3): -120.71 
(tp, J= 8.6, 4.6 Hz); HRMS (ESI-pos): calcd for C23H31FO2Na [M + Na]+ m/z 381.2200 
found m/z 381.2198. 
6.3.58. 11-(p-(4-Fluorophenoxy)phenyl)-undecanoic acid [144] 
Alcohol 152 (104 mg, 0.290 mmol) and 
NMO monohydrate (390 mg, 2.80 mmol) 
were dissolved in MeCN (1200 µL) under 
a nitrogen atmosphere. TPAP (10 mg, 0.029 mmol) was added and the reaction was 
stirred at rt for 3 hrs. The reaction was quenched with an excess of 2-propanol (IPA) 
and concentrated in vacuo to give the crude material which was purified by column 
chromatography (EtOAc containing 1% AcOH to CHCl3 containing 1% AcOH) to afford 
the title compound 144 (103 mg, 0.290 mmol, 95%) as a white solid. 
 
 Data for 144: δH(500 MHz, CDCl3): 7.12 (2H, dt, J= 8.6, 2.8, 2.1 Hz, Ph), 7.03 – 
6.93 (4H, m, o-Ph, m-Ph), 6.88 (2H, dt, J= 8.6, 2.8, 2.1 Hz, Ph), 2.57 (2H, t, J= 7.6 Hz, H-
11), 2.35 (2H, t, J= 7.5 Hz, H-2), 1.67 – 1.55 (4H, m, H-3, H-10), 1.37 – 1.24 (12H, m, 
CH2); δC(126 MHz, CDCl3): 179.80 (C=O), 158.73 (d, 1JCF = 241.0 Hz, F-ipso-C), 155.51 
(ipso-C), 153.53 (4JCF = 2.4 Hz, ipso-C), 138.04 (ipso-C), 129.71 (Ph), 120.21 (d, 3JCF = 8.1 
Hz, o-Ph), 118.48 (Ph), 116.29 (d, 2JCF = 23.3 Hz, m-Ph), 35.34 (C-11), 34.13 (C-2), 31.76 
(CH2), 29.64 (CH2), 29.60 (CH2), 29.55 (CH2), 29.40 (CH2), 29.36 (CH2), 29.19 (CH2), 24.82 
(CH2); δF(376 MHz, CDCl3): -121.14 (tt, J= 7.9, 4.6 Hz); HRMS (ESI-neg): calcd for 
C23H28FO3 [M]- m/z 371.2028 found m/z 371.2020; Anal. Calcd for C23H29FO3: C, 74.17; 
H, 7.85. Found C, 73.68; H, 8.22. 






To a solution of azide α/β-85 
(149 mg, 0.156 mmol) in 
anhydrous THF (10 mL) at 0 °C 
under argon was added 
trimethylphosphine (1M in THF, 1.100 mL, 1.100 mmol). The mixture was warmed to 
rt over 1 hr. and then stirred at rt for 4 hrs. NaOH (2M, 4 mL) was added to the reaction 
mixture and the resulting solution stirred at rt overnight to hydrolyse the imino-
phosphorane. The reaction was diluted with DCM, washed with water and the 
volatiles were removed in vacuo to give the crude amine intermediate 128 as a 
colourless oil. Rf = 0.55 (10% MeOH in CHCl3); HRMS (ESI-pos): calcd for C59H78O8N [M 
+ H]+ m/z 928.5722, found m/z 928.5728. 
 
EDCI·HCl (95 mg, 0.498 mmol) and HOBt (78 mg, 0.568 mmol) were added to a stirred 
suspension of 11-(p-fluorophenyl)-undecanoic acid 143 (60 mg, 0.213 mmol) in 
anhydrous DCM/DMF (10:4, 7 mL) at rt under argon. After 30 min a solution of crude 
amine 128 (0.156 mmol) in DCM (5 mL) was added followed by DIPEA (190 µL, 1.085 
mmol) and the reaction stirred at rt overnight. The reaction was diluted with DCM, 
washed twice with 2M aqueous NaOH (to remove excess acid) and brine. The 
combined organic extracts were concentrated in vacuo to give the residue which was 
purified by column chromatography (PE, to 6:1 PE:EtOAc) to give the title compound 
153 as its discrete anomers, α-153 (2 mg, 0.0019 mmol, 1.2% over two steps) and β-
153 (129 mg, 0.108 mmol, 70% over two steps) both as colourless oils. 
 
Data for α-153: δH(500 MHz, CDCl3): 7.51 – 7.26 (25H, m), 7.10 (2H, dd, J= 8.4, 
5.6 Hz), 6.94 (2H, t, J= 8.7 Hz), 5.63 (1H, s), 5.50 (1H, d, J= 9.1 Hz), 4.84 (1H, d, J= 12.2 
Hz), 4.78 – 4.63 (6H, m), 4.53 (2H, s), 4.40 (1H, d, J= 11.6 Hz), 4.30 – 4.21 (2H, m), 4.16 
(1H, dd, J= 10.2, 4.7 Hz), 3.88 (1H, dd, J= 10.0, 3.3 Hz), 3.84 (1H, t, J= 10.3 Hz), 3.79 – 
3.68 (3H, m), 3.64 (1H, dd, J= 10.1, 4.9 Hz), 3.58 (1H, dd, J= 6.2, 3.5 Hz), 3.51 (1H, dt, 
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J= 7.7, 3.9 Hz), 2.63 – 2.49 (2H, m), 1.94 (2H, td, J= 7.3, 4.7 Hz), 1.53 (8H, d, J= 31.7 Hz), 
1.24 (34H, d, J= 13.3 Hz), 0.88 (3H, t, J= 6.9 Hz); δC(126 MHz, CDCl3): 99.55 (d, 1JCH = 
171.67 Hz C-1). 
 
 Data for β-153: δH(500 MHz, CDCl3): 7.53 – 7.21 (25H, m, Ph), 7.11 (2H, ddd, J= 
8.7, 5.8, 3.2 Hz, o-Ph), 6.95 (2H, td, J= 8.7, 2.2 Hz, m-Ph), 5.65 (1H, d, J= 8.4 Hz, NH), 
5.60 (1H, s, H-7), 4.89 (1H, d, J= 12.3 Hz, PhCH2), 4.80 (1H, d, J= 12.2 Hz, PhCH2), 4.75 
(1H, d, J= 11.5 Hz, PhCH2), 4.69 (1H, d, J= 12.5 Hz, PhCH2), 4.61 (1H, d, J= 9.4 Hz, PhCH2), 
4.59 (1H, d, J= 10.5 Hz, PhCH2), 4.56 (1H, d, J= 6.9 Hz, PhCH2), 4.53 (1H, d, J= 6.9 Hz, 
PhCH2), 4.41 – 4.35 (2H, m, H-1, H-2’), 4.25 (1H, dd, J= 10.4, 4.8 Hz, H-6), 4.17 (1H, t, 
J= 9.6 Hz, H-4), 4.06 (1H, dd, J= 10.3, 7.9 Hz, H-1’), 3.90 – 3.83 (2H, m, H-2, H-6), 3.80 
– 3.74 (2H, m, H-1’, H-3’/H-4’), 3.59 – 3.52 (2H, m, H-3, H-3’/H-4’), 3.24 (1H, td, J= 9.7, 
4.9 Hz, H-5), 2.55 (2H, t, J= 8.0 Hz, H-11’’), 1.93 (2H, dtd, J= 23.1, 14.7, 6.9 Hz, H-2’’), 
1.70 – 1.45 (8H, m, CH2), 1.26 (26H, s, CH2), 1.22 (8H, s, CH2), 0.88 (3H, t, J= 6.9 Hz, CH3-
18’); δC(126 MHz, CDCl3): 172.92 (C=O), 161.25 (1JCF = 242.7 Hz, F ipso-C), 138.65 (ipso-
C), 138.64 (d, 4JCF = 3.1 Hz, ipso-C), 138.56 (ipso-C), 138.44 (ipso-C), 137.67 (ipso-C), 
129.76 (d, 3JCF = 7.7 Hz, o-Ph), 129.02 (Ph), 128.59 (Ph), 128.57 (Ph), 128.53 (Ph), 
128.52 (Ph), 128.45 (Ph), 128.34 (Ph), 128.31 (Ph), 128.05 (Ph), 127.98 (Ph), 127.82 
(Ph), 127.69 (Ph), 126.20 (Ph), 115.03 (d, 2JCF = 21.0 Hz, m-Ph), 102.21 (d, 1JCH = 155.50 
Hz C-1), 101.59 (C-7), 80.63 (C-3’/C-4’), 79.72 (C-3’/C-4’), 78.78 (C-4), 77.95 (C-3), 76.06 
(C-2), 74.82 (PhCH2), 73.71 (PhCH2), 72.57 (PhCH2), 72.20 (PhCH2), 68.70 (C-1’, C-6), 
67.68 (C-5), 49.93 (C-2’), 36.89 (C-2’’), 35.27 (C-11’’), 32.08 (CH2), 31.76 (CH2), 30.57 
(CH2), 29.96 (CH2), 29.87 (CH2), 29.85 (CH2), 29.82 (CH2), 29.72 (CH2), 29.65 (CH2), 29.62 
(CH2), 29.58 (CH2), 29.52 (CH2), 29.35 (CH2), 26.06 (CH2), 25.75 (CH2), 22.84 (CH2), 14.27 
(C-18’); δF(376 MHz, CDCl3): -118.66 (tt, J= 9.4, 5.6 Hz); HRMS (ESI-pos): calcd for 
C76H100O9NFNa [M + Na]+ m/z 1212.7274 found m/z 1212.7249. 






To a solution of azide 
α/β-85 (148 mg, 0.154 
mmol) in anhydrous THF 
(10 mL) at 0 °C under 
argon was added trimethylphosphine (1M in THF, 1.100 mL, 1.100 mmol). The solution 
was warmed to rt over 1 hr then stirred at rt for an additional 4 hrs. NaOH (2M, 4 mL) 
was added to the reaction mixture and the resulting solution stirred at rt overnight to 
hydrolyse the imino-phosphorane. The reaction was diluted with DCM, washed with 
water and the volatiles were removed in vacuo to give the crude amine intermediate 
128 as a colourless oil. Rf = 0.55 (10% MeOH in CHCl3); HRMS (ESI-pos): calcd for 
C59H78O8N [M + H]+ m/z 928.5722, found m/z 928.5728. 
 
EDCI·HCl (94 mg, 0.490 mmol) and HOBt (81 mg, 0.585 mmol) were added to a stirred 
suspension of 11-(p-(4-fluorophenoxy)phenyl)-undecanoic acid 144 (82 mg, 0.220 
mmol) in anhydrous DCM/DMF (10:4, 7 mL) at rt under argon. After 30 min a solution 
of crude amine 128 (143 mg, 0.154 mmol) in anhydrous DCM (5 mL) was added 
followed by DIPEA (190 µL, 1.085 mmol) and the reaction stirred at rt overnight. The 
reaction was diluted with DCM, washed with water and the aqueous layer re-extracted 
with EtOAc. The combined organics were concentrated in vacuo to give the crude 
which was purified by column chromatography (PE, to 5:1 PE:EtOAc) to give the title 
compound 154 as its discrete anomers, α-154 (11 mg, 0.0087 mmol, 5.6% over two 
steps) and β-154 117 mg, 0.091 mmol, 59% over two steps) both as colourless oils. 
 
Data for α-154: δH(400 MHz, CDCl3): 7.54 – 7.26 (25H, m), 7.16 – 7.09 (2H, m), 
7.03 – 6.92 (4H, m), 6.91 – 6.86 (2H, m), 5.63 (1H, s), 5.51 (1H, d, J= 9.0 Hz), 4.88 – 4.38 
(10H, m), 4.29 – 4.14 (3H, m), 3.91 – 3.48 (7H, m), 2.63 – 2.51 (2H, m), 1.95 (2H, td, J= 
7.3, 2.8 Hz), 1.70 – 1.46 (6H, m), 1.35 – 1.20 (36H, m), 0.91 – 0.85 (3H, m); δC(126 MHz, 
CDCl3): 99.87 (d, 1JCH = 168.77 Hz C-1). 
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Data for β-154: δH(500 MHz, CDCl3): 7.53 – 7.22 (25H, m, Ph), 7.14 – 7.09 (2H, 
m, Ph), 7.03 – 6.93 (4H, m, o-Ph, m-Ph), 6.91 – 6.85 (2H, m, Ph), 5.67 (1H, d, J= 8.3 Hz, 
NH), 5.60 (1H, s, H-7), 4.89 (1H, d, J= 12.2 Hz, PhCH2), 4.80 (1H, d, J= 12.2 Hz, PhCH2), 
4.75 (1H, d, J= 11.5 Hz, PhCH2), 4.69 (1H, d, J= 12.4 Hz, PhCH2), 4.61 (1H, d, J= 9.3 Hz, 
PhCH2), 4.59 (1H, d, J= 10.4 Hz, PhCH2), 4.56 (1H, d, J= 7.2 Hz, PhCH2), 4.53 (1H, d, J= 
7.4 Hz, PhCH2), 4.42 – 4.35 (2H, m, H-1, H-2’), 4.25 (1H, dd, J= 10.4, 4.9 Hz, H-6), 4.17 
(1H, t, J= 9.5 Hz, H-4), 4.05 (1H, dd, J= 10.3, 7.9 Hz, H-1’), 3.89 – 3.83 (2H, m, H-2, H-6), 
3.80 – 3.74 (2H, m, H-1’, H-3’/H-4’), 3.55 (2H, m, H-3, H-3’/H-4’), 3.24 (1H, td, J= 9.7, 
4.8 Hz, H-5), 2.56 (2H, t, J= 7.8 Hz, H-11’’), 1.94 (2H, qt, J= 14.6, 7.6 Hz, H-2’’), 1.72 – 
1.55 (4H, m, CH2), 1.53 – 1.45 (2H, m, CH2), 1.33 – 1.21 (36H, m, CH2), 0.88 (3H, t, J= 
6.8 Hz, CH3-18’); δC(126 MHz, CDCl3): 172.94 (C=O), 158.73 (d, 1JCF = 241.2 Hz, F ipso-
C), 155.51 (ipso-C), 153.52 (d, 4JCF = 2.4 Hz), 138.65 (ipso-C), 138.62 (ipso-C), 138.58 
(ipso-C), 138.43 (ipso-C), 138.01 (ipso-C), 137.66 (ipso-C), 129.70 (Ph), 128.59 (Ph), 
128.57 (Ph), 128.52 (Ph), 128.45 (Ph), 128.32 (Ph), 128.04 (Ph), 127.99 (Ph), 127.82 
(Ph), 127.70 (Ph), 126.20 (Ph), 120.20 (d, 3JCF = 8.1 Hz, o-Ph), 118.48 (Ph), 116.29 (d, 
2JCF = 23.3 Hz, m-Ph), 102.20 (d, 1JCH = 156.28 Hz C-1), 101.59 (C-7), 80.63 (C-3’/C-4’), 
79.71 (C-3’/C-4’), 78.77 (C-4), 77.94 (C-3), 76.07 (C-2), 74.83 (PhCH2), 73.70 (PhCH2), 
72.58 (PhCH2), 72.20 (PhCH2), 68.70 (C-1’, C-6), 67.68 (C-5), 49.94 (C-2’), 36.89 (C-2’’), 
35.35 (C-11’’), 32.08 (CH2), 31.78 (CH2), 30.57 (CH2), 29.96 (CH2), 29.87 (CH2), 29.85 
(CH2), 29.82 (CH2), 29.74 (CH2), 29.67 (CH2), 29.65 (CH2), 29.61 (CH2), 29.53 (CH2), 29.46 
(CH2), 26.05 (CH2), 25.76 (CH2), 22.84 (CH2), 14.27 (C-18’); δF(376 MHz, CDCl3): -121.12 
(tt, J= 8.7, 4.7 Hz); HRMS (ESI-pos): calcd for C82H104O10NFNa [M + Na]+ m/z 1304.7530 
found m/z 1304.7536. 
6.3.61. 4-Fluorophenyl-N-[(1S,2S,3R)-2,3-dihydroxy-1-[(β-D-
mannopyranosyloxy)methyl]heptadecyl] Undecanamide, [CI121, 140] 
To a solution of glycolipid 154 (87 
mg, 0.073 mmol) in DCM/MeOH 
(1:1, 20 mL) was added 10% 
palladium on carbon (18 mg, 0.017 
mmol). The stirred reaction mixture was degassed under vacuum and backfilled with 
hydrogen three times then left to stir overnight under a balloon of hydrogen. The 
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hydrogen atmosphere was removed and after dilution with MeOH the solution was 
filtered through Celite and washed with DCM/MeOH followed by approx. 50 mL of hot 
EtOH. The solvents were removed in vacuo to give the crude material which was 
precipitated by dissolving in hot ethanol and triturating out of solution by dropwise 
addition of water. Once a precipitate formed the mixture was heated to re-dissolve 
and the resulting solution was allowed to cool slowly to rt and then cooled in ice. The 
resulting precipitate was filtered through a Hirsch funnel and dried to a constant 
weight affording the title compound 140 (45 mg, 0.061 mmol, 83%) as a white solid. 
 
Data for 140: δH(500 MHz, 2:1 CDCl3:CD3OD): 7.39 (1H, d, J= 9.0 Hz, NH), 7.11 
– 7.06 (2H, m, o-Ph), 6.90 (2H, tt, J= 9.0, 2.1 Hz, m-Ph), 4.46 (1H, d, J= 1.1 Hz H-1), 4.17 
(1H, dqd, J= 5.9, 4.0, 2.8, 1.7 Hz, H-2’), 4.03 (1H, dd, J= 10.3, 3.8 Hz, H-1’), 3.90 – 3.81 
(2H, m, H-6, H-2), 3.74 – 3.66 (2H, m, H-1’, H-6), 3.59 – 3.48 (3H, m, H-4, H-3’, H-4’), 
3.42 (1H, dd, J= 9.4, 3.3 Hz, H-3), 3.20 (1H, ddd, J= 9.7, 5.8, 2.5 Hz, H-5), 2.53 (2H, t, J= 
7.9 Hz, H-11’’), 2.16 (2H, t, J= 7.7 Hz, H-2’’), 1.56 (6H, tq, J= 15.0, 7.7, 7.3 Hz, CH2), 1.32 
– 1.14 (40H, m, CH2), 0.84 (3H, t, J= 6.9 Hz, CH3-18’); δC(126 MHz, 2:1 CDCl3:CD3OD): 
174.66 (C=O), 161.48 (d, 1JCF = 242.2 Hz, F ipso-C), 138.81 (d, 4JCF = 3.3 Hz, ipso-C), 
129.96 (t, 3JCF = 8.0 Hz, o-Ph), 115.09 (d, 2JCF = 21.0 Hz, m-Ph), 100.39 (d, 1JCH = 157.4 
Hz, C-1), 76.87 (C-5), 74.39 (C-4), 74.14 (C-3), 72.35 (C-3’/C-4’), 71.11 (C-2), 68.49 (C-
1’), 67.52 (C-3’/C-4’), 61.85 (C-6), 50.50 (C-2’), 36.79 (C-2’’), 35.40 (C-11’’), 32.36 (CH2), 
32.23 (CH2), 31.94 (CH2), 30.10 (CH2), 30.07 (CH2), 30.03 (CH2), 30.01 (CH2), 29.98 (CH2), 
29.96 (CH2), 29.88 (CH2), 29.82 (CH2), 29.81 (CH2), 29.77 (CH2), 29.76 (CH2), 29.71 (CH2), 
29.68 (CH2), 29.66 (CH2), 29.49 (CH2), 26.26 (CH2), 26.19 (CH2), 22.96 (CH2), 14.22 (C-
18’); δF(376 MHz, 2:1 CDCl3:CD3OD): -119.07 (tt, J= 9.1, 5.3 Hz); HRMS (ESI-pos): calcd 
for C41H72O9NFNa [M + Na]+ m/z 764.5083 found m/z 764.5110; Anal. Calcd for 
C41H72NO9·2H2O: C, 66.37; H, 9.78; N, 1.89. Found C, 66.13; H, 9.49; N, 1.93; Analytical 
HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR =4.775 min. 






To a solution of glycolipid 
154 (134 mg, 0.104 mmol) 
in DCM/MeOH (1:1, 20 mL) 
was added 10% palladium 
on carbon (32 mg, 0.030 mmol). The stirred reaction mixture was degassed under 
vacuum and backfilled with hydrogen three times then left to stir overnight under a 
balloon of hydrogen. The hydrogen atmosphere and solvents were removed in vacuo 
to give the crude material which was precipitated by dissolving in hot ethanol and 
triturating out of solution with dropwise addition of water. Once a precipitate formed 
the mixture was heated to re-dissolve and the resulting solution was allowed to cool 
slowly to rt and then cooled in ice. The resulting precipitate was filtered through a 
Hirsch funnel and dried to a constant weight affording glycolipid 141 (82 mg, 0.098 
mmol, 94%) as a white solid which contained traces of the α-anomer. HRMS (ESI-pos): 
calcd for C47H76O10NFNa [M + Na]+ m/z 856.5345 found m/z 856.5348. 
 
Acetic anhydride (1 mL, 10.58 mmol) was added dropwise to a stirred solution of 
glycolipid 141 (82 mg, 0.098 mmol) in pyridine (1 mL, 12.41 mmol) at rt. The reaction 
was stirred at rt overnight, after which a standard aqueous workup was performed 
using EtOAc as the organic solvent. Additional washes of the organic extract were 
performed with 2M aqueous HCl and sat. aqueous NaHCO3 solutions. The combined 
organic extracts were concentrated in vacuo to give the crude material which was 
purified by column chromatography (PE, to 3:1 PE:EtOAc) to give the title compound 
155 as its discrete anomers, α-155 (6 mg, 0.0057 mmol, 6%) and β-155 (79 mg, 0.073 
mmol, 74%) both isolated as colourless oils. 
 
Data for α-155: δH(500 MHz, CDCl3): 7.14 – 7.08 (2H, m), 7.03 – 6.93 (4H, m), 
6.90 – 6.85 (2H, m), 6.21 (1H, d, J= 9.6 Hz), 5.55 (1H, s), 5.50 (1H, dd, J= 3.5, 1.2 Hz), 
5.11 (1H, dd, J= 10.4, 3.5 Hz), 5.06 (1H, dd, J= 9.7, 2.5 Hz), 4.83 (1H, dt, J= 10.5, 2.7 Hz), 
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4.61 (1H, d, J= 1.3 Hz), 4.40 – 4.29 (3H, m), 4.02 – 3.95 (2H, m), 3.83 (1H, t, J= 10.2 Hz), 
3.66 (1H, qt, J= 6.7, 3.3 Hz), 3.47 – 3.42 (2H, m), 3.09 (2H, qd, J= 7.4, 4.1 Hz), 2.59 – 
2.53 (4H, m), 2.22 (3H, s), 2.05 (3H, s), 2.04 (3H, s), 2.00 (3H, s), 1.68 – 1.51 (4H, m), 
1.45 (3H, s), 1.43 (3H, s), 1.25 (36H, t, J= 3.8 Hz), 0.91 – 0.86 (3H, m); δC(126 MHz, 
CDCl3): 104.49 (d, 1JCH = 163.96.77 Hz C-1). 
 
 Data for β-155: δH(500 MHz, CDCl3): 7.14 – 7.08 (2H, m, Ph), 7.03 – 6.92 (4H, 
m, m-Ph, o-Ph), 6.91 – 6.83 (2H, m, Ph), 6.27 (1H, dd, J= 9.6, 3.5 Hz, NH), 5.40 (1H, d, 
J= 3.4 Hz, H-2), 5.22 (1H, t, J= 9.9 Hz, H-4), 5.03 (2H, td, J= 9.9, 9.4, 2.9 Hz, H-3’, H-4’), 
4.82 (1H, dt, J= 10.2, 2.9 Hz, H-3), 4.54 (1H, s, H-1), 4.35 (1H, tt, J= 9.5, 2.9 Hz, H-2’), 
4.21 (1H, dd, J= 12.2, 5.3 Hz, H-6), 4.15 (1H, dd, J= 12.2, 2.7 Hz, H-6), 3.96 (1H, dd, J= 
9.5, 2.8 Hz, H-1’), 3.60 (1H, ddd, J= 10.1, 5.5, 2.7 Hz, H-5), 3.44 (1H, dd, J= 9.5, 2.7 Hz, 
H-1’), 2.56 (2H, t, J= 7.8 Hz, H-11’’), 2.22 (2H, t, J= 7.7 Hz, H-2’’), 2.20 (3H, s, CH3), 2.08 
(3H, s, CH3), 2.05 (3H, s, CH3), 2.04 (3H, s, CH3), 2.00 (6H, s, CH3), 1.60 (6H, dp, J= 20.9, 
6.9 Hz, CH2), 1.38 – 1.17 (36H, m, CH2), 0.87 (3H, t, J= 6.4 Hz, CH3-18’); δC(126 MHz, 
CDCl3): 173.21 (NC=O), 171.34 (C=O), 171.15 (C=O), 170.64 (C=O), 170.09 (C=O), 
169.72 (C=O), 169.67 (C=O), 158.69 (d, 1JCF = 241.1 Hz, F ipso-C), 155.46 (ipso-C), 
153.53 (d, 4JCF = 2.4 Hz, ipso-C), 138.04 (ipso-C), 129.70 (Ph), 120.17 (d, 3JCF = 8.2 Hz, o-
Ph), 118.46 (Ph), 116.26 (d, 2JCF = 23.2 Hz, m-Ph), 98.26 (d, 1JCH = 158.42 Hz C-1), 73.48 
(C-3), 72.50 (C-5), 71.27 (C-3’/C-4’), 70.76 (C-3’/C-4’), 68.63 (C-2), 68.17 (C-1’), 66.19 
(C-4), 62.55 (C-6), 47.41 (C-2’), 36.77 (C-2’’), 35.33 (C-11’’), 32.05 (CH2), 31.77 (CH2), 
29.82 (CH2), 29.78 (CH2), 29.74 (CH2), 29.69 (CH2), 29.65 (CH2), 29.62 (CH2), 29.49 (CH2), 
29.47 (CH2), 29.43 (CH2), 27.73 (CH2), 25.77 (CH2), 25.74 (CH2), 22.81 (CH2), 21.15 (CH2), 
21.12 (CH2), 20.83 (CH3), 20.81 (CH3), 20.79 (CH3), 20.75 (CH3), 20.73 (CH3), 20.70 (CH3), 
14.24 (C-18’); δF(376 MHz, CDCl3): -121.17 (tt, J= 8.4, 4.7 Hz); HRMS (ESI-pos): calcd for 
C59H88O16NFNa [M + Na]+ m/z 1108.5959 found m/z 1108.5979. 
 




mannopyranosyloxy)methyl]heptadecyl] Undecanamide [CI122, 141] 
Method A: To a solution of 
glycolipid 154 (75 mg, 0.058 
mmol) in DCM/MeOH (1:1, 
20 mL) was added 10% 
palladium on carbon (21 mg, 0.020 mmol). The stirred reaction mixture was degassed 
under vacuum and backfilled with hydrogen three times then left to stir overnight 
under a balloon of hydrogen. The hydrogen atmosphere was removed and after 
diluting with MeOH the solution was filtered through Celite and washed with 
DCM/MeOH followed by approx. 50 mL of hot EtOH. The solvents were removed in 
vacuo to give the crude material that was precipitated by dissolving in hot ethanol and 
triturating out of solution with dropwise addition of water. Once a precipitate formed, 
the mixture was heated to re-dissolve any solid and the resulting solution was allowed 
to cool slowly to rt and then cooled in ice. The resulting precipitate was filtered 
through a Hirsch funnel and dried to a constant weight affording the title compound 
141 (45 mg, 0.054 mmol, 93 %) as a white solid. 
 
 Data for 141: δH(500 MHz, 2:1 CDCl3:CD3OD): 7.42 (1H, d, J= 8.7 Hz, NH), 7.09 
(2H, dt, J= 8.4, 2.7 Hz, Ph), 7.00 – 6.89 (4H, m, o-Ph, m-Ph), 6.86 – 6.82 (2H, m, Ph), 
4.46 (1H, s, H-1), 4.17 (1H, dt, J= 6.4, 4.0 Hz, H-2’), 4.04 (1H, dd, J= 10.3, 3.7 Hz, H-1’), 
3.89 – 3.81 (2H, m, H-2, H-6), 3.74 – 3.67 (2H, m, H-1’, H-6), 3.62 – 3.50 (3H, m, H-4, 
H-3’, H-4’), 3.43 (1H, dd, J= 9.4, 3.3 Hz, H-3), 3.20 (1H, ddd, J= 9.6, 5.7, 2.5 Hz, H-5), 
2.54 (2H, t, J= 7.8 Hz, H-11’’), 2.16 (2H, t, J= 7.6 Hz, H-2’’), 1.68 – 1.47 (6H, m, CH2), 
1.40 – 1.19 (42H, m, CH2), 0.84 (3H, t, J= 6.9 Hz, CH3-18’); δC(126 MHz, 2:1 
CDCl3:CD3OD): 174.68 (C=O), 158.97 (d, 1JCF =240.9 Hz, F ipso-C), 155.69 (ipso-C), 
153.79 (d, 4JCF =2.4 Hz, ipso-C), 138.29 (ipso-C), 129.91 (Ph), 120.33 (d, 3JCF =8.2 Hz, o-
Ph), 118.66 (Ph), 116.41 (d, 2JCF =23.4 Hz, m-Ph), 100.44 (d, 1JCH = 158.99 Hz C-1), 76.85 
(C-5), 74.37 (C-4), 74.06 (C-3), 72.39 (C-3’/C-4’), 71.08 (C-2), 68.65 (C-1’), 67.29 (C-3’/C-
4’), 61.58 (C-6), 50.36 (C-2’), 36.77 (C-2’’), 35.49 (C-11’’), 32.34 (CH2), 32.24 (CH2), 
31.97 (CH2), 30.11 (CH2), 30.08 (CH2), 30.04 (CH2), 30.02 (CH2), 29.97 (CH2), 29.92 (CH2), 
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29.87 (CH2), 29.82 (CH2), 29.75 (CH2), 29.71 (CH2), 29.67 (CH2), 29.60 (CH2), 26.29 (CH2), 
26.22 (CH2), 22.97 (CH2), 14.22 (C-18’); δF(376 MHz, 2:1 CDCl3:CD3OD): -121.42 (tt, J= 
8.3, 4.4 Hz); HRMS (ESI-pos): calcd for C47H76O10NFNa [M + Na]+ m/z 856.5345 found 
m/z 856.5348; Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] 
tR =4.9833 min. 
 
Method B: To a solution of peracetate β-155 (69 mg, 0.064 mmol) in DCM/MeOH (2:4 
mL) was added sodium methoxide solution (2.5M in MeOH, 40 µL, 0.100 mmol) and 
the reaction mixture was stirred at rt for 3 hours. The reaction was diluted with 
DCM/MeOH (1:1, 20 mL) and the volatiles removed in vacuo. The resulting white solid 
was dissolved in hot EtOH, cooled to rt and placed in the freezer (-18°C) for an hour. 
The resulting precipitate was filtered and dried to a constant weight to afford the title 
compound 141 (45 mg, 0.054 mmol, 85%) as a white solid.  
 
1H NMR and all other analytical data were consistent with those of 141 synthesized 




To a mixture of 11C,14C-
elicosadienoic acid (42 
mg, 0.133 mmol) in 
anhydrous DCM (5mL) 
under an argon atmosphere and with the exclusion of light, was added TEA (300 µL, 
2.137 mmol) then Isopropyl chloroformate solution (130 µL, 0.130 mmol) and the 
resulting solution was stirred at rt for 50 min to give the crude mixed carbonic 
anhydride. 
 
To a solution of β-ManPhyt 50 (62 mg, 0.104 mmol) in anhydrous DMF (5 mL) at 0 °C 
under argon and with the exclusion of light was added the mixed carbonic anhydride 
solution. After 5 min the ice bath was removed and the reaction was warmed to rt. 
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When TLC indicated loss of starting material and formation of the amide intermediate 
(approx. 3 hrs), acetic anhydride (600 µL, 6.35 mmol) and DMAP (catalytic amount ≈ 1 
crystal) where added to the reaction mixture and the reaction was stirred at rt 
overnight. The reaction was diluted with DCM, washed with water and brine and 
concentrated in vacuo to give the residue that was purified by column 
chromatography (PE to 2:1 PE/EtOAc) to give the title compound 156 as its discrete 
anomers, α-156 (trace only, not isolated), and β-156 (91 mg, 0.089 mmol, 86%) as a 
colourless oil. 
 
Data for β-156: δH(500 MHz, Acetone-d6): 7.18 (1H, d, J= 9.4 Hz, NH), 5.45 – 
5.31 (5H, m, H-11’’, H-12’’, H-14’’, H-15’’, H-2), 5.19 (1H, t, J= 9.9 Hz, H-4), 5.12 (2H, 
dd, J= 10.1, 3.2 Hz, H-3’, H-4’), 4.96 (1H, dt, J= 10.6, 2.9 Hz, H-3), 4.92 (1H, s, H-1), 4.40 
(1H, ddd, J= 14.1, 6.9, 4.3 Hz, H-2’), 4.27 (1H, dd, J= 12.1, 5.5 Hz, H-6), 4.15 (1H, dd, J= 
12.2, 2.5 Hz, H-6), 4.00 (1H, dd, J= 10.0, 4.7 Hz, H-1’), 3.88 (1H, ddd, J= 9.7, 5.5, 2.6 Hz, 
H-5), 3.59 (1H, dd, J= 10.0, 2.9 Hz, H-1’), 2.83 (2H, t, J= 7.0 Hz, H-13’’), 2.25 – 2.16 (2H, 
m, H-2’’), 2.14 (3H, s, CH3), 2.08 (3H, s, CH3), 2.06 (3H, s, CH3), 2.04 (3H, s, CH3), 1.98 
(3H, s, CH3), 1.95 (3H, s, CH3), 1.83 – 1.74 (1H, m, CH2), 1.70 – 1.57 (3H, m, CH2), 1.33 
(46H, d, J= 13.1 Hz, CH2), 0.91 (6H, q, J= 6.5 Hz, CH3-18’, CH3-20’’); δC(126 MHz, 
Acetone-d6): 172.95 (NC=O), 170.98 (C=O), 170.75 (C=O), 170.72 (C=O), 170.20 (C=O), 
170.17 (C=O), 170.15 (C=O), 130.70 (C-15’’), 130.68 (C-11’’), 128.78 (C-14’’), 128.77 (C-
12’’), 98.73 (d, 1JCH = 160.16 Hz C-1), 73.56 (C-3), 72.91 (C-5), 72.50 (C-3’/C-4’), 71.82 
(C-3’/C-4’), 69.54 (C-2), 69.11 (C-1’), 66.95 (C-4), 63.16 (C-6), 48.18 (C-2’), 36.72 (C-2’’), 
32.66 (CH2), 32.25 (CH2), 30.45 (CH2), 30.40 (CH2), 30.37 (CH2), 30.32 (CH2), 30.28 (CH2), 
30.25 (CH2), 30.10 (CH2), 30.07 (CH2), 30.06 (CH2), 29.94 (CH2), 28.47 (CH2), 27.87 (CH2), 
27.81 (CH2), 26.46 (CH2), 26.31 (CH2), 26.23 (C-13’’), 23.35 (CH2), 23.23 (CH2), 20.99 
(CH3), 20.83 (CH3), 20.71 (CH3), 20.68 (CH3), 20.54 (CH3), 14.38 (C-18’/C-20’’), 14.36 (C-
18’/C-20’’); HRMS (ESI-pos): calcd for C56H95O15NNa [M + Na]+ m/z 1044.6594 found 
m/z 1044.6604. 




heptadecyl] 11Z, 14Z-Eicosadienamide, [CI123, 142] 
To a solution of glycolipid 
β-156 (32 mg, 0.032 
mmol) in DCM/MeOH 
(2:4, 10 mL) under argon 
with the exclusion of light was added sodium methoxide solution (2.5M in MeOH, 30.0 
µL, 0.075 mmol) and the reaction mixture was stirred at rt for 3 hours. The reaction 
was diluted with DCM/MeOH (1:1, 20 mL) and the volatiles removed in vacuo. The 
residue was dissolved in minimal ethanol and transferred to a 14 mL centrifuge tube 
and 10 mL water was added causing a milky white suspension to form. The tube was 
spun at 5200 rpm for 25 min before the aqueous layer was decanted leaving behind a 
white solid. The solid was re-suspended in 10 mL water and spun again to further wash 
the solid, again decanting the aqueous layer. The combined aqueous layers were 
evaporated to dryness and the procedure repeated to obtain further solid. The solids 
were dissolved in ethanol, transferred to a round bottom flask, concentrated in vacuo, 
and dried to a constant weight to afford the title compound 142 (22 mg, 0.028 mmol, 
88%) as a white solid. 
 
 Data for 142: δH(500 MHz, 2:1 CDCl3:CD3OD): 5.39 – 5.23 (4H, m, H-11’’, H-12’’, 
H-14’’, H-15’’), 4.46 (1H, s, H-1), 4.17 (1H, dt, J= 7.0, 3.9 Hz, H-2’), 4.06 (1H, dd, J= 10.2, 
3.6 Hz, H-1’), 3.88 (1H, d, J= 3.1 Hz, H-2), 3.83 (1H, dd, J= 12.0, 2.5 Hz, H-6), 3.71 (2H, 
ddd, J= 17.9, 11.1, 4.6 Hz, H-1’, H-6), 3.62 – 3.49 (3H, m, H-4, H-3’, H-4’), 3.43 (1H, dd, 
J= 9.3, 3.2 Hz, H-3), 3.19 (1H, ddd, J= 9.6, 5.2, 2.5 Hz, H-5), 2.73 (2H, t, J= 6.8 Hz, H-
13’’), 2.16 (2H, t, J= 7.7 Hz, H-2’’), 2.01 (4H, q, J= 7.0 Hz, H-10’’, H-16’’), 1.63 – 1.46 (4H, 
m, CH2), 1.40 – 1.17 (48H, m, CH2), 0.85 (6H, q, J= 6.7 Hz, CH3-18’, CH3-20’’); δC(126 
MHz, 2:1 CDCl3:CD3OD): 174.68 (C=O), 130.44 (C-15’’), 130.37 (C-11’’), 128.29 (C-14’’), 
128.25 (C-12’’), 100.41 (d, 1JCH = 156.97 Hz C-1), 76.90 (C-5), 74.41 (C-4), 74.16 (C-3), 
72.36 (C-3’/C-4’), 71.13 (C-2), 68.51 (C-1’), 67.53 (C-3’/C-4’), 61.87 (C-6), 50.52 (C-2’), 
36.81 (C-2’’), 32.38 (CH2), 32.25 (CH2), 31.85 (CH2), 30.12 (CH2), 30.09 (CH2), 30.05 
(CH2), 30.03 (CH2), 30.02 (CH2), 29.98 (CH2), 29.90 (CH2), 29.87 (CH2), 29.77 (CH2), 29.73 
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(CH2), 29.68 (CH2), 29.66 (CH2), 29.65 (CH2), 27.54 (C-10’’/C-16’’), 27.50 (C-10’’/C-16’’), 
26.28 (CH2), 26.22 (CH2), 25.92 (C-13’’), 22.98 (CH2), 22.87 (CH2), 14.23 (C-18’/C-20’’), 
14.20 (C-18’/C-20’’). HRMS (ESI-pos): calcd for C44H83O9NNa [M + Na]+ m/z 792.5960 
found m/z 792.5940; Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =5.258 min. 
6.3.66. (2S,3S,4R)-2-amino-1-(β-D-mannopyranosyloxy)-3-hydroxy-
octadecan-4-yl hexacosanoate hydrochloride, [MbMC, 161] 
To a suspension of β-ManCer (1) (50.0 mg, 58 µmol) in 
freshly distilled dioxane (16 mL, from 2,4-DNP/H2SO4) was 
added conc. HCl (60 µL, 1.928 mmol) at rt under argon. The 
reaction was heated to 65 °C for 25 min (took 5 min for β-ManCer to dissolve then 
heated for an additional 20 min). The mixture was cooled to rt and the solvents were 
removed in vacuo. The residue was dried under high vacuum to give the title 
compoundXI 161 (54 mg, quant) as a white solid that was used directly in the next step. 
 
Data for 161: δH(500 MHz, 2:1 CDCl3:CD3OD): 4.85 (1H, t, J= 7.4 Hz, H-4’), 4.49 
(1H, s, H-1), 4.02 – 3.83 (5H, m, H-2, H-6, H-1’, H-1’, H-3’), 3.73 – 3.68 (1H, m, H-6), 
3.53 (1H, t, J= 9.4 Hz, H-4), 3.44 (1H, dd, J= 9.8, 2.5 Hz, H-3), 3.35 (1H, s, H-2’), 3.21 
(1H, ddd, J= 8.8, 6.6, 2.9 Hz, H-5), 2.32 (2H, t, J= 7.3 Hz, H-2’’), 1.81 – 1.70 (1H, m, CH2), 
1.64 – 1.46 (3H, m, CH2), 1.22 (68H, s, CH2), 0.84 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’); 
δC(126 MHz, 2:1 CDCl3:CD3OD): 174.16 (C=O), 99.95 (C-1), 77.10 (C-5), 73.94 (C-3), 
73.22 (C-4’), 71.11, 70.42, 67.36, 67.23 (C-4), 65.14, 61.60 (C-6), 53.31 (C-2’), 34.84 (C-
2’’), 32.23 (CH2), 31.72 (CH2), 30.01 (CH2), 29.97 (CH2), 29.87 (CH2), 29.74 (CH2), 29.66 
(CH2), 29.49 (CH2), 25.38 (CH2), 25.22 (CH2), 22.96 (CH2), 14.21 (C-18’ & C-26’’); 
Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR =5.029 min 
(99.9%). 
                                                      
XI A mixture of constitutional isomers is assumed with the title compound representing the major 
component. See Section 4.2 for more detail. 




octadecanyl] 2,3, 4,6-tetra-O-acetyl-β-D-mannopyranoside [162] and 1-
O-[(2'S,3'S,4'R)-2'-N-acetamidyl-3'-O-hexacosanoate-4’-O-acetyl-1'-
octadecanyl] 2,3, 4,6-tetra-O-acetyl-β-D-mannopyranoside [163]  
To a solution of MbMC 
161 (16 mg, 0.017 mmol) 
in pyridine (1mL) cooled in 
an ice-water bath was 
added acetic anhydride (60 µL, 0.874 mmol) and TEA (16 µL, 0.175 mmol) and the 
reaction mixture was stirred at rt overnight. The reaction was concentrated in vacuo 
and the residue taken up into DCM and washed with water. The aqueous layer was 
back extracted and the combined organic layers concentrated in vacuo to give the 
crude material (17 mg) which was purified by flash column chromatography (PE to 1:2 
PE/EtOAc) to give an inseparable mixture of the two title compounds 162 & 163 (85:15 
162:163, 16 mg, 0.017, 79%) as a white solid. 
 
Data for 162: δH(500 MHz, CDCl3): inter alia 6.27 (1H, d, J= 9.5 Hz, NH), 5.41 
(1H, dd, J= 3.4, 1.1 Hz, H-2), 5.22 (1H, t, J= 10.0 Hz, H-4), 5.02 (2H, dd, J= 9.9, 3.2 Hz, H-
2, H-3’), 4.85 (1H, dt, J= 10.3, 3.0 Hz, H-4’), 4.55 (1H, d, J= 1.2 Hz, H-1), 4.34 (1H, tt, J= 
9.3, 3.2 Hz, H-2’), 4.23 (1H, dd, J= 12.2, 5.5 Hz, H-6), 4.15 (1H, dd, J= 12.2, 2.7 Hz, H-6), 
3.94 (1H, dd, J= 9.5, 3.3 Hz, H-1’), 3.61 (1H, ddd, J= 9.9, 5.5, 2.6 Hz, H-5), 3.47 (1H, dd, 
J= 9.5, 2.9 Hz, H-1’), 2.25 (2H, t, J= 7.6 Hz, H-2’’), 2.20 (3H, s, 2-OAc), 2.08 (3H, s, 6-
OAc), 2.05 (3H, s, OAc), 2.04 (3H, s, OAc), 2.04 (3H, s NHAc), 2.01 (3H, s, OAc), 1.57 
(2H, q, J= 7.4 Hz, CH2), 1.25 (70H, s, CH2), 0.88 (6H, t, J= 6.9 Hz, CH3-18’, CH3-26’’); 
δC(126 MHz, CDCl3): 173.94 (COC25H51), 171.35 (2-OCOCH3), 170.68 (6-OCOCH3), 
170.19 (NHCOCH3), 170.13 (3/3’-OCOCH3), 169.75 (4-OCOCH3), 169.62 (3/3’-OCOCH3), 
98.29 (C-1), 73.19 (C-4’), 72.55 (C-5), 71.50 (C-3/C-3’), 70.78 (C-3/C-3’), 68.65 (C-2), 
68.11 (C-1’), 66.20 (C-4), 62.56 (C-6), 47.71 (C-2’), 34.49 (C-2’’), 32.08 (CH2), 29.88 
(CH2), 29.85 (CH2), 29.81 (CH2), 29.75 (CH2), 29.73 (CH2), 29.70 (CH2), 29.69 (CH2), 29.66 
(CH2), 29.51 (CH2), 29.47 (CH2), 29.32 (CH2), 27.87 (CH2), 25.76 (CH2), 24.95 (CH2), 23.41 
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(NHAc), 22.84 (CH2), 20.84 (OAc), 20.81 (OAc), 20.75 (OAc), 14.27 (C-18’, C-26’’); HRMS 
(ESI-pos): calcd for C62H111O15NNa [M + Na]+ m/z 1132.7846 found m/z 1132.7832. 
6.3.68. N-(((9H-fluoren-9-yl)methyl)carbonyl)-L-valinyl-L-citrulline [HO-Cit-
Val-Fmoc, 168] 
Using oven dried glassware and operating under an 
argon atmosphere a solution of Fmoc-L-valine 165 
(1.0 g, 2.98 mmol), anhydrous THF (15 mL), and TEA 
(0.8 mL, 5.74 mmol) cooled in an ice/salt/water bath 
was added via cannula over ca 20 min to a well stirred 
solution of Isopropyl chloroformate (1M in toluene, 3.7 mL, 3.70 mmol) in anhydrous 
THF (15 mL) also cooled in an ice/salt/water bath. A white precipitate formed during 
addition. After the transfer was complete the cooling bath was removed and the 
solution stirred for another 1 hr at rt until the reaction was assessed as complete by 
HPLC. Analytical HPLC [Column C, T13, AW-BA, TFA2, F0. 40, 10-100B G8H2] Fmoc-Val-
OH: tR =5.618 min, Fmoc-Val-Cl: tR =6.872 min. 
 
The reaction mixture (solution A) was cooled with an ice/salt/water bath. A solution 
of L-citrulline 166 (650 mg, 3.69 mmol) and NaHCO3 (350 mg, 4.17 mmol) in water (20 
mL) was prepared and added portion wise to the cooled solution A over a period of 10 
min to give a biphasic reaction mixture free of precipitate. After addition the cooling 
bath was removed and the reaction was left to stir for 3 hr by which time the mixture 
had become a homogeneous pale yellow solution. The reaction was monitored by 
HPLC for formation of target material (analytical HPLC [Column C, T13, AW-BA, TFA2, 
F0. 40, 10-100B G8H2] H2N-Cit-OH: tR =0.710 min, Fmoc-Val-Cit-OH: tR =4.621 min). 
The reaction mixture was concentrated in vacuo to approx. half the reaction volume 
to give a homogeneous mixture. 1M HCl (ca 10 mL) was added to give a thick white 
precipitate. The precipitate was filtered (#2 sinter) and the filter cake washed with 
water and ice cold diethyl ether to give the crude product. Purification was achieved 
by dissolving the solid in DCM/MeOH (8:2) before adding an equal volume of water. 
The amorphous precipitate was isolated by filtration, washed with water and di-ethyl 
ether before being transferred to a round bottomed flask and azeotroped from 
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toluene several times. The material was then dried to a constant weight to afford the 
title compound 168 (1.21 g, 2.441 mmol, 82%, HPLC purity: 94%) as a white solid 
 
Data for 168: δH(500 MHz, DMSO-d6): 8.16 (1H, d, J= 7.4 Hz, Cit-NH), 7.88 (2H, 
d, J= 7.5 Hz, Fmoc), 7.74 (2H, t, J= 8.2 Hz, Fmoc), 7.41 (2H, td, J= 7.5, 1.1 Hz, Fmoc), 
7.36 (1H, d, J= 9.2 Hz, Val-NH), 7.32 (2H, tdd, J= 7.5, 2.6, 1.1 Hz, Fmoc), 4.41 – 4.18 (3H, 
m, Fmoc-CH2, Fmoc-CH), 4.14 (1H, td, J= 8.0, 5.1 Hz, Cit-CH), 3.92 (1H, dd, J= 9.2, 7.0 
Hz, Val-CH), 2.94 (2H, t, J= 6.8 Hz, NHCH2CH2), 1.97 (1H, h, J= 6.8 Hz, CH(CH3)2), 1.70 
(1H, dq, J= 13.3, 5.8 Hz, Cit-CHCH2), 1.56 (1H, dtd, J= 13.8, 9.2, 5.5 Hz, Cit-CHCH2), 1.40 
(2H, ddt, J= 13.3, 10.1, 6.8 Hz, Cit-CHCH2CH2), 0.88 (3H, d, J= 6.8 Hz, CH3), 0.85 (3H, d, 
J= 6.7 Hz, CH3); δC(126 MHz, DMSO-d6): 173.44 (C=O), 171.33 (C=O), 158.81 (C=O), 
156.09 (C=O), 143.95 (ipso-C), 143.80 (ipso-C), 140.73 (ipso-C), 140.72 (ipso-C), 127.68 
(Fmoc), 127.11 (Fmoc), 125.43 (Fmoc), 120.12 , 65.71 (Fmoc-CH2), 59.86 (Val-CH), 
51.92 (Cit-CH), 46.72 (Fmoc-CH), 38.81 (NHCH2), 30.58 (CH(CH3)2), 28.40 (Cit-CHCH2), 
26.70 (Cit-CHCH2CH2), 19.20 (CH3), 18.25 (CH3); Analytical HPLC [Column C, T13, AW-
BA, TFA2, F0. 40, 10-100B G8H2] tR =4.621 min (93.764%); HRMS (ESI-pos): calcd for 
C26H33O6N4 [M + H]+ m/z 497.2395 found m/z 497.2398; calcd for C26H32O6N4Na [M + 
Na]+ m/z 519.2214 found m/z 519.2219. 
6.3.69. N-(((9H-fluoren-9-yl)methyl)carbonyl)-L-valinyl-L-citrullinyl-(4- 
aminobenzenol [PAB-Cit-Val-Fmoc, 169] 
To the suspension of HO-Cit-Val-Fmoc 168 
(1.21 g, 2.441 mmol) in DCM/MeOH (1:1, 
10 mL) was added para-aminobenzyl 
alcohol (730 mg, 5.93 mmol) followed by 
EEDQ (1.41 g, 5.70 mmol). The mixture was 
stirred at 40°C overnight during which time a fine precipitate formed. The reaction 
was cooled to rt and methyl-tert-butyl ether (MTBE) was added, the resulting solution 
was stirred for 30 min. The thick precipitate was filtered to give the crude material 
which was transferred to a round bottom flask and stirred in a 5:2 mixture of 
EtOAc/MTBE for 30 min. The suspension was filtered and the wet filter cake washed 
with excess 5:2 EtOAc/MTBE. The product was transferred and dried to a constant 
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weight to afford the title compound 169 (725 mg, 1.206 mmol, 50%) as a pale brown 
solid. 
 
Data for 169: δH(500 MHz, DMSO-d6): 9.98 (1H, s, PAB-NH), 8.10 (1H, d, J= 7.7 
Hz, Cit-NH), 7.89 (2H, d, J= 7.6 Hz, Fmoc), 7.74 (2H, dd, J= 10.7, 7.5 Hz, Fmoc), 7.55 (2H, 
d, J= 8.2 Hz, PAB), 7.47 – 7.38 (3H, m, Fmoc, Val-NH), 7.32 (2H, t, J= 7.4 Hz, Fmoc), 7.23 
(2H, d, J= 8.3 Hz, PAB), 4.43 (3H, s, PAB-CH2, Cit-CH), 4.36 – 4.27 (1H, m, Fmoc-CH2), 
4.28 – 4.17 (2H, m, Fmoc-CH2, Fmoc-CH), 3.93 (1H, dd, J= 9.0, 6.9 Hz, Val-CH), 3.06 – 
2.89 (2H, m, NHCH2CH2), 2.09 – 1.92 (1H, m, CH(CH3)2), 1.70 (1H, dq, J= 15.3, 5.9 Hz, 
Cit-CHCH2), 1.60 (1H, dtd, J= 13.5, 9.1, 4.7 Hz, Cit-CHCH2), 1.45 (1H, dq, J= 9.7, 5.6, 5.1 
Hz, Cit-CHCH2CH2), 1.37 (1H, dq, J= 9.7, 6.4 Hz, Cit-CHCH2CH2), 0.88 (3H, d, J= 6.8 Hz, 
CH3), 0.86 (3H, d, J= 6.8 Hz, CH3); δC(126 MHz, DMSO-d6): 171.21 (C=O), 170.36 (C=O), 
158.85 (C=O), 156.10 (C=O), 143.89 (ipso-C), 143.76 (ipso-C), 140.70 (ipso-C), 140.68 
(ipso-C), 137.50 (ipso-C), 137.43 (ipso-C), 127.62 (Fmoc), 127.06 (Fmoc), 126.91 (PAB), 
125.35 (Fmoc), 120.09 (Fmoc), 118.85 (PAB), 65.67 (Fmoc-CH2), 62.58 (PAB-CH2), 
60.09 (Val-CH), 53.05 (Cit-CH), 46.68 (Fmoc-CH), 38.60 (NHCH2CH2), 30.44 (CH(CH3)2), 
29.53 (Cit-CHCH2), 26.77 (Cit-CHCH2CH2), 19.22 (CH3), 18.26 (CH3); Analytical HPLC 
[Column C, T13, AW-BA, TFA2, F0. 40, 10-100B G8H2] tR =4.823 min; HRMS (ESI-pos): 
calcd for C33H40O6N5 [M + H]+ m/z 602.2973 found m/z 602.2951; calcd for 
C33H39O6N5Na [M + Na]+ m/z 624.2793 found m/z 624.2764. 
6.3.70. N-(((9H-fluoren-9-yl)methyl)carbonyl)-L-valinyl-L-citrullinyl-(4-
aminobenzyl) 4-nitrophenyl carbonate [pNP-PAB-Cit-Val-Fmoc, 164] 
To a stirred solution of PAB-Cit-Val-
Fmoc 169 (515 mg, 0.855 mmol) in 
anhydrous DMF (6 mL) under Ar was 
added bis(4-nitrophenyl)carbonate 
(420 mg, 1.381 mmol) then DIPEA (200 
µL, 1.158 mmol). The reaction was 
stirred at rt overnight after which time it was monitored by HPLC for the loss of the 
starting material (analytical HPLC [Column C, T13, AW-BA, TFA2, F0. 40, 10-100B 
G8H2] tR =4.823 min). The crude reaction was added dropwise to a well-stirred 
Chapter VI: Experimental 
 
238 
solution of water. After stirring for 30 min to allow coagulation, the resulting 
suspension was filtered and washed with excess Et2O. The solid was dried to a 
constant weight to give the crude material (501 mg) which was purified by column 
chromatography (dry loaded from MeCN/CHCl3; run 100% CHCl3 to 15% MeOH/CHCl3) 
to afford the title compound 164 (227 mg, 0.296 mmol, 35%) as a pale yellow/tan 
colored solid. 
 
Data for 164: δH(500 MHz, 2:1 CDCl3:CD3OD): 9.63 (1H, s, PAB-NH), 8.32 – 8.18 
(2H, m, pNP), 7.90 (1H, d, J= 7.8 Hz, Cit-NH), 7.73 (2H, dd, J= 7.5, 2.4 Hz, Fmoc), 7.62 – 
7.51 (4H, m, Fmoc, PAB), 7.35 (6H, dt, J= 7.0, 2.6 Hz, pNP, Fmoc), 7.27 (2H, td, J= 7.5, 
1.2 Hz, PAB), 6.51 (1H, d, J= 8.3 Hz, Val-NH), 5.21 (2H, s, PAB-CH2), 4.52 (1H, q, J= 8.0, 
7.5 Hz, Cit-CH), 4.42 (1H, dd, J= 10.5, 7.0 Hz, Fmoc-CH2), 4.34 – 4.26 (1H, m, Fmoc-CH2), 
4.18 (1H, t, J= 6.7 Hz, Fmoc-CH), 3.96 (1H, t, J= 7.4 Hz, Val-CH), 3.19 (1H, dt, J= 13.6, 
6.7 Hz, NHCH2CH2), 3.06 (1H, dt, J= 13.4, 6.4 Hz, NHCH2CH2), 2.05 (1H, hept, J= 6.3, 5.8 
Hz, CH(CH3)2), 1.88 (1H, dt, J= 13.9, 7.3 Hz, Cit-CHCH2), 1.68 (1H, dq, J= 14.2, 7.9 Hz, 
Cit-CHCH2), 1.59 – 1.43 (2H, m, Cit-CHCH2CH2), 0.93 (3H, d, J= 7.0 Hz, CH3), 0.91 (3H, d, 
J= 6.8 Hz, CH3); δC(126 MHz, 2:1 CDCl3:CD3OD): 173.18 (C=O), 171.04 (C=O), 157.59 
(C=O), 155.97 (C=O), 152.90 (C=O), 145.74 (ipso-C), 144.15 (ipso-C), 144.03 (ipso-C), 
141.63 (ipso-C), 139.11 (ipso-C), 129.91 (Ph), 128.07 (Ph), 127.42 (Ph), 125.60 (Ph), 
125.34 (Ph), 125.29 (Ph), 122.23 (Ph), 120.48 (Ph), 120.26 (Ph), 71.02 (PAB-CH2), 67.34 
(Fmoc-CH2), 61.26 (Val-CH), 53.74 (Cit-CH), 47.49 (Fmoc-CH), 39.31 (NHCH2CH2), 31.25 
(CH(CH3)2), 29.55 (Cit-CHCH2), 26.71 (Cit-CHCH2CH2), 19.40 (CH3), 18.17 (CH3); 
Analytical HPLC [Column C, T13, AW-BA, TFA2, F0. 40, 10-100B G8H2] tR =4.6.507 min; 
Analytical HPLC [Column C, T16, AW-BM, TFA2, F0. 60, 60-100B G4H9] tR =2.763 min; 
HRMS (ESI-pos): calcd for C40H43O10N6 [M + H]+ m/z 767.3035 found m/z 767.3047; 
calcd for C40H42O10N6Na [M + Na]+ m/z 789.2855 found m/z 789.2862. 
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6.3.71. (1R,8S,9S)-Bicyclo[6.1.0]non-4-ene-9-carboxylic acid, ethyl ester, 
endo-[172] and (1R,8S,9R)-Bicyclo[6.1.0]non-4-ene-9-carboxylic acid, 
ethyl ester, exo-[172]349-350 
Ethyl 2-diazoacetate (15% in toluene, 4.5 mL, 5.29 mmol) was 
added dropwise over a period of 3 hrs to a stirred solution of 
(1Z, 5Z)-cycloocta-1,5-diene 171 (5 mL, 40.8 mmol) and 
rhodium(II) acetate dimer (4 mol%, 96 mg, 0.202 mmol) in 
anhydrous DCM (10 mL) at rt. The reaction exothermed and was 
kept bellow 28 °C by intermittent use of an ice bath. After 
addition was complete the resulting solution was stirred at rt for 48 hrs. The solvents 
and remaining cyclooctadiene were removed by vacuum distillation (0.1 mbar, 60 °C) 
to give the residue which was pre-adsorbed onto silica gel and purified by column 
chromatography (PE to 90/10 PE/Et2O). The title compound 172 was obtained as its 
discrete isomers, endo-172 (152 mg, 0.782 mmol 18%) and exo-172 (358 mg, 1.840 
mmol, 35%) both as colourless oils. 
 
Data for endo-172: δH(500 MHz, CDCl3): 5.61 (2H, t, J= 4.5 Hz, H-4, H-5), 4.11 
(2H, q, J= 7.1 Hz, OCH2CH3), 2.50 (2H, ddt, J= 16.0, 8.5, 4.2 Hz, H-3, H-6), 2.20 (2H, dtd, 
J= 13.7, 8.4, 4.8 Hz, H-2, H-7), 2.05 (2H, ddt, J= 15.4, 8.4, 5.2 Hz, H-3, H-6), 1.82 (2H, 
dtd, J= 14.1, 6.9, 4.8 Hz, H-2, H-7), 1.70 (1H, t, J= 8.8 Hz, H-9), 1.39 (2H, tt, J= 8.6, 2.9 
Hz, H-1, H-8), 1.26 (3H, t, J= 7.1 Hz, OCH2CH3); δC(126 MHz, CDCl3): 172.44 (C=O), 
129.60 (C-4, C-5), 59.86 (OCH2CH3), 27.23 (C-3, C-6), 24.33 (C-1, C-8), 22.81 (C-2, C-7), 
21.40 (C-9), 14.56 (OCH2CH3); HRMS (ESI-pos): calcd for C12H18O2Na [M + Na]+ m/z 
217.1199 found m/z 217.1189. 
 
Data for exo-172: δH(500 MHz, CDCl3): 5.63 (2H, t, J= 4.4 Hz, H-4, H-5), 4.09 (2H, 
q, J= 7.1 Hz, OCH2CH3), 2.29 (2H, ddt, J= 15.9, 8.3, 4.2 Hz, H-3, H-6), 2.19 (2H, ddt, J= 
17.5, 7.7, 4.3 Hz, H-2, H-7), 2.08 (2H, ddt, J= 14.6, 9.2, 4.8 Hz, H-3, H-6), 1.56 (2H, h, J= 
3.6 Hz, H-1, H-8), 1.47 (2H, dtd, J= 13.3, 8.6, 3.9 Hz, H-2, H-7), 1.24 (3H, t, J= 7.1 Hz, 
OCH2CH3), 1.17 (1H, t, J= 4.6 Hz, H-9); δC(126 MHz, CDCl3): 174.53 (C=O), 130.04 (C-4, 
C-5), 60.36 (OCH2CH3), 28.40 (C-2, C-7), 28.01 (C-9), 27.85 (C-1, C-8), 26.78 (C-3, C-6), 
Chapter VI: Experimental 
 
240 
14.43 (OCH2CH3); HRMS (ESI-pos): calcd for C12H18O2Na [M + Na]+ m/z 217.1199 found 
m/z 217.1184 
6.3.72.  (1R,8S,9R)-Bicyclo[6.1.0]non-4-ene-9-yl methanol, exo-[173]349-350 
To a suspension of lithium aluminium hydride (745 mg, 18.65 mmol) in 
anhydrous Et2O (10 mL) was added dropwise at 0°C a solution of ester exo-
172 (2.68 g, 13.80 mmol) in anhydrous Et2O (5 mL). This suspension was 
warmed to rt and stirred at reflux overnight. The reaction was quenched 
with the careful addition of water until the grey solid had turned white. 
Following dilution with Et2O the mixture was separated and washed with brine. The 
aqueous layer was back extracted with CHCl3 and the combined organic layers were 
dried, filtered and concentrated in vacuo to afford the title compound exo-173 (2.05 
g, 13.43 mmol) as a colourless oil that was used directly in the next step. 
 
Data for exo-173: δH(500 MHz, CDCl3): 5.67 – 5.59 (2H, ddd, J= 5.5, 4.1, 1.4 Hz, 
H-4, H-5), 3.47 (2H, d, J= 7.0 Hz, H-10), 2.29 (2H, ddt, J= 15.1, 7.7, 3.4 Hz, H-3, H-6), 
2.22 – 2.11 (2H, m, H-2, H-7), 2.10 – 2.02 (2H, m, H-3, H-6), 1.41 (2H, tdt, J= 9.6, 8.4, 
4.1 Hz, H-2, H-7), 1.30 (1H, t, J= 5.3 Hz, OH), 0.78 (2H, dddd, J= 7.4, 5.1, 3.6, 2.6 Hz, H-
1, H-8), 0.66 (1H, tt, J= 7.0, 4.9 Hz, H-9); δC(126 MHz, CDCl3): 130.31 (C-4, C-5), 67.45 
(C-10), 29.17 (C-2, C-7), 29.05 (C-9), 27.23 (C-3, C-6), 22.26 (C-1, C-8).  
6.3.73. (1R,8S,9R)-4,5-dibromo-Bicyclo[6.1.0]nonane-9-yl methanol, exo-
[174]349-350 
Cyclooctene exo-173 (150 mg, 0.985 mmol) was dried under high vacuum 
for 60 min prior to being dissolved in anhydrous DCM (1mL). At 0 °C a 
solution of elemental bromine (60 µL, 1.165 mmol) in anhydrous DCM (200 
μL) was added dropwise until the yellow/orange colour persisted. The 
reaction was warmed to rt and the mixture was quenched with addition of 
10% Na2S2O3 solution and extracted into DCM. The organic layer was dried, filtered 
and concentrated in vacuo into a flame dried flask to afford the crude dibromide 
intermediate exo-174 (285 mg, 0.913 mmol) as a colourless oil that was used directly 
in the next step. 




Data for exo-174: δH(400 MHz, CDCl3): 4.81 (2H, ddtd, J= 12.7, 7.7, 5.1, 2.4 Hz, 
H-4, H-5), 3.51 (2H, dd, J= 7.0, 1.0 Hz, H-10), 2.75 – 2.62 (1H, m, H-3/H-6), 2.61 (1H, 
dtt, J= 16.4, 5.2, 2.7 Hz, H-3/H-6), 2.25 (1H, dddd, J= 16.3, 12.6, 5.6, 2.2 Hz, H-3/H-6), 
2.13 – 2.01 (3H, m, H-3/H-6, H-2/H-7), 1.70 (1H, b, OH), 1.53 – 1.31 (2H, m, H-2/H-7), 
0.99 – 0.79 (2H, m, H-1, H-8), 0.67 (1H, tt, J= 7.0, 4.5 Hz, H-9); δC(101 MHz, CDCl3): 
66.74 (C-10), 56.33 (C-4/C-5), 53.37 (C-4/C-5), 35.08 (C-3/C-6), 34.95 (C-3/C-6), 28.30 
(C-9), 24.53 (C-2/C-7), 23.78 (C-2/C-7), 22.63 (C-1/C-8), 19.92 (C-1/C-8). 
6.3.74. (1R,8S,9R)-Bicyclo[6.1.0]non-4-yne methanol, exo-[BCN-OH, 175]349-
350 
Dibromide 174 was dried under high vacuum for 60 min then dissolved in 
anhydrous THF (5 mL, pre-dried over 4Ȧ MS for 24 hrs). Potassium tert-
butoxide solution (1M in THF, 2.2 mL, 2.167 mmol) was added dropwise at 
0°C under an argon atmosphere. Then the solution was refluxed for 2 hrs 
(90°C) under a constant stream of argon. After cooling to rt the mixture was 
quenched with saturated to NH4Cl solution and extracted with DCM. The organic layer 
was dried and concentrated in vacuo to give the residue that was purified immediately 
by column chromatography (PE to 3:1 PE/EtOAc) to afford the title compound exo-175 
(34 mg, 0.228 mmol, 26%) as colourless crystals. 
 
Data for exo-175: δH(400 MHz, CDCl3): 3.54 (2H, dd, J= 6.3, 1.1 Hz, H-10), 2.40 
(2H, dt, J= 13.9, 2.9 Hz, H-3, H-6), 2.33 – 2.22 (2H, m, H-2, H-7), 2.20 – 2.10 (2H, m, H-
2, H-7), 1.53 (1H, b, OH), 1.45 – 1.29 (2H, m, H-3, H-6), 0.74 – 0.61 (3H, m, H-1, H-8, H-
9); δC(101 MHz, CDCl3): 98.94 (C-4, C-5), 67.30 (C-10), 33.56 (C-3, C-6), 27.44 (C-9), 
22.72 (C-1, C-8), 21.61 (C-2, C-7). 
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6.3.75. ((1R,8S,9R)-Bicyclo[6.1.0]non-4-yn-9-yl)methyl 4-nitrophenyl 
carbonate, exo-[BCN-pNP, 170]349-350 
Cyclooctyne exo-175 (63 mg, 0.416 mmol) was dissolved in 
anhydrous  DCM (1.5 mL) under Ar and bis(4-nitrophenyl) 
carbonate (149 mg, 0.486 mmol) was added in one portion. 
DIPEA (85 µL, 0.483 mmol) was added over 1-2 min, a bright 
yellow colour formed immediately. The solution was warmed to 30°C to dissolve all 
material then the reaction was stirred at 20°C in a sand bath overnight. The reaction 
was diluted with DCM and concentrated in vacuo to afford the residue which was 
purified by column chromatography (PE to 3:1 PE/EtOAc) to afford the title compound 
exo-170 (71 mg, 0.225 mmol, 54%) as a colourless oil. 
 
Data for exo-170: δH(500 MHz, CDCl3): 8.33 – 8.19 (2H, m, Ph), 7.45 – 7.30 (2H, 
m, Ph), 4.22 (2H, d, J= 6.8 Hz, H-10), 2.45 (2H, dq, J= 13.5, 2.9 Hz, H-3, H-6), 2.37 – 2.25 
(2H, m, H-2, H-7), 2.19 (2H, ddd, J= 14.0, 4.3, 2.0 Hz, H-2, H-7), 1.42 (2H, dddd, J= 14.5, 
11.7, 8.5, 3.5 Hz, H-3, H-6), 0.91 – 0.74 (3H, m, H-1, H-8, H-9); δC(126 MHz, CDCl3): 
155.74 (ipso-C), 152.74 (ipso-C), 145.50 (C=O), 125.44 (Ph), 121.92 (Ph), 98.80 (C-4, C-
5), 74.11 (C-10), 33.27 (C-3, C-6), 23.41 (C-1, C-8), 23.12 (C-9), 21.43 (C-2, C-7). 
6.3.76. (2S,3S,4R)-2-(N-(((9H-fluoren-9-yl)methoxy)carbonyl)-L-valinyl-L-
citrullinyl-4-aminobenzyloxycarbonylamino)-1-(-D-
mannopyranosyloxy)-3-hydroxy-octadecan-4-yl hexacosanoate, CI124 
[MbMC-PAB-Cit-Val-Fmoc, 176] 
A mixture of crude 
MbMC 161 (52 mg, 58 
µmol) and pNP-PAB-Cit-
Val-Fmoc 164 (65 mg, 85 
µmol) were placed under 
high vacuum for 1 hr then 
backfilled with Ar. Dry pyridine (freshly distilled from CaH2, 4 mL) was added (most of 
the material dissolved after 5 min of stirring) followed by anhydrous TEA (15 µL, 108 
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µmol) and the reaction was stirred at rt overnight. The reaction was monitored by 
HPLC for the loss of MbMC 161 starting material (analytical HPLC [Column C, T16, AW-
BM, TFA2, F0.60, 60-100B G4H9] tR =5.029 min). After completion it was concentrated 
under high vacuum to give a yellow gum which was resolved in CHCl3/MeOH 
(sonication required) and concentrated in vacuo to give a yellow solid. The residue was 
dissolved in CHCl3/MeOH and concentrated onto octadecylsilyl-functionalized silica 
gel (200-400 mesh, 20-22% loading) for purification by C18 reverse phase 
chromatography (Isolute C-18(EC) cartridge with a gradient of H2O:MeOH 40:60 to 
0:100 then CHCl3:MeOH 0:100 to 60:40, eluting around 40:60 CHCl3:MeOH). The 
fractions containing the target molecule were concentrated in vacuo and dried to a 
constant weight to afford the title compound 176 (50 mg, 34 µmol, 58% over two 
steps) as an off white solid. 
 
Data for 176: δH(500 MHz, 2:1 CDCl3:CD3OD): 9.56 (1H, s, , PAB-NH), 7.90 (1H, 
d, J= 7.7 Hz, Cit-NH), 7.73 (2H, d, J= 7.5 Hz, Fmoc), 7.58 (2H, d, J= 7.5 Hz, PAB), 7.52 
(2H, d, J= 8.2 Hz, Fmoc), 7.38 – 7.32 (2H, m, Fmoc), 7.27 (4H, ddd, J= 7.5, 5.7, 1.6 Hz, 
PAB, Fmoc), 6.51 (1H, d, J= 8.2 Hz, Val-NH), 5.06 (1H, t, J= 12.9 Hz, PAB-CH2), 5.00 – 
4.89 (2H, m, PAB-CH2, H-4’), 4.51 (1H, q, J= 7.6, 7.2 Hz, Cit-CH), 4.43 (1H, dd, J= 10.9, 
6.6 Hz, Fmoc-CH2), 4.38 (1H, s, H-1), 4.30 (1H, dd, J= 10.9, 6.6 Hz, Fmoc-CH2), 4.19 (1H, 
t, J= 6.9 Hz, Fmoc-CH), 4.11 – 4.04 (1H, m, H-1’), 3.99 – 3.92 (1H, m, Val-CH), 3.89 – 
3.78 (2H, m, H-6, H-2), 3.78 – 3.71 (2H, m, H-3’, H-2’), 3.68 (1H, dd, J= 12.0, 5.5 Hz, H-
6), 3.65 – 3.59 (1H, m, H-1’), 3.55 (1H, t, J= 9.6 Hz, H-4), 3.41 (1H, ddd, J= 14.6, 9.3, 3.3 
Hz, H-3), 3.17 (2H, dddd, J= 12.5, 8.2, 6.1, 3.2 Hz, H-5, NHCH2CH2), 3.06 (1H, dt, J= 13.3, 
6.4 Hz, NHCH2CH2), 2.38 – 2.21 (2H, m, H-2’’), 2.05 (1H, h, J= 6.7 Hz, CH(CH3)2), 1.86 
(1H, dt, J= 13.8, 6.9 Hz, Cit-CHCH2), 1.72 – 1.43 (7H, m, Cit-CHCH2, Cit-CHCH2CH2, 2x 
CH2), 1.22 (70H, s, CH2), 0.91 (6H, dd, J= 9.1, 6.7 Hz, CH(CH3)2), 0.84 (6H, t, J= 6.7 Hz, 
CH3-18’, CH3-26’’); δC(126 MHz, 2:1 CDCl3:CD3OD): 174.91 (COC25H51), 173.12 (C=O), 
170.92 (C=O), 160.98 (C=O), 157.51 (C=O), 156.93 (C=O), 144.16 (ipso-C), 144.03 (ipso-
C), 141.63 (ipso-C), 138.17 (ipso-C), 132.80 (ipso-C), 129.92 (ipso-C), 129.08 (Ph), 
128.07 (Ph), 127.42 (Ph), 125.35 (Ph), 125.30 (Ph), 120.37 (Ph), 120.26 (Ph), 100.02 (C-
1), 76.77 (C-5), 75.00 (C-4’), 74.03 (C-3), 71.69 (C-3’), 70.95 (C-2), 68.16 (C-1’), 67.51 
(C-4), 67.33 (Fmoc-CH2), 66.77 (PAB-CH2), 61.93 (C-6), 61.07 (Val-CH), 53.63 (Cit-CH), 
Chapter VI: Experimental 
 
244 
52.12 (C-2’), 47.49 (Fmoc-CH), 39.35 (NHCH2CH2), 34.94 (C-2’’), 32.24 (CH2), 31.28 
(CH(CH3)2), 30.02 (CH2), 29.99 (CH2), 29.89 (CH2), 29.86 (CH2), 29.76 (CH2), 29.68 (CH2), 
29.66 (Cit-CHCH2), 29.52 (CH2), 28.86 (CH2), 26.66 (CH2), 25.67 (CH2), 25.40 (CH2), 
22.97 (CH2), 19.40 (CH(CH3)2), 18.15 (CH(CH3)2), 14.23 (C-18’, C-26’’ Analytical HPLC 
[Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR =7.721 min (92.1%); Analytical 
LCMS [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9, 22-200Pos] tR =7.522 min 
(m/z 1509.35); HRMS (ESI-pos): calcd for C84H136O16N6Na [M + Na]+ m/z 1507.9905 
found m/z 1507.9894. 
6.3.77. (2S,3S,4R)-2-(N-(amino)-L-valinyl-L-citrullinyl-4- 
aminobenzyloxycarbonylamino)-1-(-D-mannopyranosyloxy)-3-
hydroxy-octadecan-4-yl hexacosanoate, CI125 [MbMC-PAB-Cit-Val-
NH2, 177] 
To a solution of MbMC-PAB-Cit-Val-
Fmoc 176 (22 mg, 15 µmol) in 
anhydrous DMF (1 mL) at 0°C under Ar 
was added piperidine (90 µL, 718 
µmol). The reaction turned yellow 
immediately. After 5 min the reaction was warmed to rt and stirred for an additional 
30 min. The reaction mixture was concentrated under high vacuum to give a yellow 
gum. The residue was resolved in CHCl3/MeOH and concentrated in vacuo to give a 
pale yellow solid. The crude residue was dissolved in CHCl3/MeOH and concentrated 
onto octadecylsilyl-functionalized silica gel (200-400 mesh, 20-22% loading) for 
purification by C18 reverse phase chromatography (Isolute C-18(EC) cartridge) with a 
gradient of H2O:MeOH 40:60 to 0:100 then CHCl3:MeOH 0:100 to 60:40, eluting 
around 100% MeOH). The fractions containing the target molecule were concentrated 
in vacuo and dried to a constant weight to afford the title compound 177 (13 mg, 10.52 
μmol, 70%) as an off white solid. 
 
Data for 177: δH(500 MHz, 2:1 CDCl3:CD3OD): 7.50 (2H, d, J= 8.2 Hz, PAB-NH), 
7.26 (2H, d, J= 8.1 Hz, PAB-CH2), 5.09 (1H, d, J= 12.3 Hz, PAB-CH2), 4.96 – 4.87 (2H, m, 
H-4’, PAB-CH2), 4.53 (1H, dd, J= 9.4, 4.6 Hz, Cit-CH), 4.36 (1H, s, H-1), 4.07 – 4.02 (1H, 
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m, H-1’), 3.84 – 3.76 (2H, m, H-2, H-6), 3.76 – 3.59 (5H, m, H-6, H-1’, H-2’, H-3’, Val-
CH), 3.54 (1H, t, J= 9.5 Hz, H-4), 3.38 (1H, dd, J= 9.4, 3.3 Hz, H-3), 3.12 (3H, ddd, J= 18.4, 
8.9, 4.4 Hz, H-5, NHCH2CH2), 2.28 (2H, dp, J= 14.9, 7.4 Hz, H-2’’), 2.13 (1H, h, J= 6.8 Hz, 
CH(CH3)2), 1.85 (1H, dq, J= 13.1, 7.2 Hz, Cit-CHCH2), 1.73 (1H, dq, J= 14.4, 7.4 Hz, Cit-
CHCH2), 1.68 – 1.50 (6H, m, Cit-CHCH2CH2, 2x CH2), 1.21 (68H, s, CH2), 1.00 (6H, dd, J= 
6.9, 3.0 Hz, CH(CH3)2), 0.83 (6H, t, J= 6.9 Hz, CH3-18’, CH3-26’’); δC(126 MHz, 2:1 
CDCl3:CD3OD): 174.89 (COC25H51), 170.74 (C=O), 168.66 (C=O), 161.12 (C=O), 156.93 
(C=O), 138.22 (ipso-C), 132.82 (ipso-C), 129.09 (Ph), 120.30 (Ph), 100.03 (C-1), 76.75 
(C-5), 74.96 (C-4’), 73.99 (C-3), 71.77 (C-3’), 70.94 (C-2), 68.16 (C-1’), 67.43 (C-4), 66.74 
(PAB-CH2), 61.82 (C-6), 58.85 (Val-CH), 53.87 (Cit-CH), 52.09 (C-2’), 39.09 (NHCH2CH2), 
34.93 (C-2’’), 32.22 (CH2), 30.57 (CH(CH3)2), 30.01 (CH2), 29.99 (CH2), 29.97 (CH2), 29.94 
(CH2), 29.91 (CH2), 29.90 (CH2), 29.87 (CH2), 29.85 (CH2), 29.75 (CH2), 29.66 (CH2), 29.64 
(CH2), 29.63 (CH2), 29.51 (CH2), 29.41 (CH2), 28.91 (Cit-CHCH2), 26.45 (Cit-CHCH2CH2), 
25.65 (CH2), 25.39 (CH2), 22.96 (CH2), 18.47 (CH(CH3)2), 17.72 (CH(CH3)2), 14.22 (C-18’, 
C-26’’); Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR =4.973 
min (96.981%); Analytical LCMS [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9, 
22-200Pos] tR =4.669 min (1286.20 m/z); HRMS (ESI-pos): calcd for C69H127O14N6 [M + 
H]+ m/z 1263.9405 found m/z 1263.9383; calcd for C69H126O14N6Na [M + Na]+ m/z 
1285.9224 found m/z 1285.9226. 
6.3.78.  (2S,3S,4R)-2-(N-((Bicyclo[6.1.0]non-4-yn-9-yl)methoxycarbonyl)-L-
valinyl-L-citrullinyl-4- aminobenzyloxycarbonylamino)-1-(-D-
mannopyranosyloxy)-3-hydroxy-octadecan-4-yl hexacosanoate, CI206 
[MbMC-PAB-Cit-Val-BCN, 178] 
MbMC-PAB-CV-NH2 177 (32 
mg, 25 µmol) and BCN-pNP 
170 (13 mg, 40 µmol) were 
placed under high vacuum 
(10 min) then under Ar. 
Anhydrous DMF (1 mL) was 
added and the resulting solution was sonicated to dissolve the starting materials, then 
anhydrous TEA (16 µL, 115 µmol) was added. The reaction was stirred at rt overnight 
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under Ar. Following completion, the reaction was diluted with DCM and concentrated 
in vacuo to give the residue. The residue was dissolved in CHCl3/MeOH and 
concentrated onto octadecylsilyl-functionalized silica gel (200-400 mesh, 20-22% 
loading) for purification by C18 reverse phase chromatography (Isolute C-18(EC) 
cartridge) with a gradient of H2O:MeOH 20:80 to 0:100 then CHCl3:MeOH 0:100 to 
80:20, eluting around  CHCl3:MeOH 20:80). The fractions containing the target 
molecule were concentrated in vacuo and dried to a constant weight to afford the title 
compound 178 (26 mg, 18 µmol, 71%) as a white solid 
 
Data for 178: δH(500 MHz, 2:1 CDCl3:CD3OD): 9.54 (1H, s, NH), 7.84 (1H, d, J= 
7.9 Hz, NH), 7.51 (2H, d, J= 8.1 Hz, PAB-NH), 7.27 (2H, d, J= 8.1 Hz, PAB-CH2), 6.46 (1H, 
d, J= 7.6 Hz, NH), 6.20 (1H, d, J= 8.5 Hz, NH), 5.07 (1H, d, J= 12.3 Hz, PAB-CH2), 4.97 – 
4.89 (2H, m, H-4’, PAB-CH2), 4.50 (1H, q, J= 6.8 Hz, Cit-CH), 4.37 (1H, s, H-1), 4.06 (1H, 
d, J= 10.1 Hz, H-1’), 3.95 (2H, t, J= 7.3 Hz, Val-CH, H-10’’’), 3.90 (1H, dd, J= 10.9, 7.0 Hz, 
H-10’’’), 3.84 – 3.78 (2H, m, H-2, H-6), 3.76 – 3.72 (2H, m, H-2’, H-3’), 3.67 (1H, dd, J= 
12.1, 5.5 Hz, H-6), 3.64 – 3.57 (1H, m, H-1’), 3.53 (1H, t, J= 9.5 Hz, H-4), 3.38 (1H, dd, 
J= 9.5, 3.3 Hz, H-3), 3.16 (2H, dq, J= 12.5, 7.5 Hz, H-4, NHCH2CH2), 3.06 (1H, dt, J= 13.3, 
6.4 Hz, NHCH2CH2), 2.28 (6H, ddt, J= 29.1, 21.8, 14.0 Hz, H-2’’, H-2’’’, H-3’’’, H-6’’’, H-
7’’’), 2.13 – 1.91 (3H, m, H-2’’’, H-7’’’, CH(CH3)2), 1.92 – 1.78 (1H, m, Cit-CHCH2), 1.71 – 
1.42 (7H, m, Cit-CHCH2, CitCHCH2CH2, 2x CH2), 1.21 (72H, s, H-3’’’, H-6’’’, CH2), 0.91 
(6H, dd, J= 20.9, 6.7 Hz, CH(CH3)2), 0.83 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’), 0.73 – 0.59 
(3H, m, H-1’’’, H-8’’’, H-9’’’); δC(126 MHz, 2:1 CDCl3:CD3OD): 174.90 (COC25H51), 170.88 
(C=O), 160.98 (C=O), 157.90 (C=O), 156.93 (C=O), 138.18 (ipso-C), 132.81 (ipso-C), 
129.08 (Ph), 120.35 (Ph), 100.01 (C-1), 99.08 (C-4’’’, C-5’’’), 76.77 (C-5), 74.99 (C-4’), 
74.03 (C-3), 71.72 (C-3’), 70.93 (C-2), 69.97 (C-10’’’), 68.16 (C-1’), 67.54 (C-4), 66.77 
(PAB-CH2), 61.95 (C-6), 60.88 (C-2’), 53.60 (Cit-CH), 52.11 (Val-CH), 39.35 (NHCH2CH2), 
34.94 (C-2’’), 33.52 (C-3’’’, C-6’’’), 32.23 (CH(CH3)2), 31.31 (CH2), 30.02 (CH2), 30.00 
(CH2), 29.98 (CH2), 29.95 (CH2), 29.92 (CH2), 29.88 (CH2), 29.85 (CH2), 29.75 (CH2), 29.68 
(CH2), 29.65 (CH2), 29.64 (CH2), 29.52 (CH2), 28.89 (CH2), 26.67 (CH2), 25.66 (CH2), 25.40 
(CH2), 23.93 (C-9’’’), 23.32 (C-1’’’, C-8’’’), 22.97 (CH2), 21.52 (C-2’’’, C-7’’’), 19.42 
(CH(CH3)2), 17.99 (CH(CH3)2), 14.22 (C-18’, C-26’’); Analytical HPLC [Column C, T16, 
AW-BM, TFA2, F0.60, 60-100B G4H9] tR =6.728 min (91.782%); Analytical LCMS 
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[Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9, 22-200Pos] tR =7.213 min 
(1463.45 m/z); HRMS (ESI-pos): calcd for C80H138O16N6Na [M + Na]+ m/z 1462.0062 
found m/z 1462.0033. 
6.3.79. Glycopeptide vaccine construct-ISA Peptide HPV16 E7, [MbMC-PAB-
Cit-Val-BCN-FFRK-GQAEPDRAHYNIVTFCCKCDS, CI207] 
Solid MbMC-PAB-CV-BCN 178 (3.60 mg, 2.50 µmol) and Pep545 (179) (10.15 mg, 3.31 
µmol) were placed under vacuum and then backfilled with Ar before freshly 
deoxygenated DMSO (300 µL, c=18 mg mL-1) was added. The resulting solution was 
stirred at rt overnight. A 5 µL subsample was removed and diluted with 500 µL of 
deoxygenated DMSO for analysis by HPLC which showed complete loss of BCN starting 
material 178 (analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR 
=6.728 min). Tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP, 300 uL of a 
28 mg mL-1 solution in MeOH) was added to the reaction and the solution was allowed 
to stir for an additional 30 min. The reaction was filtered (syringe filter, simplepure 
PTFE 0.22 µm) and the filter washed with an additional 400 µL of deoxygenated DMSO 
to give the crude product in 1 mL of DMSO. The crude solution was purified by 
preparative HPLC (Phenomenex Luna C18(2), 5 μm, 100Å, 250 x 21.2mm, 40 °C, 20 mL 
min-1, injection volume 200 µL; Mobile phase A = 100:0.05 water/TFA; Mobile phase 
B = 100:0.05 MeOH/TFA, Method: 70% to 100% B over 8.0 min, then 100% B for 4 min, 
then 100% to 70% C over 1.0 min, then 70% C for 2.0 min). Monitored at 254 nm and 
collected a single fraction based on slope (up slope = 0.3, down slope = 0.3), trigger 
fraction collection between 8 and 13 min. The fractions containing the TM were 
combined and 2-3 mL of t-BuOH was added. The solution was concentrated in vacuo 
at 19°C until approx. 2-3 mL of solution remained. Tissue culture water (20 mL) was 
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added and the sample was lyophilized overnight to give the title compound CI207 (3.52 
mg, 0.782 µmol, 32%) as a white solid.  
 
Data for CI207: Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =4.726 min (95.602%); Analytical LCMS [Column C, T15, AW-BM, TFA2, F0.60, 
30-100B G7H5 22-200pos] tR =7.058 min (1502, 1127 m/z); HRMS (ESI-pos): calcd for 
C213H338O54N46S3 [M + 2H]2+ m/z 2250.2134 found m/z 2250.2479; calcd for 
C213H339O54N46S3 [M + 3H]3+ m/z 1500.4780 found m/z 1500.4808; calcd for 
C213H340O54N46S3 [M + 4H]4+ m/z 1125.6103 found m/z 1125.6194; calcd for 
C213H341O54N46S3 [M + 5H]5+ m/z 900.6897 found m/z 900.6968. 
6.3.80. Glycopeptide vaccine construct-OVA peptide CD4+ and CD8+ epitope 
[MbMC-PAB-Cit-Val-BCN-FFRK-KISQAVHAAHAEINEAGRESIIN 
FEKLTEWT, CI243] 
Solid MbMC-PAB-CV-BCN 178 (1.13 mg, 0.784 µmol) and Pep101 (180) (3.21 mg, 0.764 
µmol) were placed under vacuum and then backfilled with Ar before freshly 
deoxygenated DMSO (200 µL, c=18 mg mL-1) was added. The resulting solution was 
stirred at rt overnight. A 1 µL subsample was removed and diluted with 50 µL of 
deoxygenated DMSO for analysis by HPLC which showed complete loss of BCN starting 
material 178 (analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B G4H9] tR 
=6.728 min). The crude solution was purified by preparative HPLC (Phenomenex Luna 
C18(2), 5 μm, 100Å, 250 x 21.2mm, 40 °C, 20 mL min-1, injection volume 100 µL; Mobile 
phase A = 100:0.05 water/TFA; Mobile phase B = 100:0.05 MeOH/TFA, Method: 70% 
to 100% B over 8.0 min, then 100% B for 4 min, then 100% to 70% C over 1.0 min, then 
70% C for 2.0 min). Monitored at 254 nm and collected a single fraction based on slope 
(up slope = 0.3, down slope = 0.3), trigger fraction collection between 8 and 13 min. 
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The fractions containing the TM were combined and 2-3 mL of t-BuOH was added. The 
solution was concentrated in vacuo at 19°C until approx. 2-3 mL of solution remained. 
Tissue culture water (30 mL) was added and the sample was lyophilized overnight to 
give the title compound CI243 (2.81 mg, 0.498 µmol, 64%) as a white solid.  
 
Data for CI243: Analytical HPLC [Column C, T15, AW-BM, TFA2, F0.60, 30-100B 
G7H5] tR =7.268 min; Analytical LCMS [Column C, T15, AW-BM, TFA2, F0.60, 30-100B 
G7H5 22-200pos] tR =6.948 min (1411, 1129, 941 m/z); HRMS (ESI-pos): calcd for 
C269H432O70N61 [M + 3H]3+ m/z 1879.0701 found m/z 1879.0727; calcd for 
C269H433O70N61 [M + 4H]4+ m/z 1409.5544 found m/z 1409.5601; calcd for 
C269H434O70N61 [M + 5H]5+ m/z 1127.8450 found m/z 1127.8468; calcd for 




hydroxy-octadecan-4-yl hexacosanoate [MbMC-PAB-Cit-Val-C12-Fmoc, 
213] 
Solid MbMC-PAB-CV-NH2 177 (18 mg, 15 µmol) and 12-(Fmoc-amino)dodecanoic acid 
N-hydroxysuccinimide ester 212 (10 mg, 19 µmol, Analytical HPLC [Column C, T16, 
AW-BM, TFA2, F0.60, 60-100B G4H9] tR =3.201 min) were placed under high vacuum 
then under Ar. Anhydrous DMF (1 mL) followed by anhydrous DCM (0.5 mL) was 
added, once the material was dissolved ca. 10 min, distilled DIPEA (20 µL, 94 µmol) 
was added. The reaction was stirred at rt overnight before being diluted with DCM 
and concentrated in vacuo to give a yellow oil. The oil was re-concentrated from 
MeOH to give the crude material as a off white solid. The crude residue was dissolved 
in hot MeOH and cooled. The resulting ppt was filtered off using a Hirsch funnel and 
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the filtrate discarded. The ppt was dissolved with chloroform and concentrated in 
vacuo to afford the title compound 213 (16 mg, 9.56 µmol, 66%) as a white solid.  
 
Data for 213: δH(500 MHz, 2:1 CDCl3:CD3OD): 7.73 (2H, d, J= 7.5 Hz, Fmoc), 7.55 
(4H, dd, J= 23.4, 7.9 Hz, PAB, Fmoc), 7.36 (2H, t, J= 7.5 Hz, Fmoc), 7.32 – 7.14 (4H, m, 
PAB, Fmoc), 5.15 – 4.83 (3H, m, H-4’, PAB-CH2), 4.50 (1H, dd, J= 8.9, 4.9 Hz, Cit-CH), 
4.38 (1H, s, H-1), 4.34 (2H, d, J= 6.7 Hz, Fmoc-CH2), 4.17 (1H, t, J= 7.0 Hz, Val-CH), 4.13 
(1H, d, J= 7.3 Hz, H-2), 4.06 (1H, d, J= 9.7 Hz, H-6), 3.85 – 3.60 (6H, m, H-1’, H-1’, H-2’, 
H-3’, H-6), 3.54 (1H, t, J= 9.3 Hz, H-4), 3.43 – 3.37 (1H, m, H-3), 3.22 – 3.04 (3H, m, H-
5, NHCH2CH2), 2.30 (2H, q, J= 8.2 Hz, H-2’’), 2.22 (2H, td, J= 7.4, 3.2 Hz, 
NHCOCH2(CH2)10NHFmoc), 2.02 (1H, h, J= 6.9 Hz, CH(CH3)2), 1.87 (1H, td, J= 12.8, 12.2, 
5.6 Hz, CitCHCH2), 1.74 – 1.41 (11H, m, CitCHCH2, CH2), 1.22 (84H, s, CH2), 0.91 (6H, 
dd, J= 6.8, 4.3 Hz, CH(CH3)2), 0.84 (6H, t, J= 6.8 Hz, CH3-18’, CH3-26’’); δC(126 MHz, 
cd3od 2:1 CDCl3:CD3OD): 175.36 (COC25H51), 174.88 (C=O), 172.85 (C=O), 170.40 
(C=O), 169.33 (C=O), 157.54 (C=O), 156.93 (C=O), 144.30 (ipso-C), 141.62 (ipso-C), 
138.19 (ipso-C), 132.78 (ipso-C), 129.07 (PAB), 127.98 (Fmoc), 127.35 (Fmoc), 125.33 
(Fmoc), 120.34 (PAB), 120.21 (Fmoc), 100.00 (C-1), 76.75 (C-5), 74.97 (C-4’), 74.01 (C-
3), 70.92 (C-3’), 68.16 (C-6), 67.51 (C-4), 66.82 (Fmoc-CH2), 66.76 (PAB-CH2), 61.91 (C-
1’), 59.39 (C-2), 53.57 (Cit-CH), 52.09 (C-2’), 47.60 (Val-CH), 41.21 (NHCH2CH2), 36.53 
(NHCOCH2(CH2)10NHFmoc), 34.93 (C-2’’), 32.23 (CH2), 30.97 (CH(CH3)2), 30.10 (CH2), 
30.02 (CH2), 29.97 (CH2), 29.94 (CH2), 29.91 (CH2), 29.87 (CH2), 29.85 (CH2), 29.83 (CH2), 
29.78 (CH2), 29.75 (CH2), 29.72 (CH2), 29.67 (CH2), 29.65 (CH2), 29.63 (CH2), 29.60 (CH2), 
29.58 (CH2), 29.51 (CH2), 29.34 (CH2), 29.02 (CH2), 27.05 (CH2), 26.15 (CH2), 25.87 (CH2), 
25.65 (CH2), 25.61 (CH2), 25.39 (CH2), 24.85 (CH2), 22.96 (CH2), 19.42 (CH(CH3)2), 18.50 
(CH(CH3)2), 14.22 (C-18’, C-26’’); Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 
60-100B G4H9] tR =7.150 min (87.918%); Analytical LCMS [Column C, T16, AW-BM, 
TFA2, F0.60, 60-100B G4H9, 22-200Pos] tR =7.803 min (1707.51 m/z); HRMS (ESI-pos): 
calcd for C96H159O17N7Na [M + Na]+ m/z 1705.1685 found m/z 1705.1661; calcd for 
C90H149O12N7Na [M - C6H10O5 + H + Na]+ m/z 1543.1156 found m/z 1543.1151. 





hydroxy-octadecan-4-yl hexacosanoate [MbMC-PAB-Cit-Val-C12-NH2, 
214] 
To a solution of MbMC-PAB-CV-C12-Fmoc 213 (21 mg, 13 µmol) in anhydrous DMF (1 
mL) at 0°C under Ar was added piperidine (62 µL, 504 µmol). After 5 min the reaction 
was warmed to rt and was stirred for an additional 30 min. Upon complete loss of the 
starting material by analytical HPLC the reaction was concentrated in vacuo to afford 
a yellow-orange gum, which was re-concentrated from MeOH-CHCl3 to afford the 
crude material as an off white solid. The crude material was suspended in Et2O and 
transferred to a centrifuge tube. Following centrifugation at 4500 rpm for 10 min the 
Et2O was decanted. The pallet was re-suspended in fresh Et2O and the process 
repeated. Following decanting of the Et2O the pallet was dissolved in CHCl3, 
transferred to an round bottomed flask and re-concentrated in vacuo to afford the 
title compound 214 (18 mg, 12.4 µmol, 95%) as an off white solid. 
 
Data for 214: Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =5.210 min (93.996%); Analytical LCMS [Column C, T16, AW-BM, TFA2, F0.60, 
60-100B G4H9, 22-200Pos] tR =5.082 min (1487.92 m/z); HRMS (ESI-pos): calcd for 
C81H150O15N7 [M + H]+ m/z 1461.1184 found m/z 1461.1156; calcd for C75H140O10N7 [M 
– C6H10O5 + 2H]+ m/z 1299.0656 found m/z 1299.0640. 






hydroxy-octadecan-4-yl hexacosanoate, CI208 [MbMC-PAB-Cit-Val-C12-
BCN, 215] 
MbMC-PAB-CV-C12-NH2 214 (31 mg, 17 µmol) and pNP-BCN 170 (12 mg, 37 µmol) were 
placed under high vacuum (10min) then under Ar. Anhydrous DMF (2 mL) was added 
and the resulting solution was sonicated to dissolve the starting materials, then 
anhydrous TEA (20 µL, 144 µmol) was added. The reaction was stirred at rt overnight 
under Ar. After completion, the reaction was diluted with DCM and concentrated in 
vacuo to give the crude residue which was dissolved in CHCl3/MeOH and concentrated 
onto normal phase silica gel for purification by column chromatography (100% CHCl3 
to 30% MeOH/CHCl3) to give the title compound 215 (16 mg, 9.96 µmol, 58%) as a 
white solid. 
 
Data for 215: Analytical HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =6.914 min (90.121%); Analytical LCMS [Column C, T16, AW-BM, TFA2, F0.60, 
60-100B G4H9, 22-200Pos] tR =7.423 min (1660.04 m/z); HRMS (ESI-pos): calcd for 
C92H161O17N7Na [M + Na]+ m/z 1659.1841 found m/z 1659.1839. 
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6.3.84.  Glycopeptide vaccine construct-ISA Peptide HPV16 E7 [MbMC-PAB-
Cit-Val-C12-BCN-FFRK-GQAEPDRAHYNIVTFCCKCDS, CI209] 
MbMC-PAB-CV-C12-BCN 215 (1.48 mg, 0.904 µmol) and Pep545 (179) (2.82 mg, 0.921 
µmol) were placed under vacuum and then backfilled with Ar before freshly 
deoxygenated DMSO (200 µL, c=18 mg mL-1) was added. The resulting solution was 
stirred at rt overnight. A 1 µL subsample was removed and diluted with 50 µL of 
deoxygenated DMSO for analysis by HPLC-CAD-MS which showed complete loss of 
BCN starting material (analytical-HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =7.872 min). Tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP, 
100 uL of a 28 mg mL-1 solution in MeOH) was added followed by 5 µL of MS grade 
water and the resulting solution allowed to stir for an additional 30 min. The crude 
solution was purified by preparative HPLC (Phenomenex Luna C18(2), 5 μm, 100Å, 250 
x 21.2mm, 40 °C, 20 mL min-1, injection volume 100 µL; Mobile phase A = 100:0.05 
water/TFA; Mobile phase B = 100:0.05 MeOH/TFA, Method: 70% to 100% B over 8.0 
min, then 100% B for 4 min, then 100% to 70% C over 1.0 min, then 70% C for 2.0 min). 
Monitored at 254 nm and collected a single fraction based on slope (up slope = 0.3, 
down slope = 0.3), trigger fraction collection between 8 and 13 min. The fractions 
containing the TM were combined and 2-3 mL of t-BuOH was added. The solution was 
concentrated in vacuo at 19°C until approx. 2-3 mL of solution remained. Tissue 
culture water (30 mL) was added and the sample was lyophilized overnight to give the 
title compound CI209 (1.12 mg, 0.238 µmol, 26%) as a white solid.  
 
Data for CI209: Analytical LCMS [Column C, T15, AW-BM, TFA2, F0.60, 30-100B 
G7H5 22-200pos] tR =7.074 min (1568, 1176, 941 m/z); HRMS (ESI-pos): calcd for 
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C225H362O55N47S3 [M + 3H]3+ m/z 1566.2040 found m/z 1566.2037; calcd for 
C225H363O55N47S3 [M + 4H]4+ m/z 1174.9048 found m/z 1174.9091. 
6.3.85. Glycopeptide vaccine construct-OVA peptide CD4+ CD8+ [MbMC-
PAB-Cit-Val-C12-BCN-FFRK-KISQAVHAAHAEINEAGRESIINFEKLTEWT,  
CI210] 
MbMC-PAB-CV-C12-BCN 215 (1.51 mg, 0.922 µmol) and Pep101 (180) (3.88 mg, 0.924 
µmol) were placed under vacuum and then backfilled with Ar before freshly 
deoxygenated DMSO (200 µL, c=18 mg mL-1) was added. The resulting solution was 
stirred at rt overnight. A 1 µL subsample was removed and diluted with 50 µL of 
deoxygenated DMSO for analysis by HPLC-CAD-MS which showed complete loss of 
BCN starting material (analytical-HPLC [Column C, T16, AW-BM, TFA2, F0.60, 60-100B 
G4H9] tR =7.872 min). The crude solution was purified by preparative HPLC 
(Phenomenex Luna C18(2), 5 μm, 100Å, 250 x 21.2mm, 40 °C, 20 mL min-1, injection 
volume 100 µL; Mobile phase A = 100:0.05 water/TFA; Mobile phase B = 100:0.05 
MeOH/TFA, Method: 70% to 100% B over 8.0 min, then 100% B for 4 min, then 100% 
to 70% C over 1.0 min, then 70% C for 2.0 min). Monitored at 254 nm and collected a 
single fraction based on slope (up slope = 0.3, down slope = 0.3), trigger fraction 
collection between 8 and 13 min. The fractions containing the TM were combined and 
2-3 mL of t-BuOH was added. The solution was concentrated in vacuo at 19°C until 
approx. 2-3 mL of solution remained. Tissue culture water (30 mL) was added and the 
sample was lyophilized overnight to give the title compound CI210 (1.93 mg, 0.331 
µmol, 35.8%) as a white solid.  
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Data for CI210: Analytical LCMS [Column C, T15, AW-BM, TFA2, F0.60, 30-100B 
G7H5 22-200pos] tR =6.994 min (1460, 1168, 974 m/z); HRMS (ESI-pos): calcd for 
C281H455O71N62 [M + 3H]3+ m/z 1944.7961 found m/z 1944.7984; calcd for 
C281H456O71N62 [M + 4H]4+ m/z 1458.8489 found m/z 1458.8512; calcd for 
C281H457O71N62 [M + 5H]5+ m/z 1167.2806 found m/z 1167.2879; calcd for 
C281H458O71N62 [M + 6H]6+ m/z 972.9017 found m/z 972.9043. 
6.3.86. 6-O-tert-Butyldimethylsilyl-1,2-ethylidene-β-D-mannopyranoside 
[216] 
TEA (7.5 mL, 53.8 mmol), DMAP (293 mg, 02.398 mmol), and TBSCl 
(2.63 g, 17.45 mmol) where added to a stirred solution of triol 108 
(2.7 g, 13.09 mmol) in anhydrous DCM (20 mL). The solution was 
stirred at rt for 72 hr., following completion the solution was diluted 
with EtOAc and the solvents removed in vacuo to give the crude product which was 
purified by column chromatography (100% EtOAc) to give the title compound 216 
(Major/Minor =7:1, 2.79 g, 8.71 mmol, 67 %, 95 % brsm) as a colourless oil.  
 
Data for 216: Rf = 0.57 (100% EtOAc); δH(500 MHz, CDCl3): 5.30 (1H, q, J= 4.9 
Hz, , H-7), 5.23 (1H, d, J= 2.3 Hz, H-1), 4.16 (1H, dd, J= 4.0, 2.4 Hz, , H-2), 3.95 (1H, dd, 
J= 10.5, 4.6 Hz, H-6), 3.91 (1H, t, J= 9.0 Hz, H-4), 3.85 (1H, dd, J= 8.3, 3.1 Hz, H-3), 3.80 
(1H, dd, J= 10.4, 6.5 Hz, H-6), 3.56 – 3.49 (1H, b, OH), 3.29 (1H, ddd, J= 8.9, 6.4, 4.5 Hz, 
H-5), 2.77 (1H, b, OH), 1.47 (3H, d, J= 4.9 Hz, CH3-8), 0.90 (9H, s, SitBu), 0.10 (3H, s, 
Si(CH3)2), 0.09 (3H, s, Si(CH3)2); δC(126 MHz, CDCl3): 104.47 (C-7), 96.82 (C-1), 79.05 (C-
2), 73.12 (C-5), 72.43 (C-2), 71.16 (C-2), 65.09 (C-6), 25.94 (SiC(CH3)3), 21.76 (C-8), 
18.33 (SiC(CH3)3), -5.38 (SiCH3), -5.40 (SiCH3); HRMS (ESI-pos): calcd for C14H28O6SiNa 
[M + Na]+ m/z 343.1547, found m/z 343.1532. 
6.3.87. 3,4-Di-O-benzyl-6-O-tert-butyldimethylsilyl-1,2-ethylidene-β-D-
mannopyranoside [217] 
Sodium hydride (60% in oil, 1.6 g, 40.0 mmol) was added to a 
solution of crude silylane 216 (2.95 g, 9.21 mmol) in DMF (8 mL) at 
0 °C under argon and left to stir for 15 min. Benzyl bromide (10 mL, 
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84 mmol) was added dropwise and the resulting mixture allowed to slowly warm to 
rt. After stirring overnight the reaction was quenched with water and a standard 
aqueous workup preformed using EtOAc as the organic solvent. The solvents were 
removed in vacuo and the crude residue, which was purified by column 
chromatography (4:1 PE:EtOAc) to give the title compound 217 (Major/Minor =12:1, 
3.88 g, 7.75 mmol, 84 %) as a white solid. 
 
Data for 217: Rf =80 (2:1 PE/EtOAc); δH(500 MHz, CDCl3): 7.45 – 7.28 (10H, m, 
Ph), 5.33 (1H, q, J= 4.9 Hz, H-7), 5.15 (1H, d, J= 2.2 Hz, H-1), 4.94 (1H, d, J= 10.7 Hz, 
PhCH2), 4.83 (1H, d, J= 12.1 Hz, PhCH2), 4.79 (1H, d, J= 11.2 Hz, PhCH2), 4.77 (1H, d, J= 
10.5 Hz, PhCH2), 4.11 (1H, dd, J= 4.0, 2.3 Hz, H-2), 4.07 (1H, t, J= 9.3 Hz, H-4), 3.95 (1H, 
dd, J= 11.2, 3.4 Hz, H-6), 3.83 (1H, dd, J= 11.2, 2.0 Hz, H-6), 3.80 (1H, dd, J= 9.3, 4.0 Hz, 
H-3), 3.26 (1H, ddd, J= 9.3, 3.4, 2.0 Hz, H-5), 1.55 (3H, d, J= 4.9 Hz, CH3-8), 0.93 (9H, s, 
SitBu), 0.10 (3H, s, SiCH3), 0.09 (3H, s, SiCH3); δC(126 MHz, CDCl3): 138.76 (ipso-C), 
138.05 (ipso-C), 128.54 (Ph), 128.51 (Ph), 128.15 (Ph), 128.09 (Ph), 127.97 (Ph), 127.78 
(Ph), 104.44 (C-7), 96.83 (C-1), 78.87 (C-3), 78.13 (C-2), 75.47 (C-5), 75.21 (CH2Ph), 
74.61 (C-3), 72.35 (CH2Ph), 62.25 (C-6), 26.05 (SiC(CH3)3), 21.88 (C-8), 18.42 (SiC(CH3)3), 
-5.00 (SiCH3), -5.21 (SiCH3); HRMS (ESI-pos): calcd for C28H40O6SiNa [M + Na]+ m/z 
523.2486, found m/z 523.2458. 
6.3.88. 3,4-Di-O-benzyl-D-mannopyranoside [193]351-353 
Ethylidene 217 (110 mg, 0.220 mmol) was added to a solution of 
HCl 4M in Dioxane (5 mL, 20.00 mmol) and stirred at rt overnight. 
Following completion the reaction was diluted with MeOH and 
the solvent removed in vacuo to give the crude material, which was purified by column 
chromatography (100 % EtOAc) and subsequently crystallised from acetone to give 
the title compound 193 (α:β  = 2:1, 48 mg, 0.132 mmol, 60 %) as white crystals. 
 
Data for 193: Rf = 0.28 (100 % EtOAc); δH(500 MHz, CD3OD): 7.45 – 7.41 (2H, m, 
Ph), 7.36 – 7.25 (8H, m, Ph), 5.12 (1H, d, J=1.9 Hz, H-1), 4.89 (1H, d, J=11.0 Hz, PhCH2), 
4.78 (1H, d, J=11.7 Hz, PhCH2), 4.65 (1H, d, J=11.0 Hz, PhCH2), 4.62 (1H, d, J=11.6 Hz, 
PhCH2), 4.05 (1H, dd, J=3.1, 2.0 Hz, H-2), 3.91 (1H, dd, J=9.3, 3.1 Hz, H-3), 3.85 – 3.82 
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(2H, m H-4, H-5), 3.79 (2H, dd, J=11.8, 1.5 Hz, H-6), 3.74 (1H, dd, J=11.4, 3.7 Hz, H-6); 
δC(126 MHz, CD3OD): 139.99 (ipso-C), 139.89 (ipso-C), 129.31 (Ph), 129.27 (Ph), 129.06 
(Ph), 129.02 (Ph), 128.61 (Ph), 95.73 (C-1), 80.78 (C-3), 75.97 (CH2Ph), 75.64 (C-5)XII, 
73.25 (C-4)*, 72.36 (CH2Ph), 69.79 (C-2), 62.69 (C-6); HRMS (ESI-pos): calcd for 
C20H24O6Na [M + Na]+ m/z 383.1465, found m/z 383.1471. 
6.3.89. 3,4-Di-O-benzyl-6-O-tert-butyldiphenylsilyl-D-mannopyranoside 
[194] 
DIPEA (500 µL, 1.923 mmol), DMAP (16 mg, 0.135 mmol) and tert-
butyldiphenylsilyl chloride (482 mg, 1.753 mmol) were added to a 
stirred solution of triol 193 (486 mg, 1.348 mmol) in anhydrous 
DCM/DMF (10:1, 5.5 mL) and the resulting solution was stirred at rt under Ar 
overnight. The reaction was diluted with DCM and washed with Brine. The organic 
phase was concentrated in vacuo to give the crude material which was purified by 
column chromatography (PE to 2:1 PE/EtOAc) to afford the title compound 194 (α:β  
= 7:3, 488 mg, 0.815 mmol, 60%) as a colourless oil. 
 
Data for 194: Rf = 0.8 (2:1 PE/EtOAc); δH(400 MHz, CDCl3): 7.79 – 7.64 (4H, m, 
Ph), 7.44 – 7.26 (14H, m, Ph), 7.20 (2H, dt, J= 6.0, 2.9 Hz, Ph), 5.27 (1H, d, J= 1.8 Hz, H-
1), 4.89 (1H, d, J= 10.9 Hz, PhCH2), 4.74 – 4.68 (2H, m, PhCH2), 4.64 (1H, d, J= 11.1 Hz, 
PhCH2), 4.06 (1H, t, J= 2.4 Hz, H-4), 4.02 – 3.85 (5H, m, H-2, H-3, H-5, H-6), 2.54 (1H, b, 
OH), 2.41 (1H, s, OH), 1.07 (9H, s, t-Bu); δC(101 MHz, cdcl3): 138.43 (ipso-C), 137.94 
(ipso-C), 135.92 (Ph), 135.64 (Ph), 133.85 (ipso-C), 133.33 (ipso-C), 129.58 (Ph), 128.54 
(Ph), 128.35 (Ph), 127.94 (Ph), 127.92 (Ph), 127.83 (Ph), 127.65 (Ph), 127.54 (Ph), 94.02 
(C-1), 79.69 (C-3), 75.15 (CH2Ph), 74.08 (C-4)*, 72.43 (C-5)*, 72.10 (CH2Ph), 68.62 (C-2), 
63.21 (C-6), 26.86 (t-Bu); HRMS (ESI-pos): calcd for C36H42O6SiNa [M + Na]+ m/z 
621.2643, found m/z 621.2641. 
                                                      
XII Interchangeable assignment 





To a solution of silylane 217 (3.57 g, 7.14 mmol) in anhydrous 
THF (30 mL) at rt under argon was added TBAF (1 mol L-1 in 
THF, 10 mL, 10 mmol) and the reaction was stirred at rt 
overnight. The volatiles were removed in vacuo to afford the 
crude alcohol 219 as a pale yellow oil that was used directly in the next step. 
 
Sodium hydride (60% in oil, 400 mg, 10.0 mmol) was added portionwise to a stirred 
solution of the crude alcohol 219 in anhydrous DMF (8 mL) at 0°C under argon and left 
to stir for 15 min. 4-bromobenzyl bromide (2.68 g, 10.71 mmol) was added 
portionwise and the resulting mixture allowed to slowly warm to rt. The reaction was 
stirred at rt overnight, quenched with the careful addition of water and extracted into 
EtOAc. The organic phase was dried, filtered and concentrated in vacuo to afford the 
crude residue which was purified by column chromatography (PE to 2:1 PE/EtOAc) to 
afford the title compound 218 (3.39 g, 6.10 mmol, 86% over two steps) as a pale yellow 
oil. 
 
Data for 218: δH(400 MHz, CDCl3): 7.47 – 7.39 (2H, m), 7.39 (2H, dt, J= 7.7, 2.8 
Hz), 7.35 – 7.27 (7H, m), 7.25 – 7.18 (3H, m), 5.31 (1H, q, J= 4.9 Hz), 5.18 (1H, d, J= 2.4 
Hz), 4.91 (1H, d, J= 10.8 Hz), 4.82 (1H, d, J= 12.0 Hz), 4.76 (1H, d, J= 12.0 Hz), 4.60 (1H, 
d, J= 10.8 Hz), 4.56 (1H, d, J= 12.4 Hz), 4.49 (1H, d, J= 12.3 Hz), 4.17 – 4.13 (1H, m), 3.96 
(1H, t, J= 9.3 Hz), 3.80 (1H, dd, J= 9.2, 3.9 Hz), 3.74 (1H, dd, J= 10.7, 4.7 Hz), 3.68 (1H, 
dd, J= 10.7, 2.2 Hz), 3.44 (1H, ddd, J= 9.5, 4.7, 2.2 Hz), 1.54 (3H, d, J= 3.3 Hz); δC(101 
MHz, CDCl3): 138.36, 137.89, 137.52, 131.54, 129.31, 128.62, 128.57, 128.19, 128.11, 
128.09, 127.93, 121.45, 104.49, 96.85, 78.84, 77.96, 75.33, 74.91, 74.70, 72.74, 72.27, 
69.38, 21.89; HRMS (ESI-pos): calcd for C29H31O6BrNa [M + Na]+ m/z 577.1196, found 
m/z 577.1180. 
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6.3.91. 3,4-Di-O-benzyl-6-O-(4-bromobenzyl)-D-mannopyranoside [196] 
Ethylidene 218 (2.2 g, 3.98 mmol) was suspended in a 
solution of 90% TFA in water (10 mL) and was stirred at rt 
overnight. Following completion, the reaction mixture was 
diluted with toluene and concentrated in vacuo to give the 
crude material which was purified by column chromatography (100 PE to 3:1 
PE/EtOAc) to give the title compound 196 (1.2 g, 2.26 mmol, 57%) as a colourless foam. 
 
Data for 196: δH(500 MHz, CDCl3): 7.43 (2H, dd, J= 8.4, 2.9 Hz), 7.37 – 7.28 (10H, 
m), 7.18 (2H, ddt, J= 10.3, 7.9, 1.1 Hz), 5.31 (1H, d, J= 1.7 Hz), 4.85 (1H, dd, J= 11.0, 2.6 
Hz), 4.71 (3H, d, J= 5.6 Hz), 4.57 – 4.43 (4H, m), 4.07 (1H, dd, J= 3.3, 1.8 Hz), 3.95 (1H, 
dd, J= 9.2, 3.3 Hz), 3.81 – 3.73 (1H, m), 3.72 – 3.63 (1H, m), 1.73 (2H, b); δC(126 MHz, 
CDCl3): 140.83, 140.50, 139.64, 134.18, 132.32, 132.29, 131.29, 131.26, 131.13, 
131.11, 130.69, 130.59, 130.56, 130.47, 124.26, 96.60, 82.36, 77.78, 77.12, 75.29, 
74.75, 72.07, 71.17; HRMS (ESI-pos): calcd for C27H29O6BrNa [M + Na]+ m/z 551.1040, 
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6.4 Formulation of Compounds for Biological testing 
Synthetic purity of compounds for biological testing was assessed by analytical RP-
HPLC on an Agilent 1260 Infinity Quaternary HPLC equipped with both an Agilent 1260 
Multiple Wavelength Detector and either an Agilent 6130 single quadrupole mass 
spectroscopic detector using ESI (peak identification) or a Dionex Corona Ultra RS 
charged aerosol detector (CAD) (synthetic purity). Using a Phenomenex Kinetex 100Å 
C18 (2.6 µm, 3.0 x 50 mm) functionalized silica column at the specified flow rate and 
conditions. The solvent system for all analytical LC purposes on this system were the 
same as those utilizing the Shimadzu systems above.  
 
HPLC data was reported using the same convention as above. Column Time Solvents 
Acid Modifier Flow Gradient Mass range [Column X, TXX, AX-BX XXX2, FXX, XX-XXXB 
GXHX, XX-XXXPos/Neg]. 
 
Testing doses of CN138, CI120, CI121, CI122, CI123, CI164, and CI168 were supplied 
to the National Institutes of Health (NIH) as vials containing lyophilized CNXXX/CIXXX 
(200 µg), sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 mg) stored under Ar 
at -20 °C. Whereas testing doses of CI207, CI209, CI210 and CI243 were supplied to 
the National Institutes of Health (NIH) as vials containing lyophilized CIXXX (50 µg), 
sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 mg) stored under Ar at -20 °C. 
 
  




mannopyranoside 2,2,2-trifluoroacatate, CI120 [β-ManPhyt, 50] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =3.572 min (87.2492%). 
 
 
Formulation of 50 for testing: CI120; CAD purity 87.25%. Standard solutions of CI120 
were prepared by dissolving 1.80 mg of compound with 180 μL of 9:1, THF:MeOH 
solution to give a 10 mg mL-1 standard. 8 felcon tubes were prepared by adding 356 
μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 
mg)) to each tube then injecting each felcon tube with 20 μL of the 10 mg mL-1 
standard solution. The resulting mixture was frozen in liquid N2 and lyophilized 
overnight. Removed from the freeze dryer the tubes were placed under and 








mannopyranoside 2,2,2-trifluoroacatate, CI168 [α-ManPhyt, 125] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =3.572 min (91.27%). 
 
 
Formulation of 125 for testing: CI168; CAD purity 91.27%. Standard solutions of CI168 
were prepared by dissolving 510 µg of compound with 102 μL of 9:1, THF:MeOH 
solution to give a 5 mg mL-1 standard. 10x1.5 mL cyro-tubes were prepared by adding 
88 μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 
(5 mg)) to each tube then injecting each cyro-tube with 10 μL of the 5 mg mL-1 standard 
solution followed by 500 µL of endotoxin free water. The resulting mixture was frozen 
in liquid N2 and lyophilized overnight. Removed from the freeze dryer the tubes were 
placed under an atmosphere of argon, sealed and labelled. This gave 10x 50 μg 
formulated samples of CI168A1a. 
 
  




heptadecyl]-Hexacosanamide, CN138 [β-ManCer, 1] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =7.504 min (95.0553%). 
 
Formulation of 1 for testing: CN138; CAD purity 95.06%. Standard solutions of CN138 
were prepared by dissolving 2.48 mg of compound with 248 μL of 9:1, THF:MeOH 
solution to give a 10 mg mL-1 standard. To the resulting insoluble solution was added 
248 μL of DMSO to 5 mg mL-1 homogenous standard solution. . 11 felcon tubes were 
prepared by adding 356 μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 
mg), and tween-20 (5 mg) to each tube then injecting each felcon tube with 40 μL of 
the 5 mg mL-1 standard solution. This resulted in the precipitation of CN138 which was 
reconstituted by sonication in heated water. The resulting mixture was frozen in liquid 
N2 and lyophilized overnight. Removed from the freeze dryer the tubes were placed 
under and atmosphere of argon, sealed and labelled. This gave 11x 200 μg formulated 
samples of CN138H1a.  




heptadecyl]-Hexacosanamide, CI164 [α-ManCer, 118] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =7.379 min (96.62%). 
 
Formulation of 118 for testing: CI164; CAD purity 96.62%. Standard solutions of CI164 
were prepared by dissolving 490 µg of compound with 98 μL of 9:1, THF:MeOH 
solution to give a 5 mg mL-1 standard. 9x1.5 mL cyro-tubes were prepared by adding 
88 μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 
(5 mg)) to each tube then injecting each cyro-tube with 10 μL of the 5 mg mL-1 standard 
solution followed by 500 µL of endotoxin free water. The resulting mixture was frozen 
in liquid N2 and lyophilized overnight. Removed from the freeze dryer the tubes were 
placed under an atmosphere of argon, sealed and labelled. This gave 9x 50 μg 
formulated samples of CI164A1a. 
  




mannopyranosyloxy)methyl]heptadecyl]-undecanamide, CI121 [140] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =5.211 min (96.1795%). 
 
 
Formulation of 140 for testing: CI121; CAD purity 96.18%. Standard solutions of CI121 
were prepared by dissolving 2.26 mg of compound with 226 μL of 9:1, THF:MeOH 
solution to give a 10 mg mL-1 standard. To the resulting insoluble solution was added 
226 μL of DMSO to 5 mg mL-1 homogenous standard solution. . 10 felcon tubes were 
prepared by adding 356 μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 
mg), and tween-20 (5 mg)) to each tube then injecting each felcon tube with 40 μL of 
the 5 mg mL-1 standard solution. The resulting mixture was frozen in liquid N2 and 
lyophilized overnight. Removed from the freeze dryer the tubes were placed under 
and atmosphere of argon, sealed and labelled. This gave 10x 200 μg formulated 
samples of CI121A1a. 
  




mannopyranosyloxy)methyl]heptadecyl]-undecanamide, CI122 [141] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =5.395 min (94.8193%). 
 
 
Formulation of 141 for testing: CI122; CAD purity 94.82%. Standard solutions of CI122 
were prepared by dissolving 2.24 mg of compound with 224 μL of 9:1, THF:MeOH 
solution to give a 10 mg mL-1 standard. 10 felcon tubes were prepared by adding 356 
μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 
mg)) to each tube then injecting each felcon tube with 20 μL of the 10 mg mL-1 
standard solution. The resulting mixture was frozen in liquid N2 and lyophilized 
overnight. Removed from the freeze dryer the tubes were placed under and 








heptadecyl]-11Z, 14Z-Eicosadienamide, CI123 [143] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =5.758 min (94.6833%). 
 
 
Formulation of 143 for testing: CI123; CAD purity 94.68%. Standard solutions of CI123 
were prepared by dissolving 1.86 mg of compound with 186 μL of 9:1, THF:MeOH 
solution to give a 10 mg mL-1 standard. 8 felcon tubes were prepared by adding 356 
μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 
mg)) to each tube then injecting each felcon tube with 20 μL of the 10 mg mL-1 
standard solution. The resulting mixture was frozen in liquid N2 and lyophilized 
overnight. Removed from the freeze dryer the tubes were placed under and 
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6.4.8. Glycopeptide vaccine construct-ISA Peptide HPV16 E7, [MbMC-PAB-
Cit-Val-BCN-FFRK-GQAEPDRAHYNIVTFCCKCDS, CI207] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =4.944 min; Analytical HPLC [T15, AW-BM, TFA2, F0.50, 30-100B G7H5] tR 
=8.101 min (98.4806%). 
 
Formulation of CI207 for testing: CI207; CAD purity 98.48%. Standard solutions of 
CI207 were prepared by dissolving 760 µg of compound with 152 μL of deoxygenated 
DMSO to give a 5 mg mL-1 standard. 14x1.5 mL cyro-tubes were prepared by adding 
88 μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 
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(5 mg)) to each tube then injecting each cyro-tube with 10 μL of the 5 mg mL-1 standard 
solution followed by 500 µL of endotoxin free water. The resulting mixture was frozen 
in liquid N2 and lyophilized overnight. Removed from the freeze dryer the tubes were 
placed under an atmosphere of argon, sealed and labelled. This gave 14x 50 μg 
formulated samples of CI207A1a. 
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6.4.9. Glycopeptide vaccine construct-OVA peptide CD4+ CD8+ [MbMC-
PAB-Cit-Val-BCN-FFRK-KISQAVHAAHAEINEAGRESIINFEKLTEWT, CI243] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =5.097 min; Analytical HPLC [T15, AW-BM, TFA2, F0.50, 30-100B G7H5] tR 
=8.209 min (98.0991%). 
 
Formulation of CI243 for testing: CI243; CAD purity 98.10%. Standard solutions of 
CI243 were prepared by dissolving 490 µg of compound with 98 μL of deoxygenated 
DMSO to give a 5 mg mL-1 standard. 9x1.5 mL cyro-tubes were prepared by adding 88 
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μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 
mg)) to each tube then injecting each cyro-tube with 10 μL of the 5 mg mL-1 standard 
solution followed by 500 µL of endotoxin free water. The resulting mixture was frozen 
in liquid N2 and lyophilized overnight. Removed from the freeze dryer the tubes were 
placed under an atmosphere of argon, sealed and labelled. This gave 9x 50 μg 
formulated samples of CI243A1a. 
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6.4.10. Glycopeptide vaccine construct-ISA Peptide HPV16 E7 [MbMC-PAB-
Cit-Val-C12-BCN-FFRK-GQAEPDRAHYNIVTFCCKCDS, CI209] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =5.039 min; Analytical HPLC [T15, AW-BM, TFA2, F0.50, 30-100B G7H5] tR 
=8.273 min (97.8903%). 
 
Formulation of CI209 for testing: CI209; CAD purity 97.89%. Standard solutions of 
CI209 were prepared by dissolving 400 µg of compound with 80 μL of deoxygenated 
DMSO to give a 5 mg mL-1 standard. 7x1.5 mL cyro-tubes were prepared by adding 88 
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μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 
mg)) to each tube then injecting each cyro-tube with 10 μL of the 5 mg mL-1 standard 
solution followed by 500 µL of endotoxin free water. The resulting mixture was frozen 
in liquid N2 and lyophilized overnight. Removed from the freeze dryer the tubes were 
placed under an atmosphere of argon, sealed and labelled. This gave 7x 50 μg 
formulated samples of CI209A1a. 
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6.4.11. Glycopeptide vaccine construct- OVA peptide CD4+ CD8+ [MbMC-
PAB-Cit-Val-C12-BCN-FFRK-KISQAVHAAHAEINEAGRESIINFEKLTEWT, 
CI210] 
Synthetic purity assessment: Analytical HPLC [T15, AW-BM, TFA2, F0.50, 60-100B 
G4H8] tR =5.160 min; Analytical HPLC [T15, AW-BM, TFA2, F0.50, 30-100B G7H5] tR 
=8.045 min (99.0740%). 
 
Formulation of CI210 for testing: CI210; CAD purity 98.10%. Standard solutions of 
CI210 were prepared by dissolving 370 µg of compound with 74 μL of deoxygenated 
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DMSO to give a 5 mg mL-1 standard. 7x1.5 mL cyro-tubes were prepared by adding 88 
μL of matrix buffer (contains; sucrose (56 mg), L-histidine (7.5 mg), and tween-20 (5 
mg)) to each tube then injecting each cyro-tube with 10 μL of the 5 mg mL-1 standard 
solution followed by 500 µL of endotoxin free water. The resulting mixture was frozen 
in liquid N2 and lyophilized overnight. Removed from the freeze dryer the tubes were 
placed under an atmosphere of argon, sealed and labelled. This gave 7x 50 μg 
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